

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

## OM nucleic - nucleic search, using sw model

Run on: September 25, 2004, 01:02:39 ; Search time 900 Seconds  
(without alignments)  
10780.983 Million cell updates/sec

Title: US-09-944-929-82

Perfect score: 2284

Sequence: 1 gcgagagcatccgctgcgctc.....ataatcttctgtactcaa 2284

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1500 summaries

Database :

N\_Geneseq\_29Jan04:\*  
1: geneseqn1980s:\*  
2: geneseqn1990s:\*  
3: geneseqn2000s:\*  
4: geneseqn2001as:\*  
5: geneseqn2001bs:\*  
6: geneseqn2002s:\*  
7: geneseqn2003as:\*  
8: geneseqn2003bs:\*  
9: geneseqn2003cs:\*  
10: geneseqn2004s:\*

Pred. NO. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2284	100.0	2284	2	AAx80059 Human PRO
2	2284	100.0	2284	3	Aaa49567 Human PRO
3	2284	100.0	2284	5	Aaf44268 Human PRO
4	2284	100.0	2284	7	Abx75504 Human sec
5	2284	100.0	2284	7	Abx78062 Human PRO
6	2284	100.0	2284	7	Abx80474 Novel hum
7	2284	100.0	2284	7	ACA69380 Human CDN
8	2284	100.0	2284	7	ABX90451 Human sec
9	2284	100.0	2284	7	ABX64297 CDNA enco
10	2284	100.0	2284	7	ABX89495 Human PRO
11	2284	100.0	2284	7	ACA64519 Novel hum
12	2284	100.0	2284	7	ABX96832 Human CDN
13	2284	100.0	2284	7	ABX78486 DNA enco
14	2284	100.0	2284	7	ABX77120 CDNA enco
15	2284	100.0	2284	7	Abx80978 Human sec
16	2284	100.0	2284	7	ACd44487 CDNA enco
17	2284	100.0	2284	7	Abx75951 Human CDN
18	2284	100.0	2284	7	ABX89662 CDNA enco
19	2284	100.0	2284	7	Abx79658 Human sec
20	2284	100.0	2284	7	ACA93679 Novel hum
21	2284	100.0	2284	7	Abx81361 Novel hum
22	2284	100.0	2284	7	ACA93177 Novel hum
23	2284	100.0	2284	7	Abx17261 Human PRO

24	2284	100.0	2284	7	ABX34148	Abx34148 CDNA enco
25	2284	100.0	2284	8	ACA04368	ACA04368 Human PRO
26	2284	100.0	2284	8	ACA68116	ACA68116 Novel hum
27	2284	100.0	2284	8	ACA88565	ACA88565 Human sec
28	2284	100.0	2284	8	ACD82072	ACd82072 CDNA enco
29	2284	100.0	2284	8	ADA38025	Ada38025 Human CDN
30	2284	100.0	2284	8	ADA21711	Ada21711 Human CDN
31	2284	100.0	2284	8	ADA10498	Ada10498 Human CDN
32	2284	100.0	2284	8	ADA18042	Ada18042 CDNA enco
33	2284	100.0	2284	8	ADA28150	Ada28150 Human CDN
34	2284	100.0	2284	8	ADA94730	Ada94730 Human CDN
35	2284	100.0	2284	8	ADA38955	Ada38955 Human CDN
36	2284	100.0	2284	8	ADA93076	Ada93076 Human CDN
37	2284	100.0	2284	8	ACH65633	Ach65633 Human CDN
38	2284	100.0	2284	8	ADA22637	Ada22637 Human CDN
39	2284	100.0	2284	8	ACD39623	AcCd39623 Human CDN
40	2284	100.0	2284	8	ADA06803	Ada06803 Human sec
41	2284	100.0	2284	8	ADA39496	Ada39496 Human CDN
42	2284	100.0	2284	8	ADB96522	Adb96522 Human PRO
43	2284	100.0	2284	9	ADC57994	Adc57994 Human PRO
44	2284	100.0	2284	9	ADC25838	Adc25838 Human CDN
45	2284	100.0	2284	9	ADC25596	Adc25596 Human CDN
46	2284	100.0	2284	9	ADC55358	Adc55358 Human PRO
47	2284	100.0	2284	9	ADC12225	Adc12225 Human CDN
48	2284	100.0	2284	9	ADC56647	Adc56647 Human PRO
49	2284	100.0	2284	9	ADC11692	Adc11692 Human CDN
50	2284	100.0	2284	9	ADC25717	Adc25717 Human CDN
51	2284	100.0	2284	9	ADC14814	Adc14814 Novel hum
52	2284	100.0	2284	9	ADD08346	Add08346 Novel hum
53	2284	100.0	2284	9	ADC82171	Adc82171 Human PRO
54	2284	100.0	2284	9	ADD07813	Add07813 Novel hum
55	2284	100.0	2284	9	ADC82704	Adc82704 Human PRO
56	2284	100.0	2284	9	ADD08884	Add08884 Novel hum
57	2284	100.0	2284	9	ADD07133	Add07133 Novel hum
58	2284	100.0	2284	9	ADC83380	Adc83380 Human PRO
59	2284	100.0	2284	9	ADD55487	Add55487 Human PRO
60	2284	100.0	2284	9	ADD56445	Add56445 Human PRO
61	2284	100.0	2284	9	ADD54883	Add54883 Human PRO
62	2284	100.0	2284	9	ADE31902	Ade31902 Human CDN
63	2284	100.0	2284	9	ADE37037	Ade37037 Novel hum
64	2284	100.0	2284	9	ADE26504	Ade26504 Novel hum
65	2284	100.0	2284	10	ADE71551	Ade71551 Human CDN
66	2284	100.0	2284	3	AAC58593	Aac58593 Human PRO
67	2271.4	99.4	2342	3	AAC59840	Aac59840 Human sec
68	2245.6	98.3	2297	4	Aah18096	Aah18096 Human CDN
69	2045.8	89.6	2221	4	Aah13971	Aah13971 Human CDN
70	1939.4	84.9	2015	3	AAA16637	Aaa16637 Human sec

## ALIGNMENTS

RESULT 1  
AAx80059  
ID AAx80059 standard; CDNA; 2284 BP.  
XX  
AC AAx80059;  
XX  
DT 12-AUG-1999 (first entry)  
XX  
DE Human PRO361 nucleotide sequence.  
XX  
KW Human; PRO protein; tumour necrosis factor family; TNF; cytokine;  
KW secreted protein; transmembrane protein; inflammation disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9928462-A2.  
XX  
PD 10-JUN-1999.  
XX  
PF 01-DEC-1998; 98WO-US025108.

XX 03-DEC-1997; 97US-0067411P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Wood WI, Goddard A, Gurney AL, Yuan J, Baker KP, Chen J;  
XX WPI, 1999-371118/31.  
DR P-PSDB; AAY17834.  
XX  
PT Nucleic acids encoding PRO secreted and transmembrane proteins.  
XX  
PS Claim 2; Fig 36; 123p; English.  
XX  
CC The present invention describes nucleic acids encoding PRO secreted and  
CC transmembrane proteins used therapeutically. The PRO proteins have  
CC cyostatic, anti-inflammatory, anti-proliferative and immunosuppressive  
CC activity. The proteins and polynucleotides can be used in therapy,  
CC identification of homologues, raising antibodies and design of probes and  
CC primers. They can be used in a range of diseases related to proteins that  
CC they have homology with, e.g. a PRO protein having homology to complement  
CC proteins may be used in inflammatory responses  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;  
  
Query Match 100.0%; Score 2284; DB 2; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTCGCGGTCTTCCCGC 60  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1 GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTCGCGGTCTTCCCGC 60  
  
QY 61 GGGCGGACAGAGCTGTCTCTCGACCTGATGGCAGCAGGGGCGCGGGGTCTCTCGAC 120  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
61 GGGCGGACAGAGCTGTCTCTCGACCTGATGGCAGCAGGGGCGCGGGGTCTCTCGAC 120  
  
QY 121 GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAGCAAACTAAGACCAAGAGGAG 180  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
121 GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAGCAAACTAAGACCAAGAGGAG 180  
  
QY 181 GATTATCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
181 GATTATCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
181 GATTATCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
  
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATAATTGCTCTCGACACTAAGGCTGTGCT 300  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
241 GAAGGAGCTTGACTTACACTTTGGTAATAATTGCTCTCGACACTAAGGCTGTGCT 300  
241 GAAGGAGCTTGACTTACACTTTGGTAATAATTGCTCTCGACACTAAGGCTGTGCT 300  
  
QY 301 AGTCAGAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCATTTGACATCAGTCTCTT 360  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
301 AGTCAGAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCATTTGACATCAGTCTCTT 360  
301 AGTCAGAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCATTTGACATCAGTCTCTT 360  
  
QY 361 TCTAAGGGAATCAGAGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTAAT 420  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
361 TCTAAGGGAATCAGAGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTAAT 420  
361 TCTAAGGGAATCAGAGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTAAT 420  
  
QY 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480

DB 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480  
QY 481 ACTGAAAAACAGCTAGACCAACCACTGCTACCTATTTTCTGTCCCAAGAGAGGCC 540  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
481 ACTGAAAAACAGCTAGACCAACCACTGCTACCTATTTTCTGTCCCAAGAGAGGCC 540  
DB 541 TGTCATTTGAACCAAGCAAAAGACTTATGAGTTACAGATTAATACAGATTTTCCATCT 600  
QY ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
541 TGTCATTTGAACCAAGCAAAAGACTTATGAGTTACAGATTAATACAGATTTTCCATCT 600  
DB 541 TGTCATTTGAACCAAGCAAAAGACTTATGAGTTACAGATTAATACAGATTTTCCATCT 600  
QY 601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCCAAGAGATTCTCTTACATGGCCAA 660  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCCAAGAGATTCTCTTACATGGCCAA 660  
601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCCAAGAGATTCTCTTACATGGCCAA 660  
  
QY 661 TTTTCACAGCAGTCACTCCCTTAGCCCATCATCACACAGATTATTCAAAGCCCAAGAT 720  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
661 TTTTCACAGCAGTCACTCCCTTAGCCCATCATCACACAGATTATTCAAAGCCCAAGAT 720  
661 TTTTCACAGCAGTCACTCCCTTAGCCCATCATCACACAGATTATTCAAAGCCCAAGAT 720  
  
QY 721 ATCTCATGAGAGACACACTTTCTGAGAAATTGGATCCCTCAGATCACCTGGAGAAACTA 780  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
721 ATCTCATGAGAGACACACTTTCTGAGAAATTGGATCCCTCAGATCACCTGGAGAAACTA 780  
721 ATCTCATGAGAGACACACTTTCTGAGAAATTGGATCCCTCAGATCACCTGGAGAAACTA 780  
  
QY 781 TTTAAGATGATGAAGCAAGTGGCCAGCTCCTGCTTATAAGAAAGGCCATTCTCAG 840  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
781 TTTAAGATGATGAAGCAAGTGGCCAGCTCCTGCTTATAAGAAAGGCCATTCTCAG 840  
781 TTTAAGATGATGAAGCAAGTGGCCAGCTCCTGCTTATAAGAAAGGCCATTCTCAG 840  
  
QY 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGG 900  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGG 900  
841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGG 900  
  
QY 901 CTCCCAAGTACGGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
901 CTCCCAAGTACGGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
901 CTCCCAAGTACGGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
  
QY 961 ACCCTTCAACCAACCAATGCTTCAAGTACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
961 ACCCTTCAACCAACCAATGCTTCAAGTACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
961 ACCCTTCAACCAACCAATGCTTCAAGTACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
  
QY 1021 ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCTCATTTCTACA 1080  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1021 ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCTCATTTCTACA 1080  
1021 ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCTCATTTCTACA 1080  
  
QY 1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGCTTACACAGATTTCTGACTACC 1140  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGCTTACACAGATTTCTGACTACC 1140  
1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGCTTACACAGATTTCTGACTACC 1140  
  
QY 1141 ACCTTTACAGGCACTTACGACTCGAAAGGCAAGCTTAGAAACCATACCGTTACAGAAATC 1200  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1141 ACCTTTACAGGCACTTACGACTCGAAAGGCAAGCTTAGAAACCATACCGTTACAGAAATC 1200  
1141 ACCTTTACAGGCACTTACGACTCGAAAGGCAAGCTTAGAAACCATACCGTTACAGAAATC 1200  
  
QY 1201 TCCAACTTAACTTTGAACACAGGGAATGTATTAACCTTACTGCACTTCTATGTCAAT 1260  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1201 TCCAACTTAACTTTGAACACAGGGAATGTATTAACCTTACTGCACTTCTATGTCAAT 1260  
1201 TCCAACTTAACTTTGAACACAGGGAATGTATTAACCTTACTGCACTTCTATGTCAAT 1260  
  
QY 1261 GTGAGTCTTCCACTATGAATAAATCTGCTCTGGGAAGTGAAGGAGCCAGTCCAGGC 1320  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1261 GTGAGTCTTCCACTATGAATAAATCTGCTCTGGGAAGTGAAGGAGCCAGTCCAGGC 1320  
1261 GTGAGTCTTCCACTATGAATAAATCTGCTCTGGGAAGTGAAGGAGCCAGTCCAGGC 1320  
  
QY 1321 AGTTCCTCCAGGAGAGTGTTCAGAAATCAGTACGAGCTTCAATTTGAAAAATGACTT 1380  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1321 AGTTCCTCCAGGAGAGTGTTCAGAAATCAGTACGAGCTTCAATTTGAAAAATGACTT 1380  
1321 AGTTCCTCCAGGAGAGTGTTCAGAAATCAGTACGAGCTTCAATTTGAAAAATGACTT 1380  
  
QY 1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTCTGATAGGCTCGTCTCTGGGT 1440  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTCTGATAGGCTCGTCTCTGGGT 1440  
1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTCTGATAGGCTCGTCTCTGGGT 1440  
  
QY 1441 AGAATCTTTTGGAAATCACTCCGAGGAAACGTTACTCAAGACTGGAATTTGATCAAT 1500  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1441 AGAATCTTTTGGAAATCACTCCGAGGAAACGTTACTCAAGACTGGAATTTGATCAAT 1500  
1441 AGAATCTTTTGGAAATCACTCCGAGGAAACGTTACTCAAGACTGGAATTTGATCAAT 1500  
  
QY 1501 GGGATCTATGTGACATCTAAGATGAAGTGAAGTGGTGTCTTAACTTAACTTAACTTAACT 1560  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1501 GGGATCTATGTGACATCTAAGATGAAGTGAAGTGGTGTCTTAACTTAACTTAACTTAACT 1560  
1501 GGGATCTATGTGACATCTAAGATGAAGTGAAGTGGTGTCTTAACTTAACTTAACTTAACT 1560

```

QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGTGTAAGTCTTAGCAGAGGTTGATTTGA 1620
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGTGTAAGTCTTAGCAGAGGTTGATTTGA 1620
QY 1621 AGACAGAAAAATGCCCCCTTCTGCTTCTTTTCTTTTGGAGACAGAGTCTTGCTCTG 1680
Db 1621 AGACAGAAAAATGCCCCCTTCTGCTTCTTTTCTTTTGGAGACAGAGTCTTGCTCTG 1680
QY 1681 TTGCCCCAGGCTGAGTGCAGTAGACGATCTCGGCTCTACCGCAACTCCGCTCTCTG 1740
Db 1681 TTGCCCCAGGCTGAGTGCAGTAGACGATCTCGGCTCTACCGCAACTCCGCTCTCTG 1740
QY 1741 GTTCAAGCGATTCTCTGCTGACCTCTAAGTATCTGGATTACAGGATGTGCCACC 1800
Db 1741 GTTCAAGCGATTCTCTGCTGACCTCTAAGTATCTGGATTACAGGATGTGCCACC 1800
QY 1801 ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGTTTCAACATGTTGTGAGGCTG 1860
Db 1801 ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGTTTCAACATGTTGTGAGGCTG 1860
QY 1861 GTCTCAAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAGTGTGGATTACA 1920
Db 1861 GTCTCAAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAGTGTGGATTACA 1920
QY 1921 GGCATGAGCCACCAAGCTGCCCCCTTCTGTTTATGTTGGTTTGTGAGAGGAATGA 1980
Db 1921 GGCATGAGCCACCAAGCTGCCCCCTTCTGTTTATGTTGGTTTGTGAGAGGAATGA 1980
QY 1981 AGTGGGAACCAAAATTAGTAATTTGGGTAATCTGCTCTAAATAATTAGCTAAAAACAA 2040
Db 1981 AGTGGGAACCAAAATTAGTAATTTGGGTAATCTGCTCTAAATAATTAGCTAAAAACAA 2040
QY 2041 AGCTCTATGTAAAGTAATAATTTGATGTCATATAAATTCAAAATTCAACTGGCTTT 2100
Db 2041 AGCTCTATGTAAAGTAATAATTTGATGTCATATAAATTCAAAATTCAACTGGCTTT 2100
QY 2101 TAATGCAAGAAACAGGTTAGACATCTAGGTTCCAATTCATTCATCTTGTTCCAGA 2160
Db 2101 TAATGCAAGAAACAGGTTAGACATCTAGGTTCCAATTCATTCATCTTGTTCCAGA 2160
QY 2161 TAAATCAACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGATTCCT 2220
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGATTCCT 2220
QY 2221 TTAATACTTATTCAGATGATGCTTCCAATTAATATTTGAATAATCTTTGTAC 2280
Db 2221 TTAATACTTATTCAGATGATGCTTCCAATTAATATTTGAATAATCTTTGTAC 2280
QY 2281 TCAA 2284
Db 2281 TCAA 2284

```

RESULT 2  
 AAA49567  
 ID AAA49567 standard; cDNA; 2284 BP.  
 XX AAA49567;

AC  
 XX 25-SEP-2000 (first entry)  
 DT  
 XX Human PRO361 cDNA.  
 DE

XX PRO; membrane bound protein; secreted protein; PRO357; PRO327; PRO243;  
 KW PRO715; PRO241; PRO323; PRO299; PRO344; PRO347; PRO355; PRO353;  
 KW PRO361; PRO365; transmembrane polypeptide; antibody; screening;  
 KW detection; inhibition; probe; primer; human; ss.  
 XX  
 XX Homo sapiens.  
 OS

Key Location/Qualifiers  
 FT CDS 226..1521

```

FT FT /*tag= a  

XX /product= "PRO361 polypeptide"  

PN WO200032776-A2.  

XX  

PD 08-JUN-2000.  

XX  

PF 01-DEC-1999; 99WO-US028301.  

XX  

PR 01-DEC-1998; 98WO-US025108.  

PR 16-DEC-1998; 98US-0112850P.  

PR 22-DEC-1998; 98US-0113296P.  

XX  

PA (GENETH ) GENENTECH INC.  

XX  

PI Baker KP, Bolstein D, Eaton DL, Ferrara N, Filvaroff E;  

PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL;  

PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;  

XX  

DR WPI; 2000-412324/35.  

DR P-PSDB; AAB01325.  

XX  

XX New human nucleic acids encoding secreted and transmembrane polypeptides,  

PT designated as PRO polypeptides, useful as pharmaceutical and diagnostic  

PT agents.  

XX  

PS Claim 2; Fig 31; 187pp; English.  

XX  

CC New human nucleic acids encoding secreted and transmembrane polypeptides  

CC which are designated as PRO polypeptides are described. The membrane-bound  

CC proteins have various industrial applications, including as  

CC pharmaceutical and diagnostic agents. The membrane-bound proteins can  

CC also be employed for screening of potential peptide or small molecule  

CC inhibitors of the relevant receptor/ligand interaction. Anti-PRO  

CC antibodies are useful for the affinity purification of PRO from  

CC recombinant cell culture or natural sources  

XX  

SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;  


```

Query Match 100.0%; Score 2284; DB 3; Length 2284;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 GCGGAGCATCCGCTGCGGTCTCTGCGGAGACCCCGCGGATTCGCGGTCTCCGC 60
Db 1 GCGGAGCATCCGCTGCGGTCTCTGCGGAGACCCCGCGGATTCGCGGTCTCCGC 60
QY 61 GGGCGGACAGAGCTGTCTCTGCACTGTGATGGCAGGCGCGGGTCTCTCGAC 120
Db 61 GGGCGGACAGAGCTGTCTCTGCACTGTGATGGCAGGCGCGGGTCTCTCGAC 120
QY 121 GCCAGAGAAATCTCATCTGTGCAAGCTTCTTAAGCAAACTAAGACGAGGAG 180
Db 121 GCCAGAGAAATCTCATCTGTGCAAGCTTCTTAAGCAAACTAAGACGAGGAG 180
QY 181 GATTAATCTTGACCTTGAAGCAAACTAAGTAAATTTAAATGTTCTTCGGGGA 240
Db 181 GATTAATCTTGACCTTGAAGCAAACTAAGTAAATTTAAATGTTCTTCGGGGA 240
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300
Db 241 GAAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300
QY 301 AGTCAGAAATGCTCTCAAAAGAGTCTAGAAGATGTTGATGATCCAGTCATCTCT 360
Db 301 AGTCAGAAATGCTCTCAAAAGAGTCTAGAAGATGTTGATGATCCAGTCATCTCT 360
QY 361 TCTAAGGAATCAGAGGCAATGAGCCGTATATACCTCAACTCAAGAAGACTGATTAAT 420
Db 361 TCTAAGGAATCAGAGGCAATGAGCCGTATATACCTCAACTCAAGAAGACTGATTAAT 420
QY 421 TCTTGCTGTCAACAAAAACATATCAGGGGACAAAGCATGTAATCTGATGATCTTGAC 480
Db 421 TCTTGCTGTCAACAAAAACATATCAGGGGACAAAGCATGTAATCTGATGATCTTGAC 480

```



Db 421 TCTTGCTGTTCAACAATAATATCAGGGGCAAAAGCATGTAACTGATGATCTTCGAC 480  
QY 481 ACTGAAAACAGCTAGACAAACCACTGCTACCTATTTTCTGTCCCAACGAGAAGCC 540  
Db 481 ACTGAAAACAGCTAGACAAACCACTGCTACCTATTTTCTGTCCCAACGAGAAGCC 540  
QY 541 TGTCCATTGAAACCAAGAAAAGGACTTATGAGTTACAGGATATTTACAGATTTTCCATCT 600  
Db 541 TGTCCATTGAAACCAAGAAAAGGACTTATGAGTTACAGGATATTTACAGATTTTCCATCT 600  
QY 601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 660  
Db 601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 660  
QY 661 TTTTACAAAGAGTCACTCCCTAGCCCATCATCACAGATTATTCAAAAGCCACCGAT 720  
Db 661 TTTTACAAAGAGTCACTCCCTAGCCCATCATCACAGATTATTCAAAAGCCACCGAT 720  
QY 721 ATCTCATGAGAGACACACTTCTCAGAAAGTTGGATCCTCAGATCAGCTGAGAAACTA 780  
Db 721 ATCTCATGAGAGACACACTTCTCAGAAAGTTGGATCCTCAGATCAGCTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATAAGAAAAGGCCATTCTCAG 840  
Db 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATAAGAAAAGGCCATTCTCAG 840  
QY 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCCGTAAGAAATGTAGTCCG 900  
Db 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCCGTAAGAAATGTAGTCCG 900  
QY 901 CTCCAGCTACGGGTGGCAAGTGTCTTCTCAATACCACTCGGCTACTCCAAAGCCCGCC 960  
Db 901 CTCCAGCTACGGGTGGCAAGTGTCTTCTCAATACCACTCGGCTACTCCAAAGCCCGCC 960  
QY 961 ACCCTTCAACCAATGCTTCAAGTACACCTTCTGGAGCTTCCAGCACAAGCTGGCC 1020  
Db 961 ACCCTTCAACCAATGCTTCAAGTACACCTTCTGGAGCTTCCAGCACAAGCTGGCC 1020  
QY 1021 ACCACAGCTCACTGTAAACCACTGTCACTTCAAGCTTCCAGCACAAGCTTCTTACA 1080  
Db 1021 ACCACAGCTCACTGTAAACCACTGTCACTTCAAGCTTCCAGCACAAGCTTCTTACA 1080  
QY 1081 GTTTTACACGGGCTGCGGCTACACTCCAGCAATGGCTACAACAGCAGTTCTGACTACC 1140  
Db 1081 GTTTTACACGGGCTGCGGCTACACTCCAGCAATGGCTACAACAGCAGTTCTGACTACC 1140  
QY 1141 ACCTTCAAGGCACTACGGACTCGAAAGGCACTTAAAGCAATACCGTTTACAGAAATC 1200  
Db 1141 ACCTTCAAGGCACTACGGACTCGAAAGGCACTTAAAGCAATACCGTTTACAGAAATC 1200  
QY 1201 TCCAACTTAACCTTGAACACAGGGAATGTATAACCTACTGCACTTCTATGTCAAT 1260  
Db 1201 TCCAACTTAACCTTGAACACAGGGAATGTATAACCTACTGCACTTCTATGTCAAT 1260  
QY 1261 GTGAGTCTTCACTATGAATAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGC 1320  
Db 1261 GTGAGTCTTCACTATGAATAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCCTCCAGGCACTGTTCAGAAAATCAAGCGCCCTTCCATTGAAAATGGCTT 1380  
Db 1321 AGTTCCTCCAGGCACTGTTCAGAAAATCAAGCGCCCTTCCATTGAAAATGGCTT 1380  
QY 1381 CTTATCGGGTCCCTGCTCTTTGTGTCTGTTCTGGTGATAGGCTCGTCTCTGGGT 1440  
Db 1381 CTTATCGGGTCCCTGCTCTTTGTGTCTGTTCTGGTGATAGGCTCGTCTCTGGGT 1440  
QY 1441 AGAATCCTTTGGAAATCACTCCGAGGAAACGTTACTCAAGACTGATTAATTGATCAAT 1500  
Db 1441 AGAATCCTTTGGAAATCACTCCGAGGAAACGTTACTCAAGACTGATTAATTGATCAAT 1500  
QY 1501 GGGATCTATGTGACATCTAAGGATGAACCTGGTGTCTTAAATTCATTAGTAACAG 1560  
Db 1501 GGGATCTATGTGACATCTAAGGATGAACCTGGTGTCTTAAATTCATTAGTAACAG 1560

QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTACAGAGGTTGTATTTTGA 1620  
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTACAGAGGTTGTATTTTGA 1620  
QY 1621 AGACAGAAAATGCCCCCTTCTGCTTCTCTTTTCTTTTGGAGACAGAGTCTTCTG 1680  
Db 1621 AGACAGAAAATGCCCCCTTCTGCTTCTCTTTTCTTTTGGAGACAGAGTCTTCTG 1680  
QY 1681 TTGCCAGGCTGAGTGCAGTAGCAGATCTCGGCTCTCACCGCAACCTCCGCTCTG 1740  
Db 1681 TTGCCAGGCTGAGTGCAGTAGCAGATCTCGGCTCTCACCGCAACCTCCGCTCTG 1740  
QY 1741 GTTCAAGGATTTCTCTGCTCAGCCTCTAAGTATCTGGGATTAACAGCATGTGCCACC 1800  
Db 1741 GTTCAAGGATTTCTCTGCTCAGCCTCTAAGTATCTGGGATTAACAGCATGTGCCACC 1800  
QY 1801 ACACCTGGGTGATTTTGTATTTTATAGTAGACAGGGGTTTCAACATGTTGTCAGGCTG 1860  
Db 1801 ACACCTGGGTGATTTTGTATTTTATAGTAGACAGGGGTTTCAACATGTTGTCAGGCTG 1860  
QY 1861 GTCTCAAACTCTGACCTAGTATCAACCTCTCGGCTCCCAAGTCTGGGATTACA 1920  
Db 1861 GTCTCAAACTCTGACCTAGTATCAACCTCTCGGCTCCCAAGTCTGGGATTACA 1920  
QY 1921 GGATGAGCCACACAGCTGGCCCCCTCTGTTTATGTTTGGTTTGAAGGAATGA 1980  
Db 1921 GGATGAGCCACACAGCTGGCCCCCTCTGTTTATGTTTGGTTTGAAGGAATGA 1980  
QY 1981 AGTGGAAACCAATTAGTAATTTGGTAACTGTCTCTAAATATAGCTAAACAA 2040  
Db 1981 AGTGGAAACCAATTAGTAATTTGGTAACTGTCTCTAAATATAGCTAAACAA 2040  
QY 2041 AGCTCTATGTAAGTAATTAAGTAATTTGCCATATAATTTCAAAATTCAGTGGCTT 2100  
Db 2041 AGCTCTATGTAAGTAATTAAGTAATTTGCCATATAATTTCAAAATTCAGTGGCTT 2100  
QY 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAAATTCATTCATTTGTTCCAGA 2160  
Db 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAAATTCATTCATTTGTTCCAGA 2160  
QY 2161 TAAATCACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGAGATTCT 2220  
Db 2161 TAAATCACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGAGATTCT 2220  
QY 2221 TTAATACTTATTCAGATGATGTTCTTCCAATTAAATATTTGAATTAATCTTTGTAC 2280  
Db 2221 TTAATACTTATTCAGATGATGTTCTTCCAATTAAATATTTGAATTAATCTTTGTAC 2280  
QY 2281 TCAA 2284  
Db 2281 TCAA 2284

RESULT 3  
AAF44268  
ID AAF44268 standard; cDNA; 2284 BP.  
XX  
AC AAF44268;  
XX  
DT 02-APR-2001 (first entry)  
XX  
DE Human PRO361 nucleotide sequence SEQ ID NO:514.  
XX  
KW Human; secreted and transmembrane protein; PRO; cytosolic; cell death;  
KW cancer; chromosomal mapping; gene mapping; tissue typing;  
KW diagnostic assay; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200073454-A1.  
XX  
PD 07-DEC-2000.



XX 30-MAR-2000; 2000WO-US008439.  
PF  
XX  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski PJ;  
PI Grimaldi CJ, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
XX WPI; 2001-032160/04.  
DR P-PSDB; AAB65299.  
DR  
XX  
PT PRO polynucleotides used to produce polypeptides used to target bioactive  
PT molecules such as toxins, radiolabels or antibodies, to specific cells,  
PT to cause targeted cell death.  
XX  
PS Claim 2, Fig 327; 935pp; English.  
XX

CC The present invention describes human secreted and transmembrane PRO  
CC proteins. The PRO proteins have cytostatic activity. The PRO proteins can  
CC be used for targeted delivery of bioactive molecules, such as toxins,  
CC radiolabels or antibodies, that cause cell death. PRO nucleotide  
CC sequences, and their fragments, can be used as hybridisation probes, in  
CC chromosomal and gene mapping, and in the generation of anti-sense RNA and  
CC DNA. They may also be used to produce transgenic animals which are used  
CC to develop and screen therapeutically useful reagents. The PRO nucleotide  
CC and protein sequence can be used for tissue typing and in treating  
CC cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to  
CC AAF44470 represent PCR primers and hybridisation probes used in the  
CC isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to  
CC AAB65300 represent human PRO polynucleotide and protein sequences given  
CC in the exemplification of the present invention  
XX

SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

Query Match 100.0%; Score 2284; DB 5; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GCGGAGCATCCGCTGCGGTCCTGCGGAGAACCCCGCGGATTCGCGGTCCTCCCGC 60  
DB 1 GCGGAGCATCCGCTGCGGTCCTGCGGAGAACCCCGCGGATTCGCGGTCCTCCCGC 60  
OY 61 GGGCGGCAAGAGCTGTCTCTGCGACCTGAGTGAGCAGCAGGGGGCGCGGCTCTCTGAC 120  
DB 61 GGGCGGCAAGAGCTGTCTCTGCGACCTGAGTGAGCAGCAGGGGGCGCGGCTCTCTGAC 120

OY 121 GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAAGCAAACTAAGACGAGGGAG 180  
DB 121 GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAAGCAAACTAAGACGAGGGAG 180  
OY 181 GATTATCCTTGACCTTTGAAGCAAACTAACTGAATTTAAATGTTCTCGGGGA 240  
DB 181 GATTATCCTTGACCTTTGAAGCAAACTAACTGAATTTAAATGTTCTCGGGGA 240  
OY 241 GAAGGAGCTTGACTTACCTTGTGTAATATTTGCTTCCCTGACACTAAGGCTGTGCT 300  
DB 241 GAAGGAGCTTGACTTACCTTGTGTAATATTTGCTTCCCTGACACTAAGGCTGTGCT 300  
OY 301 AGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTTGCAITTGACATCCAGTCTCTT 360  
DB 301 AGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTTGCAITTGACATCCAGTCTCTT 360  
OY 361 TCTAAGGAATCAGAGCAATGAGCCGCTATATATCTTCAACTCAAGAAGACTGCATTAAT 420  
DB 361 TCTAAGGAATCAGAGCAATGAGCCGCTATATATCTTCAACTCAAGAAGACTGCATTAAT 420  
OY 421 TCTGCTGTTCAACAAAAACATATCAGGGGCAAAAGCATGTAACTTGATGATCTTGAC 480  
DB 421 TCTGCTGTTCAACAAAAACATATCAGGGGCAAAAGCATGTAACTTGATGATCTTGAC 480  
OY 481 ACTCGAAAAACAGCTAGACCAACCAACTGCTACCTATTTTCTGTCGCCAACGAGAGCC 540  
DB 481 ACTCGAAAAACAGCTAGACCAACCAACTGCTACCTATTTTCTGTCGCCAACGAGAGCC 540  
OY 541 TGTCATTTGAAACAGCAAAAGAGCTATAGATTACAGATTAATTAAGATTTTCATCT 600  
DB 541 TGTCATTTGAAACAGCAAAAGAGCTATAGATTACAGATTAATTAAGATTTTCATCT 600  
OY 601 TTGACAGAAATTTGGCAAGCCAGAGATTACCCAGAGAAATTTCTCTTACATGAGCAA 660  
DB 601 TTGACAGAAATTTGGCAAGCCAGAGATTACCCAGAGAAATTTCTCTTACATGAGCAA 660  
OY 661 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACACAGATTAATCAAGCCACCGAT 720  
DB 661 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACACAGATTAATCAAGCCACCGAT 720  
OY 721 ATCTCATGAGAGACACACTTTCTCAGAAGTTTGATTCCTCATCACTGAGAACTA 780  
DB 721 ATCTCATGAGAGACACACTTTCTCAGAAGTTTGATTCCTCATCACTGAGAACTA 780  
OY 781 TTTAAGATGATGAAGCAAGTGCCAGCTCTTGCTTATTAAGAAAAAGCCATTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTGCCAGCTCTTGCTTATTAAGAAAAAGCCATTCTCAG 840  
OY 841 AGTTCAAAATTTCTCTGATCAGAATAAGCTCATCTGCTGCTGAAATGTGAGTGC 900  
DB 841 AGTTCAAAATTTCTCTGATCAGAATAAGCTCATCTGCTGCTGAAATGTGAGTGC 900  
OY 901 CTCCAGCTACGGTGCGAGTTGCTTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
DB 901 CTCCAGCTACGGTGCGAGTTGCTTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
OY 961 ACCCTTCAACCAATGCTTCAAGTGAACACTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
DB 961 ACCCTTCAACCAATGCTTCAAGTGAACACTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
OY 1021 ACCACAGCTCACTGTAAACCACTGTCACTTCTCAGGCTCCAGACCCCTCATTTCTACA 1080  
DB 1021 ACCACAGCTCACTGTAAACCACTGTCACTTCTCAGGCTCCAGACCCCTCATTTCTACA 1080  
OY 1081 GTTTTACACGGGCTGCGGCTCACTTCAAGCAATGCTTCAACAGCAGTTCGACTACC 1140  
DB 1081 GTTTTACACGGGCTGCGGCTCACTTCAAGCAATGCTTCAACAGCAGTTCGACTACC 1140  
OY 1141 ACCTTCAAGCAGCTACGAGCTGGAAGGAGAGCTTAGAAACCATACCGTTTACAGAAATC 1200  
DB 1141 ACCTTCAAGCAGCTACGAGCTGGAAGGAGAGCTTAGAAACCATACCGTTTACAGAAATC 1200

QY 1201 TCCAACTTAATTGGAACACAGGAATGTGTATAACCTACTGCACTTCTATGTCAAT 1260  
Db 1201 TCCAACTTAATTGGAACACAGGAATGTGTATAACCTACTGCACTTCTATGTCAAT 1260  
QY 1261 GTGAGTCTTCCACTATAGATAAACTGCTCTCGGGAAGTAGGAGGCCAGTCCAGGC 1320  
Db 1261 GTGAGTCTTCCACTATAGATAAACTGCTCTCGGGAAGTAGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
Db 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTATCGGTCCTGCTCTTTGGTGTCTGTCTCTGTGTATAGGCTCTGCTCTGGGT 1440  
Db 1381 CTATCGGTCCTGCTCTTTGGTGTCTGTCTCTGTGTATAGGCTCTGCTCTGGGT 1440  
QY 1441 AGAATCCTTCGGAATCACTCCGAGAAAAGTCTCAAGACTGATTAATTGATCAAT 1500  
Db 1441 AGAATCCTTCGGAATCACTCCGAGAAAAGTCTCAAGACTGATTAATTGATCAAT 1500  
QY 1501 GGGATCTATGTGACATCTAAGATGGAATCGGTGTCTTAATTCATTAGTAACCA 1560  
Db 1501 GGGATCTATGTGACATCTAAGATGGAATCGGTGTCTTAATTCATTAGTAACCA 1560  
QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGTAGTCTTAGCAGAGGTGTATTGTA 1620  
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGTAGTCTTAGCAGAGGTGTATTGTA 1620  
QY 1621 AGACAGGAAAATGCCCTTCTGCTTCTTTTTTTGGAGACAGAGTCTGCTCTG 1680  
Db 1621 AGACAGGAAAATGCCCTTCTGCTTCTTTTTTTGGAGACAGAGTCTGCTCTG 1680  
QY 1681 TTGCCCAGGCTGGAGTGCAGTAGACAGATCTGGCTCTCACCGCAACTCGTCTCTGG 1740  
Db 1681 TTGCCCAGGCTGGAGTGCAGTAGACAGATCTGGCTCTCACCGCAACTCGTCTCTGG 1740  
QY 1741 GTTCAAGCGATTCTCTGCTCAGCCTCTCAAGTATCTGGATTACAGGCATGTGCCACC 1800  
Db 1741 GTTCAAGCGATTCTCTGCTCAGCCTCTCAAGTATCTGGATTACAGGCATGTGCCACC 1800  
QY 1801 ACACCTGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTGTGTCAGGCTG 1860  
Db 1801 ACACCTGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTGTGTCAGGCTG 1860  
QY 1861 GTCTCAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAGTGTGGATTACA 1920  
Db 1861 GTCTCAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAGTGTGGATTACA 1920  
QY 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTATTTATGTTTGTGAGAGGAATGA 1980  
Db 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTATTTATGTTTGTGAGAGGAATGA 1980  
QY 1981 AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTTAAATATTAGCTAAACA 2040  
Db 1981 AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTTAAATATTAGCTAAACA 2040  
QY 2041 AGCTCTATGTAAAGTAATAAGTATAATGCCATATAAATTCAAAATCAACTGGCTTT 2100  
Db 2041 AGCTCTATGTAAAGTAATAAGTATAATGCCATATAAATTCAAAATCAACTGGCTTT 2100  
QY 2101 TATGCAAGAAACAGGTTAGGACATCTAGTTCCAATTCAATTCATCTTGGTCCAGA 2160  
Db 2101 TATGCAAGAAACAGGTTAGGACATCTAGTTCCAATTCAATTCATCTTGGTCCAGA 2160  
QY 2161 TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTTATATATGATTCCT 2220  
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTTATATATGATTCCT 2220  
QY 2221 TTAAACTTATTCAGATGTAGTCTTCCAAATTAATATTTGAATAAATCTTTGTTAC 2280  
Db 2221 TTAAACTTATTCAGATGTAGTCTTCCAAATTAATATTTGAATAAATCTTTGTTAC 2280  
QY 2281 TCAA 2284

Db 2281 TCAA 2284  
RESULT 4  
ABX75504  
ID ABX75504 standard; cDNA; 2284 BP.  
XX  
AC ABX75504;  
XX  
DT 26-MAR-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein PRO361 cDNA.  
XX  
KW Human; ss; gene; PRO; secreted protein; transmembrane protein; anti-HIV;  
KW cytosolic; antiarteriosclerotic; antiinflammatory; antidiabetic;  
KW cardiatic; AIDS; acquired immunodeficiency syndrome; cancer;  
KW atherosclerosis; inflammatory disease; diabetic complication;  
KW cardiac injury; organ failure.  
XX  
OS Homo sapiens.  
XX  
PN US2002142959-A1.  
XX  
PD 03-OCT-2002.  
PF 31-AUG-2001; 2001US-00944654.  
XX  
PR 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Eaton DL, Ferrara N, Flivaroff E;  
PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kijavyn IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX  
DR WPI; 2003-174141/17.  
DR P-PSDB; ABUS5934.  
XX  
PT New isolated PRO polypeptide and encoding nucleic acid, useful for the  
PT diagnosis and treatment of disorders associated with the PRO polypeptide,  
PT such as AIDS, cancer, atherosclerosis, inflammatory disease and diabetes.  
XX  
PS Claim 2; Fig 31; 178bp; English.  
XX  
CC The invention relates to an isolated PRO polypeptide (a secreted or  
CC transmembrane protein) comprising: (a) at least 80% sequence identity or  
CC positives when compared to any of 15 sequences, fully defined in the  
CC specification, lacking or with its associated signal peptide; or (b) at  
CC least 80% sequence identity to a sequence encoded by the full-length  
CC coding sequence of a DNA deposited in the American Type Culture  
CC Collection (ATCC). Also included are: (1) an isolated nucleic acid  
CC comprising: (a) at least 80% sequence identity to a nucleotide sequence  
CC that encodes a PRO protein; (b) at least 80% sequence identity to a  
CC nucleotide sequence of full-length coding sequence with any of 15 fully  
CC defined sequences of 957-3441 base pairs, given in the specification; or  
CC (c) at least 80% sequence identity to a full-length coding sequence of a

CC DNA deposited under ATCC Accession No. 209526, 209508, 209524, 209528,  
CC 209530, 209523, 209492, 209532, 209531, 209529, 209527, 209570, 209618,  
CC 209621 or 209619; (2) a vector comprising the nucleic acid; (3) a host  
CC cell comprising the vector which, when cultured under conditions suitable  
CC for expression of the PRO polypeptide, produces the PRO protein; (4) a  
CC chimeric molecule comprising PRO fused to a heterologous amino acid  
CC sequence; and (5) an anti-PRO antibody. The methods and compositions of  
CC the present invention are useful for the diagnosis and treatment of  
CC disorders associated with the PRO polypeptide, such as AIDS (acquired  
CC immunodeficiency syndrome), cancer, atherosclerosis, inflammatory  
CC disease, diabetic complications, cardiac injury and organ failure. The  
CC antibodies can also be used in the different screening, therapeutic and  
CC biological assays. The present sequence is the cDNA encoding a PRO  
CC protein  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGCATCCGCTGCGGTCTCGCGAGACCCCGCGGATTCGCCGCTTCCGCGC 60  
DB 1 GCGGAGCATCCGCTGCGGTCTCGCGAGACCCCGCGGATTCGCCGCTTCCGCGC 60  
QY 61 GGGCGCGACAGAGCTGTCTCGCACTGTGATGGCAGCAGGGCGCGGGTCTCTGCAC 120  
DB 61 GGGCGCGACAGAGCTGTCTCGCACTGTGATGGCAGCAGGGCGCGGGTCTCTGCAC 120  
QY 121 GCCAGAGAGAAATCTCATCTGTCAGACCTTCTTAAGCAAACTAAGACCAAGGAG 180  
DB 121 GCCAGAGAGAAATCTCATCTGTCAGACCTTCTTAAGCAAACTAAGACCAAGGAG 180  
QY 181 GATTATCTTGACCTTGAAGACCAAACTAAATTTAAATGTTCTTCGGGGA 240  
DB 181 GATTATCTTGACCTTGAAGACCAAACTAAATTTAAATGTTCTTCGGGGA 240  
QY 241 GAAGGAGCTTGACTTACACTTGTGTAATTTGCTTCTGACACTAAGGCTGTGCT 300  
DB 241 GAAGGAGCTTGACTTACACTTGTGTAATTTGCTTCTGACACTAAGGCTGTGCT 300  
QY 301 AGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTGTCAATTGACATCCAGTCATCTT 360  
DB 301 AGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTGTCAATTGACATCCAGTCATCTT 360  
QY 361 TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTCACTCAAGAAAGCTGCATTAAT 420  
DB 361 TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTCACTCAAGAAAGCTGCATTAAT 420  
QY 421 TCTGCTGTTCACAAAAAAATATCAGGGGACAAAGCATGTAATTGATGATCTTGAC 480  
DB 421 TCTGCTGTTCACAAAAAAATATCAGGGGACAAAGCATGTAATTGATGATCTTGAC 480  
QY 481 ACTGAAAAACAGCTAGACCACTGCTACCTATTTCTGTCCCAAGAGAGGCC 540  
DB 481 ACTGAAAAACAGCTAGACCACTGCTACCTATTTCTGTCCCAAGAGAGGCC 540  
QY 541 TGTCCATTGAAACCAAGCAAGACTTATGAGTTACAGGATTAATTACAGATTTCCATCT 600  
DB 541 TGTCCATTGAAACCAAGCAAGACTTATGAGTTACAGGATTAATTACAGATTTCCATCT 600  
QY 601 TTGACCAAGAAATTTGCCAAGCCAGAAGTTACCCCAAGAAAGTTCTCTTACATGGCCA 660  
DB 601 TTGACCAAGAAATTTGCCAAGCCAGAAGTTACCCCAAGAAAGTTCTCTTACATGGCCA 660  
QY 661 TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTAATTCAAAAGCCACCGAT 720  
DB 661 TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTAATTCAAAAGCCACCGAT 720  
QY 721 ATCTCATGAGAGACACACTTCTCAGAAGTTTGATCCTGAGATCACTGAGAAACTA 780  
DB 721 ATCTCATGAGAGACACACTTCTCAGAAGTTTGATCCTGAGATCACTGAGAAACTA 780

QY 781 TTTAAGATGATGAAGCAAGTCCCAAGCTCTGCTTATTAAGAAAAAGGCCATTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTCCCAAGCTCTGCTTATTAAGAAAAAGGCCATTCTCAG 840  
QY 841 AGTTCACAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGATGCG 900  
DB 841 AGTTCACAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGATGCG 900  
QY 901 CTCACAGCTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCC 960  
DB 901 CTCACAGCTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCC 960  
QY 961 ACCCTTCTACCCCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
DB 961 ACCCTTCTACCCCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
QY 1021 ACCACAGCTCCACCTGTATACCACTGTCACTTCTCAGCCTCCCAAGCCTCATTTCTACA 1080  
DB 1021 ACCACAGCTCCACCTGTATACCACTGTCACTTCTCAGCCTCCCAAGCCTCATTTCTACA 1080  
QY 1081 GTTTTTCACAGGGCTGCGGCTACACTCCAAAGCAATGGCTACAAAGAGATTCTGACTACC 1140  
DB 1081 GTTTTTCACAGGGCTGCGGCTACACTCCAAAGCAATGGCTACAAAGAGATTCTGACTACC 1140  
QY 1141 ACCTTTCAGGACCTACGCACTGAAAGGACGCTTAGAAACCATACCGTTACAGAAATC 1200  
DB 1141 ACCTTTCAGGACCTACGCACTGAAAGGACGCTTAGAAACCATACCGTTACAGAAATC 1200  
QY 1201 TCCAACTTAACCTTGAACACAGGGAATGTGATATAACCTTACACTTCTATGTCAAT 1260  
DB 1201 TCCAACTTAACCTTGAACACAGGGAATGTGATATAACCTTACACTTCTATGTCAAT 1260  
QY 1261 GTGAGTCTTCCACTATGATAATAAAGTCTTCTGGAAGTAGGAGGCCAGTCCAGGC 1320  
DB 1261 GTGAGTCTTCCACTATGATAATAAAGTCTTCTGGAAGTAGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCCTCCAGGAGGAGTGTCCAGAAATCAGTACGGCTTCCATTGAAAAATGGCTT 1380  
DB 1321 AGTTCCTCCAGGAGGAGTGTCCAGAAATCAGTACGGCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTATTCGGGTCCCTGCTCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1440  
DB 1381 CTATTCGGGTCCCTGCTCTTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1440  
QY 1441 AGAATCCTTTCGAATCACTCCGACAGAAACGTTACTCAAGACTGATTATTGATCAAT 1500  
DB 1441 AGAATCCTTTCGAATCACTCCGACAGAAACGTTACTCAAGACTGATTATTGATCAAT 1500  
QY 1501 GGGATCTATGTGACATCTAAGGATGGAATCGGTCTCTTAATTCAATTAGTAACGAG 1560  
DB 1501 GGGATCTATGTGACATCTAAGGATGGAATCGGTCTCTTAATTCAATTAGTAACGAG 1560  
QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGCTTTAGCAGAGAGTTGATTTGA 1620  
DB 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGCTTTAGCAGAGAGTTGATTTGA 1620  
QY 1621 AAGCAGAAATGCCCCCTTCTGCTTCTCTTTTGGAGACAGAGTCTTGCTCTG 1680  
DB 1621 AAGCAGAAATGCCCCCTTCTGCTTCTCTTTTGGAGACAGAGTCTTGCTCTG 1680  
QY 1681 TTGCCAGGCTGAGTGAAGTAGACAGATCTCGGCTCTCACCGCAACCTCGTCTCTG 1740  
DB 1681 TTGCCAGGCTGAGTGAAGTAGACAGATCTCGGCTCTCACCGCAACCTCGTCTCTG 1740  
QY 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGATGTGCCACC 1800  
DB 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGATGTGCCACC 1800  
QY 1801 ACACTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACCATGTTGGTCAAGCTG 1860  
DB 1801 ACACTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACCATGTTGGTCAAGCTG 1860  
QY 1861 GTCTCAAACCTCTGACCTAGTATCCACCCTCTCTGGCTCCCAAAGTGTGGGATTACA 1920



Db 1861 GTCTCAAACTCTGACCTAGTATCCACCTCTCGGCCCTCCCAAGTGTGGATTACA 1920  
Qy 1921 GGCATGAGCCACCACTGCCCCCTTCTGTTTATGTTGTTTGAAGAATGA 1980  
Db 1921 GGCATGAGCCACCACTGCCCCCTTCTGTTTATGTTGTTTGAAGAATGA 1980  
Qy 1981 AGTGGAAACCAATTAGTAATTTGGGTAATCTGCTCTAAATAATTAGCTAAACA 2040  
Db 1981 AGTGGAAACCAATTAGTAATTTGGGTAATCTGCTCTAAATAATTAGCTAAACA 2040  
Qy 2041 AGCTCTATGTAAAGTAATAAGTATGCGCATATAATTCCAATTCACACTGGCTTT 2100  
Db 2041 AGCTCTATGTAAAGTAATAAGTATGCGCATATAATTCCAATTCACACTGGCTTT 2100  
Qy 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAATTCATTCACTTGTGTCAGA 2160  
Db 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAATTCATTCACTTGTGTCAGA 2160  
Qy 2161 TAAATCAACTGTTTATATCAATTTCTAAATGATTTGCTTTCTTTTATATGATTCCT 2220  
Db 2161 TAAATCAACTGTTTATATCAATTTCTAAATGATTTGCTTTCTTTTATATGATTCCT 2220  
Qy 2221 TTAATACTTAATCCAGATGTAGTCTCTTCCAATTAATATTTGAATAATCTTTGTAC 2280  
Db 2221 TTAATACTTAATCCAGATGTAGTCTCTTCCAATTAATATTTGAATAATCTTTGTAC 2280  
Qy 2281 TCAA 2284  
Db 2281 TCAA 2284

RESULT 5

ABX78062  
ID ABX78062 standard; cDNA; 2284 BP.

XX ABX78062;

XX 14-APR-2003 (first entry)

DE Human PRO polynucleotide #146.

XX Human; PRO; gene; ss; cytostatic; tumour; cancer; breast; lung; stomach;  
KW liver; horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;  
KW antibody-dependent enzyme mediated prodnrg therapy.

OS Homo sapiens.

XX US2003027163-A1.

XX 06-FEB-2003.

PF 15-NOV-2001; 2001US-00997666.

XX 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.

PR	04-AUG-1998;	98US-0095285P.
PR	04-AUG-1998;	98US-0095303P.
PR	04-AUG-1998;	98US-0095302P.
PR	04-AUG-1998;	98US-0095318P.
PR	04-AUG-1998;	98US-0095321P.
PR	04-AUG-1998;	98US-0095325P.
PR	10-AUG-1998;	98US-0095916P.
PR	10-AUG-1998;	98US-0095929P.
PR	10-AUG-1998;	98US-0096012P.
PR	11-AUG-1998;	98US-0096143P.
PR	11-AUG-1998;	98US-0096149P.
PR	12-AUG-1998;	98US-0096312P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096768P.
PR	17-AUG-1998;	98US-0096773P.
PR	17-AUG-1998;	98US-0096791P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096895P.
PR	17-AUG-1998;	98US-0096899P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096950P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0096960P.
PR	18-AUG-1998;	98US-0097022P.
PR	19-AUG-1998;	98US-0097141P.
PR	20-AUG-1998;	98US-0097218P.
PR	24-AUG-1998;	98US-0097651P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0097978P.
PR	26-AUG-1998;	98US-0097979P.
PR	26-AUG-1998;	98US-0097986P.
PR	26-AUG-1998;	98US-0098014P.
PR	31-AUG-1998;	98US-0098525P.
PR	16-SEP-1998;	98US-0100634P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100858P.
PR	17-SEP-1998;	98WO-US019437.
PR	07-OCT-1998;	98WO-US021141.
PR	01-DEC-1998;	98WO-US025108.
PR	22-DEC-1998;	98US-0113296P.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	12-MAR-1999;	99US-0123957P.
PR	02-JUN-1999;	99WO-US012252.
PR	23-JUN-1999;	99US-0141037P.
PR	07-JUL-1999;	99US-0143048P.
PR	20-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	99US-0145698P.
PR	28-JUL-1999;	99US-0146222P.
PR	17-AUG-1999;	99US-0149396P.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	08-OCT-1999;	99US-0158663P.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	06-JAN-2000;	2000WO-US0000376.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003365.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.

PR	10-MAR-2000;	2000OWO-US006319.
PR	15-MAR-2000;	2000OWO-US006884.
PR	20-MAR-2000;	2000OWO-US007377.
PR	30-MAR-2000;	2000OWO-US008439.
PR	15-MAY-2000;	2000OWO-US013358.
PR	17-MAY-2000;	2000OWO-US013705.
PR	22-MAY-2000;	2000OWO-US014042.
PR	30-MAY-2000;	2000OWO-US014941.
PR	02-JUN-2000;	2000OWO-US015264.
PR	23-JUN-2000;	2000US-0213637P.
PR	28-JUL-2000;	2000OWO-US020710.
PR	11-AUG-2000;	2000OWO-US022031.
PR	23-AUG-2000;	2000OWO-US023522.
PR	24-AUG-2000;	2000OWO-US023328.
PR	07-SEP-2000;	2000US-0230978P.

Query Match	100.0%;	Score 2284;	DB 7;	Length 2284;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 2284; Conservative	0;	Mismatches	0;	Indels 0; Gaps 0;

QY	1	GGGGAGCATCCGCTGCGGTCTCTGCGCCGAGACCCCCGCGCGATTGCGCCGCTCTTCCGC	60
Db	1	GGGGAGCATCCGCTGCGGTCTCTGCGAGACCCCCGCGGATTGCGCGTCTTCCGC	60
QY	61	GGGCGCAGACAGAGCTGTCTCTGCACTTGATGGCAGAGGGCGCGGGTCTCTCGAC	120
Db	61	GGGCGCAGACAGAGCTGTCTCTGCACTTGATGGCAGAGGGCGCGGGTCTCTCGAC	120
QY	121	GCCAGAGAAATCTCATCTCTGTCAGCCTTCTTAAAGCAACTAAGCCAGAGGAG	180
Db	121	GCCAGAGAAATCTCATCTCTGTCAGCCTTCTTAAAGCAACTAAGCCAGAGGAG	180
QY	181	GATTATCCTTGACCTTTGAAGACCAAACTAACTGAAATTTAAATGTCTTCGGGGA	240
Db	181	GATTATCCTTGACCTTTGAAGACCAAACTAACTGAAATTTAAATGTCTTCGGGGA	240
QY	241	GAAGGAGCTTGACTTACACTTTGTAATATTGCTTCTGACACTAAGGCTGTGCT	300
Db	241	GAAGGAGCTTGACTTACACTTTGTAATATTGCTTCTGACACTAAGGCTGTGCT	300
QY	301	AGTCAGATTGCCTCAAAAAGTCTAGAAGATGTTGTCATTGACATCCAGTCCTT	360
Db	301	AGTCAGATTGCCTCAAAAAGTCTAGAAGATGTTGTCATTGACATCCAGTCCTT	360
QY	361	TCTAAGGGAATCAGAGGCAATGAGCCCCGTATATCTTCAACTCAGAGAAGCTGCATTAAT	420
Db	361	TCTAAGGGAATCAGAGGCAATGAGCCCCGTATATCTTCAACTCAGAGAAGCTGCATTAAT	420
QY	421	TCTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC	480
Db	421	TCTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC	480
QY	481	ACTCGAAAAACAGCTAGACAACCAACTGCTACTATTTTCTGTCCAAAGGAAGCC	540
Db	481	ACTCGAAAAACAGCTAGACAACCAACTGCTACTATTTTCTGTCCAAAGGAAGCC	540
QY	541	TGTCCATTGAAACCAAGCAAAAGGACTTATGAGTTACAGGATAATTACAGATTTTCCATCT	600
Db	541	TGTCCATTGAAACCAAGCAAAAGGACTTATGAGTTACAGGATAATTACAGATTTTCCATCT	600
QY	601	TTGACCAAGAAATTTGCCAAGCCAAGAGTTACCCCAAGAAAGATTCTCTTACATGGCCAA	660
Db	601	TTGACCAAGAAATTTGCCAAGCCAAGAGTTACCCCAAGAAAGATTCTCTTACATGGCCAA	660
QY	661	TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTAATCAAAAGCCACCGAT	720
Db	661	TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTAATCAAAAGCCACCGAT	720
QY	721	ATCTCATGAGAGACACACTTTCTCAGAAAGTTGGATCCTCAGATCACTGAGAAACTA	780
Db	721	ATCTCATGAGAGACACACTTTCTCAGAAAGTTGGATCCTCAGATCACTGAGAAACTA	780
QY	781	TTTAAGATGATGAAGCAAGTGCACAGCTCCTTGCTTATAAGAAAAAGCCATTCTCAG	840

Db 781 |||||TTTAAGATGATGAAGCAAGTGCACAGCTCTGCTTATAGGAAAAAGCCATTCTCAG 840  
Qy 841 AGTTCACAAATTTCTCTGTATCAGAAATAGCTCATCTGTGCTGAAATGTGAGTGC 900  
Db 841 AGTTCACAAATTTCTCTGTATCAGAAATAGCTCATCTGTGCTGAAATGTGAGTGC 900  
Qy 901 CTCCAGCTACGGGTGGCAGTGTCTTCCACATACCACCTCGGCTACTCCAAAGCCGCC 960  
Db 901 CTCCAGCTACGGGTGGCAGTGTCTTCCACATACCACCTCGGCTACTCCAAAGCCGCC 960  
Qy 961 ACCCTTCTACCCACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGCC 1020  
Db 961 ACCCTTCTACCCACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGCC 1020  
Qy 1021 ACCACAGCTCCACCTGTATAACCACTGTCACTTCTCAGCCTCCACGACCTCATTTCTACA 1080  
Db 1021 ACCACAGCTCCACCTGTATAACCACTGTCACTTCTCAGCCTCCACGACCTCATTTCTACA 1080  
Qy 1081 GTTTTACACGGGCTCGGGCTACACTCCAGCAATGGCTACAAACAGCAGTTCTGACTACC 1140  
Db 1081 GTTTTACACGGGCTCGGGCTACACTCCAGCAATGGCTACAAACAGCAGTTCTGACTACC 1140  
Qy 1141 ACCTTTCAGGCACTACCGGACTCGAAAGGAGCTTAGAAACCATACCGTTTACAGAAATC 1200  
Db 1141 ACCTTTCAGGCACTACCGGACTCGAAAGGAGCTTAGAAACCATACCGTTTACAGAAATC 1200  
Qy 1201 TCCAACTTAATTGAAACACAGGGAATGTATTAACCTACTGCACTTCTATGTCAAAAT 1260  
Db 1201 TCCAACTTAATTGAAACACAGGGAATGTATTAACCTACTGCACTTCTATGTCAAAAT 1260  
Qy 1261 GTGAGTCTTCCACTATGATAAATCTGCTCTGGGAGGTAGGGGCCAGTCCAGGC 1320  
Db 1261 GTGAGTCTTCCACTATGATAAATCTGCTCTGGGAGGTAGGGGCCAGTCCAGGC 1320  
Qy 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
Db 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
Qy 1381 CTTATCGGGTCTGCTCTTTGGTGTCTGTCTCTGTGATAGGCTGCTCCTGGGT 1440  
Db 1381 CTTATCGGGTCTGCTCTTTGGTGTCTGTCTGTGATAGGCTGCTCCTGGGT 1440  
Qy 1441 AGAATCCTTTCGGAATCACTCCGAGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
Db 1441 AGAATCCTTTCGGAATCACTCCGAGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
Qy 1501 GGGATCTATGTGACATCTAAGGATGAACCTGGTCTCTTAATTCAATTAGTAACAG 1560  
Db 1501 GGGATCTATGTGACATCTAAGGATGAACCTGGTCTCTTAATTCAATTAGTAACAG 1560  
Qy 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGCTTAGCAGAGGTGTATTTGA 1620  
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGCTTAGCAGAGGTGTATTTGA 1620  
Qy 1621 AGACAGGAAAAATGCCCCCTTCTGCTTTCTTTTGGAGACAGAGTCTGCTCTG 1680  
Db 1621 AGACAGGAAAAATGCCCCCTTCTGCTTTCTTTTGGAGACAGAGTCTGCTCTG 1680  
Qy 1681 TTGCCCAGGCTGGAGTGACAGTACGATCTCGGCTCTCACCGCAACCTTCGCTCCTGG 1740  
Db 1681 TTGCCCAGGCTGGAGTGACAGTACGATCTCGGCTCTCACCGCAACCTTCGCTCCTGG 1740  
Qy 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGATGTGCCACC 1800  
Db 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGATGTGCCACC 1800  
Qy 1801 ACACCTGGGTGATTTTGTATTTTATAGTAGACGGGGTTTCAACCATGTGTGAGGCTG 1860  
Db 1801 ACACCTGGGTGATTTTGTATTTTATAGTAGACGGGGTTTCAACCATGTGTGAGGCTG 1860  
Qy 1861 GTCTCAAACCTCTGACCTAGTATCCACCCTCTCGGCTCTCCAAAGTGTGGGATTACA 1920  
Db 1861 GTCTCAAACCTCTGACCTAGTATCCACCCTCTCGGCTCTCCAAAGTGTGGGATTACA 1920

Db 1861 GTCTCAAACCTCTGACCTAGTATCCACCCTCTCGGCTCTCCAAAGTGTGGATTACA 1920  
Qy 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTTTGGAGAAGGAATGA 1980  
Db 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTTTGGAGAAGGAATGA 1980  
Qy 1981 AGTGGGAACCAATTAGTAATTTGGGTAATCTGTCTGTAATAATATAGCTAAAAACAA 2040  
Db 1981 AGTGGGAACCAATTAGTAATTTGGGTAATCTGTCTGTAATAATATAGCTAAAAACAA 2040  
Qy 2041 AGCTCTATGTAAAGTAAATAGTAAATTTGCCATATAAATTTCAAAATTCAACTGGCTTT 2100  
Db 2041 AGCTCTATGTAAAGTAAATAGTAAATTTGCCATATAAATTTCAAAATTCAACTGGCTTT 2100  
Qy 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAATTCAATTCATTTCTGTTCCAGA 2160  
Db 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAATTCAATTCATTTCTGTTCCAGA 2160  
Qy 2161 TAAATCAACTGTTTATATCAATTTCTAATGGATTGCTTTCTTTTATATGATTCCT 2220  
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGGATTGCTTTCTTTTATATGATTCCT 2220  
Qy 2221 TTAATACTTATTCAGATGATGTTCTTCCAATTAATAATTTGAATAAATCTTTGTATAC 2280  
Db 2221 TTAATACTTATTCAGATGATGTTCTTCCAATTAATAATTTGAATAAATCTTTGTATAC 2280  
Qy 2281 TCAG 2284  
Db 2281 TCAG 2284  
RESULT 6  
ABX80474  
ID ABX80474 standard; DNA; 2284 BP.  
XX  
AC ABX80474;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Novel human secreted or transmembrane protein PRO846 DNA.  
XX  
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
cardiac insufficiency disorder; cancer; tumour; immune response;  
adrenal cortical capillary endothelial growth; c-fos induction;  
vascular endothelial growth factor inhibition; VEGF inhibition;  
endothelial cell growth inhibitor; T-lymphocyte stimulation;  
retinal neurons cell survival; rod photoreceptor cell survival;  
retinal disorder; retinitis pigmentosa; kidney disease;  
mammalian kidney mesangial cell proliferation; Berger disease;  
dermatitis; herpesiformis; Crohn's disease; chondrocyte proliferation;  
chondrocyte redifferentiation; sports injury; arthritis; gene; ds.  
XX  
OS Homo sapiens.  
XX  
PN US2002132252-A1.  
XX  
PD 19-SEP-2002.  
XX  
PF 14-NOV-2001; 2001US-00990442.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97MO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.



PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.

PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin LJ, Napier MA, Pan J, Paoni NP;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
DR WPI; 2003-247083/24.  
DR P-PSDB; ABUS9193.  
XX  
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346  
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
PT are therapeutically useful for enhancing immune response and in cancer  
PT treatments.  
XX  
XX  
PS Claim 2; Fig 329; 648bp; English.  
XX  
CC The invention describes an isolated human PRO polypeptide. The PRO  
CC polypeptides are useful in detecting PRO polypeptides in a sample, in  
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
CC in modulating at least one biological activity of a cell expressing a PRO  
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
CC useful for treating cardiac insufficiency disorders. PRO154 and PRO1186  
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,  
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,  
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus  
CC useful for treating conditions or disorders where angiogenesis would be  
CC beneficial, e.g. wound healing and antagonist of this polypeptide are  
CC useful for treating cancerous tumours. PRO812 inhibits vascular  
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial  
CC cells and is thus useful for inhibiting endothelial cell growth in  
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,  
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of  
CC stimulated T-lymphocytes and are therapeutically useful for enhancing  
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of  
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of  
CC rod photoreceptor cells) and therefore are useful for treating retinal  
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813  
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,  
CC and therefore are useful for treating kidney disorders associated with  
CC decreased mesangial cell function such as Berger disease or other  
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's  
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the  
CC proliferation and/or redifferentiation of chondrocytes in culture and are  
CC thus useful for treating sports injuries, and arthritis. This sequence  
CC represents a novel human PRO protein polynucleotide  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;  
  
Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGAGATTGCGCGTCTCCGCG 60  
DB 1 GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGAGATTGCGCGTCTCCGCG 60  
  
QY 61 GGGCGGACAGAGCTGTCTCTGCACTGATGCGACGAGGGCGCGGGTCTCTGCAC 120  
DB 61 GGGCGGACAGAGCTGTCTCTGCACTGATGCGACGAGGGCGCGGGTCTCTGCAC 120  
  
QY 121 GCCAGAGAGAAATCTCATCTGTGACAGCCTTCTTAAAGCAAATAAGACCAAGAGGAG 180  
DB 121 GCCAGAGAGAAATCTCATCTGTGACAGCCTTCTTAAAGCAAATAAGACCAAGAGGAG 180

QY	181	GATTATCCTTGACCTTTGGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA	240
Db	181	GATTATCCTTGACCTTTGGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA	240
QY	241	GAAGGAGCTTGACTTACACTTTGGTAATTAATTGGCTTCCTGACACTAAGGCTGTCGCT	300
Db	241	GAAGGAGCTTGACTTACACTTTGGTAATTAATTGGCTTCCTGACACTAAGGCTGTCGCT	300
QY	301	AGTCAGAAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATCCAGTCACTCTT	360
Db	301	AGTCAGAAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATCCAGTCACTCTT	360
QY	361	TCTAAGGGAATCAGAGGCAATGAGCCCCGTATATATTCTCAACTCAAGAAAGCTGCATTAA	420
Db	361	TCTAAGGGAATCAGAGGCAATGAGCCCCGTATATATTCTCAACTCAAGAAAGCTGCATTAA	420
QY	421	TCTTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC	480
Db	421	TCTTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC	480
QY	481	ACTCGAAAAACAGCTAGACAAACCAACTGCTACCTATTTTCTGTCCCAACGAGAAAGCC	540
Db	481	ACTCGAAAAACAGCTAGACAAACCAACTGCTACCTATTTTCTGTCCCAACGAGAAAGCC	540
QY	541	TGTCATTGAAAACAGCAAAAGAACTTATGAGTTACAGGATTAATTACAGATTTTCCACT	600
Db	541	TGTCATTGAAAACAGCAAAAGAACTTATGAGTTACAGGATTAATTACAGATTTTCCACT	600
QY	601	TTGACCAAGAAATTTGCCAAGCCAAAGAGTTACCCCAAGAGATTCTCTTTACATGSCCA	660
Db	601	TTGACCAAGAAATTTGCCAAGCCAAAGAGTTACCCCAAGAGATTCTCTTTACATGSCCA	660
QY	661	TTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACAGATTATTCAAAGCCCAACGAT	720
Db	661	TTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACAGATTATTCAAAGCCCAACGAT	720
QY	721	ATCTCATGGAGAGACACACTTCTCAGAAGTTGGATCCTCAGATCACCTGAGAAACTA	780
Db	721	ATCTCATGGAGAGACACACTTCTCAGAAGTTGGATCCTCAGATCACCTGAGAAACTA	780
QY	781	TTTAAAGATGATGAAGCAAGTGCCTCAGCTCCTTGCTTAAGAAGAAAGGCCATTCTCAG	840
Db	781	TTTAAAGATGATGAAGCAAGTGCCTCAGCTCCTTGCTTAAGAAGAAAGGCCATTCTCAG	840
QY	841	AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG	900
Db	841	AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG	900
QY	901	CTCCAGCTACGGTGGCAGTTCCTTCTCCACATACACACTCGGCTACTCCAAAGCCGCC	960
Db	901	CTCCAGCTACGGTGGCAGTTCCTTCTCCACATACACACTCGGCTACTCCAAAGCCGCC	960
QY	961	ACCCTTCTACCCACCAATGCTTACGTACACACACTTCTGGAATTTCCACGCCACAGCTGGCC	1020
Db	961	ACCCTTCTACCCACCAATGCTTACGTACACACACTTCTGGAATTTCCACGCCACAGCTGGCC	1020
QY	1021	ACCACAGCTCCACCTGTAAACACTGTCACTTCTCAGCTCCCAAGACCTCATTTCTACA	1080
Db	1021	ACCACAGCTCCACCTGTAAACACTGTCACTTCTCAGCTCCCAAGACCTCATTTCTACA	1080
QY	1081	GTTTTTACACGGGCTGCGGCTACACTCCAAAGCAATGGCTACAACAGCAGTTCTGACTACC	1140
Db	1081	GTTTTTACACGGGCTGCGGCTACACTCCAAAGCAATGGCTACAACAGCAGTTCTGACTACC	1140
QY	1141	ACCTTTACAGGACCTACGACTCGAAAGGACGCTTAGAAACCATATACCGTTTACAGAAATC	1200
Db	1141	ACCTTTACAGGACCTACGACTCGAAAGGACGCTTAGAAACCATATACCGTTTACAGAAATC	1200
QY	1201	TCCAACCTTAATTGAACACAGGGAATGTGTATAACCTTAAGTCACTTCTATATGCAAA	1260
Db	1201	TCCAACCTTAATTGAACACAGGGAATGTGTATAACCTTAAGTCACTTCTATATGCAAA	1260

QY	1261	GTGAGTCTTCCACTATGAATAAAC	TGCTTCTCGGGAAGGTAGGAGGCCAGTCCAGGC	1320
Db	1261	GTGAGTCTTCCACTATGAATAAAC	TGCTTCTCGGGAAGGTAGGAGGCCAGTCCAGGC	1320
QY	1321	AGTTCCTCCAGGGCAGTGTCCAGAAAT	CAGTACGGCCTTCCATTGAAAAATGGCTT	1380
Db	1321	AGTTCCTCCAGGGCAGTGTCCAGAAAT	CAGTACGGCCTTCCATTGAAAAATGGCTT	1380
QY	1381	CTTATCGGGTCCCTGCTTTTGGTGT	CTCTGTCTCGGTGATAGGCTCGTCCCTGGGT	1440
Db	1381	CTTATCGGGTCCCTGCTTTTGGTGT	CTCTGTCTCGGTGATAGGCTCGTCCCTGGGT	1440
QY	1441	AGAATCCTTTCGGAATCACTCCG	CAGAAACGTTACTCAAGACTGGATTATTGATCAAT	1500
Db	1441	AGAATCCTTTCGGAATCACTCCG	CAGAAACGTTACTCAAGACTGGATTATTGATCAAT	1500
QY	1501	GGGATCTATGTGACATCTAAGGAT	TGGAATCGGTGCTCTTAATTCATTTAGTAAACAG	1560
Db	1501	GGGATCTATGTGACATCTAAGGAT	TGGAATCGGTGCTCTTAATTCATTTAGTAAACAG	1560
QY	1561	AAGCCCAATGCAATGAGTTTCTG	CTGACTTGCTAGTCTTAGCAGAGAGTTGTAATTTGA	1620
Db	1561	AAGCCCAATGCAATGAGTTTCTG	CTGACTTGCTAGTCTTAGCAGAGAGTTGTAATTTGA	1620
QY	1621	AGACAGGAAAAATGCCCTTCTG	CTTCTCTTTTTTTGGAGACAGAGTCTTGCTG	1680
Db	1621	AGACAGGAAAAATGCCCTTCTG	CTTCTCTTTTTTTGGAGACAGAGTCTTGCTG	1680
QY	1681	TTGCCCAGGCTGAGTGCAGTAG	CAACGATCTGGCTCTCACCGCAACCTCCGCTCTG	1740
Db	1681	TTGCCCAGGCTGAGTGCAGTAG	CAACGATCTGGCTCTCACCGCAACCTCCGCTCTG	1740
QY	1741	GTTCAAGCGATTCTCTGCTCAG	CCCTCCTAAGTATCTGGATTACAGGCATGCGCAC	1800
Db	1741	GTTCAAGCGATTCTCTGCTCAG	CCCTCCTAAGTATCTGGATTACAGGCATGCGCAC	1800
QY	1801	ACACCTGGTGATTTTGTATTTT	TAGTAGAGACGGGTTTCACCATGTTGGTCAAGCTG	1860
Db	1801	ACACCTGGTGATTTTGTATTTT	TAGTAGAGACGGGTTTCACCATGTTGGTCAAGCTG	1860
QY	1861	GTTCTCAACTCTCTGACCTA	TGATCCACCCTCTCGGCTCCCAAAGTCTGGGATTCA	1920
Db	1861	GTTCTCAACTCTCTGACCTA	TGATCCACCCTCTCGGCTCCCAAAGTCTGGGATTCA	1920
QY	1921	GGCATGAGCCACACAGCTGG	CCCCCTCTGTGTTTATGTTGGTTTTTGAGAAAGGATGA	1980
Db	1921	GGCATGAGCCACACAGCTGG	CCCCCTCTGTGTTTATGTTGGTTTTTGAGAAAGGATGA	1980
QY	1981	AGTGGGAACCAATTAGGTAA	TTTTGGGTAAATCTGCTCTAAATATTAGCTAAAAACA	2040
Db	1981	AGTGGGAACCAATTAGGTAA	TTTTGGGTAAATCTGCTCTAAATATTAGCTAAAAACA	2040
QY	2041	AGCTCTATGTAAAGTAA	TAAAGTATTAATGGCCATTAATAATTTCAAAATTCAACTGGCTTT	2100
Db	2041	AGCTCTATGTAAAGTAA	TAAAGTATTAATTAATGGCCATTAATAATTTCAAAATTCAACTGGCTTT	2100
QY	2101	TATGCAAAAGAAACAGTTAG	GACATCTAGGTTCCAATTCATTCACATTCCTTGTTCCAGA	2160
Db	2101	TATGCAAAAGAAACAGTTAG	GACATCTAGGTTCCAATTCATTCACATTCCTTGTTCCAGA	2160
QY	2161	TAAATCAACTGTTTATCA	ATTTCTAATGGAATTTGCTTTTATATGATGATTCCT	2220
Db	2161	TAAATCAACTGTTTATCA	ATTTCTAATGGAATTTGCTTTTATATGATGATTCCT	2220
QY	2221	TTAAAACTTATTCAGATGA	TAGTTCCTTCCAATTAATAATTTGGAATAAATCTTTGTTAC	2280
Db	2221	TTAAAACTTATTCAGATGA	TAGTTCCTTCCAATTAATAATTTGGAATAAATCTTTGTTAC	2280
QY	2281	TCAA	2284	
Db	2281	TCAA	2284	

RESULT 7  
ACA69380  
ID ACA69380 standard; cDNA; 2284 BP.  
XX  
AC ACA69380;  
XX  
DT 26-JUN-2003 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane protein PRO361.  
XX  
KW Human; ss; gene; PRO; secreted protein; transmembrane protein;  
KW cardiac insufficiency disorders; angiogenesis; wound healing;  
KW cancerous tumour; immune response; retinal disorder; sight loss;  
KW retinitis pigmentosa; age-related macular degeneration; AMD;  
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpeticiformis;  
KW Crohn's disease; sports injury; arthritis.  
XX  
OS Homo sapiens.  
XX  
PN US2003032023-A1.  
XX  
PD 13-FEB-2003.  
XX  
PF 14-NOV-2001; 2001US-00990711.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096112P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.



```
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
```

Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GCGGAGCATCCGTCGGTCTCTCGCCGAGACCCCGCGGATTGCGCGTCTTCCCGC 60
    |||
Db 1 GCGGAGCATCCGTCGGTCTCTCGCCGAGACCCCGCGGATTGCGCGTCTTCCCGC 60

QY 61 GGGCGGACAGAGCTGTCTCGACCTGAGTGCGAGGGGCGCGGGTCTCTCGAC 120
    |||
Db 61 GGGCGGACAGAGCTGTCTCTCGACCTGAGTGCGAGGGGCGCGGGTCTCTCGAC 120

QY 121 GCCAGAGAGAAATCTCATCATCTGTGCAAGCTTCTTAAAGCAACTAAGACGAGGGAG 180
    |||
Db 121 GCCAGAGAGAAATCTCATCATCTGTGCAAGCTTCTTAAAGCAACTAAGACGAGGGAG 180
```

```
QY 181 GATTATCCTTGACCTTTGAAGACCAAACTAAACTGAATTTAAATGTTCTTCGGGGG 240
    |||
Db 181 GATTATCCTTGACCTTTGAAGACCAAACTAAACTGAATTTAAATGTTCTTCGGGGG 240

QY 241 GAAGGAGCTTGACTTACACTTTGGTAAATAATTGCTTCCTGACACTAAGGCTGTCTGCT 300
    |||
Db 241 GAAGGAGCTTGACTTACACTTTGGTAAATAATTGCTTCCTGACACTAAGGCTGTCTGCT 300

QY 301 AGTCAGAAATTCCTCAAAAAGAGTCTAGAAAGATGTTGTTCATTGACATCCAGTCATCTT 360
    |||
Db 301 AGTCAGAAATTCCTCAAAAAGAGTCTAGAAAGATGTTGTTCATTGACATCCAGTCATCTT 360

QY 361 TCTAAGGGAATCAGAGGCAATGAGCCGTATATATCTTCAACTCAAGAAGACTGCATTAA 420
    |||
Db 361 TCTAAGGGAATCAGAGGCAATGAGCCGTATATATCTTCAACTCAAGAAGACTGCATTAA 420

QY 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480
    |||
Db 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480

QY 481 ACTGAAAAACAGCTAGACAACCCCACTGTACTATTTTCTGTGCCAACGAGAAGCC 540
    |||
Db 481 ACTGAAAAACAGCTAGACAACCCCACTGTACTATTTTCTGTGCCAACGAGAAGCC 540

QY 541 TGTCCATTGAAACCAAGCAAAAGACTTAAGATTACAGGATTAACAGATTTTCCATCT 600
    |||
Db 541 TGTCCATTGAAACCAAGCAAAAGACTTAAGATTACAGGATTAACAGATTTTCCATCT 600

QY 601 TTGACCAAGAAATTTGCCAAGCCAAAGTTAACCACGAGAAGATCTCTTACATGGCCAA 660
    |||
Db 601 TTGACCAAGAAATTTGCCAAGCCAAAGTTAACCACGAGAAGATCTCTTACATGGCCAA 660

QY 661 TTTTCACAAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720
    |||
Db 661 TTTTCACAAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720

QY 721 ATCTCATGAGAGACACACTTCTCAGAAATTGATCCTCAGATCACTGAGAAACTA 780
    |||
Db 721 ATCTCATGAGAGACACACTTCTCAGAAATTGATCCTCAGATCACTGAGAAACTA 780

QY 781 TTTAAGATGATGAAGCAAGTGCCCACTCTTGCTTATAAGAAAAAGCCATTCTCAG 840
    |||
Db 781 TTTAAGATGATGAAGCAAGTGCCCACTCTTGCTTATAAGAAAAAGCCATTCTCAG 840

QY 841 AGTTCACAAATTTCTCTGTATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGCG 900
    |||
Db 841 AGTTCACAAATTTCTCTGTATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGCG 900

QY 901 CTCCAGCTACGGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960
    |||
Db 901 CTCCAGCTACGGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960

QY 961 ACCCTTCAACCAACCAATGCTTCAGTGACAACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020
    |||
Db 961 ACCCTTCAACCAACCAATGCTTCAGTGACAACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020

QY 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCAGACCCCTCATTTCTACA 1080
    |||
Db 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCAGACCCCTCATTTCTACA 1080

QY 1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGCGTACACAGCAGTTCTGACTACC 1140
    |||
Db 1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGCGTACACAGCAGTTCTGACTACC 1140

QY 1141 ACCTTTCAGGCACTACGGACTCGAAAGGCAAGCTTAGAAACCATACCGTTTACAGAAATC 1200
    |||
Db 1141 ACCTTTCAGGCACTACGGACTCGAAAGGCAAGCTTAGAAACCATACCGTTTACAGAAATC 1200

QY 1201 TCCAACTTAACCTTGAACACAGGGAATGTGTATAACCCCTACTGCACTTCTATGTCAAA 1260
    |||
Db 1201 TCCAACTTAACCTTGAACACAGGGAATGTGTATAACCCCTACTGCACTTCTATGTCAAA 1260

QY 1261 GTGAGTCTTCCAATATGAATAAACTGCTTCTCGGAAGGTAGGAGCCAGTCCAGGC 1320
```

Db 1261 GTGAGTCTTCCACTATGAATAAACTGCTTCTCGGAAGGTAGGAGCCAGTCCAGGC 1320  
Qy 1321 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGCGCTTCCATTGAAAAATGCGTT 1380  
Db 1321 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGCGCTTCCATTGAAAAATGCGTT 1380  
Qy 1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCCTGGTATAGGCTCGTCTCGGGT 1440  
Db 1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCCTGGTATAGGCTCGTCTCGGGT 1440  
Qy 1441 AGAATCCTTTCCGAATCACTCCGAGGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
Db 1441 AGAATCCTTTCCGAATCACTCCGAGGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
Qy 1501 GGGATCTATGTGACATCTAAGGATGGAACCTCGGTCTCTTAATTCATTAGTAACCAAG 1560  
Db 1501 GGGATCTATGTGACATCTAAGGATGGAACCTCGGTCTCTTAATTCATTAGTAACCAAG 1560  
Qy 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGCTAGTCTTAGCAGAGGTTGTATTTTGA 1620  
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGCTAGTCTTAGCAGAGGTTGTATTTTGA 1620  
Qy 1621 AGACAGGAAAAATGCCCCCTTCTGCTTTCTTTTTTTGGAGACAGAGTCTGCTCTG 1680  
Db 1621 AGACAGGAAAAATGCCCCCTTCTGCTTTCTTTTTTTGGAGACAGAGTCTGCTCTG 1680  
Qy 1681 TTGCCCCAGGCTGGAGTGCAGTACGAGATCTCGGCTCTACCGCAACCTCCGCTCCTGG 1740  
Db 1681 TTGCCCCAGGCTGGAGTGCAGTACGAGATCTCGGCTCTACCGCAACCTCCGCTCCTGG 1740  
Qy 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGTGCCACC 1800  
Db 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGTGCCACC 1800  
Qy 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGCGGTTTCAACATGTTGGTCAAGCTG 1860  
Db 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGCGGTTTCAACATGTTGGTCAAGCTG 1860  
Qy 1861 GTCTCAAACTCCTGACCTAGTGATCCACCCTCCTCGGCTCCCAAGTGTGGATTACA 1920  
Db 1861 GTCTCAAACTCCTGACCTAGTGATCCACCCTCCTCGGCTCCCAAGTGTGGATTACA 1920  
Qy 1921 GGCATGAGCCACCACAGCTGGCCCCCTTCTGTTTATGTTTGGTTTTTGAGAGGAATGA 1980  
Db 1921 GGCATGAGCCACCACAGCTGGCCCCCTTCTGTTTATGTTTGGTTTTTGAGAGGAATGA 1980  
Qy 1981 AGTGGGAACCAATTAGTAAATTTGGGTAATCTGTCTTAAATATTTAGCTAAAAACAA 2040  
Db 1981 AGTGGGAACCAATTAGTAAATTTGGGTAATCTGTCTTAAATATTTAGCTAAAAACAA 2040  
Qy 2041 AGCTCTATGTAAAGTAAAGTAAATTTGCCATATATAATTTCAAAATTCAACTGGCTTT 2100  
Db 2041 AGCTCTATGTAAAGTAAAGTAAATTTGCCATATATAATTTCAAAATTCAACTGGCTTT 2100  
Qy 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAAATTCATTCACATTCTTGTTCCAGA 2160  
Db 2101 TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAAATTCATTCACATTCTTGTTCCAGA 2160  
Qy 2161 TAAATCAACTGTTTATATCAATTTCTAATGGAATTGCTTTTCTTTTATATGGAATCCT 2220  
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGGAATTGCTTTTCTTTTATATGGAATCCT 2220  
Qy 2221 TTAAAACTTATTCAGATGAGTTCCTTCCAATTAATAATTTGAAATAATCTTTGTATAC 2280  
Db 2221 TTAAAACTTATTCAGATGAGTTCCTTCCAATTAATAATTTGAAATAATCTTTGTATAC 2280  
Qy 2281 TCAA 2284  
Db 2281 TCAA 2284

RESULT 8

ABX90451  
ID ABX90451 standard; cDNA; 2284 BP.  
XX AC ABX90451;  
XX DT 01-MAY-2003 (first entry)  
DE Human secreted/transmembrane protein cDNA, #182.  
XX KW Human; gene; ss; PRO; secreted; transmembrane; signal peptide;  
KW pharmaceutical; diagnostic; therapeutic; gene therapy.  
XX OS Homo sapiens.  
XX PN US2002160384-A1.  
XX PD 31-OCT-2002.  
XX PF 14-NOV-2001; 2001US-00992598.  
XX PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089588P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98US-0089908P.  
PR 17-SEP-1998; 98WO-US019330.  
PR 07-OCT-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.

PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-009411992.  
XX  
XX (GETH ) GENENTECH INC.  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,  
PI Ferrera N, Fong S, Gerber H, Gerlitsen ME, Goddard A, Godowski PJ,  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF,  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,  
PI Zhang Z;  
XX  
DR WPI; 2003-288106/28.  
DR P-PSDB; ABU60623.  
XX  
XX New transmembrane polypeptides and nucleic acids encoding the  
PT polypeptides, useful in gene therapy, in chromosome identification, as  
PT chromosome markers, or in generating probes.  
XX  
XX Claim 2; Fig 327; 650pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC comprising a sequence without signal peptide and the nucleic acid  
CC encoding them. The polypeptides can be used to raise antibodies that  
CC specifically bind to the PRO polypeptide, for linking a bioactive  
CC molecule to a cell expressing a PRO protein and for modulating at least  
CC one biological activity of a cell. The PRO polypeptides or  
CC polynucleotides are also useful in gene therapy, in chromosome  
CC identification, as chromosome markers, or in generating probes. The PRO  
CC polypeptides are useful as molecular markers for protein electrophoresis,  
CC and the isolated nucleic acids may be used for recombinantly expressing  
CC those markers. The PRO polypeptides and nucleic acids may also be used in  
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for  
CC PRO, and in affinity purification of PRO from recombinant cell culture or  
CC natural sources. The sequences presented in ABX90083-ABX90468 are the  
CC genes encoding, the primers amplifying and the probes detecting the PRO

CC polynucleotides of the invention. Note: The sequence data for this patent  
CC is also available in electronic format from USPTO at  
CC seqdata.uspto.gov/sequence.html  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGCATCCGCTGCGGTCTCTCGCCGAGACCCCGCGCGGATTCCCGCTTCCCGC 60  
DB 1 GCGGAGCATCCGCTGCGGTCTCTCGCCGAGACCCCGCGCGGATTCCCGCTTCCCGC 60  
QY 61 GGGCGGACAGAGCTGTCTCTCGACCTGGATGGCAGGGGGCGGGGTCTCTCGAC 120  
DB 61 GGGCGGACAGAGCTGTCTCTCGACCTGGATGGCAGGGGGCGGGGTCTCTCGAC 120  
QY 121 GCCAGAGAGAAATCTCATCATCTGTGCAAGCCTTCTTAAAGCAAACTAAGACGAGGAG 180  
DB 121 GCCAGAGAGAAATCTCATCATCTGTGCAAGCCTTCTTAAAGCAAACTAAGACGAGGAG 180  
QY 181 GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTCGGGGA 240  
DB 181 GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTCGGGGA 240  
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATTAATTGCTTCTCGACACTAAGGCTGTCTCT 300  
DB 241 GAAGGAGCTTGACTTACACTTTGGTAATTAATTGCTTCTCGACACTAAGGCTGTCTCT 300  
QY 301 AGTCAGAAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCAATGACATCCAGTCATCTCT 360  
DB 301 AGTCAGAAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCAATGACATCCAGTCATCTCT 360  
QY 361 TCTAAGGAATCAGAGGCAATGAGCCGTATATACCTTCAACTCAAGAAGACTCATTAAT 420  
DB 361 TCTAAGGAATCAGAGGCAATGAGCCGTATATACCTTCAACTCAAGAAGACTCATTAAT 420  
QY 421 TCTTGCTGTCAACAAAAAACAATACAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480  
DB 421 TCTTGCTGTCAACAAAAAACAATACAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480  
QY 481 ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCCAAGAGAGGCC 540  
DB 481 ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCCAAGAGAGGCC 540  
QY 541 TGTCCATTGAAACCAAGCAAAAGACTTATGAGTTACAGGATTAATTACAGATTTCCATCT 600  
DB 541 TGTCCATTGAAACCAAGCAAAAGACTTATGAGTTACAGGATTAATTACAGATTTCCATCT 600  
QY 601 TTGACCAAGAAATTTGCCAAGGCCAAGGTTACCCCAAGGAAGATTCTCTTACATGGCCAA 660  
DB 601 TTGACCAAGAAATTTGCCAAGGCCAAGGTTACCCCAAGGAAGATTCTCTTACATGGCCAA 660  
QY 661 TTTTCAAGACAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT 720  
DB 661 TTTTCAAGACAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT 720  
QY 721 ATCTCATGAGAGACACACTTTCTCAGAAGTTGGATCCTCAGATCACTGAGAAACTA 780  
DB 721 ATCTCATGAGAGACACACTTTCTCAGAAGTTGGATCCTCAGATCACTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATAAGGAAAAAGGCCATTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATAAGGAAAAAGGCCATTCTCAG 840  
QY 841 AGTTCAAAATTTCTCTGATCAAGAAATGCTCATCTGTGCTGAAATGTGAGTGCG 900  
DB 841 AGTTCAAAATTTCTCTGATCAAGAAATGCTCATCTGTGCTGAAATGTGAGTGCG 900  
QY 901 CTCCCACTACGGTGGCAGTTGCTTCTCAACATACCACTCGGCTACTCCAAAGCCCGCC 960  
DB 901 CTCCCACTACGGTGGCAGTTGCTTCTCAACATACCACTCGGCTACTCCAAAGCCCGCC 960



```
QY 961 ACCCTCTACCCACCAATGCTTCAGTGACACCTTCTGGACTTCCAGCCACAGCTGGCC 1020
    |||||
Db 961 ACCCTCTACCCACCAATGCTTCAGTGACACCTTCTGGACTTCCAGCCACAGCTGGCC 1020
QY 1021 ACCACAGCTCCACCTGTGAACCACTGTCACTTCTCAGCCTCCCAAGACCCCTCATTTCTACA 1080
    |||||
Db 1021 ACCACAGCTCCACCTGTGAACCACTGTCACTTCTCAGCCTCCCAAGACCCCTCATTTCTACA 1080
QY 1081 GTTTTACACGGGCTGCGGCTACCTCCAGCAATGGCTACACAGCAGTCTGACTACC 1140
    |||||
Db 1081 GTTTTACACGGGCTGCGGCTACCTCCAGCAATGGCTACACAGCAGTCTGACTACC 1140
QY 1141 ACCTTTCAGGCACCTACGCACTCGAAGGCACTTAGAACCATAACGTTTACAGAAATC 1200
    |||||
Db 1141 ACCTTTCAGGCACCTACGCACTCGAAGGCACTTAGAACCATAACGTTTACAGAAATC 1200
QY 1201 TCCAACTTAACCTTGAACACAGGGAATGTGTATAACCCCTACTGCACTTCTATGTCAAAAT 1260
    |||||
Db 1201 TCCAACTTAACCTTGAACACAGGGAATGTGTATAACCCCTACTGCACTTCTATGTCAAAAT 1260
QY 1261 GTGAGTCTTCCACTATGATAATAAACTGCTTCTGGAAGGTAGGAGGCCAGTCCAGGC 1320
    |||||
Db 1261 GTGAGTCTTCCACTATGATAATAAACTGCTTCTGGAAGGTAGGAGGCCAGTCCAGGC 1320
QY 1321 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTTGAAAAATGGCTT 1380
    |||||
Db 1321 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTTGAAAAATGGCTT 1380
QY 1381 CTTATCGGGTCCCTGCTCTTGTGTCTGTCTCTGTGATAGGCTCGTCTCCTGGGT 1440
    |||||
Db 1381 CTTATCGGGTCCCTGCTCTTGTGTCTGTCTCTGTGATAGGCTCGTCTCCTGGGT 1440
QY 1441 AGAATCCTTTCGGAATCACTCCGAGAAAGCTTACTCAAGACTGATTAATTGATCAAT 1500
    |||||
Db 1441 AGAATCCTTTCGGAATCACTCCGAGAAAGCTTACTCAAGACTGATTAATTGATCAAT 1500
QY 1501 GGGATCTATGTGACATCTAAGATGGAATCGGCTGTCTTAATTCAATTAGTAACCAAG 1560
    |||||
Db 1501 GGGATCTATGTGACATCTAAGATGGAATCGGCTGTCTTAATTCAATTAGTAACCAAG 1560
QY 1561 AAGCCCAAATGCAATGAGTTTCTGTGACTTGTAGTCTTAGCAGAGGTTGTATTTGA 1620
    |||||
Db 1561 AAGCCCAAATGCAATGAGTTTCTGTGACTTGTAGTCTTAGCAGAGGTTGTATTTGA 1620
QY 1621 AGACAGGAAATGCCCTTCTGTCTCTTTTCTTTTGGAGACAGAGTCTGTCTGTG 1680
    |||||
Db 1621 AGACAGGAAATGCCCTTCTGTCTCTTTTCTTTTGGAGACAGAGTCTGTCTGTG 1680
QY 1681 TTGCCAGGCTGAGTGACAGATCTCGGCTCTCACCGCAACTCCGCTCTCTGG 1740
    |||||
Db 1681 TTGCCAGGCTGAGTGACAGATCTCGGCTCTCACCGCAACTCCGCTCTCTGG 1740
QY 1741 GTTCAAGCGATTCTCTGCTCAGCCTCTAAGTATCTGGGATTACAGGCAATGTGCCACC 1800
    |||||
Db 1741 GTTCAAGCGATTCTCTGCTCAGCCTCTAAGTATCTGGGATTACAGGCAATGTGCCACC 1800
QY 1801 ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGGTTTACCAATGTTGGTCAAGGCTG 1860
    |||||
Db 1801 ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGGTTTACCAATGTTGGTCAAGGCTG 1860
QY 1861 GTCTCAAACTCTGACCTAGTATCCACCTCTCGGCTCTCCAAAGTGTGGATTACA 1920
    |||||
Db 1861 GTCTCAAACTCTGACCTAGTATCCACCTCTCGGCTCTCCAAAGTGTGGATTACA 1920
QY 1921 GGCATGAGCCACCAAGCTGGCCCCCTTCTGTTTATGTTTGGTTTGAAGAAGATGA 1980
    |||||
Db 1921 GGCATGAGCCACCAAGCTGGCCCCCTTCTGTTTATGTTTGGTTTGAAGAAGATGA 1980
QY 1981 AGTGGGAACCAATTAAGTAAATTTGGTAAATCTGTCTCTAAATATTAAGCTAAACAA 2040
    |||||
Db 1981 AGTGGGAACCAATTAAGTAAATTTGGTAAATCTGTCTCTAAATATTAAGCTAAACAA 2040
```

```
QY 2041 AGCTCTATGTAAAGTAAATAGTAAATTAATGCCATATAAATTTCAAATTCACACTGGCTT 2100
    |||||
Db 2041 AGCTCTATGTAAAGTAAATAGTAAATTAATGCCATATAAATTTCAAATTCACACTGGCTT 2100
QY 2101 TATGCAAGAAACAGGTTAGACATCTAGGTTCCAAATTCATTCTTGTTCCAGA 2160
    |||||
Db 2101 TATGCAAGAAACAGGTTAGACATCTAGGTTCCAAATTCATTCTTGTTCCAGA 2160
QY 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTCCT 2220
    |||||
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTCCT 2220
QY 2221 TTAACCTTATTCAGATGATGTTCTTCCAAATTAATTAATTGAATAAATCTTTGTAC 2280
    |||||
Db 2221 TTAACCTTATTCAGATGATGTTCTTCCAAATTAATTAATTGAATAAATCTTTGTAC 2280
QY 2281 TCAA 2284
    |||||
Db 2281 TCAA 2284

RESULT 9
ABX64297
ID ABX64297 standard; cDNA; 2284 BP.
XX
AC ABX64297;
XX
DT 26-FEB-2003 (first entry)
XX
DE cDNA encoding human PRO361 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive; transgenic;
KW gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2002103125-A1.
XX
PD 01-AUG-2002.
XX
PF 20-NOV-2001; 2001US-00989731.
XX
PR 16-JUN-1997; 97US-0049787P.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
```

PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98US-0089930P.  
PR 17-SEP-1998; 98US-0089937P.  
PR 07-OCT-1998; 98US-0089937P.  
PR 01-DEC-1998; 98US-0089937P.  
PR 05-JAN-1999; 99US-0000106P.  
PR 08-MAR-1999; 99US-0000502P.  
PR 02-JUN-1999; 99US-00012252.  
PR 15-SEP-1999; 99US-00021090.  
PR 15-SEP-1999; 99US-00021547.  
PR 30-NOV-1999; 99US-00028313.  
PR 01-DEC-1999; 99US-00028301.  
PR 01-DEC-1999; 99US-00028634.  
PR 16-DEC-1999; 99US-00030095.  
PR 20-DEC-1999; 99US-00030911.  
PR 06-JAN-2000; 2000US-0000219.  
PR 06-JAN-2000; 2000US-0000376.  
PR 11-FEB-2000; 2000US-00003565.  
PR 18-FEB-2000; 2000US-00004341.  
PR 22-FEB-2000; 2000US-00004414.  
PR 24-FEB-2000; 2000US-00004914.  
PR 24-FEB-2000; 2000US-00005004.  
PR 02-MAR-2000; 2000US-00005841.  
PR 10-MAR-2000; 2000US-00006319.  
PR 15-MAR-2000; 2000US-00006884.  
PR 20-MAR-2000; 2000US-00007377.  
PR 30-MAR-2000; 2000US-00008439.  
PR 15-MAY-2000; 2000US-00013358.  
PR 17-MAY-2000; 2000US-00013705.  
PR 22-MAY-2000; 2000US-00014042.  
PR 30-MAY-2000; 2000US-00014941.  
PR 02-JUN-2000; 2000US-00015264.  
PR 28-JUN-2000; 2000US-00020710.  
PR 11-AUG-2000; 2000US-00022031.  
PR 23-AUG-2000; 2000US-00023522.  
PR 24-AUG-2000; 2000US-00023328.  
PR 08-NOV-2000; 2000US-00030952.  
PR 01-DEC-2000; 2000US-00032678.  
PR 28-FEB-2001; 2001US-00006520.  
PR 01-JUN-2001; 2001US-00017800.  
PR 20-JUN-2001; 2001US-00019692.  
PR 29-JUN-2001; 2001US-00021066.  
PR 09-JUL-2001; 2001US-00021735.  
PR 28-AUG-2001; 2001US-000941992.  
XX  
PA (GETH ) GENENTECH LTD.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,  
PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ,  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF,  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,  
PI Zhang Z,  
XX  
DR WPI; 2003-102117/09.

DR P-PSDB; ABU14005.  
XX  
PT Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, identifying agonists or  
PT antagonists of polypeptide, and as molecular weight markers.  
XX  
PS Claim 2; Fig 327; 649pp; English.  
XX  
CC The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides are useful for detecting other PRO polypeptides, for linking  
CC bioactive molecules to cells expressing PRO polypeptides, and for for  
CC biological activities of cells expressing PRO polypeptides, and for for  
CC identifying agonists or antagonists. The polynucleotide sequences  
CC encoding PRO polypeptides are useful as hybridization probes, in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC in the preparation of PRO polypeptides, for generating transgenic animals  
CC or knockout animals, to construct hybridization probes for mapping the  
CC gene which encodes the PRO polypeptide, and for the genetic analysis of  
CC individuals with genetic disorders, in gene therapy, for chromosome  
CC identification, as chromosome markers, and for generating probes for PCR,  
CC Northern analysis, Southern analysis and Western analysis. The present  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent was obtained in electronic format directly  
CC from the USPTO web site at [seqdata.uspto.gov/patseq/identry.html](http://seqdata.uspto.gov/patseq/identry.html)  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;  
Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 GCGGAGCATCCGCTGCGGTCTCTCCGCGAGACCCCGCGGATTCGCGGTCTCCCGC 60  
DB 1 GCGGAGCATCCGCTGCGGTCTCTCCGCGAGACCCCGCGGATTCGCGGTCTCCCGC 60  
QY 61 GGGCGGACAGAGCTGTCTCTCGACCTGGATGGCAGAGGGGGCGGGGTCTCTCGAC 120  
DB 61 GGGCGGACAGAGCTGTCTCTCGACCTGGATGGCAGAGGGGGCGGGGTCTCTCGAC 120  
QY 121 GCCAGAGAAATCTCATCATCTGTGACGCTTCTTAAAGCAAATAAGACGAGGGAG 180  
DB 121 GCCAGAGAAATCTCATCATCTGTGACGCTTCTTAAAGCAAATAAGACGAGGGAG 180  
QY 181 GATTATCTTGACCTTTGAAGACCAAATAAAGTAAATTTAAATGTTCTTCGGGGGA 240  
DB 181 GATTATCTTGACCTTTGAAGACCAAATAAAGTAAATTTAAATGTTCTTCGGGGGA 240  
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATAATTGCTTCCGTACACTAAGGCTGTCTGCT 300  
DB 241 GAAGGAGCTTGACTTACACTTTGGTAATAATTGCTTCCGTACACTAAGGCTGTCTGCT 300  
QY 301 AGTCAGAAATTCCTCAAAAAGAGTCTAGAAAGATGTTGTCAATGACATCCAGTCATCTT 360  
DB 301 AGTCAGAAATTCCTCAAAAAGAGTCTAGAAAGATGTTGTCAATGACATCCAGTCATCTT 360  
QY 361 TCTAAGGATCAGAGGCAATGAGCCGTATATACCTCAACTCAAGAAGCTGCATTAAT 420  
DB 361 TCTAAGGATCAGAGGCAATGAGCCGTATATACCTCAACTCAAGAAGCTGCATTAAT 420  
QY 421 TCTTGTCTTCAACAAAAACATATCAGGGGACAAAGCATGTAATTGATGATCTTCGAC 480  
DB 421 TCTTGTCTTCAACAAAAACATATCAGGGGACAAAGCATGTAATTGATGATCTTCGAC 480  
QY 481 ACTGAAAAACAGCTAGACAAACCACTGCTACCTATTTTCTGTCCCAAGGAGAGCC 540  
DB 481 ACTGAAAAACAGCTAGACAAACCACTGCTACCTATTTTCTGTCCCAAGGAGAGCC 540  
QY 541 TGTCATTTGAACCAAGCAAAAGACTTATGAGTTACAGAGATAATTAAGATTTCATCT 600  
DB 541 TGTCATTTGAACCAAGCAAAAGACTTATGAGTTACAGAGATAATTAAGATTTCATCT 600

QY 601 TTGACCAGAATTTGGCCAAGCCAAAGATTACCACCAGGAAGATTCTCTTACATGGCCAA 660  
Db 601 TTGACCAGAATTTGCCAAGCCAAAGATTACCACCAGGAAGATTCTCTTACATGGCCAA 660  
QY 661 TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT 720  
Db 661 TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT 720  
QY 721 ATCTCATGAGAGACACACTTTCTCGAAGTTTGATCCTCAGATCACTGAGAAACTA 780  
Db 721 ATCTCATGAGAGACACACTTTCTCGAAGTTTGATCCTCAGATCACTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTGCCAGCTCCTTGTTATAAGAAAGGCCATTCTCAG 840  
Db 781 TTTAAGATGATGAAGCAAGTGCCAGCTCCTTGTTATAAGAAAGGCCATTCTCAG 840  
QY 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGG 900  
Db 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGG 900  
QY 901 CTCCAGCTACGGGTGGCAGTTGTTCTTCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
Db 901 CTCCAGCTACGGGTGGCAGTTGTTCTTCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
QY 961 ACCCTTCTAACCCCAATGCTTCAGTACACCTTCTGGAGCTTCCAGCCACAGCTGGCC 1020  
Db 961 ACCCTTCTAACCCCAATGCTTCAGTACACCTTCTGGAGCTTCCAGCCACAGCTGGCC 1020  
QY 1021 ACCAAGCTCCACCTGTAAACCACTGCACTTCTCAGCCTCCAGCACTCATTTCTACA 1080  
Db 1021 ACCAAGCTCCACCTGTAAACCACTGCACTTCTCAGCCTCCAGCACTCATTTCTACA 1080  
QY 1081 GTTTTACAACGGGCTGGGCTACACTTCCAAGCAATGGCTACAACAGCAGTTCTGACTACC 1140  
Db 1081 GTTTTACAACGGGCTGGGCTACACTTCCAAGCAATGGCTACAACAGCAGTTCTGACTACC 1140  
QY 1141 ACCTTTCAAGGCACTCAGGACTCGAAAGGCACTTAGAAACATACCGTTTACAGAAATC 1200  
Db 1141 ACCTTTCAAGGCACTCAGGACTCGAAAGGCACTTAGAAACATACCGTTTACAGAAATC 1200  
QY 1201 TCCAATTAACTTTGAACACAGGAATGTGTATAACCTACTGCACTTCTATGTCAAAAT 1260  
Db 1201 TCCAATTAACTTTGAACACAGGAATGTGTATAACCTACTGCACTTCTATGTCAAAAT 1260  
QY 1261 GTGAGTCTTCCACTATGAATAAACTGCTTCTGGGAAGTAGGAGCCAGTCCAGGC 1320  
Db 1261 GTGAGTCTTCCACTATGAATAAACTGCTTCTGGGAAGTAGGAGCCAGTCCAGGC 1320  
QY 1321 AGTTCTTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
Db 1321 AGTTCTTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTTATCGGCTCCCTGCTCTTTGGTGTCTGTCTCTGTGATAGGCTGCTCCTGGGT 1440  
Db 1381 CTTATCGGCTCCCTGCTCTTTGGTGTCTGTCTCTGTGATAGGCTGCTCCTGGGT 1440  
QY 1441 AGAATCTTTTGGGAATCACTCCGCAAGAAACGTTACTCAAGACTGATTTATGATCAAT 1500  
Db 1441 AGAATCTTTTGGGAATCACTCCGCAAGAAACGTTACTCAAGACTGATTTATGATCAAT 1500  
QY 1501 GGGATCTATGTGGAATCTAAGGATGGAATCGGTGTCTCTTAATCATTTAGTAACCAAG 1560  
Db 1501 GGGATCTATGTGGAATCTAAGGATGGAATCGGTGTCTCTTAATCATTTAGTAACCAAG 1560  
QY 1561 AAGCCAAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAAGCAGAGGTGTATTTGA 1620  
Db 1561 AAGCCAAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAAGCAGAGGTGTATTTGA 1620  
QY 1621 AGACAGGAAATGCCCCCTTCTGCTTCTTTTCTTTTGGAGACAGAGTCTGCTCTG 1680  
Db 1621 AGACAGGAAATGCCCCCTTCTGCTTCTTTTCTTTTGGAGACAGAGTCTGCTCTG 1680  
QY 1681 TTGCCAGGCTGGAAGTGACAGATCTCGGCTCTCACCGCAACTCGTCTCCTGG 1740

Db 1681 TTGCCAGGCTGGAAGTGACAGATCTCGGCTCTCACCGCAACTCGTCTCCTGG 1740  
QY 1741 GTTCAAGCATTCTCCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGTGCCACC 1800  
Db 1741 GTTCAAGCATTCTCCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGTGCCACC 1800  
QY 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACATGTTGTGAGGCTG 1860  
Db 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACATGTTGTGAGGCTG 1860  
QY 1861 GTTCAAACTCTCTGACCTAGTATCCACCCTCCTCGGCTTCCCAAAGTGTGGATTACA 1920  
Db 1861 GTTCAAACTCTCTGACCTAGTATCCACCCTCCTCGGCTTCCCAAAGTGTGGATTACA 1920  
QY 1921 GGCAATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTTGGTTTGGAGAGGAATGA 1980  
Db 1921 GGCAATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTTGGTTTGGAGAGGAATGA 1980  
QY 1981 AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTTAATAATATTAGCTAAAAACAA 2040  
Db 1981 AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTTAATAATATTAGCTAAAAACAA 2040  
QY 2041 AGCTTATGTAAAGTAAATTAAGTAAATTTGCCATATAAATTTCAAATGAGCTTT 2100  
Db 2041 AGCTTATGTAAAGTAAATTAAGTAAATTTGCCATATAAATTTCAAATGAGCTTT 2100  
QY 2101 TATGCAAGAAACAGGTTAGGACATCAGTTCCAATTCAATTCACATTTCTGTTCCAGA 2160  
Db 2101 TATGCAAGAAACAGGTTAGGACATCAGTTCCAATTCAATTCACATTTCTGTTCCAGA 2160  
QY 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTCCT 2220  
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTCCT 2220  
QY 2221 TTAATACTTATTCAGATGATGTTCTTCCAATTAAATTTGAATAAATCTTTGTATC 2280  
Db 2221 TTAATACTTATTCAGATGATGTTCTTCCAATTAAATTTGAATAAATCTTTGTATC 2280  
QY 2281 TCAA 2284  
Db 2281 TCAA 2284  
  
RESULT 10  
ABX89495  
ID ABX89495 standard; cDNA; 2284 BP.  
XX  
AC ABX89495;  
XX  
DT 24-APR-2003 (first entry)  
XX  
DE Human PRO polynucleotide #15.  
XX  
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; cancer; inflammatory disease; atherosclerosis; cardiac injury; AIDS; infertility; birth defect; premature aging; diabetes; dog; cat; horse; acquired immunodeficiency syndrome; cow; sheep; pig; goat; rabbit; industry; cystostatic; antiinflammatory; cardiac; antiinfertility; anti-HIV; antiarteriosclerotic; antidiabetic.  
OS Homo sapiens.  
XX  
PN US2002132768-A1.  
XX  
PD 19-SEP-2002.  
XX  
PF 31-AUG-2001; 2001US-00945015.  
XX  
PR 03-DEC-1997; 97US-0067411P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 11-DEC-1997; 97US-0069335P.



PR 12-DEC-1997; 97US-0069425P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 16-DEC-1998; 98US-00216021.  
PR 16-DEC-1998; 98US-0112850P.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 03-MAR-1999; 99US-00254311.  
PR 22-JUN-1999; 99WO-US012252.  
PR 28-JUL-1999; 99US-0146222P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Guirney AL;  
PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX  
DR WPI; 2003-174088/17.  
DR P-PSDB; ABU60244.  
XX  
PT New secreted and transmembrane polypeptides (e.g. PRO241, for use in  
PT pharmaceuticals, diagnostics or bioreactors, particularly for detecting  
PT or treating e.g. cancers, infertility or acquired immunodeficiency  
PT syndrome in mammals.  
XX  
PS Claim 2; Fig 31; 173pp; English.  
XX  
CC The invention relates to a human secreted and transmembrane polypeptide  
CC (PRO) and the polynucleotide encoding it. The PRO polypeptide or  
CC polynucleotide is useful in pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are particularly useful for detecting or treating  
CC cancers, inflammatory diseases, atherosclerosis, cardiac injury,  
CC infertility, birth defects, premature aging, acquired immunodeficiency  
CC syndrome (AIDS) and diabetic complications in mammals, e.g. humans, dogs,  
CC cats, cattle, horses, sheep, pigs, goats or rabbits. The sequences are  
CC also useful in biotechnological and medical research and in various  
CC industrial applications. This sequence represents a human PRO  
CC polynucleotide of the invention  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGCATCCGCTGCGGTCCTCGCGAGAGACCCCGCGGATTGCGCGGTCCTTCCCGC 60  
DB 1 GCGGAGCATCCGCTGCGGTCCTCGCGAGAGACCCCGCGGATTGCGCGGTCCTTCCCGC 60

QY 61 GGGCGGACAGAGCTGTCTCGCACTGATGCGAGAGGCGCGGGGTCTCTCGAC 120  
DB 61 GGGCGGACAGAGCTGTCTCGCACTGATGCGAGAGGCGCGGGGTCTCTCGAC 120  
QY 121 GCCAGAGAAATCTCATCATCTGTCAGCCTTCTTAAGCAAACTAAGACCAGAGGAG 180  
DB 121 GCCAGAGAAATCTCATCATCTGTCAGCCTTCTTAAGCAAACTAAGACCAGAGGAG 180  
QY 181 GATTATCTTGACCTTTGAAGCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
DB 181 GATTATCTTGACCTTTGAAGCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATTAATTGCTTCCGACACTAAGGCTGTGCT 300  
DB 241 GAAGGAGCTTGACTTACACTTTGGTAATTAATTGCTTCCGACACTAAGGCTGTGCT 300  
QY 301 AGTCAGATTGCTCAAAAAGAGCTAGAAAGATGTTGTCATTGACATCCAGTCATCTT 360  
DB 301 AGTCAGATTGCTCAAAAAGAGCTAGAAAGATGTTGTCATTGACATCCAGTCATCTT 360  
QY 361 TCTAAGGAATCAGAGCAATGAGCCGTATATATCTTCACTCAAGAAGACTGCATTAAT 420  
DB 361 TCTAAGGAATCAGAGCAATGAGCCGTATATATCTTCACTCAAGAAGACTGCATTAAT 420  
QY 421 TCTTGCTGTTCACAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGAC 480  
DB 421 TCTTGCTGTTCACAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGAC 480  
QY 481 ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCCAACGAGAAAGCC 540  
DB 481 ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCCAACGAGAAAGCC 540  
QY 541 TGTCCATTGAAACCGACAAAGAGCTTATGAGTTACAGGATTAATTACAGATTTCCATCT 600  
DB 541 TGTCCATTGAAACCGACAAAGAGCTTATGAGTTACAGGATTAATTACAGATTTCCATCT 600  
QY 601 TTGACAGAAATTTGCCAAGCCAAAGAGTTAACCAGAAAGATTTCTTACATGCGCAA 660  
DB 601 TTGACAGAAATTTGCCAAGCCAAAGAGTTAACCAGAAAGATTTCTTACATGCGCAA 660  
QY 661 TTTTCAGAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCCAACGAT 720  
DB 661 TTTTCAGAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCCAACGAT 720  
QY 721 ATCTCATGAGAGACACACTTTCTCAGAAGTTTGATCTCTCAGATCACTGAGAAACTA 780  
DB 721 ATCTCATGAGAGACACACTTTCTCAGAAGTTTGATCTCTCAGATCACTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTGCCCACTCTTGCTTATAGGAAAAAGGCCATTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTGCCCACTCTTGCTTATAGGAAAAAGGCCATTCTCAG 840  
QY 841 AGTTCAATTTTCTCTGATCAAGAATAGCTCATCTGCTGCAAAATGTGAGTGC 900  
DB 841 AGTTCAATTTTCTCTGATCAAGAATAGCTCATCTGCTGCAAAATGTGAGTGC 900  
QY 901 CTCCAGCTAAGGTGGCAGTTGCTTCCACATACCACTGGGCTACTCCAAAGCCCGCC 960  
DB 901 CTCCAGCTAAGGTGGCAGTTGCTTCCACATACCACTGGGCTACTCCAAAGCCCGCC 960  
QY 961 ACCCTTCAACCAATATGCTTCAAGTACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
DB 961 ACCCTTCAACCAATATGCTTCAAGTACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
QY 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTAGCCTCCACAGACCTCATTTCTACA 1080  
DB 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTAGCCTCCACAGACCTCATTTCTACA 1080  
QY 1081 GTTTTACAGGGGCTGCGGCTACACTCCAAAGCAATGGCTACAAAGAGTTCTGACTACC 1140  
DB 1081 GTTTTACAGGGGCTGCGGCTACACTCCAAAGCAATGGCTACAAAGAGTTCTGACTACC 1140  
QY 1141 ACCTTCAAGGACCTAGGACTGAAAGGACGCTTAGAAAACATACCGTTTACAGAAATC 1200

```

Db      1141  |||
Qy      1201  |||
Db      1201  |||
Qy      1261  |||
Db      1261  |||
Qy      1320  |||
Db      1320  |||
Qy      1380  |||
Db      1380  |||
Qy      1440  |||
Db      1440  |||
Qy      1500  |||
Db      1500  |||
Qy      1560  |||
Db      1560  |||
Qy      1620  |||
Db      1620  |||
Qy      1680  |||
Db      1680  |||
Qy      1740  |||
Db      1740  |||
Qy      1800  |||
Db      1800  |||
Qy      1860  |||
Db      1860  |||
Qy      1920  |||
Db      1920  |||
Qy      1980  |||
Db      1980  |||
Qy      2040  |||
Db      2040  |||
Qy      2100  |||
Db      2100  |||
Qy      2160  |||
Db      2160  |||
Qy      2220  |||
Db      2220  |||
Qy      2280  |||

```

```

Db      2221  TTAATACTTATTCAGATGTAGTTCCTTCCAATTAATATTTGAATAAATCTTTGTAC 2280
Qy      2281  TCAA 2284
Db      2281  TCAA 2284

RESULT 11
ACA64519
ID ACA64519 standard; cDNA; 2284 BP.
XX
AC ACA64519;
XX
DT 17-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO361 cDNA.
KW Human; secreted and transmembrane protein; cyostatic; anti-HIV;
KW virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;
KW PRO; pharmaceutical; diagnostic; biosensor; bioindicator; malignancy;
KW cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;
KW lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;
KW drug screening; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003003531-A1.
XX
PD 02-JAN-2003.
XX
PF 19-NOV-2001; 2001US-00989734.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.

```

PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Geritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kijavini IU, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
XX WPI; 2003-352829/33.  
DR P-PSDB; ABU72590.  
XX  
XX  
PT New genes and secreted and transmembrane polypeptides (e.g. PRO183 or  
PT PRO184), useful for treating or diagnosing e.g. ovarian cancer, Kaposi's  
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's  
PT disease.  
XX  
PS Claim 1; Fig 327; 663pp; English.  
XX  
CC The invention describes a new isolated nucleic acid molecule comprising  
CC the full length coding sequence of the DNA deposited with the American

CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,  
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DNA  
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are  
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These  
CC are particularly useful for detecting or treating e.g. malignancies or  
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,  
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's  
CC disease in mammals. The PRO polypeptides are useful in drug screening,  
CC particularly as targets for therapeutic intervention in these diseases,  
CC and in the diagnostic determination of the presence of these diseases.  
CC The PRO polypeptides are also useful as molecular weight markers, or for  
CC chromosome identification. The PRO genes are useful as hybridisation  
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.  
CC The PRO genes may also be used in gene therapy, particularly for  
CC replacing a defective gene. This sequence encodes a novel human secreted  
CC and transmembrane PRO polypeptide  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;  
  
Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 GCGGAGATCCGCTCGGTCTCCGCGAGACCCCGCGGATTCGCGCTTCCCGC 60  
Db 1 GCGGAGATCCGCTCGGTCTCCGCGAGACCCCGCGGATTCGCGCTTCCCGC 60  
  
QY 61 GGGCGGACAGAGCTGTCTCCGACCTGGATGGCAGCAGGGCGCGGGTCTCTGCAC 120  
Db 61 GGGCGGACAGAGCTGTCTCCGACCTGGATGGCAGCAGGGCGCGGGTCTCTGCAC 120  
  
QY 121 GCCAGAGAAATCTCATCATCTGTGACGCTTCTTAAAGCAAATAAGACGAGAGGAG 180  
Db 121 GCCAGAGAAATCTCATCATCTGTGACGCTTCTTAAAGCAAATAAGACGAGAGGAG 180  
  
QY 181 GATTATCTTGACCTTGAAGACCAAATACTAACTGAAATTTAAATGTTCTTCGGGGGA 240  
Db 181 GATTATCTTGACCTTGAAGACCAAATACTAACTGAAATTTAAATGTTCTTCGGGGGA 240  
  
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300  
Db 241 GAAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300  
  
QY 301 AGTCAGATTGCTCAAAAAAGAGCTAGAAAGTGTGTCACTGACATCCAGTCATCTT 360  
Db 301 AGTCAGATTGCTCAAAAAAGAGCTAGAAAGTGTGTCACTGACATCCAGTCATCTT 360  
  
QY 361 TCTAAGGAATCAGAGCAATGAGCCGATATATCTTCACTCAAGAAGACTGCATTAAT 420  
Db 361 TCTAAGGAATCAGAGCAATGAGCCGATATATCTTCACTCAAGAAGACTGCATTAAT 420  
  
QY 421 TCTTGTCTTCAACAAAAACATATCAGGGGACAAAGCATGTAATTGATGATCTTCGAC 480  
Db 421 TCTTGTCTTCAACAAAAACATATCAGGGGACAAAGCATGTAATTGATGATCTTCGAC 480  
  
QY 481 ACTCGAAAAACAGCTAGACAACCCCACTGCTAATTTTCTGTCTCCCAAGGAAGCC 540  
Db 481 ACTCGAAAAACAGCTAGACAACCCCACTGCTAATTTTCTGTCTCCCAAGGAAGCC 540  
  
QY 541 TGTCCATTGAAACGACAAAGAGACTTATGAGTTACAGGATTAATTACAGATTTTCATCT 600  
Db 541 TGTCCATTGAAACGACAAAGAGACTTATGAGTTACAGGATTAATTACAGATTTTCATCT 600  
  
QY 601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 660  
Db 601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 660  
  
QY 661 TTTTCAACAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720  
Db 661 TTTTCAACAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720  
  
QY 721 ATTCATGAGAGACACACTTTCTCAGAGTTTGATCTCTCAGATCACTGGAGAACTA 780  
Db 721 ATTCATGAGAGACACACTTTCTCAGAGTTTGATCTCTCAGATCACTGGAGAACTA 780



Db 721 ATCTCATGAGAGACACACTTTCTGAGAAAGTTGGATCCTTCAGATCACTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTCCCAAGCTCTTGCTTATATAGGAAAAAGGCCATTCTCAG 840  
Db 781 TTTAAGATGATGAAGCAAGTCCCAAGCTCTTGCTTATATAGGAAAAAGGCCATTCTCAG 840  
QY 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGTAATAATGTAGTGG 900  
Db 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGTAATAATGTAGTGG 900  
QY 901 CTCACGCTACGGGTGAGTGTCTCTCCACATACCACCTGGCTACTCCAAAGCCGGCC 960  
Db 901 CTCACGCTACGGGTGAGTGTCTCTCCACATACCACCTGGCTACTCCAAAGCCGGCC 960  
QY 961 ACCCTTCTACCCCAACCAATGCTTCACTGACACCTTCTGGAGCTTCCAGCCACAGCTGGCC 1020  
Db 961 ACCCTTCTACCCCAACCAATGCTTCACTGACACCTTCTGGAGCTTCCAGCCACAGCTGGCC 1020  
QY 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCCTCCCAAGCACTCATTTCTACA 1080  
Db 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCCTCCCAAGCACTCATTTCTACA 1080  
QY 1081 GTTTTACACGGGCTGGCTACCTCAAGCAATGGCTACACAGCAAGTCTGACTTACC 1140  
Db 1081 GTTTTACACGGGCTGGCTACCTCAAGCAATGGCTACACAGCAAGTCTGACTTACC 1140  
QY 1141 ACCTTACAGCACTTACGCACTCGAAGGCAAGCTTAGAAACCAATCCGTTTACAGAAATC 1200  
Db 1141 ACCTTACAGCACTTACGCACTCGAAGGCAAGCTTAGAAACCAATCCGTTTACAGAAATC 1200  
QY 1201 TCCAACTTAATTGAAACACAGGAATGTATTAACCCCTACTGCACTTCTATGTCAAT 1260  
Db 1201 TCCAACTTAATTGAAACACAGGAATGTATTAACCCCTACTGCACTTCTATGTCAAT 1260  
QY 1261 GTGAGTCTTCCACTATGAAATAAACTGCTTCTGGAAGGTAGGAGGCCAGTCCAGGC 1320  
Db 1261 GTGAGTCTTCCACTATGAAATAAACTGCTTCTGGAAGGTAGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCTTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
Db 1321 AGTTCTTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTTATCGGCTCCCTGCTCTTGTGTCTGTCTCTGCTGATAGGCTCTGCTCCTGGGT 1440  
Db 1381 CTTATCGGCTCCCTGCTCTTGTGTCTGTCTCTGCTGATAGGCTCTGCTCCTGGGT 1440  
QY 1441 AGAATCTTTCCGAATCACTCCGAGAAACGTTACTCAAGACTGGAATTTGATCAAT 1500  
Db 1441 AGAATCTTTCCGAATCACTCCGAGAAACGTTACTCAAGACTGGAATTTGATCAAT 1500  
QY 1501 GGGATCTATGTGACATCTAAGGATGAACTCGGTGTCTTAAATTCATTAGTAACCAAG 1560  
Db 1501 GGGATCTATGTGACATCTAAGGATGAACTCGGTGTCTTAAATTCATTAGTAACCAAG 1560  
QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGTAGTCTTAGCAGAGGTGTATTGTA 1620  
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGTAGTCTTAGCAGAGGTGTATTGTA 1620  
QY 1621 AGACAGGAAAAATGCCCTTCTGCTTCTTTTCTTTTGTGAGACAGAGTCTGCTCTG 1680  
Db 1621 AGACAGGAAAAATGCCCTTCTGCTTCTTTTCTTTTGTGAGACAGAGTCTGCTCTG 1680  
QY 1681 TTGCCAGGCTGAGTGCAGTACGATCTCGGCTCTACCGCAACTCCGCTCCTGG 1740  
Db 1681 TTGCCAGGCTGAGTGCAGTACGATCTCGGCTCTACCGCAACTCCGCTCCTGG 1740  
QY 1741 GTTCAAGCAATCTCTGCTCAGCCTCTAAGTATCTGGATTAAGGATGTGCCACC 1800  
Db 1741 GTTCAAGCAATCTCTGCTCAGCCTCTAAGTATCTGGATTAAGGATGTGCCACC 1800  
QY 1801 ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTTGGTCAAGGCTG 1860  
Db 1801 ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTTGGTCAAGGCTG 1860

QY 1861 GTCTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGTGGATTACA 1920  
Db 1861 GTCTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGTGGATTACA 1920  
QY 1921 GGCAATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTTTGTGAGAAGGAATGA 1980  
Db 1921 GGCAATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTTTGTGAGAAGGAATGA 1980  
QY 1981 AGTGGGAACCAATTAGTAATTTTGGGTAATCTGTCTTAAATATATTAGCTAAAAACAA 2040  
Db 1981 AGTGGGAACCAATTAGTAATTTTGGGTAATCTGTCTTAAATATATTAGCTAAAAACAA 2040  
QY 2041 AGCTCTATGTAAAGTAATAAGTATTAATGGCATATATAATTCAAAATCAACTGGCTTT 2100  
Db 2041 AGCTCTATGTAAAGTAATAAGTATTAATGGCATATATAATTCAAAATCAACTGGCTTT 2100  
QY 2101 TATGCAAGAAGAACAGGTTAGACATCTAGTTCCAATTCAATTCACATTTCTGGTCCAGA 2160  
Db 2101 TATGCAAGAAGAACAGGTTAGACATCTAGTTCCAATTCAATTCACATTTCTGGTCCAGA 2160  
QY 2221 TTAATACTTATTCAGATGTAGTTCCTTCCAAATTAATAATTGAATAAATCTTTGTAC 2280  
Db 2221 TTAATACTTATTCAGATGTAGTTCCTTCCAAATTAATAATTGAATAAATCTTTGTAC 2280  
QY 2281 TCAA 2284  
Db 2281 TCAA 2284

RESULT 12  
ABX96832  
ID ABX96832 standard; cDNA; 2284 BP.  
XX  
AC ABX96832;  
XX  
DT 15-MAY-2003 (first entry)  
XX  
DE Human cDNA encoding secreted/transmembrane protein PRO361.  
XX  
KW Human; ss; gene; PRO; secreted protein; transmembrane protein;  
Cornelia de Lange syndrome; gene therapy; immune disorder;  
inflammatory disease; organ failure; atherosclerosis; cardiac injury;  
infertility; birth defect; premature aging; cardiac injury; AIDS; cancer;  
diabetic complication.  
XX  
OS Homo sapiens.  
XX  
PN US2002173463-A1.  
XX  
PD 21-NOV-2002.  
XX  
PF 31-AUG-2001; 2001US-00944944.  
XX  
PR 03-DEC-1997; 97US-0067411P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.

PR 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 16-DEC-1998; 98US-0112850P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 28-JUL-1999; 99US-0146222P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kijavln IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX  
DR WPI; 2003-311003/30.  
DR P-PSDB; ABU64930.  
XX  
PT New transmembrane polypeptides and polynucleotides useful for chromosome  
PT identification, tissue typing, gene therapy, in chromosome and gene  
PT mapping, or as molecular weight markers.  
XX  
PS Claim 2; Fig 31; 172pp; English.  
XX  
CC The invention relates to an isolated nucleic acid encoding a secreted/  
CC transmembrane polypeptide (designated as PRO proteins). 15 PRO  
CC polypeptides and their encoding polynucleotides are disclosed. Also  
CC included are a vector comprising the PRO nucleic acid, a host cell  
CC comprising the vector, a process for producing a PRO polypeptide (by  
CC culturing the host cell under conditions for the expression of the PRO  
CC polypeptide, and recovering the PRO polypeptide from the cell culture, an  
CC isolated polypeptide having at least 80% amino acid sequence identity to  
CC the PRO polypeptides, a chimaeric molecule comprising PRO fused to a  
CC heterologous amino acid sequence and an antibody which specifically binds  
CC to PRO. The PRO nucleotide sequences are useful as hybridisation probes,  
CC in chromosome and gene mapping, in generating sense and antisense RNA or  
CC DNA, in generating transgenic or knock-out animals which can be used in  
CC the development and screening of therapeutically useful reagents, and in  
CC gene therapy. The polypeptides may be used as molecular weight markers  
CC for protein electrophoresis purposes. The PRO polypeptides and nucleic  
CC acids may also be used for chromosome identification, and tissue typing.  
CC PRO241 (identified as Chordin) is a candidate gene for Cornelia de Lange  
CC syndrome. Other PRO proteins are variously implicated in immune  
CC disorders, inflammatory disease, organ failure, atherosclerosis, cardiac  
CC injury, infertility, birth defects, premature aging, cardiac injury,  
CC AIDS, cancer and diabetic complications. The present sequence encodes a  
CC PRO protein  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGCATCGCTGCGGTCTCTGCGCGAGACCCCGCGGATTCGCGGTCTTCCGCG 60  
DB 1 GCGGAGCATCGCTGCGGTCTCTGCGCGAGACCCCGCGGATTCGCGGTCTTCCGCG 60  
QY 61 GCGGCGAGACGAGCTGTCTCTGCGACCTGATGGCAGCAGGGCGCGGGGTCTCTCGAC 120  
DB 61 GCGGCGAGACGAGCTGTCTCTGCGACCTGATGGCAGCAGGGCGCGGGGTCTCTCGAC 120

QY 121 GCCAGAGAGAAATCTCATCTGTGCGAGCCTTCTTAAAGCAAATAAGACCGAGGGAG 180  
DB 121 GCCAGAGAGAAATCTCATCTGTGCGAGCCTTCTTAAAGCAAATAAGACCGAGGGAG 180  
QY 181 GATTATCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
DB 181 GATTATCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
QY 241 GAAGGAGCTTGACCTTACACTTGGTAAATAATTTGCTTCGACACTAAGGCTGTCTGCT 300  
DB 241 GAAGGAGCTTGACCTTACACTTGGTAAATAATTTGCTTCGACACTAAGGCTGTCTGCT 300  
QY 301 AGTCAGAAATTGCTCAAAAAGAGTCTAGAAGATGTTGTCAATTGACATCCAGTCATCTT 360  
DB 301 AGTCAGAAATTGCTCAAAAAGAGTCTAGAAGATGTTGTCAATTGACATCCAGTCATCTT 360  
QY 361 TCTAAGGGAATCAGAGGCAATGAGCCGTATATCTTCAACTCAAGAAGACTGCATTAAAT 420  
DB 361 TCTAAGGGAATCAGAGGCAATGAGCCGTATATCTTCAACTCAAGAAGACTGCATTAAAT 420  
QY 421 TCTTGCTGTCAACAAAAACATATCAGGGGACAAAGCATGTAATCTGATGATCTTCGAC 480  
DB 421 TCTTGCTGTCAACAAAAACATATCAGGGGACAAAGCATGTAATCTGATGATCTTCGAC 480  
QY 481 ACTGAAAAACAGCTAGACAAACCACTGTACTATTTTCTGTCCCAAGAGAAAGCC 540  
DB 481 ACTGAAAAACAGCTAGACAAACCACTGTACTATTTTCTGTCCCAAGAGAAAGCC 540  
QY 541 TGTCATTTGAACCAAGCAAAAGACTTATAGTTACAGATTAATACAGATTTTCCATCT 600  
DB 541 TGTCATTTGAACCAAGCAAAAGACTTATAGTTACAGATTAATACAGATTTTCCATCT 600  
QY 601 TTGACCAAGAAATTTGCCAAGCCCAAGAGTTACCCCAAGAAAGTTCTCTTACATGGCCAA 660  
DB 601 TTGACCAAGAAATTTGCCAAGCCCAAGAGTTACCCCAAGAAAGTTCTCTTACATGGCCAA 660  
QY 661 TTTTCAAGAGAGTCACTCCCTTAGCCCATCATCACACAGATTAATTCAAAGCCCAAGAT 720  
DB 661 TTTTCAAGAGAGTCACTCCCTTAGCCCATCATCACACAGATTAATTCAAAGCCCAAGAT 720  
QY 721 ATCTCATGAGAGACACACTTCTCAGAAATTGGATCTCAGATCACTGGAGAAACTA 780  
DB 721 ATCTCATGAGAGACACACTTCTCAGAAATTGGATCTCAGATCACTGGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTGTTATTAAGAAAGGCCATTTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTGTTATTAAGAAAGGCCATTTCTCAG 840  
QY 841 AGTTCACAATTTTCTCTGTATCAAGAAATAGCTCATCTGCTGCTGAATAATGTGAGTGG 900  
DB 841 AGTTCACAATTTTCTCTGTATCAAGAAATAGCTCATCTGCTGCTGAATAATGTGAGTGG 900  
QY 901 CTCCAGCTACGGTGCGAGTTGCTTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
DB 901 CTCCAGCTACGGTGCGAGTTGCTTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
QY 961 ACCCTTCAACCAACCAATGCTTCAGTGAACACTTCTGGAGCTTCCAGCAGCTGGCC 1020  
DB 961 ACCCTTCAACCAACCAATGCTTCAGTGAACACTTCTGGAGCTTCCAGCAGCTGGCC 1020  
QY 1021 ACCACAGCTCCACCTGTAAACCACTTCTCAGCCTCCAGCAGCCTCATTTCTACA 1080  
DB 1021 ACCACAGCTCCACCTGTAAACCACTTCTCAGCCTCCAGCAGCCTCATTTCTACA 1080  
QY 1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGCGTACACAGCAGTTCTGACTACC 1140  
DB 1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGCGTACACAGCAGTTCTGACTACC 1140  
QY 1141 ACCTTTACAGGCACTACGGACTCGAAAGGCAAGCTTAAAGAACATACGTTTACAGAAATC 1200  
DB 1141 ACCTTTACAGGCACTACGGACTCGAAAGGCAAGCTTAAAGAACATACGTTTACAGAAATC 1200

QY 1201 TCCAACTTAATTGGAACACAGGGAAATGTGTATTAACCCCTACTGCACTTCTATGTCAAAAT 1260  
Db 1201 TCCAACTTAATTGGAACACAGGGAAATGTGTATTAACCCCTACTGCACTTCTATGTCAAAAT 1260  
QY 1261 GTGAGTCTTCCACTATGAAATAAACTGCTTCTCTGGAGGTAGGGAGGCCAGTCCAGGC 1320  
Db 1261 GTGAGTCTTCCACTATGAAATAAACTGCTTCTCTGGAGGTAGGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGCGCTTCCATTGAAAAATGGCTT 1380  
Db 1321 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGCGCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTCTCTGTATAGGCTCTGCTCTGGGT 1440  
Db 1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTCTCTGTATAGGCTCTGCTCTGGGT 1440  
QY 1441 AGAATCTTTCCGAATCACTCCGACAGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
Db 1441 AGAATCTTTCCGAATCACTCCGACAGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
QY 1501 GGGATCTATGTGACATCTAAGATGGAACCTCGGTGTCTCTTAATTCAATTAGTAACCAAG 1560  
Db 1501 GGGATCTATGTGACATCTAAGATGGAACCTCGGTGTCTCTTAATTCAATTAGTAACCAAG 1560  
QY 1561 AAGCCAAATGCAATGAGTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGTATTGTA 1620  
Db 1561 AAGCCAAATGCAATGAGTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGTATTGTA 1620  
QY 1621 AGACAGGAAATGCCCCCTTCTGCTTCTTTTGGAGAAGAGTCTGCTCTG 1680  
Db 1621 AGACAGGAAATGCCCCCTTCTGCTTCTTTTGGAGAAGAGTCTGCTCTG 1680  
QY 1681 TTGCCAGGCTGAGTGCAGTAGACGATCTCGGCTCTCACCGCAACTCCGCTCTCTGG 1740  
Db 1681 TTGCCAGGCTGAGTGCAGTAGACGATCTCGGCTCTCACCGCAACTCCGCTCTCTGG 1740  
QY 1741 GTTCAAGCGATTCTCTGCTCAGCTCTCTAAGTATCTGGGATTAAGGCATGTGCCACC 1800  
Db 1741 GTTCAAGCGATTCTCTGCTCAGCTCTCTAAGTATCTGGGATTAAGGCATGTGCCACC 1800  
QY 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACATGTGTGTCAGGCTG 1860  
Db 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACATGTGTGTCAGGCTG 1860  
QY 1861 GTTCAAACTCTGACCTAGTATCAACCTCTCGGCTCTCCAAAGTGTGGATTACA 1920  
Db 1861 GTTCAAACTCTGACCTAGTATCAACCTCTCGGCTCTCCAAAGTGTGGATTACA 1920  
QY 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTGTTTGGTGAAGAAGATGA 1980  
Db 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTGTTTGGTGAAGAAGATGA 1980  
QY 1981 AGTGGAAACCAATTAGGTAATTTGGGTAATCTGTCTCTAATAATTAGCTAAAAACAA 2040  
Db 1981 AGTGGAAACCAATTAGGTAATTTGGGTAATCTGTCTCTAATAATTAGCTAAAAACAA 2040  
QY 2041 AGCTCTATGTAAAGTAATAAGTAAATGCCATATAAAATTCAAAATCACTGGCTTT 2100  
Db 2041 AGCTCTATGTAAAGTAATAAGTAAATGCCATATAAAATTCAAAATCACTGGCTTT 2100  
QY 2101 TATGCAAGAAACAGGTAGACATCTAGGTTCCAATTCAATTCATTCCTTGTCCAGA 2160  
Db 2101 TATGCAAGAAACAGGTAGACATCTAGGTTCCAATTCAATTCATTCCTTGTCCAGA 2160  
QY 2161 TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTTATATGATGATTCCT 2220  
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTTATATGATGATTCCT 2220  
QY 2221 TTAAACTTATTCAGATGTAGTCTTCCCAATTAATATTGAATAAATCTTTGTTAC 2280  
Db 2221 TTAAACTTATTCAGATGTAGTCTTCCCAATTAATATTGAATAAATCTTTGTTAC 2280  
QY 2281 TCAA 2284

Db 2281 TCAA 2284  
RESULT 13  
ABX78486  
ID ABX78486 standard; DNA; 2284 BP.  
XX AC ABX78486;  
XX DT 14-APR-2003 (first entry)  
XX DE DNA encoding Novel human secreted protein PRO361.  
KW Human; antiinflammatory; antiarteriosclerotic; cardiant; gynecological;  
KW anti-HIV; cyostatic; antidiabetic; BMP-agonist; BMP-Antagonist;  
KW cytokine-agonist; cytokine-antagonist; gene-Therapy;  
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;  
KW infertility; birth defect; premature aging; AIDS; cancer;  
KW diabetic complication; gene; ds.  
OS Homo sapiens.  
XX US2002150976-A1.  
XX PD 17-OCT-2002.  
XX PF 30-AUG-2001; 2001US-00943851.  
XX 03-DEC-1997; 97US-0067411P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 16-DEC-1998; 98US-00216021.  
PR 16-DEC-1998; 98US-0112850P.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 03-MAR-1999; 99US-00254311.  
PR 02-JUN-1999; 99WO-US012252.  
PR 28-JUL-1999; 99US-0146222P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US030095.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX  
PA (GENE ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;



XX WPI; 2003-198285/19.  
DR P-PSDB; ABUS8364.  
XX  
PT New isolated PRO polypeptide and encoding nucleic acids, useful for the  
PT diagnosis and treatment of disorders such as inflammatory disease,  
PT atherosclerosis, cardiac injury, infertility, AIDS, cancer and diabetic  
PT complications.  
XX  
PS Claim 2; Fig 31; 171pp; English.  
XX  
CC The invention describes a novel isolated PRO polypeptide. The methods and  
CC compositions of the present invention are useful for the diagnosis and  
CC treatment of disorders such as inflammatory disease, organ failure,  
CC atherosclerosis, cardiac injury, infertility, birth defects, premature  
CC aging, AIDS, cancer, diabetic complications and mutations in general.  
CC This sequence encodes a novel human secreted PRO protein  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGATCCGCTGCGGTCTCGCGGAGACCCCGCGGATTCGCGGTCTTCCCGC 60  
DB 1 GCGGAGATCCGCTGCGGTCTCGCGGAGACCCCGCGGATTCGCGGTCTTCCCGC 60  
QY 61 GGGCGCGACAGAGCTGTCTCGCACTTGATGGCAGCAGGGGCGCGGGGTCTCTGCAC 120  
DB 61 GGGCGCGACAGAGCTGTCTCGCACTTGATGGCAGCAGGGGCGCGGGGTCTCTGCAC 120  
QY 121 GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAAGCAAACTTAAGACCAGAGGGAG 180  
DB 121 GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAAGCAAACTTAAGACCAGAGGGAG 180  
QY 181 GATTATCCTTGACCTTGAGAGACCAAACTGAAATTTAAATGTTCTTCGGGGGA 240  
DB 181 GATTATCCTTGACCTTGAGAGACCAAACTGAAATTTAAATGTTCTTCGGGGGA 240  
QY 241 GAAGGAGCTGACTTACACTTTGTAATAATTGCTTCTGACACTAAGGCTGTGCT 300  
DB 241 GAAGGAGCTGACTTACACTTTGTAATAATTGCTTCTGACACTAAGGCTGTGCT 300  
QY 301 AGTCAGAAATGCTCAAAAAAGAGCTAGAGATGTGTCAATTGACATCCAGTCATCTT 360  
DB 301 AGTCAGAAATGCTCAAAAAAGAGCTAGAGATGTGTCAATTGACATCCAGTCATCTT 360  
QY 361 TCTAAGGGAATCAGAGGCAATGAGCCCGTAATACTTCAACTCAAGAGA CTGATTAAAT 420  
DB 361 TCTAAGGGAATCAGAGGCAATGAGCCCGTAATACTTCAACTCAAGAGA CTGATTAAAT 420  
QY 421 TCTTGCTGTCAACAAAAACATATCAGGGGCAAAAGCATGTAACCTGATGATCTTGAC 480  
DB 421 TCTTGCTGTCAACAAAAACATATCAGGGGCAAAAGCATGTAACCTGATGATCTTGAC 480  
QY 481 ACTGAAAAACAGCTAGACAACCCAACTGCTACTATTTTCTGTCCCAAGAGAGCC 540  
DB 481 ACTGAAAAACAGCTAGACAACCCAACTGCTACTATTTTCTGTCCCAAGAGAGCC 540  
QY 541 TGTCCATTGAAACAGAAAAAGACTTATAGTTACAGGATAATTACGATTTTCCATCT 600  
DB 541 TGTCCATTGAAACAGAAAAAGACTTATAGTTACAGGATAATTACGATTTTCCATCT 600  
QY 601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCCAAGGAAGATTCTCTTACATGGCCAA 660  
DB 601 TTGACCAAGAAATTTGCCAAGCCAAAGATTACCCCAAGGAAGATTCTCTTACATGGCCAA 660  
QY 661 TTTTCAACAAGAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT 720  
DB 661 TTTTCAACAAGAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT 720  
QY 721 ATCTCATGAGAGACACACTTCTCAGAAATTGGATCCTCAGATCACTGAGAAACTA 780

DB 721 ATCTCATGAGAGACACACTTCTCAGAAATTGGATCCTCAGATCACTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATTAAGAAAAAGCCATTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATTAAGAAAAAGCCATTCTCAG 840  
QY 841 AGTTCAGAAATTTCTCTGATCAAGAAATAGCTCATCTGCTCTGAAAAATGTGAGTGC 900  
DB 841 AGTTCAGAAATTTCTCTGATCAAGAAATAGCTCATCTGCTCTGAAAAATGTGAGTGC 900  
QY 901 CTCCAGCTACGGTGAGTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
DB 901 CTCCAGCTACGGTGAGTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
QY 961 ACCCTTCTACCCCAACCAATGCTTCAAGTACACCTTCTGGGACTTCCCAAGCAGCTGGCC 1020  
DB 961 ACCCTTCTACCCCAACCAATGCTTCAAGTACACCTTCTGGGACTTCCCAAGCAGCTGGCC 1020  
QY 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCTCATTTCTACA 1080  
DB 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCTCATTTCTACA 1080  
QY 1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGGCTACACAGCAGTTCTGACTACC 1140  
DB 1081 GTTTTACACGGGCTGCGGCTACACTCCAAGCAATGGCTACACAGCAGTTCTGACTACC 1140  
QY 1141 ACCTTTCAAGGCACTACGAGCTCGAAAGGAGCTTAAGAAACATACCCTTACAGAAATC 1200  
DB 1141 ACCTTTCAAGGCACTACGAGCTCGAAAGGAGCTTAAGAAACATACCCTTACAGAAATC 1200  
QY 1201 TCCAACCTTAACCTTGAACACAGGGAATGTGTATAACCTTACTGCACTTCTATGTCAAAAT 1260  
DB 1201 TCCAACCTTAACCTTGAACACAGGGAATGTGTATAACCTTACTGCACTTCTATGTCAAAAT 1260  
QY 1261 GTGAGTCTTCCACTATGATTAATACTGCTTCTCGGGAAGTTAGGAGGCCAGTCCAGGC 1320  
DB 1261 GTGAGTCTTCCACTATGATTAATACTGCTTCTCGGGAAGTTAGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCTCTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
DB 1321 AGTTCTCTCCAGGGCAGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTTATCGGGTCCCTGCTCTTGTGTCTGTTCTCTGTGATAGGCTCGTCTCTCGGGT 1440  
DB 1381 CTTATCGGGTCCCTGCTCTTGTGTCTGTTCTCTGTGATAGGCTCGTCTCTCGGGT 1440  
QY 1441 AGAATCCTTTCGAATCACTCCGAGAAACGTTACTCAAGACTGATTATTGATCAAT 1500  
DB 1441 AGAATCCTTTCGAATCACTCCGAGAAACGTTACTCAAGACTGATTATTGATCAAT 1500  
QY 1501 GGGATCTATGTGACATCTAAGATGGAACCTGGTGTCTTAATTATTAGTAACCAAG 1560  
DB 1501 GGGATCTATGTGACATCTAAGATGGAACCTGGTGTCTTAATTATTAGTAACCAAG 1560  
QY 1561 AAGCCCAATGCAATGAGTTTCTGTGACTTGTCTAGTCTTACAGAGAGTTGTATTTTGA 1620  
DB 1561 AAGCCCAATGCAATGAGTTTCTGTGACTTGTCTAGTCTTACAGAGAGTTGTATTTTGA 1620  
QY 1621 AGACAGAAAAATGCCCCCTTCTGCTTCTTTTCTTTTGGAGACAGAGTCTTGCTCTG 1680  
DB 1621 AGACAGAAAAATGCCCCCTTCTGCTTCTTTTCTTTTGGAGACAGAGTCTTGCTCTG 1680  
QY 1681 TTGCCAGGCTGAGTGACATGACATCTCGGCTCTCACCGCAACTCCGTCTCTGG 1740  
DB 1681 TTGCCAGGCTGAGTGACATGACATCTCGGCTCTCACCGCAACTCCGTCTCTGG 1740  
QY 1741 GTTCAAGGATTTCTCTGCTCAGGCTCCTAAGTATCTGGATTACAGGCATGTGCCACC 1800  
DB 1741 GTTCAAGGATTTCTCTGCTCAGGCTCCTAAGTATCTGGATTACAGGCATGTGCCACC 1800  
QY 1801 ACACCTGGTGATTTTGTATTTTTATGAGACGGGGTTTCACTGTTGGTCAAGGCTG 1860

Db 1801 AACCTGGGTGATTTTGTATTTTAGTAGAGACGGGGTTTCAACCATGTTGGTCAGGCTG 1860  
QY 1861 GTCTCAAACTCCTGACCTAGTATGCCACCTCTCGGCTCCCAAAGTGCTGGATTACA 1920  
Db 1861 GTCTCAAACTCCTGACCTAGTATGCCACCTCTCGGCTCCCAAAGTGCTGGATTACA 1920  
QY 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTTTGGAGAAGGAATGA 1980  
Db 1921 GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTTTGGAGAAGGAATGA 1980  
QY 1981 AGTGGAAACCAATTAGTAAATTTGGGTAATCTGTCTTAAATAATTAGCTAAAGAACAA 2040  
Db 1981 AGTGGAAACCAATTAGTAAATTTGGGTAATCTGTCTTAAATAATTAGCTAAAGAACAA 2040  
QY 2041 AGCTCTATGTAAAGTAAATTAAGTAAATTTGCCATATAAATTCAAAATTCACCTGGCTTT 2100  
Db 2041 AGCTCTATGTAAAGTAAATTAAGTAAATTTGCCATATAAATTCAAAATTCACCTGGCTTT 2100  
QY 2101 TATGCAAAAGAACAGGTAGACATCTAGGTTCCAATTCAATTCACATTCTTGTTCCAGA 2160  
Db 2101 TATGCAAAAGAACAGGTAGACATCTAGGTTCCAATTCAATTCACATTCTTGTTCCAGA 2160  
QY 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTGCTTTCTTTTATATGATTCTT 2220  
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTGCTTTCTTTTATATGATTCTT 2220  
QY 2221 TTAATACTTATTCAGATGATGTTCTTCCCAATTAATATTTGAATAAATCTTTGTTCAC 2280  
Db 2221 TTAATACTTATTCAGATGATGTTCTTCCCAATTAATATTTGAATAAATCTTTGTTCAC 2280  
QY 2281 TCAG 2284  
Db 2281 TCAG 2284

RESULT 14

ABX77120  
ID ABX77120 standard; cDNA; 2284 BP.

XX ABX77120;

DT 04-APR-2003 (first entry)

DE cDNA encoding human PRO361 protein.

XX Gene; ss; human; antiinflammatory; antiarteriosclerotic; cardiant;  
KW anti-infertility; anti-HIV; cytostatic; antidiabetic; transmembrane;  
KW antiinflammatory; anti-HIV; antiarteriosclerotic; cardiant; infertility;  
KW anti-infertility; cytostatic; antidiabetic; gene therapy; birth defect;  
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;  
KW premature aging; AIDS; cancer; diabetic complication.

OS Homo sapiens.

PN US2002142958-A1.

XX 03-OCT-2002.

PF 30-AUG-2001; 2001US-00943762.

XX 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.

PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Botstein D, Baton DL, Ferrara N, Filvaroff E;  
PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kijavini IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX WPI; 2003-174140/17.  
DR P-PSDB; ABUS7251.  
PT New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
PT cancer.  
XX Claim 2; Fig 31; 173pp; English.  
PS This invention relates to a nucleotide sequence encoding an isolated  
CC secreted and/or transmembrane protein. The nucleotide sequences of the  
CC invention may have antiinflammatory, antiarteriosclerotic, cardiant, anti  
CC -infertility, anti-HIV, cytostatic and antidiabetic activities and may be  
CC used in gene therapy. The nucleic acids and polypeptides are useful for  
CC treating inflammatory diseases, organ failure, atherosclerosis, cardiac  
CC injury, infertility, birth defects, premature aging, AIDS, cancer, or  
CC diabetic complications. The nucleic acids are useful as hybridisation  
CC probes, in chromosome and gene mapping, and in generating antisense RNA  
CC or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,  
CC biosensors or bioreactors. Both are useful in tissue typing. The present  
CC sequence represents a nucleic acid sequence of the invention  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;  
Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 GCGGAGCATCCGCTGCGTCTCGCCGAGACCCCGCGGATTCGCCGCTTCCCGC 60  
Db 1 GCGGAGCATCCGCTGCGTCTCGCCGAGACCCCGCGGATTCGCCGCTTCCCGC 60  
QY 61 GGGCGGACAGAGCTGTCTTCGCACTTGATGACAGAGGGCGCGGGTCTCTGCAC 120  
Db 61 GGGCGGACAGAGCTGTCTTCGCACTTGATGACAGAGGGCGCGGGTCTCTGCAC 120  
QY 121 GCCAGAGAGAAATCTCATCTGTGTGACGCTTCTTAAAGCAACTAAGACAGAGGGAG 180  
Db 121 GCCAGAGAGAAATCTCATCTGTGTGACGCTTCTTAAAGCAACTAAGACAGAGGGAG 180  
QY 181 GATTATCCTTGACCTTTGAAGACCAAACTAAACTGAAATTAAATGTTCTTGGGGGA 240  
Db 181 GATTATCCTTGACCTTTGAAGACCAAACTAAACTGAAATTAAATGTTCTTGGGGGA 240  
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATAATTGCTTCTGACACTAAGGCTGTCTGCT 300  
Db 241 GAAGGAGCTTGACTTACACTTTGGTAATAATTGCTTCTGACACTAAGGCTGTCTGCT 300  
QY 301 AGTCAGATTGCTCTCAAAAAGAGTCTAGAAGATGTTGCAATGACATCCAGTCACTCTT 360  
Db 301 AGTCAGATTGCTCTCAAAAAGAGTCTAGAAGATGTTGCAATGACATCCAGTCACTCTT 360  
QY 361 TCTAAGGGAATCAGAGGCAATGAGCCCGTATATATCTTCAACTCAAGAAGACTGCATTAA 420  
Db 361 TCTAAGGGAATCAGAGGCAATGAGCCCGTATATATCTTCAACTCAAGAAGACTGCATTAA 420  
QY 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGCAC 480  
Db 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGCAC 480  
QY 481 ACTGAAAAACAGCTAGACAAACCACTGCTACCTATTTTCTGTCCCAAGAGGAGGCC 540

```
Db 481 ACTCGAAAAACAGCTAGACAAACCACTGCTACTATTCTTCTGTCCTCAACGAGGAAGCC 540
Qy 541 TGTCCATTGAAACAGCAAAAGGACTTAAGAGTTACAGAGATAATTACAGATTTTCCATCT 600
Db 541 TGTCCATTGAAACAGCAAAAGGACTTAAGAGTTACAGAGATAATTACAGATTTTCCATCT 600
Qy 601 TTGACCAAAATTTGCCAAGCCAAAGATTACCCAGAAAGATTCTCTTACATGGCCAA 660
Db 601 TTGACCAAAATTTGCCAAGCCAAAGATTACCCAGAAAGATTCTCTTACATGGCCAA 660
Qy 661 TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACAGATTATTCAAAAGCCACCGAT 720
Db 661 TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACAGATTATTCAAAAGCCACCGAT 720
Qy 721 ATCTCATGGAGAGACACACTTCTCAGAGTTTGATCCTCAGATCACTGAGAACTA 780
Db 721 ATCTCATGGAGAGACACACTTCTCAGAGTTTGATCCTCAGATCACTGAGAACTA 780
Qy 781 TTTAAGATGAGTGAAGCAAGTGCCCGAGCTTGTCTTATAAGAAAGGCCATTCTCAG 840
Db 781 TTTAAGATGAGTGAAGCAAGTGCCCGAGCTTGTCTTATAAGAAAGGCCATTCTCAG 840
Qy 841 AGTTCAAAATTTTCTCTGTATCAAGAAATAGCTCATCTGTGCTGAAATGTGAGTGG 900
Db 841 AGTTCAAAATTTTCTCTGTATCAAGAAATAGCTCATCTGTGCTGAAATGTGAGTGG 900
Qy 901 CTCACAGCTACGGGTGGCAGTTGCTTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960
Db 901 CTCACAGCTACGGGTGGCAGTTGCTTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960
Qy 961 ACCCTTCAACCCACCAATGCTTCAGTGACACTTCTGGAGCTTCCGAGCCACAGCTGGCC 1020
Db 961 ACCCTTCAACCCACCAATGCTTCAGTGACACTTCTGGAGCTTCCGAGCCACAGCTGGCC 1020
Qy 1021 ACCACAGCTCACTGTGAACCACTGTCACTTCTCAGCCTCCCAAGACCTCATTTCTACA 1080
Db 1021 ACCACAGCTCACTGTGAACCACTGTCACTTCTCAGCCTCCCAAGACCTCATTTCTACA 1080
Qy 1081 GTTTTACACGGGGCTGGGCTACACTCCAAAGCAATGGCTACAACAGCAGTTCTGACTACC 1140
Db 1081 GTTTTACACGGGGCTGGGCTACACTCCAAAGCAATGGCTACAACAGCAGTTCTGACTACC 1140
Qy 1141 ACCTTTCAGGCACTACGGACTCGAAAGGCACTTAGAAACCATACCGTTTACAGAAATC 1200
Db 1141 ACCTTTCAGGCACTACGGACTCGAAAGGCACTTAGAAACCATACCGTTTACAGAAATC 1200
Qy 1201 TCCAACTTAATTGAAACACAGGGAATGTATTAACCTACTGCACTTCTATGTCAAAAT 1260
Db 1201 TCCAACTTAATTGAAACACAGGGAATGTATTAACCTACTGCACTTCTATGTCAAAAT 1260
Qy 1261 GTGAGTCTTCCACTATGATAAAACTGCTTCTGGGAGGTAGGAGGCCAGTCCAGGC 1320
Db 1261 GTGAGTCTTCCACTATGATAAAACTGCTTCTGGGAGGTAGGAGGCCAGTCCAGGC 1320
Qy 1321 AGTTCCTCCAGGGCAGTGTTCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380
Db 1321 AGTTCCTCCAGGGCAGTGTTCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380
Qy 1381 CTTATCGGGTCCCTGCTCTTGTGTCTCTGTCTCTGTGATAGGCTGCTCTCTGGGT 1440
Db 1381 CTTATCGGGTCCCTGCTCTTGTGTCTCTGTCTCTGTGATAGGCTGCTCTCTGGGT 1440
Qy 1441 AGAATCCTTTCGGAATCACTCCGAGAAAGCTTACTCAAGACTGATTAATTGATCAAT 1500
Db 1441 AGAATCCTTTCGGAATCACTCCGAGAAAGCTTACTCAAGACTGATTAATTGATCAAT 1500
Qy 1501 GGGATCTATGTGACATCTAAGATGAACTCGGTGTCTTAAATCAATTAGTAACCAAG 1560
Db 1501 GGGATCTATGTGACATCTAAGATGAACTCGGTGTCTTAAATCAATTAGTAACCAAG 1560
Qy 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTCTTAGCAGAGGTGTATTTTGA 1620
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTCTTAGCAGAGGTGTATTTTGA 1620
```

```
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTCTAGTCTTAGCAGAGGTGTATTTTGA 1620
Qy 1621 AGACAGAAATATGCCCCCTTCTGCTTCTCTTTTGTGAGACAGAGTCTGTCTGTG 1680
Db 1621 AGACAGAAATATGCCCCCTTCTGCTTCTCTTTTGTGAGACAGAGTCTGTCTGTG 1680
Qy 1681 TTGCCAGGCTGAGTGCAGTAGACATCTCGGCTCTCACCCCAACTCTCGTCTCTGG 1740
Db 1681 TTGCCAGGCTGAGTGCAGTAGACATCTCGGCTCTCACCCCAACTCTCGTCTCTGG 1740
Qy 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTAACAGGCATGTGCCACC 1800
Db 1741 GTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTAACAGGCATGTGCCACC 1800
Qy 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACATGTTGTCAGGCTG 1860
Db 1801 ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACATGTTGTCAGGCTG 1860
Qy 1861 GTCTCAAACTCTGACCTAGTAGATCCACCCCTCTCGGCTCCCAAGTGCTGGGATTACA 1920
Db 1861 GTCTCAAACTCTGACCTAGTAGATCCACCCCTCTCGGCTCCCAAGTGCTGGGATTACA 1920
Qy 1921 GGCATAGCCACACACAGCTGGCCCCCTCTGTTTATATGTTGGTTTTTGAAGAAGATGA 1980
Db 1921 GGCATAGCCACACACAGCTGGCCCCCTCTGTTTATATGTTGGTTTTTGAAGAAGATGA 1980
Qy 1981 AGTGGGAACCAATTAGGTAAATTTTGGGTATCTGTCTCTAAATATTTAGCTAAAAACA 2040
Db 1981 AGTGGGAACCAATTAGGTAAATTTTGGGTATCTGTCTCTAAATATTTAGCTAAAAACA 2040
Qy 2041 AGCTTATGTAAAGTAAATAAAGTAAATTTGCCATATAATTTCAAAATTTCAACTGGCTTT 2100
Db 2041 AGCTTATGTAAAGTAAATAAAGTAAATTTGCCATATAATTTCAAAATTTCAACTGGCTTT 2100
Qy 2101 TATGCAAGAAACAGGTTAGACATCTAGGTTCCAAATTCATTCACTTCTGTTCCAGA 2160
Db 2101 TATGCAAGAAACAGGTTAGACATCTAGGTTCCAAATTCATTCACTTCTGTTCCAGA 2160
Qy 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTCCT 2220
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTCCT 2220
Qy 2221 TTAATACTTATTCAGATGATGTTCTTCCAAATTAATATTTGAATAATCTTTGTAC 2280
Db 2221 TTAATACTTATTCAGATGATGTTCTTCCAAATTAATATTTGAATAATCTTTGTAC 2280
Qy 2281 TCAG 2284
Db 2281 TCAG 2284
```

```
RESULT 15
ABX80978
ID ABX80978 standard; cDNA; 2284 BP.
XX
AC ABX80978;
XX
DT 22-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein cDNA, #182.
XX
KW Human; gene; ss; PRO; secreted; transmembrane; pharmaceutical;
KW diagnostic; biosensor; bioreactor; tumour; therapeutic; gene therapy;
KW tumour-associated antigenic target; TAT; ADAPT;
KW antibody-dependent enzyme mediated prodruq therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003027162-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-00997428.
```



XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090577P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 31-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.

PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 2284; DB 7; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGCATCCGCTGCGGTCTCGCAGACCCCGCGGATTCGCGGTCTTCCCGC 60  
|||  
1 GCGGAGCATCCGCTGCGGTCTCGCAGACCCCGCGGATTCGCGGTCTTCCCGC 60  
DB 61 GGGCGGACAGAGCTGTCTCGACCTGGATGGCAGAGGGCGCGGGGTCTCTGCAC 120  
|||  
QY 61 GGGCGGACAGAGCTGTCTCGACCTGGATGGCAGAGGGCGCGGGGTCTCTGCAC 120  
|||  
DB 61 GGGCGGACAGAGCTGTCTCGACCTGGATGGCAGAGGGCGCGGGGTCTCTGCAC 120  
|||  
QY 121 GCCAGAGAGAAATCTCATCATCTGTGCAGCCTTTAAAGCAAACTAAGACAGAGGAG 180  
|||  
DB 121 GCCAGAGAGAAATCTCATCATCTGTGCAGCCTTTAAAGCAAACTAAGACAGAGGAG 180  
|||  
QY 181 GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA 240  
|||  
DB 181 GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA 240  
|||  
QY 241 GAAGGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300  
|||  
DB 241 GAAGGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300  
|||  
QY 301 AGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTTGTCAATGACATCCAGTCACTCTT 360  
|||  
DB 301 AGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTTGTCAATGACATCCAGTCACTCTT 360  
|||  
QY 361 TCTAAGGGAATCAGAGGCAATGAGCCGGTAATTACTTCAACTCAAGAGACTGCATTAAT 420  
|||  
DB 361 TCTAAGGGAATCAGAGGCAATGAGCCGGTAATTACTTCAACTCAAGAGACTGCATTAAT 420  
|||  
QY 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480  
|||  
DB 421 TCTTGCTGTTCACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480  
|||  
QY 481 ACTGAAAAACAGCTAGACAAACCAACTGCTAATTTTCTGTCTCCAAAGAGGAGGCC 540  
|||

DB 481 ACTGAAAAACAGCTAGACAAACCAACTGCTAATTTTCTGTCCCAAGAGAGGCC 540  
|||  
QY 541 TGTCCATTGAAACAGCAAAAGACTTATGAGTTACAGATAATTAACAGATTTTCCATCT 600  
|||  
DB 541 TGTCCATTGAAACAGCAAAAGACTTATGAGTTACAGATAATTAACAGATTTTCCATCT 600  
|||  
QY 601 TTGACCAGAAATTTGCCAAGCCCAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 660  
|||  
DB 601 TTGACCAGAAATTTGCCAAGCCCAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 660  
|||  
QY 661 TTTTCACAAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720  
|||  
DB 661 TTTTCACAAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720  
|||  
QY 721 ATCTCATGAGAGACACACTTCTCAGAAAGTTGGATCCTCAGATCACCTGGAGAACTA 780  
|||  
DB 721 ATCTCATGAGAGACACACTTCTCAGAAAGTTGGATCCTCAGATCACCTGGAGAACTA 780  
|||  
QY 781 TTTAAGATGGATGAAGCAAGTCCAGCTCCTGTTATTAAGAAAAAGCCATTCTCAG 840  
|||  
DB 781 TTTAAGATGGATGAAGCAAGTCCAGCTCCTGTTATTAAGAAAAAGCCATTCTCAG 840  
|||  
QY 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCCCTGAATGTGAGTGCG 900  
|||  
DB 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCCCTGAATGTGAGTGCG 900  
|||  
QY 901 CTCCCACTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
|||  
DB 901 CTCCCACTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
|||  
QY 961 ACCCTTCAACCCACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
|||  
DB 961 ACCCTTCAACCCACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
|||  
QY 1021 ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCCTCATTTCTACA 1080  
|||  
DB 1021 ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCCTCATTTCTACA 1080  
|||  
QY 1081 GTTTTACACGGGCTGCGGCTACCTCCAAGCAATGGCTACACAGAGTTCTGACTACC 1140  
|||  
DB 1081 GTTTTACACGGGCTGCGGCTACCTCCAAGCAATGGCTACACAGAGTTCTGACTACC 1140  
|||  
QY 1141 ACCTTTCAGGCACTACGAGCTCGAAAGGCAAGCTTAGAAACCATACCGTTACAGAAATC 1200  
|||  
DB 1141 ACCTTTCAGGCACTACGAGCTCGAAAGGCAAGCTTAGAAACCATACCGTTACAGAAATC 1200  
|||  
QY 1201 TCCAACCTTAACCTTGAACACAGGGAATGTATTAACCTTACCTGCACTTCTATGTCAAT 1260  
|||  
DB 1201 TCCAACCTTAACCTTGAACACAGGGAATGTATTAACCTTACCTGCACTTCTATGTCAAT 1260  
|||  
QY 1261 GTGAGTCTTCCACTATGAATTAACCTGCTTCTGGGAAGGTAGGGAGGCCAGTCCAGGC 1320  
|||  
DB 1261 GTGAGTCTTCCACTATGAATTAACCTGCTTCTGGGAAGGTAGGGAGGCCAGTCCAGGC 1320  
|||  
QY 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAAATCAGTACGGCCTTCAATTGAAAAATGCTT 1380  
|||  
DB 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAAATCAGTACGGCCTTCAATTGAAAAATGCTT 1380  
|||  
QY 1381 CTTATCGGCTCCCTGCTCTTGTGTCTCTGCTCGGTGATAGGCCCTCGTCTCTGGGT 1440  
|||  
DB 1381 CTTATCGGCTCCCTGCTCTTGTGTCTCTGCTCGGTGATAGGCCCTCGTCTCTGGGT 1440  
|||  
QY 1441 AGAATCCTTTCGGAATCACTCCGAGGAAACGTTACTCAAGACTGGAATTTTGATCAAT 1500  
|||  
DB 1441 AGAATCCTTTCGGAATCACTCCGAGGAAACGTTACTCAAGACTGGAATTTTGATCAAT 1500  
|||  
QY 1501 GGGATCTATGTGACATCTAAGATGAAGTGGTGTCTTAATTCATTTAGTAACAG 1560  
|||  
DB 1501 GGGATCTATGTGACATCTAAGATGAAGTGGTGTCTTAATTCATTTAGTAACAG 1560  
|||  
QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGCTAGTCTTAGCAGAGAGTTGTATTTGA 1620  
|||  
DB 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGCTAGTCTTAGCAGAGAGTTGTATTTGA 1620  
|||

```
QY 1621 AGACAGAAAAATGCCCCCTTCTGCTTTCCTTTTTTTTGGAGACAGAGTCTTGCTG 1680
    |||||
Db 1621 AGACAGAAAAATGCCCCCTTCTGCTTTCCTTTTTTTTGGAGACAGAGTCTTGCTG 1680
    |||||
QY 1681 TTGCCAGGCTGAGTGCAGTAGCAGATCTGGCTCTCACCGCACTCCGCTCCTGG 1740
    |||||
Db 1681 TTGCCAGGCTGAGTGCAGTAGCAGATCTGGCTCTCACCGCACTCCGCTCCTGG 1740
    |||||
QY 1741 GTTCAAGCGATTCTCTGCTGCTCAGCTCTTAAGTATCTGGGATTACAGGCATGTGCCACC 1800
    |||||
Db 1741 GTTCAAGCGATTCTCTGCTGCTCAGCTCTTAAGTATCTGGGATTACAGGCATGTGCCACC 1800
    |||||
QY 1801 ACACTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACATGTGTGTCAGGCTG 1860
    |||||
Db 1801 ACACTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACATGTGTGTCAGGCTG 1860
    |||||
QY 1861 GTCTCAAACTCCTGACCTAGTATCCACCCTCTCGGCTCCCAAGTGTGGATTACA 1920
    |||||
Db 1861 GTCTCAAACTCCTGACCTAGTATCCACCCTCTCGGCTCCCAAGTGTGGATTACA 1920
    |||||
QY 1921 GGCATGAGCCACCAAGCTGGCCCCCTTCTGTTTATGTTGGTTTTTGAGAAGGAATGA 1980
    |||||
Db 1921 GGCATGAGCCACCAAGCTGGCCCCCTTCTGTTTATGTTGGTTTTTGAGAAGGAATGA 1980
    |||||
QY 1981 AGTGGGAACCAATTAGTAATTTGGGTAATCTGTCTCTAAATATTAGCTAAAAACAA 2040
    |||||
Db 1981 AGTGGGAACCAATTAGTAATTTGGGTAATCTGTCTCTAAATATTAGCTAAAAACAA 2040
    |||||
QY 2041 AGCTCTATGTAAAGTAATAAAGTAAATGCCATATAAATTCAAAATTCAACTGGCTTT 2100
    |||||
Db 2041 AGCTCTATGTAAAGTAATAAAGTAAATGCCATATAAATTCAAAATTCAACTGGCTTT 2100
    |||||
QY 2101 TATGCAAAAGAAACAGGTTAGACATCTAGGTTCCAATTCATTCACATCTTGTTCCAGA 2160
    |||||
Db 2101 TATGCAAAAGAAACAGGTTAGACATCTAGGTTCCAATTCATTCACATCTTGTTCCAGA 2160
    |||||
QY 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATTCCT 2220
    |||||
Db 2161 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATTCCT 2220
    |||||
QY 2221 TTAATACTTATTCAGATGTAGTCTTCCAATTAAATATTGAATAAATCTTTGTAC 2280
    |||||
Db 2221 TTAATACTTATTCAGATGTAGTCTTCCAATTAAATATTGAATAAATCTTTGTAC 2280
    |||||
QY 2281 TCAA 2284
    |||||
Db 2281 TCAA 2284
```

Search completed: September 25, 2004, 10:16:48  
Job time : 1038 secs



**THIS PAGE BLANK (USPTO)**


> O <  
O|O IntelliGenetics  
> O <

FastDB - Fast Pairwise Comparison of Sequences  
Release 5.4

Results file 944929\_x\_select.res made by spaula on Thu 30 Sep 104 7:56:24-PST.

Query sequence being compared: US-09-944-929-82 (1-2284)  
Number of sequences searched: 15  
Number of scores above cutoff: 15

Results of the initial comparison of US-09-944-929-82 (1-2284) with:  
File : vogel-rge.seq



Sequence Name	Description	Length	Score	Score	Sig.	Frame
1. ACA69380.SEQ	Human cDNA encoding secreted/	2284	2284	2284	0.55	0
2. ACA64519.SEQ	Novel human secreted and tran	2284	2284	2284	0.55	0
3. ABX96832.SEQ	Human cDNA encoding secreted/	2284	2284	2284	0.55	0
4. ABX90451.SEQ	Human secreted/transmembrane	2284	2284	2284	0.55	0
5. ABX80978.SEQ	Human secreted/transmembrane	2284	2284	2284	0.55	0
6. ABX80474.SEQ	Novel human secreted or trans	2284	2284	2284	0.55	0
7. ABX78486.SEQ	DNA encoding Novel human secr	2284	2284	2284	0.55	0
8. ABX77120.SEQ	cDNA encoding human PRO361 pr	2284	2284	2284	0.55	0
9. ABX75504.SEQ	Human secreted/transmembrane	2284	2284	2284	0.55	0
10. ABX64297.SEQ	cDNA encoding human PRO361 po	2284	2284	2284	0.55	0

A 100% similar sequence to the query sequence was found:

Sequence Name	Description	Length	Score	Score	Sig.	Frame
11. AAC58593.SEQ	Human PRO361 protein UNQ316 e	2418	2284	2284	0.55	0

The list of other best scores is:

Sequence Name	Description	Length	Score	Score	Sig.	Frame
12. AAC59840.SEQ	Human secreted protein encodi	2342	1834	2282	-0.89	0
13. AAH18096.SEQ	Human cDNA sequence SEQ ID NO	2297	1833	2258	-0.89	0
14. AAH13971.SEQ	Human cDNA sequence SEQ ID NO	2221	1467	2138	-2.06	0
15. AAH16637.SEQ	Human secreted protein clone	2015	1423	1983	-2.20	0

1. US-09-944-929-82 (1-2284)

ACA69380.SEQ Human cDNA encoding secreted/transmembrane protein

TOIG of: aca69380 check: 5044 from: 1 to: 2284

ID	ACA69380 standard; cDNA; 2284 BP.
AC	ACA69380;
XX	
DT	26-JUN-2003 (first entry)
XX	
DE	Human cDNA encoding secreted/transmembrane protein PRO361.
XX	
KW	Human; ss; gene; PRO; secreted protein; transmembrane protein;
KW	cardiac insufficiency disorders; angiogenesis; wound healing;
KW	cancerous tumour; immune response; retinal disorder; sight loss;
KW	retinitis pigmentosa; age-related macular degeneration; AMD;
KW	kidney disorder; Berger disease; nephropathy; dermatitis; herpeticiformis;
KW	Crohn's disease; sports injury; arthritis.
XX	
OS	Homo sapiens.
XX	
PN	US2003032023-A1.
XX	
PD	13-FEB-2003.
XX	
PF	14-NOV-2001; 2001US-00990711.
XX	
PR	16-JUN-1997; 97US-0049787P.
PR	17-OCT-1997; 97US-0062250P.
PR	05-NOV-1997; 97WO-US020069.
PR	12-NOV-1997; 97US-0065186P.
PR	13-NOV-1997; 97US-0065311P.
PR	24-NOV-1997; 97US-0066770P.
PR	25-FEB-1998; 98US-0075945P.
PR	20-MAR-1998; 98US-0078910P.
PR	28-APR-1998; 98US-0083322P.
PR	07-MAY-1998; 98US-0084600P.
PR	28-MAY-1998; 98US-0087106P.
PR	02-JUN-1998; 98US-0087607P.
PR	02-JUN-1998; 98US-0087609P.
PR	02-JUN-1998; 98US-0087759P.
PR	03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090577P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.

PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.





TTACATGGCCAAATTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAGCCACCGAT  
650 660 670 680 690 700 710 720  
ATCTCATGAGAGACACACTTTCTCAGAAAGTTTGATCCCTGAGTCACTGAGAAACTATTAAAGATGAT  
730 740 750 760 770 780 790  
ATCTCATGAGAGACACACTTTCTCAGAAAGTTTGATCCCTGAGTCACTGAGAAACTATTAAAGATGAT  
730 740 750 760 770 780 790  
GAAGCAAGTGGCCAGCTCCTTGTCTTATAAGAAAGGCCATTCTCAGAGTTCAACAATTTCTCTGATCAA  
800 810 820 830 840 850 860  
GAAGCAAGTGGCCAGCTCCTTGTCTTATAAGAAAGGCCATTCTCAGAGTTCAACAATTTCTCTGATCAA  
800 810 820 830 840 850 860  
GAAATAGCTCATCTGCTGCTGAAATGTGAGTGCCTCCAGCTACGGTGGCAGTTGCTTCTCCACATACC  
870 880 890 900 910 920 930  
GAAATAGCTCATCTGCTGCTGAAATGTGAGTGCCTCCAGCTACGGTGGCAGTTGCTTCTCCACATACC  
870 880 890 900 910 920 930  
940 950 960 970 980 990 1000  
ACCTCGGCTACTCCAAAGCCCGCCACTTCTTACCCACCAATGCTTCAGTGACACCTTGGAGCTTCCAG  
ACCTCGGCTACTCCAAAGCCCGCCACTTCTTACCCACCAATGCTTCAGTGACACCTTGGAGCTTCCAG  
940 950 960 970 980 990 1000  
1010 1020 1030 1040 1050 1060 1070 1080  
CCACAGCTGGCCACACAGCTCCACTGTAAACCACTGTCACTTCTCAGCCTCCACAGACCTCATTTCTACA  
CCACAGCTGGCCACACAGCTCCACTGTAAACCACTGTCACTTCTCAGCCTCCACAGACCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080  
1010 1020 1030 1040 1050 1060 1070 1080  
GTTTTTACACGGGCTGCGGCTACCTCCAAGCAATGGCTTACAACAGCAGTCTGACTTACCACTTTGAGCA  
GTTTTTACACGGGCTGCGGCTACCTCCAAGCAATGGCTTACAACAGCAGTCTGACTTACCACTTTGAGCA  
1090 1100 1110 1120 1130 1140 1150  
GTTTTTACACGGGCTGCGGCTACCTCCAAGCAATGGCTTACAACAGCAGTCTGACTTACCACTTTGAGCA  
1090 1100 1110 1120 1130 1140 1150  
1160 1170 1180 1190 1200 1210 1220  
CCTAGGACTCGAAAGCAGCTTAGAAACCATACCGTTTACAGAAATCTCCAACCTTAACCTTTGAACACAGG  
CCTAGGACTCGAAAGCAGCTTAGAAACCATACCGTTTACAGAAATCTCCAACCTTAACCTTTGAACACAGG  
1160 1170 1180 1190 1200 1210 1220  
1230 1240 1250 1260 1270 1280 1290  
AATGTGTATAACCTACTGCACTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAAACTGCTTCTG  
AATGTGTATAACCTACTGCACTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAAACTGCTTCTG  
1230 1240 1250 1260 1270 1280 1290  
1300 1310 1320 1330 1340 1350 1360  
GAAGGTAGGGAGGCGCAGTCCAGGCACTTCTCCCAAGGCGCAGTGTCCAGAAAATCAGTAGCGGCTTCCATTT  
GAAGGTAGGGAGGCGCAGTCCAGGCACTTCTCCCAAGGCGCAGTGTCCAGAAAATCAGTAGCGGCTTCCATTT  
1300 1310 1320 1330 1340 1350 1360  
1370 1380 1390 1400 1410 1420 1430 1440  
GAAAAATGGCTTCTTATCGGGTCCCTGCTCTTGTGTCCTGTCCTGATAGGCCCTGCTCCTGGGT  
GAAAAATGGCTTCTTATCGGGTCCCTGCTCTTGTGTCCTGTCCTGATAGGCCCTGCTCCTGGGT  
1370 1380 1390 1400 1410 1420 1430 1440  
1450 1460 1470 1480 1490 1500 1510  
AGAATCCTTTCCGAATCACTCCGAGAGAAACGTTACTCAAGACTGGATTATTGATCAATGGGATCTATGTG  
AGAATCCTTTCCGAATCACTCCGAGAGAAACGTTACTCAAGACTGGATTATTGATCAATGGGATCTATGTG  
1450 1460 1470 1480 1490 1500 1510  
1520 1530 1540 1550 1560 1570 1580  
GACATCTTAAGGATGGAAGTGGTGTCTCTTAATTCAATTAGTAACAGAAAGCCCAAAATGCAATGAGTTTCTG  
GACATCTTAAGGATGGAAGTGGTGTCTCTTAATTCAATTAGTAACAGAAAGCCCAAAATGCAATGAGTTTCTG

1520 1530 1540 1550 1560 1570 1580  
1590 1600 1610 1620 1630 1640 1650  
CTGACTTGTAGTCTTACGAGGAGTGTGATTTTGAAGACAGGAAATGCCCCCTTCTGCTTTCTTTT  
CTGACTTGTAGTCTTACGAGGAGTGTGATTTTGAAGACAGGAAATGCCCCCTTCTGCTTTCTTTT  
1590 1600 1610 1620 1630 1640 1650  
1660 1670 1680 1690 1700 1710 1720  
TTTGGAGACAGAGTCTGCTCTGTTGCCAGGCTGAGTGACAGATCTCGGCTCTCACCGCAACC  
TTTGGAGACAGAGTCTGCTCTGTTGCCAGGCTGAGTGACAGATCTCGGCTCTCACCGCAACC  
1660 1670 1680 1690 1700 1710 1720  
1730 1740 1750 1760 1770 1780 1790 1800  
TCCGTCTCCTGGGTTCAAGCGATTCTCCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGCATGTGCCACC  
TCCGTCTCCTGGGTTCAAGCGATTCTCCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGCATGTGCCACC  
1730 1740 1750 1760 1770 1780 1790 1800  
1810 1820 1830 1840 1850 1860 1870  
ACAACCTGGGATTTTGTATTTTGTAGTAGAGACGGGGTTTCAACCATGTTGTGTCAGGCTGGTCTCAACTCC  
ACAACCTGGGATTTTGTATTTTGTAGTAGAGACGGGGTTTCAACCATGTTGTGTCAGGCTGGTCTCAACTCC  
1810 1820 1830 1840 1850 1860 1870  
1880 1890 1900 1910 1920 1930 1940  
TGACCTAGTGATTCACCTCTCTCGGCTCCCAAGTGTCTGGGATTACAGCATGAGCCACACAGCTGGCCC  
TGACCTAGTGATTCACCTCTCTCGGCTCCCAAGTGTCTGGGATTACAGCATGAGCCACACAGCTGGCCC  
1880 1890 1900 1910 1920 1930 1940  
1950 1960 1970 1980 1990 2000 2010  
CCTTCTGTTTATGTTGGTTTTTGAAGAAGATGAAGTGGGAACCAATTAGTAAATTTGGTAAATCTGT  
CCTTCTGTTTATGTTGGTTTTTGAAGAAGATGAAGTGGGAACCAATTAGTAAATTTGGTAAATCTGT  
1950 1960 1970 1980 1990 2000 2010  
2020 2030 2040 2050 2060 2070 2080  
CTCTAAATATTTAGCTTAAACCAAGCTCTATGTAAAGTAAATTAAGTAAATTTGCCATATAATTTCAAAAT  
CTCTAAATATTTAGCTTAAACCAAGCTCTATGTAAAGTAAATTAAGTAAATTTGCCATATAATTTCAAAAT  
2020 2030 2040 2050 2060 2070 2080  
2090 2100 2110 2120 2130 2140 2150 2160  
TCAACTGGCTTTTATGCAAAAGAACAGGTTAGACATCTAGGTTCCAATTCAATTCACATTTCTGTTCCAGA  
TCAACTGGCTTTTATGCAAAAGAACAGGTTAGACATCTAGGTTCCAATTCAATTCACATTTCTGTTCCAGA  
2090 2100 2110 2120 2130 2140 2150 2160  
2170 2180 2190 2200 2210 2220 2230  
TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTCTTTTATGAGATTCTTTAAACTAATTT  
TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTCTTTTATGAGATTCTTTAAACTAATTT  
2170 2180 2190 2200 2210 2220 2230  
2240 2250 2260 2270 2280 X  
CCAGATGTAGTTCCTTCCAATTAATATTTGAATAAATCTTTGTTACTCAA  
CCAGATGTAGTTCCTTCCAATTAATATTTGAATAAATCTTTGTTACTCAA  
2240 2250 2260 2270 2280 X

2. US-09-944-929-82 (1-2284)  
ACA64519.SEQ Novel human secreted and transmembrane protein PRO  
TOIG of: aca64519 check: 5044 from: 1 to: 2284

ID ACA64519 standard; cDNA; 2284 BP.  
XX  
AC ACA64519;  
XX  
DT 17-JUN-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO361 cDNA.  
XX KW Human; secreted and transmembrane protein; cytosstatic; anti-HIV;  
KW virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;  
KW PRO; pharmaceutical; diagnostic; biosensor; bioreactor; malignancy;  
KW cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;  
KW lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;  
KW drug screening; gene; ss.  
XX OS Homo sapiens.  
XX PN US2003003531-A1.  
XX PD 02-JAN-2003.  
XX PF 19-NOV-2001; 2001US-00989734.  
XX PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX PA (GETH ) GENENTECH INC.  
XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Pong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX WPI; 2003-352829/33.  
DR P-PSDB; ABU72590.  
XX PT New genes and secreted and transmembrane polypeptides (e.g. PRO183 or  
PT PRO184), useful for treating or diagnosing e.g. ovarian cancer, Kaposi's  
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's  
PT disease.  
XX Claim 1; Fig 327; 663pp; English.  
PS The invention describes a new isolated nucleic acid molecule comprising  
XX the full length coding sequence of the DNA deposited with the American  
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,  
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DNA  
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are  
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These  
CC are particularly useful for detecting or treating e.g. malignancies or  
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,  
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's  
CC disease in mammals. The PRO polypeptides are useful in drug screening,  
CC particularly as targets for therapeutic intervention in these diseases,  
CC and in the diagnostic determination of the presence of these diseases.  
CC The PRO polypeptides are also useful as molecular weight markers, or for  
CC chromosome identification. The PRO genes are useful as hybridisation  
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.  
CC The PRO genes may also be used in gene therapy, particularly for



CC replacing a defective gene. This sequence encodes a novel human secreted  
CC and transmembrane PRO polypeptide

SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ACA64519 Length: 2284 September 29, 2004 14:41 Type: N Check: 5044 .

Initial Score	=	2284	Optimized Score	=	2284	Significance	=	0.55
Residue Identity	=	100%	Matches	=	2284	Mismatches	=	0
Gaps	=	0	Conservative Substitutions	=			=	0

X 10 20 30 40 50 60 70  
GCGGAGCATCCGCTGCGGTCTCCGCGAGACCCCGCGGATTCGCGGTCTTCCCGCGCGGCGAGAGA  
GCGGAGCATCCGCTGCGGTCTCCGCGAGACCCCGCGGATTCGCGGTCTTCCCGCGCGGCGAGAGA  
X 10 20 30 40 50 60 70  
GCTGTCCTCGACCTGGATGGCAGAGGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
GCTGTCCTCGACCTGGATGGCAGAGGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
80 90 100 110 120 130 140  
TGACGCTTCTTAAAGCAACTAAGACCAGAGGAGGATTATCCTTGACCTTTGAAGACCAAACTAACTG  
TGACGCTTCTTAAAGCAACTAAGACCAGAGGAGGATTATCCTTGACCTTTGAAGACCAAACTAACTG  
150 160 170 180 190 200 210  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTACACTTTGGTAATTAATTGCTTCTGACACTA  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTACACTTTGGTAATTAATTGCTTCTGACACTA  
220 230 240 250 260 270 280  
AGCGTCTGTAGTGTAGCAATGTGCTCAAAAAGAGTCTAGAGAGTGTGATTCATTCAGATCCAGTCTCTT  
AGCGTCTGTAGTGTAGCAATGTGCTCAAAAAGAGTCTAGAGAGTGTGATTCATTCAGATCCAGTCTCTT  
290 300 310 320 330 340 350 360  
TCTAAGGGAATCAGAGCAATGAGCCCGGTATATCTTCACTCAAGAGACTGCATTAATTCCTGCTTCA  
TCTAAGGGAATCAGAGCAATGAGCCCGGTATATCTTCACTCAAGAGACTGCATTAATTCCTGCTTCA  
370 380 390 400 410 420 430  
ACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTAGACAAACC  
ACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTAGACAAACC  
440 450 460 470 480 490 500  
AACTGCTACCTATTTTCTGTCTCCCAAGGAAAGCCTGTCCATTGAAACGCAAAAGACTTTAGTTAC  
AACTGCTACCTATTTTCTGTCTCCCAAGGAAAGCCTGTCCATTGAAACGCAAAAGACTTTAGTTAC  
510 520 530 540 550 560 570  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGTTACCCAGAGATTCCTCC  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGTTACCCAGAGATTCCTCC  
580 590 600 610 620 630 640  
TTACATGGCCAAATTTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT  
TTACATGGCCAAATTTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAAGCCACCGAT  
650 660 670 680 690 700 710 720  
ATCTCATGGAGACACACTTTCTCAGAAGTTTGATCTCTCAGATACCTGGAGAAACTATTTAAGATGAT

ATCTCATGAGAGACACACTTTCTCAGAGTTTGATCCTCAGATCACCTGGAGAACTATTTAAGATGAT  
730 740 750 760 770 780 790

GAAGCAGTGGCCAGCTCCTTGCTTATAGGAAAAAGGCCATTCTCAGAGTTCACAATTTTCTCTGATCAA  
800 810 820 830 840 850 860

GAAGCAGTGGCCAGCTCCTTGCTTATAGGAAAAAGGCCATTCTCAGAGTTCACAATTTTCTCTGATCAA  
800 810 820 830 840 850 860

GAAATAGCTCATCTGCTGCTGAAATGTGAGTGGCTCCAGCTACCGTGGCAGTTGCTTCTCCACATACC  
870 880 890 900 910 920 930

GAAATAGCTCATCTGCTGCTGAAATGTGAGTGGCTCCAGCTACCGTGGCAGTTGCTTCTCCACATACC  
870 880 890 900 910 920 930

ACCTGGGCTACTCCAAAGCCCGCCACCTTCTACCCACCAATGCTTCAGTGAACACCTTCTGGGACTCCAG  
940 950 960 970 980 990 1000

ACCTGGGCTACTCCAAAGCCCGCCACCTTCTACCCACCAATGCTTCAGTGAACACCTTCTGGGACTCCAG  
940 950 960 970 980 990 1000

CCACAGCTGGCCACACAGCTCCACCTGTGAACCACTGTCACTTCTCAGCCTCCACGACCCCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080

CCACAGCTGGCCACACAGCTCCACCTGTGAACCACTGTCACTTCTCAGCCTCCACGACCCCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080

CCACAGCTGGCCACACAGCTCCACCTGTGAACCACTGTCACTTCTCAGCCTCCACGACCCCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080

GTTTTCACCGGGCTCGGCTACACTCCAAGCAATGGCTACACAGCAGTTCTGACTAACCACTTTCAAGCA  
1090 1100 1110 1120 1130 1140 1150

GTTTTCACCGGGCTCGGCTACACTCCAAGCAATGGCTACACAGCAGTTCTGACTAACCACTTTCAAGCA  
1090 1100 1110 1120 1130 1140 1150

GTTTTCACCGGGCTCGGCTACACTCCAAGCAATGGCTACACAGCAGTTCTGACTAACCACTTTCAAGCA  
1090 1100 1110 1120 1130 1140 1150

CCTACGAGCTCGAAAGGCAGCTTAGAAACCATACCGTTTACAGAAATCTCCAATTAACTTTGAACACAGGG  
1160 1170 1180 1190 1200 1210 1220

CCTACGAGCTCGAAAGGCAGCTTAGAAACCATACCGTTTACAGAAATCTCCAATTAACTTTGAACACAGGG  
1160 1170 1180 1190 1200 1210 1220

CCTACGAGCTCGAAAGGCAGCTTAGAAACCATACCGTTTACAGAAATCTCCAATTAACTTTGAACACAGGG  
1160 1170 1180 1190 1200 1210 1220

AATGTGTATAACCTTACTGCACTTTCTATGTCAATATGTGAGTCTTCCACTATGAATAAACTGCTTCTGCG  
1230 1240 1250 1260 1270 1280 1290

AATGTGTATAACCTTACTGCACTTTCTATGTCAATATGTGAGTCTTCCACTATGAATAAACTGCTTCTGCG  
1230 1240 1250 1260 1270 1280 1290

AATGTGTATAACCTTACTGCACTTTCTATGTCAATATGTGAGTCTTCCACTATGAATAAACTGCTTCTGCG  
1230 1240 1250 1260 1270 1280 1290

GAAGGTAGGAGGAGCCAGTCCAGGCGAGTTCTCCAGGGCAGTGTTCAGAAAAATCAGTACGGCCTTCCATTT  
1300 1310 1320 1330 1340 1350 1360

GAAGGTAGGAGGAGCCAGTCCAGGCGAGTTCTCCAGGGCAGTGTTCAGAAAAATCAGTACGGCCTTCCATTT  
1300 1310 1320 1330 1340 1350 1360

GAAGGTAGGAGGAGCCAGTCCAGGCGAGTTCTCCAGGGCAGTGTTCAGAAAAATCAGTACGGCCTTCCATTT  
1300 1310 1320 1330 1340 1350 1360

GAAAAATGAGCTTCTTATCGGGTCCCTGCTTTGGTGTCTGTTCTGTTCTGTTGATGAGCCCTGCTCTGGGT  
1370 1380 1390 1400 1410 1420 1430 1440

GAAAAATGAGCTTCTTATCGGGTCCCTGCTTTGGTGTCTGTTCTGTTCTGTTGATGAGCCCTGCTCTGGGT  
1370 1380 1390 1400 1410 1420 1430 1440

GAAAAATGAGCTTCTTATCGGGTCCCTGCTTTGGTGTCTGTTCTGTTCTGTTGATGAGCCCTGCTCTGGGT  
1370 1380 1390 1400 1410 1420 1430 1440

AGAATCCCTTTCGGAATCACTCCGAGGAAACGTTACTCAAGACTGATTTATTTGATCAATGGGATCTATGTG  
1450 1460 1470 1480 1490 1500 1510

AGAATCCCTTTCGGAATCACTCCGAGGAAACGTTACTCAAGACTGATTTATTTGATCAATGGGATCTATGTG  
1450 1460 1470 1480 1490 1500 1510

AGAATCCCTTTCGGAATCACTCCGAGGAAACGTTACTCAAGACTGATTTATTTGATCAATGGGATCTATGTG  
1450 1460 1470 1480 1490 1500 1510

GACATCTTAAGGATGGAATCGGTTGTTCTTTAATTCAATTTAGTAAACGAGAAATGCAATGAGTTTCTG  
1520 1530 1540 1550 1560 1570 1580

GACATCTTAAGGATGGAATCGGTTGTTCTTTAATTCAATTTAGTAAACGAGAAATGCAATGAGTTTCTG  
1520 1530 1540 1550 1560 1570 1580

GACATCTTAAGGATGGAATCGGTTGTTCTTTAATTCAATTTAGTAAACGAGAAATGCAATGAGTTTCTG  
1520 1530 1540 1550 1560 1570 1580

CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTGAAGACAGGAAATGCCCTTCTGCTTCTTTTCTT  
1590 1600 1610 1620 1630 1640 1650

CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTGAAGACAGGAAATGCCCTTCTGCTTCTTTTCTT  
1590 1600 1610 1620 1630 1640 1650

CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTGAAGACAGGAAATGCCCTTCTGCTTCTTTTCTT  
1590 1600 1610 1620 1630 1640 1650

```

CTGACTTGCTAGTCTTAGCAGAGGTTGTAATTTGAAGACAGAAAAATGCCCTTCTGCTTTCTTTT
1590      1600      1610      1620      1630      1640      1650
1660      1670      1680      1690      1700      1710      1720
TTTGGAGACAGAGTCTTGTCTGTGGCCAGGCTGAGTGCAGTACGATCTCGGCTCTCACCGCAAC
TTTTGGAGACAGAGTCTTGTCTGTGGCCAGGCTGAGTGCAGTACGATCTCGGCTCTCACCGCAAC
1660      1670      1680      1690      1700      1710      1720
1730      1740      1750      1760      1770      1780      1790      1800
TCCGTCCTCTGGGTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGCGCAC
TCCGTCCTCTGGGTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGCGCAC
1730      1740      1750      1760      1770      1780      1790      1800
1810      1820      1830      1840      1850      1860      1870
ACACCTGGGTGATTTTGTATTATTGATGAGACGGGGTTTACACCATGTTGTCAGGCTGTCAACTCC
ACACCTGGGTGATTTTGTATTATTGATGAGACGGGGTTTACACCATGTTGTCAGGCTGTCAACTCC
1810      1820      1830      1840      1850      1860      1870
ACACCTGGGTGATTTTGTATTATTGATGAGACGGGGTTTACACCATGTTGTCAGGCTGTCAACTCC
1810      1820      1830      1840      1850      1860      1870
1880      1890      1900      1910      1920      1930      1940
TGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGTCTGGATTACAGGCATGAGCCACCAAGTGGCCC
TGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGTCTGGATTACAGGCATGAGCCACCAAGTGGCCC
1880      1890      1900      1910      1920      1930      1940
TGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGTCTGGATTACAGGCATGAGCCACCAAGTGGCCC
1880      1890      1900      1910      1920      1930      1940
1950      1960      1970      1980      1990      2000      2010
CCTTCTGTTTATGTTTGGTTTGTGAGAGAGATGAAGTGGGAACCAATTAGGTAATTTGGTAACTGT
CCTTCTGTTTATGTTTGGTTTGTGAGAGAGATGAAGTGGGAACCAATTAGGTAATTTGGTAACTGT
1950      1960      1970      1980      1990      2000      2010
CCTTCTGTTTATGTTTGGTTTGTGAGAGAGATGAAGTGGGAACCAATTAGGTAATTTGGTAACTGT
1950      1960      1970      1980      1990      2000      2010
2020      2030      2040      2050      2060      2070      2080
CTCTAAAAATATAGCTAAACAAGCTATATGTAAGTAAATTAATGCGCATATAAATTTCAAAT
CTCTAAAAATATAGCTAAACAAGCTATATGTAAGTAAATTAATGCGCATATAAATTTCAAAT
2020      2030      2040      2050      2060      2070      2080
CTCTAAAAATATAGCTAAACAAGCTATATGTAAGTAAATTAATGCGCATATAAATTTCAAAT
2020      2030      2040      2050      2060      2070      2080
2090      2100      2110      2120      2130      2140      2150      2160
TCAACTGGCTTTTATGCAAGAAGACAGTTAGACATCTAGGTTCCAATTCAATTCACATTTCTGGTCCAGA
TCAACTGGCTTTTATGCAAGAAGACAGTTAGACATCTAGGTTCCAATTCAATTCACATTTCTGGTCCAGA
2090      2100      2110      2120      2130      2140      2150      2160
TCAACTGGCTTTTATGCAAGAAGACAGTTAGACATCTAGGTTCCAATTCAATTCACATTTCTGGTCCAGA
2090      2100      2110      2120      2130      2140      2150      2160
2170      2180      2190      2200      2210      2220      2230
TAAATCACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGAGATTCCTTTAAACTTATT
TAAATCACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGAGATTCCTTTAAACTTATT
2170      2180      2190      2200      2210      2220      2230
TAAATCACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGAGATTCCTTTAAACTTATT
2170      2180      2190      2200      2210      2220      2230
2240      2250      2260      2270      2280      X
CCAGATGTAGTCTCTCCCAATTAATATATGAATAAATCTTTGTTACTCAA
CCAGATGTAGTCTCTCCCAATTAATATATGAATAAATCTTTGTTACTCAA
2240      2250      2260      2270      2280      X
CCAGATGTAGTCTCTCCCAATTAATATATGAATAAATCTTTGTTACTCAA
2240      2250      2260      2270      2280      X

```

## 3. US-09-944-929-82 (1-2284)

ABX96832.SEQ Human cDNA encoding secreted/transmembrane protein

TOIG of: abx96832 check: 5044 from: 1 to: 2284

```

ID  ABX96832 standard; cDNA; 2284 BP.
XX
AC  ABX96832;
XX
DT  15-MAY-2003 (first entry)
XX
DE  Human cDNA encoding secreted/transmembrane protein PRO361.
XX
KW  Human; ss; gene; PRO; secreted protein; transmembrane protein;
    Cornelia de Lange syndrome; gene therapy; immune disorder;

```

```

KW  inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW  infertility; birth defect; premature aging; cardiac injury; AIDS; cancer;
KW  diabetic complication.
XX  Homo sapiens.
XX  US2002173463-A1.
XX  21-NOV-2002.
XX
PF  31-AUG-2001; 2001US-00944944.
XX
PR  03-DEC-1997; 97US-0067411P.
PR  11-DEC-1997; 97US-0069278P.
PR  11-DEC-1997; 97US-0069334P.
PR  11-DEC-1997; 97US-0069335P.
PR  12-DEC-1997; 97US-0069425P.
PR  16-DEC-1997; 97US-0069694P.
PR  16-DEC-1997; 97US-0069696P.
PR  16-DEC-1997; 97US-0069702P.
PR  17-DEC-1997; 97US-0069870P.
PR  17-DEC-1997; 97US-0069873P.
PR  18-DEC-1997; 97US-0068017P.
PR  05-JAN-1998; 98US-0070440P.
PR  09-FEB-1998; 98US-0074086P.
PR  09-FEB-1998; 98US-0074092P.
PR  25-FEB-1998; 98US-0075945P.
PR  16-SEP-1998; 98WO-US019330.
PR  01-DEC-1998; 98WO-US025108.
PR  16-DEC-1998; 98US-0112850P.
PR  22-DEC-1998; 98US-0113296P.
PR  02-JUN-1999; 99WO-US012252.
PR  28-JUL-1999; 99US-0146222P.
PR  15-SEP-1999; 99WO-US021090.
PR  30-NOV-1999; 99WO-US028313.
PR  30-NOV-1999; 99WO-US028409.
PR  01-DEC-1999; 99WO-US028301.
PR  16-DEC-1999; 99WO-US030095.
PR  11-FEB-2000; 2000WO-US003565.
PR  22-FEB-2000; 2000WO-US004414.
PR  02-MAR-2000; 2000WO-US005841.
PR  30-MAR-2000; 2000WO-US008439.
PR  22-MAY-2000; 2000WO-US014042.
PR  28-JUL-2000; 2000WO-US020710.
PR  01-DEC-2000; 2000WO-US032678.
PR  28-FEB-2001; 2001WO-US006520.
PR  25-MAY-2001; 2001US-00866028.
XX  (GETH ) GENENTECH INC.
XX
PA  Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;
PI  Geritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
PI  Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;
XX  WPI; 2003-311003/30.
XX  P-PSDB; ABU64930.
XX
PT  New transmembrane polypeptides and polynucleotides useful for chromosome
PT  identification, tissue typing, gene therapy, in chromosome and gene
PT  mapping, or as molecular weight markers.
XX
PS  Claim 2; Fig 31; 172pp; English.
XX
XX  The invention relates to an isolated nucleic acid encoding a secreted/
XX  transmembrane polypeptide (designated as PRO proteins). 15 PRO
XX  polypeptides and their encoding polynucleotides are disclosed. Also
XX  included are a vector comprising the PRO nucleic acid, a host cell
XX  comprising the vector, a process for producing a PRO polypeptide (by
XX  culturing the host cell under conditions for the expression of the PRO
XX  polypeptide, and recovering the PRO polypeptide from the cell culture, an
XX  isolated polypeptide having at least 80% amino acid sequence identity to
XX  the PRO polypeptides, a chimeric molecule comprising PRO fused to a
XX  heterologous amino acid sequence and an antibody which specifically binds

```

CC to PRO. The PRO nucleotide sequences are useful as hybridisation probes,  
CC in chromosome and gene mapping, in generating sense and antisense RNA or  
CC DNA, in generating transgenic or knock-out animals which can be used in  
CC the development and screening of therapeutically useful reagents, and in  
CC gene therapy. The polypeptides may be used as molecular weight markers  
CC for protein electrophoresis purposes. The PRO polypeptides and nucleic  
CC acids may also be used for chromosome identification, and tissue typing.  
CC PRO241 (identified as Chordin) is a candidate gene for Cornelia de Lange  
CC syndrome. Other PRO proteins are variously implicated in immune  
CC disorders, inflammatory disease, organ failure, atherosclerosis, cardiac  
CC injury, infertility, birth defects, premature aging, cardiac injury,  
CC AIDS, cancer and diabetic complications. The present sequence encodes a  
CC PRO protein

XX Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ABX86832 Length: 2284 September 29, 2004 14:41 Type: N Check: 5044 ..

Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
GCGGAGCATCCGCTGCGGTCCCTCCGCGGAGACCCCGCGCGGATTGCCCGTCCCGCGCGCGGACAGA  
GCGGAGCATCCGCTGCGGTCCCTCCGCGGAGACCCCGCGCGGATTGCCCGTCCCGCGCGCGGACAGA  
X 10 20 30 40 50 60 70

80 90 100 110 120 130 140  
GCTGTCCTCGACCTGGATGGACGAGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
GCTGTCCTCGACCTGGATGGACGAGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
80 90 100 110 120 130 140

150 160 170 180 190 200 210  
TGCAGCCTTCTTAAGCAAACTAAGACCAAGAGGAGATTAATCTTGACCTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAGCAAACTAAGACCAAGAGGAGATTAATCTTGACCTTGAAGACCAAACTAACTG  
150 160 170 180 190 200 210

220 230 240 250 260 270 280  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTAACCTTGGTAATAATTGCTTCTGACACTA  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTAACCTTGGTAATAATTGCTTCTGACACTA  
220 230 240 250 260 270 280

290 300 310 320 330 340 350 360  
AGGCTGCTCTAGTCAAGATTGCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATCCAGTCTCTT  
AGGCTGCTCTAGTCAAGATTGCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATCCAGTCTCTT  
290 300 310 320 330 340 350 360

370 380 390 400 410 420 430  
TCTAAGGGAATCAGAGGCAATGAGCCCTATATATTCAACTCAAGAAGACTGCATTAATCTTGCTGTTCA  
TCTAAGGGAATCAGAGGCAATGAGCCCTATATATTCAACTCAAGAAGACTGCATTAATCTTGCTGTTCA  
370 380 390 400 410 420 430

440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGAGCAAAAGCATGTAATTGATGATCTTCGACACTCGAAAAACAGCTAGACACCC  
ACAAAAACATATCAGGGGAGCAAAAGCATGTAATTGATGATCTTCGACACTCGAAAAACAGCTAGACACCC  
440 450 460 470 480 490 500

510 520 530 540 550 560 570  
AACTGCTACCTATTTTCTGTGCTCCAAAGAGGAGGCTGTCCATTGAAAACAGCAAAAGACTTATGAGTTAC  
AACTGCTACCTATTTTCTGTGCTCCAAAGAGGAGGCTGTCCATTGAAAACAGCAAAAGACTTATGAGTTAC  
510 520 530 540 550 560 570

580 590 600 610 620 630 640  
AGGATTAATTACAGATTTTCCATTGACCAAGAAATTTGCGAAGCAAGAGTTACCCAGAGAAATTTCTCTC  
AGGATTAATTACAGATTTTCCATTGACCAAGAAATTTGCGAAGCAAGAGTTACCCAGAGAAATTTCTCTC

AGGATTAATTACAGATTTTCCATTGACCAAGAAATTTGCGAAGCAAGAGTTACCCAGAGAAATTTCTCTC  
580 590 600 610 620 630 640  
650 660 670 680 690 700 710 720  
TTACATGGCCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACAGATTATTCAAGCCACCGAT  
TTACATGGCCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACAGATTATTCAAGCCACCGAT  
650 660 670 680 690 700 710 720

730 740 750 760 770 780 790  
ATCTCATGAGAGACACACTTTCTCAGAAGTTTGATCCTCAGATCACCTGGAGAAACTATTTAAGATGAT  
ATCTCATGAGAGACACACTTTCTCAGAAGTTTGATCCTCAGATCACCTGGAGAAACTATTTAAGATGAT  
730 740 750 760 770 780 790

800 810 820 830 840 850 860  
GAAGCAAGTGGCCAGCTCTCTGCTTATTAAGGAAAAAGGCCATTCTCAGAGTTCACAATTTCTCTGATCAA  
GAAGCAAGTGGCCAGCTCTCTGCTTATTAAGGAAAAAGGCCATTCTCAGAGTTCACAATTTCTCTGATCAA  
800 810 820 830 840 850 860

870 880 890 900 910 920 930  
GAAATAGCTCATCTGCTGCTGCTGAAATGTGAGTGCCTCCAGCTACAGGTGCAAGTTGCTTCTCCACATAAC  
GAAATAGCTCATCTGCTGCTGCTGAAATGTGAGTGCCTCCAGCTACAGGTGCAAGTTGCTTCTCCACATAAC  
870 880 890 900 910 920 930

940 950 960 970 980 990 1000  
ACCTGGCTACTCCAAAGCCCGCCACCCCTTCTTAACCAACCAATGCTTCAAGTACACCTTCTGGACTTCCAG  
ACCTGGCTACTCCAAAGCCCGCCACCCCTTCTTAACCAACCAATGCTTCAAGTACACCTTCTGGACTTCCAG  
940 950 960 970 980 990 1000

1010 1020 1030 1040 1050 1060 1070 1080  
CCACAGCTGGCCACCAAGCTCCACCTGTAAACCACTGTCATCTCAGCCTCCACAGACCCCTCATTTCTACA  
CCACAGCTGGCCACCAAGCTCCACCTGTAAACCACTGTCATCTCAGCCTCCACAGACCCCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080

1090 1100 1110 1120 1130 1140 1150  
GTTTTTACAGGGCTGCGGCTACCTCCAAAGCAATGGCTTACAACAGCAGTTCTGACTACCACTTTGAGCA  
GTTTTTACAGGGCTGCGGCTACCTCCAAAGCAATGGCTTACAACAGCAGTTCTGACTACCACTTTGAGCA  
1090 1100 1110 1120 1130 1140 1150

1160 1170 1180 1190 1200 1210 1220  
CCTACGAGCTCGAAAGCAGCTTAGAAACCATACCGTTTACAGAAATCTCAACTTAATTGAACACAGGG  
CCTACGAGCTCGAAAGCAGCTTAGAAACCATACCGTTTACAGAAATCTCAACTTAATTGAACACAGGG  
1160 1170 1180 1190 1200 1210 1220

1230 1240 1250 1260 1270 1280 1290  
AATGTGTATAACCTTACTGCACTTCTATATGTAATGTGAGTCTTCCACTATGAATTAATAACTGCTTCTGG  
AATGTGTATAACCTTACTGCACTTCTATATGTAATGTGAGTCTTCCACTATGAATTAATAACTGCTTCTGG  
1230 1240 1250 1260 1270 1280 1290

1300 1310 1320 1330 1340 1350 1360  
GAAGTAGGAGGCGCAGTCCAGGAGTTCCTCCAGGCGAGTGTCCAGAAAATCAGTAGCGCTTCCATT  
GAAGTAGGAGGCGCAGTCCAGGAGTTCCTCCAGGCGAGTGTCCAGAAAATCAGTAGCGCTTCCATT  
1300 1310 1320 1330 1340 1350 1360

1370 1380 1390 1400 1410 1420 1430 1440  
GAAAAATGGCTTCTTAATCGGGTCCCTGCTCTTGTGCTGCTGTTCCGTGGTATAGGCGCTCCTCGGGT  
GAAAAATGGCTTCTTAATCGGGTCCCTGCTCTTGTGCTGCTGTTCCGTGGTATAGGCGCTCCTCGGGT  
1370 1380 1390 1400 1410 1420 1430 1440

1450 1460 1470 1480 1490 1500 1510  
AGAAATCCTTTGGAATCACTCCGAGGAAACGTTACTCAAGAGCTGATTAATTGATCAATGGGATCTATGTG  
AGAAATCCTTTGGAATCACTCCGAGGAAACGTTACTCAAGAGCTGATTAATTGATCAATGGGATCTATGTG  
1450 1460 1470 1480 1490 1500 1510



```

1450      1460      1470      1480      1490      1500      1510
1520      1530      1540      1550      1560      1570      1580
GACATCTAAGAGATGGAAGTGGGCTGCTCTTAATTCATTAGTACAGAGCCCAATGCAATGAGTTCTG
|||||
GACATCTAAGAGATGGAAGTGGGCTGCTCTTAATTCATTAGTACAGAGCCCAATGCAATGAGTTCTG
1520      1530      1540      1550      1560      1570      1580
CTGACTGCTAGTCTTAGCAGAGAGTGTATTTTGAAGACAGAGAAATGCCCTTCTGCTTCTCTTTT
|||||
CTGACTGCTAGTCTTAGCAGAGAGTGTATTTTGAAGACAGAGAAATGCCCTTCTGCTTCTCTTTT
1590      1600      1610      1620      1630      1640      1650
TTTGGAGACAGAGTCTTGTCTGTGCTGCCAGGCTGAGTGCAGTACGATCTCGGCTTCAACCGCAAC
|||||
TTTGGAGACAGAGTCTTGTCTGTGCTGCCAGGCTGAGTGCAGTACGATCTCGGCTTCAACCGCAAC
1660      1670      1680      1690      1700      1710      1720
TCCGTCCTCTGGGTTCAGCGGATTCCTCTGCTCAGCCCTCTTAAGTATCTGGATTACAGGATGTGCCAC
|||||
TCCGTCCTCTGGGTTCAGCGGATTCCTCTGCTCAGCCCTCTTAAGTATCTGGATTACAGGATGTGCCAC
1730      1740      1750      1760      1770      1780      1790      1800
ACACCTGGGTGATTTTGTATTTTGAAGACAGCGGCTTCAACCATGTGTGTCAGGCTGTCTCAACTCC
|||||
ACACCTGGGTGATTTTGTATTTTGAAGACAGCGGCTTCAACCATGTGTGTCAGGCTGTCTCAACTCC
1810      1820      1830      1840      1850      1860      1870
TGACCTAGTATCCACCCCTCGGCTCCCAAGTGTGGATTAAGGATGAGCCACACAGCTGGCCC
|||||
TGACCTAGTATCCACCCCTCGGCTCCCAAGTGTGGATTAAGGATGAGCCACACAGCTGGCCC
1880      1890      1900      1910      1920      1930      1940
CCTTCTGTTTATGTTGGTTTGGAGAGGAATGAAGTGGGAAACCAATTAGTAAATTTGGGTAATCTGT
|||||
CCTTCTGTTTATGTTGGTTTGGAGAGGAATGAAGTGGGAAACCAATTAGTAAATTTGGGTAATCTGT
1950      1960      1970      1980      1990      2000      2010
CTCTAATAATATTAGCTAAAAACAAGCTCTATGTAAAGTAAATGAATTTGCCATTAATTTTCAAAT
|||||
CTCTAATAATATTAGCTAAAAACAAGCTCTATGTAAAGTAAATGAATTTGCCATTAATTTTCAAAT
2020      2030      2040      2050      2060      2070      2080
TCAACTGGCTTTTATGCAAGAGAAAGAGTTAGGACATCTAGGTTCCAATTCATTCAATTTGGTTCAGA
|||||
TCAACTGGCTTTTATGCAAGAGAAAGAGTTAGGACATCTAGGTTCCAATTCATTCAATTTGGTTCAGA
2090      2100      2110      2120      2130      2140      2150      2160
TAAAAACAAGTGTATATCAATTTCTAATGATTGCTTTCTTTTATATGAGATTCTTTAAAACTTAT
|||||
TAAAAACAAGTGTATATCAATTTCTAATGATTGCTTTCTTTTATATGAGATTCTTTAAAACTTAT
2170      2180      2190      2200      2210      2220      2230
CCAGATGATGTTCTTCCAAATTAATATTTGAATAAATCTTTGTTACTCAA
|||||
CCAGATGATGTTCTTCCAAATTAATATTTGAATAAATCTTTGTTACTCAA
2240      2250      2260      2270      2280      X

```

4. US-09-944-929-82 (1-2284)  
 ABX90451.SEQ Human secreted/transmembrane protein cDNA, #182.  
 TOIG of: abx90451 check: 5044 from: 1 to: 2284

ID	ABX90451 standard; cDNA; 2284 BP.
XX	ABX90451;
AC	
XX	
DT	01-MAY-2003 (first entry)
XX	
DE	Human secreted/transmembrane protein cDNA, #182.
XX	
KW	Human; gene; ss; PRO; secreted; transmembrane; signal peptide;
KW	pharmaceutical; diagnostic; therapeutic; gene therapy.
XX	
OS	Homo sapiens.
XX	
PN	US2002160384-A1.
XX	
PD	31-OCT-2002.
XX	
PF	14-NOV-2001; 2001US-00992598.
XX	
PR	16-JUN-1997; 97US-0049787P.
PR	17-OCT-1997; 97US-0062250P.
PR	05-NOV-1997; 97WO-US020069.
PR	12-NOV-1997; 97US-0065186P.
PR	13-NOV-1997; 97US-0065311P.
PR	24-NOV-1997; 97US-0066770P.
PR	25-FEB-1998; 98US-0075945P.
PR	20-MAR-1998; 98US-0078910P.
PR	28-APR-1998; 98US-0083322P.
PR	07-MAY-1998; 98US-0084600P.
PR	28-MAY-1998; 98US-0087106P.
PR	02-JUN-1998; 98US-0087607P.
PR	02-JUN-1998; 98US-0087609P.
PR	02-JUN-1998; 98US-0087759P.
PR	03-JUN-1998; 98US-0087827P.
PR	04-JUN-1998; 98US-0088021P.
PR	04-JUN-1998; 98US-0088025P.
PR	04-JUN-1998; 98US-0088026P.
PR	04-JUN-1998; 98US-0088028P.
PR	04-JUN-1998; 98US-0088029P.
PR	04-JUN-1998; 98US-0088030P.
PR	04-JUN-1998; 98US-0088033P.
PR	04-JUN-1998; 98US-0088326P.
PR	05-JUN-1998; 98US-0088167P.
PR	05-JUN-1998; 98US-0088202P.
PR	05-JUN-1998; 98US-0088212P.
PR	05-JUN-1998; 98US-0088217P.
PR	09-JUN-1998; 98US-0088655P.
PR	10-JUN-1998; 98US-0088734P.
PR	10-JUN-1998; 98US-0088738P.
PR	10-JUN-1998; 98US-0088742P.
PR	10-JUN-1998; 98US-0088810P.
PR	10-JUN-1998; 98US-0088824P.
PR	10-JUN-1998; 98US-0088826P.
PR	11-JUN-1998; 98US-0088858P.
PR	11-JUN-1998; 98US-0088861P.
PR	11-JUN-1998; 98US-0088876P.
PR	12-JUN-1998; 98US-0089105P.
PR	16-JUN-1998; 98US-0089440P.
PR	16-JUN-1998; 98US-0089512P.
PR	16-JUN-1998; 98US-0089514P.
PR	17-JUN-1998; 98US-0089532P.
PR	17-JUN-1998; 98US-0089538P.
PR	17-JUN-1998; 98US-0089598P.
PR	17-JUN-1998; 98US-0089599P.
PR	17-JUN-1998; 98US-0089600P.
PR	17-JUN-1998; 98US-0089653P.
PR	18-JUN-1998; 98US-0089801P.
PR	18-JUN-1998; 98US-0089907P.
PR	18-JUN-1998; 98US-0089908P.
PR	16-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98WO-US019437.
PR	07-OCT-1998; 98WO-US021141.

PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrera N, Fong S, Gerber H, Gertlesen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
DR WPI; 2003-288106/28.  
DR P-PSDB; ABU60623.  
XX  
PT New transmembrane polypeptides and nucleic acids encoding the  
PT polypeptides, useful in gene therapy, in chromosome identification, as  
PT chromosome markers, or in generating probes.  
XX  
PS Claim 2; Fig 327; 650bp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC comprising a sequence without signal peptide and the nucleic acid  
CC encoding them. The polypeptides can be used to raise antibodies that  
CC specifically bind to the PRO polypeptide, for linking a bioactive  
CC molecule to a cell expressing a PRO protein and for modulating at least  
CC one biological activity of a cell. The PRO polypeptides or  
CC polynucleotides are also useful in gene therapy, in chromosome  
CC identification, as chromosome markers, or in generating probes. The PRO  
CC polypeptides are useful as molecular markers for protein electrophoresis,  
CC and the isolated nucleic acids may be used for recombinantly expressing  
CC those markers. The PRO polypeptides and nucleic acids may also be used in  
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for  
CC PRO, and in affinity purification of PRO from recombinant cell culture or  
CC natural sources. The sequences presented in ABX90083-ABX90468 are the  
CC genes encoding, the primers amplifying and the probes detecting the PRO

CC polynucleotides of the invention. Note: The sequence data for this patent  
CC is also available in electronic format from USPTO at  
CC [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html)  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ABX90451 Length: 2284 September 29, 2004 14:41 Type: N Check: 5044 ..

Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
GCGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTGCGCGCTTCCCGCGCGGCGACAGA  
|||||  
GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTGCGCGGTCTTCCCGCGCGGCGACAGA  
X 10 20 30 40 50 60 70  
GCTGTCTCGCACCTGGATGGCAGCAGGGGCGCGGGCTCTCTCGACCCGACAGAGAAATCTCATCTG  
|||||  
GCTGTCTCGCACCTGGATGGCAGCAGGGGCGCGGGCTCTCTCGACCCGACAGAGAAATCTCATCTG  
80 90 100 110 120 130 140  
TGACGCTTCTTAAAGCAAACTAAGACCAGAGGAGGATTATCTTGACCTTTGAAGACCAGAACTTAACTG  
|||||  
TGACGCTTCTTAAAGCAAACTAAGACCAGAGGAGGATTATCTTGACCTTTGAAGACCAGAACTTAACTG  
150 160 170 180 190 200 210  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTACACTTTGTAATATTGCTTCGACACTA  
|||||  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTACACTTTGTAATATTGCTTCGACACTA  
220 230 240 250 260 270 280  
AGGCTGTCTGTAGTGAATATGCTTCAAAAGAGTCTAGAAGATGTTGATTTGACATCCAGTCACTCTT  
|||||  
AGGCTGTCTGTAGTGAATATGCTTCAAAAGAGTCTAGAAGATGTTGATTTGACATCCAGTCACTCTT  
290 300 310 320 330 340 350 360  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGAGCTGATTAATCTTGTCTTCA  
370 380 390 400 410 420 430  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGAGCTGATTAATCTTGTCTTCA  
370 380 390 400 410 420 430  
ACAAAAACATATCAGAGGCAAAAGCATGTAATTGATGATCTTGCACCTGAAAAACAGCTAGACAAACC  
440 450 460 470 480 490 500  
ACAAAAACATATCAGAGGCAAAAGCATGTAATTGATGATCTTGCACCTGAAAAACAGCTAGACAAACC  
440 450 460 470 480 490 500  
AACTGCTACCTATTTTCTGTCCCAACGAGAGAGCTTCCATTTGAACCAAGCAAAAGAGCTTATGATTAC  
510 520 530 540 550 560 570  
AACTGCTACCTATTTTCTGTCCCAACGAGAGAGCTTCCATTTGAACCAAGCAAAAGAGCTTATGATTAC  
510 520 530 540 550 560 570  
AGGATTAATTACAGATTCTTTCATCTTGACGAGAAATTTGCCAAGCCAGAGTTACCCGAGAGATTCTCTC  
580 590 600 610 620 630 640  
AGGATTAATTACAGATTCTTTCATCTTGACGAGAAATTTGCCAAGCCAGAGTTACCCGAGAGATTCTCTC  
580 590 600 610 620 630 640  
TTACATGGCCAAATTTTCAAGCAGTCACTCCCTAGCCCATCATCAACAGATTATTCAAGCCCAAGAT  
650 660 670 680 690 700 710 720  
TTACATGGCCAAATTTTCAAGCAGTCACTCCCTAGCCCATCATCAACAGATTATTCAAGCCCAAGAT  
650 660 670 680 690 700 710 720  
730 740 750 760 770 780 790

ATCTCATGAGAGACACACTTCTCAGAGTTGGATCCTCAGATCACTGGAGAAACTATTTAAGATGAT  
|||||  
ATCTCATGAGAGACACACTTCTCAGAGTTGGATCCTCAGATCACTGGAGAAACTATTTAAGATGAT  
730 740 750 760 770 780 790  
800 810 820 830 840 850 860  
GAAGCAATGCCCCAGCTCCTGCTTTATAGGAAAAAGGCCATTCTCAGAGTTCAACAATTTCTCTGATCAA  
|||||  
GAAGCAATGCCCCAGCTCCTGCTTTATAGGAAAAAGGCCATTCTCAGAGTTCAACAATTTCTCTGATCAA  
800 810 820 830 840 850 860  
GAAATAGCTCATCTGCTGCTGAAATGTGAGTCCGCTCCAGCTAGCGGTGGCAGTTGCTTCTCAGATACC  
|||||  
GAAATAGCTCATCTGCTGCTGAAATGTGAGTCCGCTCCAGCTAGCGGTGGCAGTTGCTTCTCAGATACC  
870 880 890 900 910 920 930  
940 950 960 970 980 990 1000  
ACCTCGGCTACTCCAAAGCCCGCCACCTCTTACCCCAACCAATGCTTCACTGACACCTTCTGGGACTTCCAG  
|||||  
ACCTCGGCTACTCCAAAGCCCGCCACCTCTTACCCCAACCAATGCTTCACTGACACCTTCTGGGACTTCCAG  
940 950 960 970 980 990 1000  
1010 1020 1030 1040 1050 1060 1070 1080  
CCACAGCTGGCCACACAGCTCCACCTGTAACCACTGTCACTTCTCAAGCTCCACAGACCTCTCAATTTCTACA  
|||||  
CCACAGCTGGCCACACAGCTCCACCTGTAACCACTGTCACTTCTCAAGCTCCACAGACCTCTCAATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080  
1090 1100 1110 1120 1130 1140 1150  
GTTTTCACACGGGCTGCGGCTACCTCAAGCAATGGCTACAACAGAGTTCTGACTACACCTTTTCAAGCA  
|||||  
GTTTTCACACGGGCTGCGGCTACCTCAAGCAATGGCTACAACAGAGTTCTGACTACACCTTTTCAAGCA  
1090 1100 1110 1120 1130 1140 1150  
1160 1170 1180 1190 1200 1210 1220  
CCTACGGACTCGAAAGCAGCTTAGAAACCATACCGTTTACAGAAATCTCCAACCTTAACCTTTGAACAGAGG  
|||||  
CCTACGGACTCGAAAGCAGCTTAGAAACCATACCGTTTACAGAAATCTCCAACCTTAACCTTTGAACAGAGG  
1160 1170 1180 1190 1200 1210 1220  
1230 1240 1250 1260 1270 1280 1290  
AATGTGTATTAACCTACTGCACTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAACTGCTTCTG  
|||||  
AATGTGTATTAACCTACTGCACTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAACTGCTTCTG  
1230 1240 1250 1260 1270 1280 1290  
1300 1310 1320 1330 1340 1350 1360  
GAAGTAGGAGAGGCGCAGTCCAGGCACTTCTCCAGGGCAGTGTCCAGAAATCAGTAGCGGCTTCCATTT  
|||||  
GAAGTAGGAGAGGCGCAGTCCAGGCACTTCTCCAGGGCAGTGTCCAGAAATCAGTAGCGGCTTCCATTT  
1300 1310 1320 1330 1340 1350 1360  
1370 1380 1390 1400 1410 1420 1430 1440  
GAAAAATGCTTCTTATCGGCTCCTGCTTTGGTGTCTGTTCCCTGGTATAGGCTCGTCTCTGCTGGGT  
|||||  
GAAAAATGCTTCTTATCGGCTCCTGCTTTGGTGTCTGTTCCCTGGTATAGGCTCGTCTCTGCTGGGT  
1370 1380 1390 1400 1410 1420 1430 1440  
1450 1460 1470 1480 1490 1500 1510  
AGAAATCCTTTCCGAATCACTCCCGAGGAAACGTTACTCAAGACTGGATTTATTTGATCAATGGGATCTATGTG  
|||||  
AGAAATCCTTTCCGAATCACTCCCGAGGAAACGTTACTCAAGACTGGATTTATTTGATCAATGGGATCTATGTG  
1450 1460 1470 1480 1490 1500 1510  
1520 1530 1540 1550 1560 1570 1580  
GACATCTTAAGGATGGAATCGGTGCTCTTAATTCATTAGTAACAGAAAGCCCAATGCAATGAGTTTCTG  
|||||  
GACATCTTAAGGATGGAATCGGTGCTCTTAATTCATTAGTAACAGAAAGCCCAATGCAATGAGTTTCTG  
1520 1530 1540 1550 1560 1570 1580  
1590 1600 1610 1620 1630 1640 1650  
CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTTGAAGACAGGAAATGCCCTTCTGCTTCTTTT

CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTTGAAGACAGGAAATGCCCTTCTGCTTCTTTT  
1590 1600 1610 1620 1630 1640 1650  
1660 1670 1680 1690 1700 1710 1720  
TTTGGAGACAGAGTCTTGTCTCTGTTGCCAGGCTGAGTGCATGACCATCTCGGCTCTCAACCGCAACC  
|||||  
TTTGGAGACAGAGTCTTGTCTCTGTTGCCAGGCTGAGTGCATGACCATCTCGGCTCTCAACCGCAACC  
1660 1670 1680 1690 1700 1710 1720  
1730 1740 1750 1760 1770 1780 1790 1800  
TCCGTCTCCTGGGTTCAAGCGATTCTCTGCTCAGCTCCTCAAGTATCTGGATTACAGGCAATGTCACC  
|||||  
TCCGTCTCCTGGGTTCAAGCGATTCTCTGCTCAGCTCCTCAAGTATCTGGATTACAGGCAATGTCACC  
1730 1740 1750 1760 1770 1780 1790 1800  
1810 1820 1830 1840 1850 1860 1870  
ACACCTGGGTGATTTTGTATTTTATAGTAGACGCGGTTTCAACATGTTGTCAGGCTGCTCAAACTCC  
|||||  
ACACCTGGGTGATTTTGTATTTTATAGTAGACGCGGTTTCAACATGTTGTCAGGCTGCTCAAACTCC  
1810 1820 1830 1840 1850 1860 1870  
1880 1890 1900 1910 1920 1930 1940  
TGACCTAGTATCCACCCTCTCGGCTCCCAAAGTGTGGATTAACGATGAGCCACAGCTGGCCC  
|||||  
TGACCTAGTATCCACCCTCTCGGCTCCCAAAGTGTGGATTAACGATGAGCCACAGCTGGCCC  
1880 1890 1900 1910 1920 1930 1940  
1950 1960 1970 1980 1990 2000 2010  
CCTTCTGTTTATGTTGTTTGAAGAAGATGAAGTGGGAAACCAATTAGGTAATTTGGGTAATCTGT  
|||||  
CCTTCTGTTTATGTTGTTTGAAGAAGATGAAGTGGGAAACCAATTAGGTAATTTGGGTAATCTGT  
1950 1960 1970 1980 1990 2000 2010  
2020 2030 2040 2050 2060 2070 2080  
CTCTAAATATTTAGCTAAACCAAGCTCTATGTAAAGTAAATTAATTTGCAATTAATTTCAAAAT  
|||||  
CTCTAAATATTTAGCTAAACCAAGCTCTATGTAAAGTAAATTAATTTGCAATTAATTTCAAAAT  
2020 2030 2040 2050 2060 2070 2080  
2090 2100 2110 2120 2130 2140 2150 2160  
TCAACTGCTTTTATGCAAGAAACAGGTTAGACATCTGCTTCAATTCATTCTGTTCCAGA  
|||||  
TCAACTGCTTTTATGCAAGAAACAGGTTAGACATCTGCTTCAATTCATTCTGTTCCAGA  
2090 2100 2110 2120 2130 2140 2150 2160  
2170 2180 2190 2200 2210 2220 2230  
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGAGATTCCTTTAAACTTATT  
|||||  
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGAGATTCCTTTAAACTTATT  
2170 2180 2190 2200 2210 2220 2230  
2240 2250 2260 2270 2280 X  
CCAGATGATGTTCTTCCCAATTAATTAATTTGAATTAATCTTTGTTACTCAA  
|||||  
CCAGATGATGTTCTTCCCAATTAATTAATTTGAATTAATCTTTGTTACTCAA  
2240 2250 2260 2270 2280 X  
5. US-09-944-929-82 (1-2284)  
ABX80978.SEQ Human secreted/transmembrane protein cDNA, #182.  
TOIG of: abx80978 check: 5044 From: 1 to: 2284  
ID ABX80978 standard; cDNA; 2284 BP.  
XX AC ABX80978;  
XX DT 22-APR-2003 (first entry)  
XX DE Human secreted/transmembrane protein cDNA, #182.  
XX Human; gene; ss; PRO; secreted; transmembrane; pharmaceutical;



KW	diagnostic; biosensor; bio reactor; tumour; therapeutic; gene therapy;	PR	24-JUN-1998;	98US-0090444P.
KW	tumour-associated antigenic target; TAT; ADEPT;	PR	24-JUN-1998;	98US-0090445P.
KW	antibody-dependent enzyme mediated prodrug therapy; cytostatic.	PR	24-JUN-1998;	98US-0090472P.
XX		PR	24-JUN-1998;	98US-0090535P.
OS	Homo sapiens.	PR	24-JUN-1998;	98US-0090540P.
XX		PR	24-JUN-1998;	98US-0090542P.
PN	US2003027162-A1.	PR	24-JUN-1998;	98US-0090557P.
XX		PR	25-JUN-1998;	98US-0090676P.
PD	06-FEB-2003.	PR	25-JUN-1998;	98US-0090678P.
XX		PR	25-JUN-1998;	98US-0090690P.
PF	15-NOV-2001; 2001US-00997428.	PR	25-JUN-1998;	98US-0090694P.
XX		PR	25-JUN-1998;	98US-0090695P.
XX		PR	25-JUN-1998;	98US-0090696P.
PR	16-JUN-1997;	PR	26-JUN-1998;	98US-0090862P.
PR	17-OCT-1997;	PR	26-JUN-1998;	98US-0090863P.
PR	05-NOV-1997;	PR	01-JUL-1998;	98US-0091360P.
PR	12-NOV-1997;	PR	01-JUL-1998;	98US-0091544P.
PR	13-NOV-1997;	PR	02-JUL-1998;	98US-0091478P.
PR	24-NOV-1997;	PR	02-JUL-1998;	98US-0091519P.
PR	25-FEB-1998;	PR	02-JUL-1998;	98US-0091626P.
PR	20-MAR-1998;	PR	02-JUL-1998;	98US-0091628P.
PR	28-APR-1998;	PR	02-JUL-1998;	98US-0091633P.
PR	07-MAY-1998;	PR	02-JUL-1998;	98US-0091646P.
PR	28-MAY-1998;	PR	02-JUL-1998;	98US-0091673P.
PR	02-JUN-1998;	PR	07-JUL-1998;	98US-0091978P.
PR	02-JUN-1998;	PR	07-JUL-1998;	98US-0091982P.
PR	02-JUN-1998;	PR	09-JUL-1998;	98US-0092182P.
PR	03-JUN-1998;	PR	10-JUL-1998;	98US-0092472P.
PR	04-JUN-1998;	PR	20-JUL-1998;	98US-0093339P.
PR	04-JUN-1998;	PR	30-JUL-1998;	98US-0094651P.
PR	04-JUN-1998;	PR	04-AUG-1998;	98US-0095282P.
PR	04-JUN-1998;	PR	04-AUG-1998;	98US-0095285P.
PR	04-JUN-1998;	PR	04-AUG-1998;	98US-0095301P.
PR	04-JUN-1998;	PR	04-AUG-1998;	98US-0095318P.
PR	04-JUN-1998;	PR	04-AUG-1998;	98US-0095321P.
PR	05-JUN-1998;	PR	04-AUG-1998;	98US-0095325P.
PR	05-JUN-1998;	PR	10-AUG-1998;	98US-0095916P.
PR	05-JUN-1998;	PR	10-AUG-1998;	98US-0095929P.
PR	09-JUN-1998;	PR	10-AUG-1998;	98US-0096012P.
PR	10-JUN-1998;	PR	11-AUG-1998;	98US-0096143P.
PR	10-JUN-1998;	PR	11-AUG-1998;	98US-0096146P.
PR	10-JUN-1998;	PR	12-AUG-1998;	98US-0096329P.
PR	10-JUN-1998;	PR	17-AUG-1998;	98US-0096757P.
PR	10-JUN-1998;	PR	17-AUG-1998;	98US-0096766P.
PR	10-JUN-1998;	PR	17-AUG-1998;	98US-0096768P.
PR	11-JUN-1998;	PR	17-AUG-1998;	98US-0096773P.
PR	11-JUN-1998;	PR	17-AUG-1998;	98US-0096791P.
PR	12-JUN-1998;	PR	17-AUG-1998;	98US-0096867P.
PR	16-JUN-1998;	PR	17-AUG-1998;	98US-0096894P.
PR	16-JUN-1998;	PR	17-AUG-1998;	98US-0096895P.
PR	16-JUN-1998;	PR	17-AUG-1998;	98US-0096897P.
PR	17-JUN-1998;	PR	18-AUG-1998;	98US-0096949P.
PR	17-JUN-1998;	PR	18-AUG-1998;	98US-0096950P.
PR	17-JUN-1998;	PR	18-AUG-1998;	98US-0096959P.
PR	17-JUN-1998;	PR	18-AUG-1998;	98US-0096960P.
PR	17-JUN-1998;	PR	18-AUG-1998;	98US-0097022P.
PR	17-JUN-1998;	PR	19-AUG-1998;	98US-0097141P.
PR	18-JUN-1998;	PR	20-AUG-1998;	98US-0097218P.
PR	18-JUN-1998;	PR	24-AUG-1998;	98US-0097661P.
PR	18-JUN-1998;	PR	26-AUG-1998;	98US-0097952P.
PR	19-JUN-1998;	PR	26-AUG-1998;	98US-0097954P.
PR	19-JUN-1998;	PR	26-AUG-1998;	98US-0097955P.
PR	19-JUN-1998;	PR	26-AUG-1998;	98US-0097971P.
PR	22-JUN-1998;	PR	26-AUG-1998;	98US-0097974P.
PR	22-JUN-1998;	PR	26-AUG-1998;	98US-0097978P.
PR	22-JUN-1998;	PR	26-AUG-1998;	98US-0097979P.
PR	23-JUN-1998;	PR	26-AUG-1998;	98US-0097986P.
PR	23-JUN-1998;	PR	26-AUG-1998;	98US-0098014P.
PR	24-JUN-1998;	PR	31-AUG-1998;	98US-0098525P.
PR	24-JUN-1998;	PR	16-SEP-1998;	98US-0100634P.
PR	24-JUN-1998;	PR	16-SEP-1998;	98US-0090435P.

PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 07-SEP-2000; 2000US-0230978P.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,  
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ,  
PI Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF,  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,  
PI Zhang Z;  
XX  
DR WPI; 2003-201194/19.  
DR P-PSDB; ABUS9339.  
XX  
PT New antibodies that bind tumor-associated antigenic target (TAT)  
PT polypeptides, useful for treating and diagnosing tumor (e.g. breast,  
PT lung, liver or stomach tumor) in mammals, e.g. dogs, cats, cattle, pigs,  
PT goats, rabbits or humans.  
XX  
PS Claim 2; Fig 327; 579pp; English.  
XX

CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein, for modulating at  
CC least one biological activity of a cell and as a tumour-associated  
CC antigenic target (TAT) polypeptide inhibitor. The PRO polypeptides,  
CC polynucleotides and antibodies are also useful as pharmaceuticals,  
CC diagnostics, biosensors or bioreactors, for detecting or treating e.g.  
CC tumours (e.g. breast, lung, liver or stomach tumour) in mammals (e.g.  
CC dogs, cats, cattle, horses, sheep, pigs, goats, rabbits or preferably  
CC humans). The PRO polypeptides are also useful as molecular weight markers  
CC or for chromosome identification. The PRO genes are useful as  
CC hybridisation probes or for screening libraries of human cDNA, genomic  
CC DNA or mRNA. The PRO genes may also be used in gene therapy, particularly  
CC for replacing a defective gene. The antibody may also be used in antibody  
CC -dependent enzyme mediated prodrug therapy (ADEPT). The sequences  
CC presented in ABX80610-ABX80992 and ABX10647-ABX10648 are the genes  
CC encoding, the primers amplifying and the probes detecting the PRO  
CC polynucleotides of the invention. Note: The sequence data for this patent  
CC is also available in electronic format from USPTO at  
CC segdata.uspto.gov/sequence.html. In addition some of the sequences after  
CC ABX80734 (SEQ ID NO:163) are not referred to or shown in the  
CC specification as the source document appears to missing a number of pages  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ABX80978 Length: 2284 September 29, 2004 14:42 Type: N Check: 5044 ..

Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
GCGAGCATCCGCTGCGGTCTCCGCCGAGACCCCGCGGATTCGCCGCTTCCCGCGCGGACAGAGA  
GCGAGCATCCGCTGCGGTCTCCGCCGAGACCCCGCGGATTCGCCGCTTCCCGCGCGGACAGAGA  
X 10 20 30 40 50 60 70  
GCTGTCTTCGACCTGGATGGCAGAGGGCGCGGGTCTCTCTCGACGCCAGAGAGAAATCTCATCTG  
GCTGTCTTCGACCTGGATGGCAGAGGGCGCGGGTCTCTCTCGACGCCAGAGAGAAATCTCATCTG  
150 160 170 180 190 200 210  
TGCAGCCTTCTTAAGCAAACTAAGCAGAGGAGATTAATCTTGAACCTTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAGCAAACTAAGCAGAGGAGATTAATCTTGAACCTTTGAAGACCAAACTAACTG  
150 160 170 180 190 200 210  
220 230 240 250 260 270 280  
AAATTAAATGTTCTTCGGGGAGAGAGGAGCTTGACTTACACTTTGTAATAATTTGCTTCTGACACTA  
AAATTAAATGTTCTTCGGGGAGAGAGGAGCTTGACTTACACTTTGTAATAATTTGCTTCTGACACTA  
220 230 240 250 260 270 280  
290 300 310 320 330 340 350 360  
AGGCTGTCTGTAGTCAGAAATGGCTCAAAAAGAGTCTAGAGATGTTGTCATTGACATTCATCTCTT  
AGGCTGTCTGTAGTCAGAAATGGCTCAAAAAGAGTCTAGAGATGTTGTCATTGACATTCATCTCTT  
290 300 310 320 330 340 350 360  
370 380 390 400 410 420 430  
TCTAAGGATTCAGAGGCAATGAGCCGCTATATATCTTCACTCAAGAAGACTGCATTAATCTTGCTGTCA  
TCTAAGGATTCAGAGGCAATGAGCCGCTATATATCTTCACTCAAGAAGACTGCATTAATCTTGCTGTCA  
370 380 390 400 410 420 430  
440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGCACACTCGAAAAACAGCTAGACAACC  
ACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGCACACTCGAAAAACAGCTAGACAACC  
440 450 460 470 480 490 500





CCAGATGTAAGTTCCTTCCAATTAAATTTGATAAATCTTTGTTACTCAA  
 |||||  
 CCAGATGTAAGTTCCTTCCAATTAAATTTGATAAATCTTTGTTACTCAA  
 2240 2250 2260 2270 2280 X

6. US-09-944-929-82 (1-2284)

ABX80474.SEQ Novel human secreted or transmembrane protein PRO8

TOIG of: abx80474 check: 5044 from: 1 to: 2284

ID ABX80474 standard; DNA; 2284 BP.  
 XX  
 AC ABX80474;  
 XX  
 DT 28-APR-2003 (first entry)  
 XX  
 DE Novel human secreted or transmembrane protein PRO846 DNA.  
 XX  
 KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
 KW cardiac insufficiency disorder; cancer; tumour; immune response;  
 KW adrenal cortical capillary endothelial growth; c-fos induction;  
 KW vascular endothelial growth factor inhibition; VEGF inhibition;  
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;  
 KW retinal neurons cell survival; rod photoreceptor cell survival;  
 KW retinal disorder; retinitis pigmentosa; kidney disease;  
 KW mammalian kidney mesangial cell proliferation; Berger disease;  
 KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;  
 KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002132252-A1.  
 XX  
 PD 19-SEP-2002.  
 XX  
 PF 14-NOV-2001; 2001US-00990442.  
 XX  
 PR 16-JUN-1997; 97US-0049787P.  
 PR 17-OCT-1997; 97US-0062250P.  
 PR 05-NOV-1997; 97WO-US020069.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 13-NOV-1997; 97US-0065311P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 25-FEB-1998; 98US-0075945P.  
 PR 20-MAR-1998; 98US-0078910P.  
 PR 28-APR-1998; 98US-0083322P.  
 PR 07-MAY-1998; 98US-0084600P.  
 PR 28-MAY-1998; 98US-0087106P.  
 PR 02-JUN-1998; 98US-0087607P.  
 PR 02-JUN-1998; 98US-0087609P.  
 PR 02-JUN-1998; 98US-0087759P.  
 PR 03-JUN-1998; 98US-0087827P.  
 PR 04-JUN-1998; 98US-0088021P.  
 PR 04-JUN-1998; 98US-0088025P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 04-JUN-1998; 98US-0088028P.  
 PR 04-JUN-1998; 98US-0088029P.  
 PR 04-JUN-1998; 98US-0088030P.  
 PR 04-JUN-1998; 98US-0088033P.  
 PR 04-JUN-1998; 98US-0088326P.  
 PR 05-JUN-1998; 98US-0088167P.  
 PR 05-JUN-1998; 98US-0088202P.  
 PR 05-JUN-1998; 98US-0088212P.  
 PR 05-JUN-1998; 98US-0088217P.  
 PR 09-JUN-1998; 98US-0088655P.  
 PR 10-JUN-1998; 98US-0088734P.  
 PR 10-JUN-1998; 98US-0088742P.  
 PR 10-JUN-1998; 98US-0088810P.  
 PR 10-JUN-1998; 98US-0088824P.  
 PR 10-JUN-1998; 98US-0088826P.  
 PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.  
 PR 11-JUN-1998; 98US-0088876P.  
 PR 12-JUN-1998; 98US-0089105P.  
 PR 16-JUN-1998; 98US-0089440P.  
 PR 16-JUN-1998; 98US-0089512P.  
 PR 16-JUN-1998; 98US-0089514P.  
 PR 17-JUN-1998; 98US-0089532P.  
 PR 17-JUN-1998; 98US-0089538P.  
 PR 17-JUN-1998; 98US-0089598P.  
 PR 17-JUN-1998; 98US-0089599P.  
 PR 17-JUN-1998; 98US-0089600P.  
 PR 17-JUN-1998; 98US-0089653P.  
 PR 18-JUN-1998; 98US-0089801P.  
 PR 18-JUN-1998; 98US-0089907P.  
 PR 18-JUN-1998; 98US-0089908P.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 06-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 15-MAY-2000; 2000WO-US013358.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023322.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 28-AUG-2001; 2001US-00941992.

(GETH ) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;  
 Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
 Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
 Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
 Zhang Z;

WPI; 2003-247083/24.  
 P-PSDB; ABUS9193.

Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346  
 and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
 are therapeutically useful for enhancing immune response and in cancer

PT treatments.  
XX  
PS Claim 2; Fig 329; 648bp; English.  
XX

CC The invention describes an isolated human PRO polypeptide. The PRO  
CC polypeptides are useful in detecting PRO polypeptides in a sample, in  
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
CC in modulating at least one biological activity of a cell expressing a PRO  
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186  
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,  
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,  
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus  
CC useful for treating conditions or disorders where angiogenesis would be  
CC beneficial, e.g. wound healing and antagonist of this polypeptide are  
CC useful for treating cancerous tumours. PRO812 inhibits vascular  
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial  
CC cells and is thus useful for inhibiting endothelial cell growth in  
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,  
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of  
CC stimulated T-lymphocytes and are therapeutically useful for enhancing  
CC immune response. PRO828, PRO826, PRO1068 or PRO132 enhance survival of  
CC retinal neurons cells (PRO132 is also enhances survival/proliferation of  
CC rod photoreceptor cells) and therefore are useful for treating retinal  
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813  
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,  
CC and therefore are useful for treating kidney disorders associated with  
CC decreased mesangial cell function such as Berger disease or other  
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's  
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the  
CC proliferation and/or redifferentiation of chondrocytes in culture and are  
CC thus useful for treating sports injuries, and arthritis. This sequence  
CC represents a novel human PRO protein polynucleotide  
XX

SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ABX80474 Length: 2284 September 29, 2004 14:40 Type: N Check: 5044 ..

Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
GGGAGCATCCGCTGGCTCTCGCGGAGACCCCGCGGATTGCGCGTCTCCCGCGGCGGACAGA  
GCGGAGCATCCGCTGGCTCTCGCGGAGACCCCGCGGATTGCGCGTCTCCCGCGGCGGACAGA  
X 10 20 30 40 50 60 70  
80 90 100 110 120 130 140  
GCTGTCTCGCACCTGGATGGAGCGGCGCGGCTCTCTCGACGCCAGAGAGAAATCTCATCTG  
GCTGTCTCGCACCTGGATGGAGCGGCGCGGCTCTCTCGACGCCAGAGAGAAATCTCATCTG  
80 90 100 110 120 130 140  
150 160 170 180 190 200 210  
TGCAGCCTTCTTAAGCAAACTAAGACCAAGAGGAGATTATCTTGACCTTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAGCAAACTAAGACCAAGAGGAGATTATCTTGACCTTTGAAGACCAAACTAACTG  
150 160 170 180 190 200 210  
220 230 240 250 260 270 280  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTTGCTTCTGACACTA  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTTGCTTCTGACACTA  
220 230 240 250 260 270 280  
290 300 310 320 330 340 350 360  
AGGCTGTCTGCTAGTACAGAAATGCTCAAAAAGAGTCTAGAGATGTTGTCAATTGACATCCAGTCATCTT  
AGGCTGTCTGCTAGTACAGAAATGCTCAAAAAGAGTCTAGAGATGTTGTCAATTGACATCCAGTCATCTT  
290 300 310 320 330 340 350 360  
370 380 390 400 410 420 430

TCTAAGGAATCAGAGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATCTTGTCTCA  
TCTAAGGAATCAGAGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATCTTGTCTCA  
370 380 390 400 410 420 430  
440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGACAAAGCATGTACTGTATGATCTTCGACACTCGAAAAACAGTAGACACCC  
ACAAAAACATATCAGGGGACAAAGCATGTACTGTATGATCTTCGACACTCGAAAAACAGTAGACACCC  
440 450 460 470 480 490 500  
510 520 530 540 550 560 570  
AACTGCTACCTATTTTCTGTCCCAACGAGAGAGCTTCCATTGAAACCAAGCAAAAGACTTATGAGTTAC  
AACTGCTACCTATTTTCTGTCCCAACGAGAGAGCTTCCATTGAAACCAAGCAAAAGACTTATGAGTTAC  
510 520 530 540 550 560 570  
580 590 600 610 620 630 640  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAAAGAGTACCAGAGATTCTC  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAAAGAGTACCAGAGATTCTC  
580 590 600 610 620 630 640  
650 660 670 680 690 700 710 720  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAGCCCAAGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAGCCCAAGAT  
650 660 670 680 690 700 710 720  
730 740 750 760 770 780 790  
ATCTCATGAGAGACACACTTTTCTCAGAAGTTTGATCTCCAGATCACCTGGAGAGAACTATTTAAGATGAT  
ATCTCATGAGAGACACACTTTTCTCAGAAGTTTGATCTCCAGATCACCTGGAGAGAACTATTTAAGATGAT  
730 740 750 760 770 780 790  
800 810 820 830 840 850 860  
GAAGCAAGTGGCCAGCTCTCTGCTTATTAAGAAAAAGCCATTCTCAGAGTTCAACAATTTCTCTGATCA  
GAAGCAAGTGGCCAGCTCTCTGCTTATTAAGAAAAAGCCATTCTCAGAGTTCAACAATTTCTCTGATCA  
800 810 820 830 840 850 860  
870 880 890 900 910 920 930  
GAAATAGCTCATCTGCTGCTGCTGAATATGTAGTGGCTCCAGCTACCGTGGAGAGTCTTCCACATACC  
GAAATAGCTCATCTGCTGCTGCTGAATATGTAGTGGCTCCAGCTACCGTGGAGAGTCTTCCACATACC  
870 880 890 900 910 920 930  
940 950 960 970 980 990 1000  
ACCTGGCTACTCCAAAGCCCGCCACCTTTCTTACCCACCAATGTCTTCACTGACACACCTTCTGGACTTCCAG  
ACCTGGCTACTCCAAAGCCCGCCACCTTTCTTACCCACCAATGTCTTCACTGACACACCTTCTGGACTTCCAG  
940 950 960 970 980 990 1000  
1010 1020 1030 1040 1050 1060 1070 1080  
CCACAGCTGGCCACACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCTCCACAGACCTCATTTCTACA  
CCACAGCTGGCCACACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCTCCACAGACCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080  
1090 1100 1110 1120 1130 1140 1150  
GTTTTTACACGGGCTGGCTTACACTCCAAAGCAATGGCTACAAACAGCAGTCTGACTACACCTTTGAGCA  
GTTTTTACACGGGCTGGCTTACACTCCAAAGCAATGGCTACAAACAGCAGTCTGACTACACCTTTGAGCA  
1090 1100 1110 1120 1130 1140 1150  
1160 1170 1180 1190 1200 1210 1220  
CCTACGAGCTCGAAAGGAGCTTAGAAACCATACCGTTTACAGAAATCTTCAACTTAACTTTGAACACAGG  
CCTACGAGCTCGAAAGGAGCTTAGAAACCATACCGTTTACAGAAATCTTCAACTTAACTTTGAACACAGG  
1160 1170 1180 1190 1200 1210 1220  
1230 1240 1250 1260 1270 1280 1290  
AATGTGTATAACCTTACTGCACTTCTTATGTCAAATGTGAGTCTTCCACTATGATTAATAAACTGCTTCTCG

```
|||||
AATGTGTAATACCCCTACTGCACCTTTCTATGTCAATGTGGAGTCTTCCACTATGAATAAACTGCTTCCGTGG
1230      1240      1250      1260      1270      1280      1290
1300      1310      1320      1330      1340      1350      1360
GAAGTAGGAGGAGCCAGTCCAGGAGTCTCTCCAGGGCAGGTGTTCCAGAAATCAGTACGGCTTCCATT
|||||
GAAGTAGGAGGAGCCAGTCCAGGAGTCTCTCCAGGGCAGGTGTTCCAGAAATCAGTACGGCTTCCATT
1300      1310      1320      1330      1340      1350      1360
GAAAAATGGCTTCTTATCGGGTCCCTGCTCTTGGTGTCTGTCGTGATAGGCCCTGCTCTCTGGGT
1370      1380      1390      1400      1410      1420      1430      1440
1450      1460      1470      1480      1490      1500      1510
AGAAATCCTTTCGGAATCACTCCGCGAGAAACGTTACTCAAGACTGGAATTATTGGATCAATGGGATCTATGTG
|||||
AGAAATCCTTTCGGAATCACTCCGCGAGAAACGTTACTCAAGACTGGAATTATTGGATCAATGGGATCTATGTG
1450      1460      1470      1480      1490      1500      1510
GACATCTAAGGATGGAACCTGGTGTCTTAAATTCATTAGTAACAGAAACCCAAATGCAATGAGTTTCTG
|||||
GACATCTAAGGATGGAACCTGGTGTCTTAAATTCATTAGTAACAGAAACCCAAATGCAATGAGTTTCTG
1520      1530      1540      1550      1560      1570      1580
1590      1600      1610      1620      1630      1640      1650
CTGACTTGCTAGTCTTAGCAGAGGTTGTAATTTGAAGACAGGAAATGCCCCCTTCTGCTTCTTTT
|||||
CTGACTTGCTAGTCTTAGCAGAGGTTGTAATTTGAAGACAGGAAATGCCCCCTTCTGCTTCTTTT
1590      1600      1610      1620      1630      1640      1650
1660      1670      1680      1690      1700      1710      1720
TTTGGAGACAGAGTCTGCTGCTGCCAGGCTGAGTGACAGATCTCGGCTCTCAACCGCAACC
1660      1670      1680      1690      1700      1710      1720
1730      1740      1750      1760      1770      1780      1790      1800
TCCGTCCTCTGGGTCAAGCCGATTCCTCTGCTCAGCCCTCCTAAGTATCTGGATTACAGGCAATGTCACAC
|||||
TCCGTCCTCTGGGTCAAGCCGATTCCTCTGCTCAGCCCTCCTAAGTATCTGGATTACAGGCAATGTCACAC
1730      1740      1750      1760      1770      1780      1790      1800
1810      1820      1830      1840      1850      1860      1870
ACACCTGGGTGATTTTGTATTTTAGAGAGACGGGTTTCACCAATGTTGTCAGGCTGCTCAAACTCC
|||||
ACACCTGGGTGATTTTGTATTTTAGAGAGACGGGTTTCACCAATGTTGTCAGGCTGCTCAAACTCC
1810      1820      1830      1840      1850      1860      1870
1880      1890      1900      1910      1920      1930      1940
TGACCTAGTATCCACCCTCTCGGCTCCCAAAGTCTGGGATTAACAGGCATGAGCCACACAGCTGGCCC
|||||
TGACCTAGTATCCACCCTCTCGGCTCCCAAAGTCTGGGATTAACAGGCATGAGCCACACAGCTGGCCC
1880      1890      1900      1910      1920      1930      1940
1950      1960      1970      1980      1990      2000      2010
CCTTCTGTTTATGTTTGGTTTGGAGAAAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT
|||||
CCTTCTGTTTATGTTTGGTTTGGAGAAAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT
1950      1960      1970      1980      1990      2000      2010
2020      2030      2040      2050      2060      2070      2080
CTCTAAATAATATTAGCTAAACAAAGCTCTATGTAAAGTAATAAGTAAATGGCATATTAATTCCAAT
|||||
CTCTAAATAATATTAGCTAAACAAAGCTCTATGTAAAGTAATAAGTAAATGGCATATTAATTCCAAT
2020      2030      2040      2050      2060      2070      2080
2090      2100      2110      2120      2130      2140      2150      2160
TCAACTGGCTTTTATGCAAGAAACAGGTTAGGACATCTAGGTTCCAATTCAATTCACATTTCTGGTTCAGA
|||||
```

```
TCAACTGGCTTTTATGCAAGAAACAGGTTAGGACATCTAGGTTCCAATTCAATTCACATTTCTGGTTCAGA
2090      2100      2110      2120      2130      2140      2150      2160
2170      2180      2190      2200      2210      2220      2230
TAAATCAACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGATGATTCCTTTAAACTTATT
|||||
TAAATCAACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTTATATGATGATTCCTTTAAACTTATT
2170      2180      2190      2200      2210      2220      2230
2240      2250      2260      2270      2280      X
CCAGATGATGTTCTCTTCCAATTAATATTGGAATTAATCTTTGTTACTCAA
|||||
CCAGATGATGTTCTCTTCCAATTAATATTGGAATTAATCTTTGTTACTCAA
2240      2250      2260      2270      2280      X
7. US-09-944-929-82 (1-2284)
ABX78486.SEQ DNA encoding Novel human secreted protein PRO361.
TOIG of: abx78486 check: 5044 from: 1 to: 2284
ID ABX78486 standard; DNA; 2284 BP.
XX
AC ABX78486;
XX
DT 14-APR-2003 (first entry)
XX
DE DNA encoding Novel human secreted protein PRO361.
XX
KW Human; antiinflammatory; antiarteriosclerotic; cardiant; gynecological;
KW anti-HIV; cyostatic; antidiabetic; BMP-agonist; BMP-Antagonist;
KW cytokine-agonist; cytokine-antagonist; gene-Therapy;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defect; premature aging; AIDS; cancer;
KW diabetic complication; gene; ds.
XX
OS Homo sapiens.
XX
PN US2002150976-A1.
XX
PD 17-OCT-2002.
XX
PF 30-AUG-2001; 2001US-00943851.
XX
PR 03-DEC-1997; 97US-0067411P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 16-DEC-1997; 97US-0069694P.
PR 16-DEC-1997; 97US-0069696P.
PR 16-DEC-1997; 97US-0069702P.
PR 17-DEC-1997; 97US-0069870P.
PR 17-DEC-1997; 97US-0069873P.
PR 18-DEC-1997; 97US-0068017P.
PR 05-JAN-1998; 98US-0070440P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 25-FEB-1998; 98US-0075945P.
PR 16-SEP-1998; 98WO-US019330.
PR 01-DEC-1998; 98WO-US025108.
PR 16-DEC-1998; 98US-00216021.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 03-MAR-1999; 99US-00254311.
PR 02-JUN-1999; 99WO-US012252.
PR 28-JUL-1999; 99US-0146222P.
PR 15-SEP-1999; 99WO-US021090.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US030095.
```



PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.

XX (GETH ) GENENTECH INC.

PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvarof E;

PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;

PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;

XX WPI; 2003-198285/19.

DR P-PSDB; ABUS8364.

XX New isolated PRO polypeptide and encoding nucleic acids, useful for the  
PT diagnosis and treatment of disorders such as inflammatory disease,  
PT atherosclerosis, cardiac injury, infertility, AIDS, cancer and diabetic  
PT complications.

XX Claim 2; Fig 31; 171pp; English.

XX The invention describes a novel isolated PRO polypeptide. The methods and  
CC compositions of the present invention are useful for the diagnosis and  
CC treatment of disorders such as inflammatory disease, organ failure,  
CC atherosclerosis, cardiac injury, infertility, birth defects, premature  
CC aging, AIDS, cancer, diabetic complications and mutations in general.  
CC This sequence encodes a novel human secreted PRO protein

XX SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ABX78486 length: 2284 September 29, 2004 14:42 Type: N Check: 5044 ..

Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
GGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTCGCCGCTTCCCGCGGCGGACAGA  
|||||  
GCGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTCGCCGCTTCCCGCGGCGGACAGA  
X 10 20 30 40 50 60 70

80 90 100 110 120 130 140  
GCTGTCTCGCACCCTGATGGACAGAGGGGGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
|||||  
GCTGTCTCGCACCCTGATGGACAGAGGGGGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
80 90 100 110 120 130 140

150 160 170 180 190 200 210  
TGCAGCCTTCTTAAAGCAAACTAAGACCAGAGGAGATTATCTTGACCTTTGAAGCAAAACTAACTG  
|||||  
TGCAGCCTTCTTAAAGCAAACTAAGACCAGAGGAGATTATCTTGACCTTTGAAGCAAAACTAACTG  
150 160 170 180 190 200 210

220 230 240 250 260 270 280  
AAATTTAAATGTTCTTCGGGGGAAAGGAGCTTGACTTACACTTTGGTAATATTTGCTTCTGACACTA  
|||||  
AAATTTAAATGTTCTTCGGGGGAAAGGAGCTTGACTTACACTTTGGTAATATTTGCTTCTGACACTA  
220 230 240 250 260 270 280

290 300 310 320 330 340 350 360  
AGGCTGTCTGCTAGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATCCAGTCATCTT  
|||||  
AGGCTGTCTGCTAGTCAGAAATGCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATCCAGTCATCTT  
290 300 310 320 330 340 350 360

370 380 390 400 410 420 430  
TCTAAGGGAATCAGAGGCAATGACCCCGTATATATCTTCAACTCAAGAAAGACTGCATTAAATCTTGCTGTTCA

|||||  
TCTAAGGGAATCAGAGGCAATGACCCCGTATATATCTTCAACTCAAGAAAGACTGCATTAAATCTTGCTGTTCA  
370 380 390 400 410 420 430

440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTAGACACC  
|||||  
ACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTAGACACC  
440 450 460 470 480 490 500

510 520 530 540 550 560 570  
AACTGCTACCTATTTTCTGTGCCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGACTTATGAGTTAC  
|||||  
AACTGCTACCTATTTTCTGTGCCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGACTTATGAGTTAC  
510 520 530 540 550 560 570

580 590 600 610 620 630 640  
AGGATAATTACAGATTTTCCATCTTTGACCCAGAAATTTGCCAAGCCAAAGTTACCCAGAGATTCTTC  
|||||  
AGGATAATTACAGATTTTCCATCTTTGACCCAGAAATTTGCCAAGCCAAAGTTACCCAGAGATTCTTC  
580 590 600 610 620 630 640

650 660 670 680 690 700 710 720  
TTACATGGCCCAATTTTCAAGCAGTCACTCCCTTAGCCCATCATCACAGATTATTCAAGCCACCGAT  
|||||  
TTACATGGCCCAATTTTCAAGCAGTCACTCCCTTAGCCCATCATCACAGATTATTCAAGCCACCGAT  
650 660 670 680 690 700 710 720

730 740 750 760 770 780 790  
ATCTCATGAGAGACACTTTCTCAGAAAGTTGGATCTCAGATCACCTGGAGAAACTATTTAAGATGAT  
|||||  
ATCTCATGAGAGACACTTTCTCAGAAAGTTGGATCTCAGATCACCTGGAGAAACTATTTAAGATGAT  
730 740 750 760 770 780 790

800 810 820 830 840 850 860  
GAAGCAAGTGCCCAAGCTTCTGCTTATATAAGAAAGGCCATTCTCAGAGTTCACAATTTCTCTGATCAA  
|||||  
GAAGCAAGTGCCCAAGCTTCTGCTTATATAAGAAAGGCCATTCTCAGAGTTCACAATTTCTCTGATCAA  
800 810 820 830 840 850 860

870 880 890 900 910 920 930  
GAAATAGCTCATCTGCTGCTGAAATGTGAGTGGCTCCAGCTACCGTGGCAGTGTCTTCCACATACC  
|||||  
GAAATAGCTCATCTGCTGCTGAAATGTGAGTGGCTCCAGCTACCGTGGCAGTGTCTTCCACATACC  
870 880 890 900 910 920 930

940 950 960 970 980 990 1000  
ACCTGGCTACTCCAAAGCCCGCACCCCTTCTACCCCAATGCTTCACTGACACACTTCTGGACTTCCAG  
|||||  
ACCTGGCTACTCCAAAGCCCGCACCCCTTCTACCCCAATGCTTCACTGACACACTTCTGGACTTCCAG  
940 950 960 970 980 990 1000

1010 1020 1030 1040 1050 1060 1070 1080  
CCACAGCTGGCCACACAGCTCCACCTGTAACCACTGTCACTTCTCAGCCTCCACGAGCCCTCATTTCTACA  
|||||  
CCACAGCTGGCCACACAGCTCCACCTGTAACCACTGTCACTTCTCAGCCTCCACGAGCCCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080

1090 1100 1110 1120 1130 1140 1150  
GTTTTTACACGGGCTGGGCTACACTCCAGCAATGGCTACACAGCAGCAGTTCTGACTACACACTTTACGGCA  
|||||  
GTTTTTACACGGGCTGGGCTACACTCCAGCAATGGCTACACAGCAGCAGTTCTGACTACACACTTTACGGCA  
1090 1100 1110 1120 1130 1140 1150

1160 1170 1180 1190 1200 1210 1220  
CCTAAGGACTCGAAAGCAGCTTAGAAACCAATACCGTTTACAGAAATCTCCAACCTTGAACACAGGG  
|||||  
CCTAAGGACTCGAAAGCAGCTTAGAAACCAATACCGTTTACAGAAATCTCCAACCTTGAACACAGGG  
1160 1170 1180 1190 1200 1210 1220

1230 1240 1250 1260 1270 1280 1290  
AATGTGTATAACCCCTACTGCACTTCTATGTGAAATGTGAGTCTTCCACTATGAATAAAACTGCTTCTCGG  
|||||

AATGTGTATAACCCTACTGCACTTTCATGTGCTAAATGTGGAGTCTTCCACTATGATTAATACTGCTTCCTGG  
1230 1240 1250 1260 1270 1280 1290  
1300 1310 1320 1330 1340 1350 1360  
GAAGTAGGAGGACCAGTCCAGCAGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGGCTTCCATT  
|||||  
GAAGTAGGAGGACCAGTCCAGCAGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGGCTTCCATT  
1300 1310 1320 1330 1340 1350 1360  
1370 1380 1390 1400 1410 1420 1430 1440  
GAAAAATGCGCTTCTTATCGGGTCCCTGCTCTTGGGTCCTGTTCCGTGATAGGCTCGTCCCTGGGT  
|||||  
GAAAAATGCGCTTCTTATCGGGTCCCTGCTCTTGGGTCCTGTTCCGTGATAGGCTCGTCCCTGGGT  
1370 1380 1390 1400 1410 1420 1430 1440  
1450 1460 1470 1480 1490 1500 1510  
AGAAATCCTTTCCGAATCACTCCGCAAGAAACGTTACTCAAGACTGGATTATTGATCAATGGGATCTATGTG  
|||||  
AGAAATCCTTTCCGAATCACTCCGCAAGAAACGTTACTCAAGACTGGATTATTGATCAATGGGATCTATGTG  
1450 1460 1470 1480 1490 1500 1510  
1520 1530 1540 1550 1560 1570 1580  
GACATCTAAGAGTAGAACTCGGTCTCTTAATTCATTTAGTAAACCAAGAGCCCAATGCAATGAGTTCTG  
|||||  
GACATCTAAGAGTAGAACTCGGTCTCTTAATTCATTTAGTAAACCAAGAGCCCAATGCAATGAGTTCTG  
1520 1530 1540 1550 1560 1570 1580  
1590 1600 1610 1620 1630 1640 1650  
CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTGAGAACAAGAAATGCCCCCTTCGTCTTCTTTT  
|||||  
CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTGAGAACAAGAAATGCCCCCTTCGTCTTCTTTT  
1590 1600 1610 1620 1630 1640 1650  
1660 1670 1680 1690 1700 1710 1720  
TTTGGAGACAGAGTCTTGCTCTGTGCCCCAGGCTGGAGTGCAGTAGCAGCATCTCGGCTCTCAACGCAACC  
|||||  
TTTGGAGACAGAGTCTTGCTCTGTGCCCCAGGCTGGAGTGCAGTAGCAGCATCTCGGCTCTCAACGCAACC  
1660 1670 1680 1690 1700 1710 1720  
1730 1740 1750 1760 1770 1780 1790 1800  
TCCGTCCTCGGTTCAAGCGATTCTCCTGCCCTCAGCCTCTAAGTATCTGGATTACAGGCATGTGCCACC  
|||||  
TCCGTCCTCGGTTCAAGCGATTCTCCTGCCCTCAGCCTCTAAGTATCTGGATTACAGGCATGTGCCACC  
1730 1740 1750 1760 1770 1780 1790 1800  
1810 1820 1830 1840 1850 1860 1870  
ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGGTTTCAACCATGTTGTCAGGGCTGCTCAAACTCC  
|||||  
ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGGTTTCAACCATGTTGTCAGGGCTGCTCAAACTCC  
1810 1820 1830 1840 1850 1860 1870  
1880 1890 1900 1910 1920 1930 1940  
TGACCTAGTGATCCACCCTCTCGGCTCCCAAAGTGTCTGGATTACAGGCATGAGCCACCAAGCTGGCCC  
|||||  
TGACCTAGTGATCCACCCTCTCGGCTCCCAAAGTGTCTGGATTACAGGCATGAGCCACCAAGCTGGCCC  
1880 1890 1900 1910 1920 1930 1940  
1950 1960 1970 1980 1990 2000 2010  
CCTTCTGTTTATGTTGGTTTGTGAGAGGAATGAAGTGGAAACCAATTAGGTATTTGGGTATCTGT  
|||||  
CCTTCTGTTTATGTTGGTTTGTGAGAGGAATGAAGTGGAAACCAATTAGGTATTTGGGTATCTGT  
1950 1960 1970 1980 1990 2000 2010  
2020 2030 2040 2050 2060 2070 2080  
CTCTTAAATATTTAGCTAAACCAAGCTCTATGTAAAGTAAATTAAGTATTAATGCAATTAATAATTCCAAT  
|||||  
CTCTTAAATATTTAGCTAAACCAAGCTCTATGTAAAGTAAATTAAGTATTAATGCAATTAATAATTCCAAT  
2020 2030 2040 2050 2060 2070 2080  
2090 2100 2110 2120 2130 2140 2150 2160  
TCAACTGGCTTTTATGCAAAAGAAACAGGTTAGACATCTAGGTTCCCAATTCATTCAATCTTGGTTCCAGA  
|||||  
TCAACTGGCTTTTATGCAAAAGAAACAGGTTAGACATCTAGGTTCCCAATTCATTCAATCTTGGTTCCAGA  
2090 2100 2110 2120 2130 2140 2150 2160

	2090	2100	2110	2120	2130	2140	2150	2160
	2170	2180	2190	2200	2210	2220	2230	
	TAAATCAACTGTTTATATCAATTCTAATGATTTGGCTTTCTTTTATATGAGATTCCTTTAAACTTATTT							
	TAAAATCAACTGTATTATATCAATTCTAATGATTTGGCTTTCTTTTATATGAGATTCCTTTAAACTTATTT							
	2170	2180	2190	2200	2210	2220	2230	
	CCAGATGTAGTTCCTTCCAATTAATATTTGAATAAATCTTTGTTACTCAA							
	2240	2250	2260	2270	2280	X		
	CCAGATGTAGTTCCTTCCAATTAATATTTGAATAAATCTTTGTTACTCAA							
	2240	2250	2260	2270	2280	X		

8. US-09-944-929-82 (1-2284)  
ABX77120.SEQ cDNA encoding human PRO361 protein.

TOIG of: abx77120 check: 5044 from: 1 to: 2284

ID	ABX77120 standard; cDNA; 2284 BP.
XX	
AC	ABX77120;
XX	
DT	04-APR-2003 (first entry)
XX	
DE	cDNA encoding human PRO361 protein.
XX	
KW	Gene; ss; human; antiinflammatory; antiarteriosclerotic; cardiant;
KW	anti-infertility; anti-HIV; cyostatic; antidiabetic; transmembrane;
KW	anti-inflammatory; anti-HIV; antiarteriosclerotic; cardiant; infertility;
KW	anti-infertility; cyostatic; antidiabetic; gene therapy; birth defect;
KW	inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW	premature aging; AIDS; cancer; diabetic complication.
XX	
OS	Homo sapiens.
XX	
PN	US2002142958-A1.
XX	
PD	03-OCT-2002.
XX	
PF	30-AUG-2001; 2001US-00943762.
XX	
PR	16-SEP-1998; 98WO-US019330.
PR	01-DEC-1998; 98WO-US025108.
PR	22-JUN-1999; 99WO-US012252.
PR	15-SEP-1999; 99WO-US021090.
PR	30-NOV-1999; 99WO-US028313.
PR	30-NOV-1999; 99WO-US028409.
PR	01-DEC-1999; 99WO-US028301.
PR	16-DEC-1999; 99WO-US030095.
PR	11-FEB-2000; 2000WO-US003565.
PR	22-FEB-2000; 2000WO-US004414.
PR	02-MAR-2000; 2000WO-US005841.
PR	30-MAR-2000; 2000WO-US008439.
PR	22-MAY-2000; 2000WO-US014042.
PR	28-JUL-2000; 2000WO-US020710.
PR	01-DEC-2000; 2000WO-US032678.
PR	28-FEB-2001; 2001WO-US006520.
PR	25-MAY-2001; 2001US-00866028.
XX	
PA	(GETH ) GENENTECH INC.
XX	
P1	Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;
P1	Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
P1	Hillan KJ, Kijavlin IJ, Napier MA, Roy MA, Tumas D, Wood WI;
DR	WI; 2003-174140/17.
DR	P-PSDB; ABUS7251.
XX	
PT	New secreted and transmembrane nucleic acids and polypeptides, designated
PT	as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT	cardiac injury, infertility, birth defects, premature aging, AIDS, or

PT cancer.  
XX  
PS Claim 2; Fig 31; 173pp; English.  
XX  
CC This invention relates to a nucleotide sequence encoding an isolated  
CC secreted and/or transmembrane protein. The nucleotide sequences of the  
CC invention may have antiinflammatory, antiarteriosclerotic, cardiant, anti-  
CC -infectivity, anti-HIV, cytostatic and antidiabetic activities and may be  
CC used in gene therapy. The nucleic acids and polypeptides are useful for  
CC treating inflammatory diseases, organ failure, atherosclerosis, cardiac  
CC injury, infertility, birth defects, premature aging, AIDS, cancer, or  
CC diabetic complications. The nucleic acids are useful as hybridisation  
CC probes, in chromosome and gene mapping, and in generating antisense RNA  
CC or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,  
CC biosensors or bioreactors. Both are useful in tissue typing. The present  
CC sequence represents a nucleic acid sequence of the invention  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ABX77120 Length: 2284 September 29, 2004 14:42 Type: N Check: 5044 ..

Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
GCGGAGCATCCGCTGCGGTCCTCGCGAGACCCCGCGCGGATTCGCCGCTTCCCGCGGGCGGACAGA  
|||||  
GCGGAGCATCCGCTGCGGTCCTCGCGAGACCCCGCGCGGATTCGCCGCTTCCCGCGGGCGGACAGA  
X 10 20 30 40 50 60 70  
GCTGTCTTCGCACCTGGATGGCAGAGGGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
|||||  
GCTGTCTTCGCACCTGGATGGCAGAGGGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
80 90 100 110 120 130 140  
GCTGTCTTCGCACCTGGATGGCAGAGGGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
80 90 100 110 120 130 140  
GCTGTCTTCGCACCTGGATGGCAGAGGGGGCGCGGGTCTCTCGACGCCAGAGAGAAATCTCATCTG  
150 160 170 180 190 200 210  
TGAGCCTTCTTAAAGCAAACTAGACCAAGAGGAGATATCTTGACCTTGAAGACCAAACTAAACTG  
150 160 170 180 190 200 210  
TGAGCCTTCTTAAAGCAAACTAGACCAAGAGGAGATATCTTGACCTTGAAGACCAAACTAAACTG  
220 230 240 250 260 270 280  
AAATTTAAATGTTCTTCGGGGGAAGGAGCTTGACTTACACTTTGGTATATATTTGCTTCTGACACTA  
|||||  
AAATTTAAATGTTCTTCGGGGGAAGGAGCTTGACTTACACTTTGGTATATATTTGCTTCTGACACTA  
220 230 240 250 260 270 280  
AAATTTAAATGTTCTTCGGGGGAAGGAGCTTGACTTACACTTTGGTATATATTTGCTTCTGACACTA  
290 300 310 320 330 340 350 360  
AGGCTGTCTGCTAGTCAGAAATGCTCTCAAAAAGAGTCTAGAGAGATGTTGTCATTGACATCCAGTCTCTT  
|||||  
AGGCTGTCTGCTAGTCAGAAATGCTCTCAAAAAGAGTCTAGAGAGATGTTGTCATTGACATCCAGTCTCTT  
290 300 310 320 330 340 350 360  
AGGCTGTCTGCTAGTCAGAAATGCTCTCAAAAAGAGTCTAGAGAGATGTTGTCATTGACATCCAGTCTCTT  
370 380 390 400 410 420 430  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATACTTCACTCAAGAAGACTGCATTAATCTTGCTGTTCA  
370 380 390 400 410 420 430  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATACTTCACTCAAGAAGACTGCATTAATCTTGCTGTTCA  
440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGACAAAGCATGTACTTGATGATCTTGCACACTCGAAAAACAGCTAGACACCC  
440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGACAAAGCATGTACTTGATGATCTTGCACACTCGAAAAACAGCTAGACACCC  
510 520 530 540 550 560 570  
AACTGCTAATCTATTTTCTGTCCTCAAGGAGAGGCTGTGCTGATGAAACAGCAAAAGACTTATGAGTTAC  
510 520 530 540 550 560 570  
AACTGCTAATCTATTTTCTGTCCTCAAGGAGAGGCTGTGCTGATGAAACAGCAAAAGACTTATGAGTTAC

580 590 600 610 620 630 640  
AGGATAATTACAGATTTTCCATCTTTGACCCAGAAATTTGCCAGCCAGAGTTAACCCAGAGATTCTCTC  
|||||  
AGGATAATTACAGATTTTCCATCTTTGACCCAGAAATTTGCCAGCCAGAGTTAACCCAGAGATTCTCTC  
580 590 600 610 620 630 640  
AGGATAATTACAGATTTTCCATCTTTGACCCAGAAATTTGCCAGCCAGAGTTAACCCAGAGATTCTCTC  
650 660 670 680 690 700 710 720  
TTACATGGCCAAATTTTCAACAAGCAGTCACTCCCTTAGCCCATCATCACACAGATTATTCAAGGCCACCGAT  
|||||  
TTACATGGCCAAATTTTCAACAAGCAGTCACTCCCTTAGCCCATCATCACACAGATTATTCAAGGCCACCGAT  
650 660 670 680 690 700 710 720  
TTACATGGCCAAATTTTCAACAAGCAGTCACTCCCTTAGCCCATCATCACACAGATTATTCAAGGCCACCGAT  
730 740 750 760 770 780 790  
ATCTCATGAGAGACACACTTTCTCAGAAAGTTGGATCCCTCAGATCACCTGGAGAAACTATTTAAGATGAT  
|||||  
ATCTCATGAGAGACACACTTTCTCAGAAAGTTGGATCCCTCAGATCACCTGGAGAAACTATTTAAGATGAT  
730 740 750 760 770 780 790  
ATCTCATGAGAGACACACTTTCTCAGAAAGTTGGATCCCTCAGATCACCTGGAGAAACTATTTAAGATGAT  
800 810 820 830 840 850 860  
GAAGCAAGTGCCCAAGCTCTTGCTTATAGAAAGGCAATTCACAGTTTCCATCAATTTCTCTGATCAA  
|||||  
GAAGCAAGTGCCCAAGCTCTTGCTTATAGAAAGGCAATTCACAGTTTCCATCAATTTCTCTGATCAA  
800 810 820 830 840 850 860  
GAAGCAAGTGCCCAAGCTCTTGCTTATAGAAAGGCAATTCACAGTTTCCATCAATTTCTCTGATCAA  
870 880 890 900 910 920 930  
GAAATAGCTCATCTGCTGCTGCTGAAATGTGAGTGGCTCCAGCTACGGTGGCAGTTGCTTCTCCATACC  
|||||  
GAAATAGCTCATCTGCTGCTGCTGAAATGTGAGTGGCTCCAGCTACGGTGGCAGTTGCTTCTCCATACC  
870 880 890 900 910 920 930  
GAAATAGCTCATCTGCTGCTGCTGAAATGTGAGTGGCTCCAGCTACGGTGGCAGTTGCTTCTCCATACC  
940 950 960 970 980 990 1000  
ACCTGGCTACTCCAAAGCCCGCCACCTTCTTACCCCAATGCTTCAAGTGAACCTTCTGGACTTCCAG  
|||||  
ACCTGGCTACTCCAAAGCCCGCCACCTTCTTACCCCAATGCTTCAAGTGAACCTTCTGGACTTCCAG  
940 950 960 970 980 990 1000  
ACCTGGCTACTCCAAAGCCCGCCACCTTCTTACCCCAATGCTTCAAGTGAACCTTCTGGACTTCCAG  
1010 1020 1030 1040 1050 1060 1070 1080  
CCACAGCTGGCCACCAAGCTCCACCTGTACCACTGTCACTTCTCAGCTCCACGAGACCTCATTTCTACA  
|||||  
CCACAGCTGGCCACCAAGCTCCACCTGTACCACTGTCACTTCTCAGCTCCACGAGACCTCATTTCTACA  
1010 1020 1030 1040 1050 1060 1070 1080  
CCACAGCTGGCCACCAAGCTCCACCTGTACCACTGTCACTTCTCAGCTCCACGAGACCTCATTTCTACA  
1090 1100 1110 1120 1130 1140 1150  
GTTTTCACAGGGCTGCGGCTACACTCAAGCAATGGCTACACAGCAGTTCTGACTACACCTTTGAGGCA  
|||||  
GTTTTCACAGGGCTGCGGCTACACTCAAGCAATGGCTACACAGCAGTTCTGACTACACCTTTGAGGCA  
1090 1100 1110 1120 1130 1140 1150  
GTTTTCACAGGGCTGCGGCTACACTCAAGCAATGGCTACACAGCAGTTCTGACTACACCTTTGAGGCA  
1160 1170 1180 1190 1200 1210 1220  
CCTACGACTCGAAAGGACAGCTTAGAAACCAATACCGTTTACAGAAATCTCCAATTTGAACACAGGG  
|||||  
CCTACGACTCGAAAGGACAGCTTAGAAACCAATACCGTTTACAGAAATCTCCAATTTGAACACAGGG  
1160 1170 1180 1190 1200 1210 1220  
CCTACGACTCGAAAGGACAGCTTAGAAACCAATACCGTTTACAGAAATCTCCAATTTGAACACAGGG  
1230 1240 1250 1260 1270 1280 1290  
AATGTGTATAACCTTAAGTCACTTCTATGTCAAATGTGAGTCTTCCACTATGAATAAACTGCTTCTG  
|||||  
AATGTGTATAACCTTAAGTCACTTCTATGTCAAATGTGAGTCTTCCACTATGAATAAACTGCTTCTG  
1230 1240 1250 1260 1270 1280 1290  
AATGTGTATAACCTTAAGTCACTTCTATGTCAAATGTGAGTCTTCCACTATGAATAAACTGCTTCTG  
1300 1310 1320 1330 1340 1350 1360  
GAAAGTAGGAGGCGCAGTCCAGGAGTTCCTCCAGGAGGAGTTCGAAATCAAGTACGGCTTCCATT  
|||||  
GAAAGTAGGAGGCGCAGTCCAGGAGTTCCTCCAGGAGGAGTTCGAAATCAAGTACGGCTTCCATT  
1300 1310 1320 1330 1340 1350 1360  
GAAAGTAGGAGGCGCAGTCCAGGAGTTCCTCCAGGAGGAGTTCGAAATCAAGTACGGCTTCCATT  
1370 1380 1390 1400 1410 1420 1430 1440  
GAAATAGCTTCTTATCGGGTCCCTGCTTGTGTCCTGTTCCCTGATAGGCTCGTCTCTGGGT  
|||||  
GAAATAGCTTCTTATCGGGTCCCTGCTTGTGTCCTGTTCCCTGATAGGCTCGTCTCTGGGT  
1370 1380 1390 1400 1410 1420 1430 1440  
GAAATAGCTTCTTATCGGGTCCCTGCTTGTGTCCTGTTCCCTGATAGGCTCGTCTCTGGGT  
1450 1460 1470 1480 1490 1500 1510



AGAATCCTTTGGAATCACTCCGAGAAAGCTTACTCAAGACTGATTATTGATCAATGCATCTATGTG  
 |||||  
 AGAATCCTTTGGAATCACTCCGAGAAAGCTTACTCAAGACTGATTATTGATCAATGCATCTATGTG  
 1450 1460 1470 1480 1490 1500 1510  
 1520 1530 1540 1550 1560 1570 1580  
 GACATCTAAGAGTGAAGTCCGCTGCTCTTAATTCATTAGTACAGAGCCCAATGCAATGATTCTG  
 |||||  
 GACATCTAAGAGTGAAGTCCGCTGCTCTTAATTCATTAGTACAGAGCCCAATGCAATGATTCTG  
 1520 1530 1540 1550 1560 1570 1580  
 1590 1600 1610 1620 1630 1640 1650  
 CTGACTTGTAGTCTTAGCAGAGGTTGATTTTGAAGACAGAAATGCCCTTCTGCTTTCTTTT  
 |||||  
 CTGACTTGTAGTCTTAGCAGAGGTTGATTTTGAAGACAGAAATGCCCTTCTGCTTTCTTTT  
 1590 1600 1610 1620 1630 1640 1650  
 1660 1670 1680 1690 1700 1710 1720  
 TTTTGAGACAGAGTCTTGTCTGTTGCCAGCTGAGTGCAGTACGATCTCGGCTTCAACGCAACC  
 |||||  
 TTTTGAGACAGAGTCTTGTCTGTTGCCAGCTGAGTGCAGTACGATCTCGGCTTCAACGCAACC  
 1660 1670 1680 1690 1700 1710 1720  
 1730 1740 1750 1760 1770 1780 1790 1800  
 TCCGTCCTCGGTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGATTACAGGATGTCACAC  
 |||||  
 TCCGTCCTCGGTTCAAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGATTACAGGATGTCACAC  
 1730 1740 1750 1760 1770 1780 1790 1800  
 1810 1820 1830 1840 1850 1860 1870  
 ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGGTTTACCATGTTGTGTCAGGCTGTCTCAAACTCC  
 |||||  
 ACACCTGGGTGATTTTGTATTTTAGTAGAGACGGGGTTTACCATGTTGTGTCAGGCTGTCTCAAACTCC  
 1810 1820 1830 1840 1850 1860 1870  
 1880 1890 1900 1910 1920 1930 1940  
 TGACCTAGTATCCACCTCTCGGCTCCCAAGTGTGGATTACAGGATGAGCCACACAGCTGGCCC  
 |||||  
 TGACCTAGTATCCACCTCTCGGCTCCCAAGTGTGGATTACAGGATGAGCCACACAGCTGGCCC  
 1880 1890 1900 1910 1920 1930 1940  
 1950 1960 1970 1980 1990 2000 2010  
 CCTTCTGTTTATGTTTGTGTTTGAAGAAGATGAAGTGGGAACCAATTAGTAATTTGGGTAATCTGT  
 |||||  
 CCTTCTGTTTATGTTTGTGTTTGAAGAAGATGAAGTGGGAACCAATTAGTAATTTGGGTAATCTGT  
 1950 1960 1970 1980 1990 2000 2010  
 2020 2030 2040 2050 2060 2070 2080  
 CTCTAAATATTTAGCTAAACCAAGCTCTATGTAAGTAATTAATTTAGCCATATTAATTTCAAAAT  
 |||||  
 CTCTAAATATTTAGCTAAACCAAGCTCTATGTAAGTAATTAATTTAGCCATATTAATTTCAAAAT  
 2020 2030 2040 2050 2060 2070 2080  
 2090 2100 2110 2120 2130 2140 2150 2160  
 TCAACTGCTTTTATGCAAGAAGACGTTAGGACATCTAGTTCCAATTCATTCAATCTTGGTTCCAGA  
 |||||  
 TCAACTGCTTTTATGCAAGAAGACGTTAGGACATCTAGTTCCAATTCATTCAATCTTGGTTCCAGA  
 2090 2100 2110 2120 2130 2140 2150 2160  
 2170 2180 2190 2200 2210 2220 2230  
 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTTCTTTTAAACTTATTT  
 |||||  
 TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTTATATGATTTCTTTTAAACTTATTT  
 2170 2180 2190 2200 2210 2220 2230  
 2240 2250 2260 2270 2280 X  
 CCAGATGATGTTCTCTTCAATTAATTAATTTGAATTAATCTTTGTTACTCAA  
 |||||  
 CCAGATGATGTTCTCTTCAATTAATTAATTTGAATTAATCTTTGTTACTCAA  
 2240 2250 2260 2270 2280 X  
 9. US-09-944-929-82 (1-2284)

ABX75504.SEQ Human secreted/transmembrane protein PRO361 cDNA.  
 TOIG of: abx75504 check: 5044 from: 1 to: 2284  
 ID ABX75504 standard; cDNA; 2284 BP.  
 XX  
 AC ABX75504;  
 DT 26-MAR-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein PRO361 cDNA.  
 XX  
 KW Human; ss; gene; PRO; secreted protein; transmembrane protein; anti-HIV;  
 KW cytosolic; antiarteriosclerotic; antiinflammatory; antidiabetic;  
 KW cardiatic; AIDS; acquired immunodeficiency syndrome; cancer;  
 KW atherosclerosis; inflammatory disease; diabetic complication;  
 KW cardiac injury; organ failure.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002142959-A1.  
 XX  
 PD 03-OCT-2002.  
 XX  
 PF 31-AUG-2001; 2001US-00944654.  
 XX  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-JUN-1999; 99WO-US012252.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 25-MAY-2001; 2001US-00866028.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
 PI Hillan KJ, Kijavyn IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
 XX  
 DR WPI; 2003-174141/17.  
 DR P-PSDB; ABUS5934.  
 XX  
 PT New isolated PRO polypeptide and encoding nucleic acid, useful for the  
 PT diagnosis and treatment of disorders associated with the PRO polypeptide,  
 PT such as AIDS, cancer, atherosclerosis, inflammatory disease and diabetes.  
 XX  
 PS Claim 2; Fig 31; 178pp; English.  
 XX  
 CC The invention relates to an isolated PRO polypeptide (a secreted or  
 CC transmembrane protein) comprising: (a) at least 80% sequence identity or  
 CC positives when compared to any of 15 sequences, fully defined in the  
 CC specification, lacking or with its associated signal peptide; or (b) at  
 CC least 80% sequence identity to a sequence encoded by the full-length  
 CC coding sequence of a DNA deposited in the American Type Culture  
 CC Collection (ATCC). Also included are: (1) an isolated nucleic acid  
 CC comprising: (a) at least 80% sequence identity to a nucleotide sequence  
 CC that encodes a PRO protein; (b) at least 80% sequence identity to a  
 CC nucleotide sequence or full-length coding sequence with any of 15 fully  
 CC defined sequences of 957-3441 base pairs, given in the specification; or  
 CC (c) at least 80% sequence identity to a full-length coding sequence of a  
 CC DNA deposited under ATCC Accession No. 209526, 209508, 209524, 209528,  
 CC 209530, 209523, 209492, 209532, 209531, 209529, 209527, 209570, 209618,



1520 1530 1540 1550 1560 1570 1580  
GACATCTAAGATGGAAGTCCGTCCTCTTAATTCATTAGTAACCGAAGCCCAATGAATGAAGTCTCTG  
GACATCTAAGATGGAAGTCCGTCCTCTTAATTCATTAGTAACCGAAGCCCAATGAATGAAGTCTCTG  
1520 1530 1540 1550 1560 1570 1580  
1590 1600 1610 1620 1630 1640 1650  
CTGACTTGCTAGTCTTTAGCAGAGGTTGTAATTTTGAAGACAGAAATGCCCCCTTCTGCTTTCTTTT  
CTGACTTGCTAGTCTTTAGCAGAGGTTGTAATTTTGAAGACAGAAATGCCCCCTTCTGCTTTCTTTT  
1590 1600 1610 1620 1630 1640 1650  
1660 1670 1680 1690 1700 1710 1720  
TTTGGAGACAGAGTCTTGTCTGTGGCCAGCTGAGTGCAGTACGATCTCGGCTCTCAGCCGCAAC  
TTTGGAGACAGAGTCTTGTCTGTGGCCAGCTGAGTGCAGTACGATCTCGGCTCTCAGCCGCAAC  
1660 1670 1680 1690 1700 1710 1720  
1730 1740 1750 1760 1770 1780 1790 1800  
TCCGTCCTCTGGGTTCAAGCGATTCTCTGCTCAGCCCTCCTAAGTATCTGGATTACAGGCGATGCGCACC  
TCCGTCCTCTGGGTTCAAGCGATTCTCTGCTCAGCCCTCCTAAGTATCTGGATTACAGGCGATGCGCACC  
1730 1740 1750 1760 1770 1780 1790 1800  
1810 1820 1830 1840 1850 1860 1870  
ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTTGGTCAAGGCTGGTCTCAACTCC  
ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTTGGTCAAGGCTGGTCTCAACTCC  
1810 1820 1830 1840 1850 1860 1870  
1880 1890 1900 1910 1920 1930 1940  
TGACCTAGTATCCACCCTCCTCGGCTCCAAAGTCTGGATGAGGCGATGAGCCACACAGCTGGCCCC  
TGACCTAGTATCCACCCTCCTCGGCTCCAAAGTCTGGATGAGGCGATGAGCCACACAGCTGGCCCC  
1880 1890 1900 1910 1920 1930 1940  
1950 1960 1970 1980 1990 2000 2010  
CCTTCTGTTTATGTTTGGTTTGTAGAGAAGATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT  
CCTTCTGTTTATGTTTGGTTTGTAGAGAAGATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT  
1950 1960 1970 1980 1990 2000 2010  
2020 2030 2040 2050 2060 2070 2080  
CTCTAAATAATTTAGCTAAACAAGCTCTATGTAAAGTAATAAAGTAAATGGCATATAAATTTCAAAAT  
CTCTAAATAATTTAGCTAAACAAGCTCTATGTAAAGTAATAAAGTAAATGGCATATAAATTTCAAAAT  
2020 2030 2040 2050 2060 2070 2080  
2090 2100 2110 2120 2130 2140 2150 2160  
TCAACTGGCTTTTATGCAAGAAGACAGGTAGACATCTAGGTTCCAATTCAATTCACATCTCTGGTCCAGA  
TCAACTGGCTTTTATGCAAGAAGACAGGTAGACATCTAGGTTCCAATTCAATTCACATCTCTGGTCCAGA  
2090 2100 2110 2120 2130 2140 2150 2160  
2170 2180 2190 2200 2210 2220 2230  
TAAATCAACTGTTTATATCAATTTCTAATGATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTAT  
TAAATCAACTGTTTATATCAATTTCTAATGATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTAT  
2170 2180 2190 2200 2210 2220 2230  
2240 2250 2260 2270 2280 2290  
CCAGATGATGTTCTTCCAAATTAATATTTGAATAAATCTTTGTTACTCAA  
CCAGATGATGTTCTTCCAAATTAATATTTGAATAAATCTTTGTTACTCAA  
2240 2250 2260 2270 2280 2290

10. US-09-944-929-82 (1-2284)  
ABX64297.SEQ cDNA encoding human PRO361 polypeptide.

TOIG of: abx64297 check: 5044 from: 1 to: 2284

ID ABX64297 standard; cDNA; 2284 BP.  
XX AC ABX64297;  
XX DT 26-FEB-2003 (first entry)  
DE cDNA encoding human PRO361 polypeptide.  
XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;  
KW generic disorder; antibacterial; immunosuppressive; transgenic;  
KW gene therapy; gene; ss.  
OS Homo sapiens.  
PN US2002103125-A1.  
XX PD 01-AUG-2002.  
PF 20-NOV-2001; 2001US-00989731.  
XX PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.



PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH LTD.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gertschen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
XX WPI, 2003-102117/09.  
DR P-PSDB; ABU14005.  
DR  
XX  
PT Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, identifying agonists or  
PT antagonists of polypeptide, and as molecular weight markers.  
XX  
XX  
XX Claim 2; Fig 327; 649pp; English.  
XX  
CC The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides are useful for detecting other PRO polypeptides, for linking  
CC bioactive molecules to cells expressing PRO polypeptides, for modulating  
CC biological activities of cells expressing PRO polypeptides, and for for  
CC identifying agonists or antagonists. The polynucleotide sequences  
CC encoding PRO polypeptides are useful as hybridisation probes, in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC in the preparation of PRO polypeptides, for generating transgenic animals  
CC or knockout animals, to construct hybridisation probes for mapping the  
CC gene which encodes the PRO polypeptide, and for the genetic analysis of  
CC individuals with genetic disorders, in gene therapy, for chromosome  
CC identification, as chromosome markers, and for generating probes for PCR,  
CC Northern analysis, Southern analysis and Western analysis. The present

CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent was obtained in electronic format directly  
CC from the USPTO web site at [seqdata.uspto.gov/psipdb/entry.html](http://seqdata.uspto.gov/psipdb/entry.html)  
XX  
SQ Sequence 2284 BP; 612 A; 576 C; 464 G; 632 T; 0 U; 0 Other;

ABX64297 Length: 2284 September 29, 2004 14:41 Type: N Check: 5044 ..

Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTGCGCGTCTTCCCGCGCGGACAGAG  
CGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTGCGCGTCTTCCCGCGCGGACAGAG  
GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTGCGCGTCTTCCCGCGCGGACAGAG  
X 10 20 30 40 50 60 70  
GCTGTCTCGACCTGGATGGCAGCAGGCGCGCGGTCTCTCGAGCCAGAGAAATCTCATCTG  
GCTGTCTCGACCTGGATGGCAGCAGGCGCGCGGTCTCTCGAGCCAGAGAAATCTCATCTG  
GCTGTCTCGACCTGGATGGCAGCAGGCGCGCGGTCTCTCGAGCCAGAGAAATCTCATCTG  
X 150 160 170 180 190 200 210  
TGCAGCCTTCTTAAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
X 150 160 170 180 190 200 210  
TGCAGCCTTCTTAAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
X 220 230 240 250 260 270 280  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTA  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTA  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTA  
X 220 230 240 250 260 270 280  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTA  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTA  
AAATTTAAATGTTCTTGGGGGAGAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTA  
X 290 300 310 320 330 340 350 360  
AGGCTGTCTGTAGTCAAGATTGCTTCAAAAGAGTCTAGAAGATGTTGCTTATGACATCCATCTTT  
AGGCTGTCTGTAGTCAAGATTGCTTCAAAAGAGTCTAGAAGATGTTGCTTATGACATCCATCTTT  
AGGCTGTCTGTAGTCAAGATTGCTTCAAAAGAGTCTAGAAGATGTTGCTTATGACATCCATCTTT  
X 290 300 310 320 330 340 350 360  
AGGCTGTCTGTAGTCAAGATTGCTTCAAAAGAGTCTAGAAGATGTTGCTTATGACATCCATCTTT  
AGGCTGTCTGTAGTCAAGATTGCTTCAAAAGAGTCTAGAAGATGTTGCTTATGACATCCATCTTT  
AGGCTGTCTGTAGTCAAGATTGCTTCAAAAGAGTCTAGAAGATGTTGCTTATGACATCCATCTTT  
X 370 380 390 400 410 420 430  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATTTCTGCTTCA  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATTTCTGCTTCA  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATTTCTGCTTCA  
X 370 380 390 400 410 420 430  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATTTCTGCTTCA  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATTTCTGCTTCA  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATCTTCAACTCAAGAGACTGCATTATTTCTGCTTCA  
X 440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGCAAAAGCATGTAATCTGATGATCTTGCACCTCGAAAAACAGCTAGACACCC  
ACAAAAACATATCAGGGGCAAAAGCATGTAATCTGATGATCTTGCACCTCGAAAAACAGCTAGACACCC  
ACAAAAACATATCAGGGGCAAAAGCATGTAATCTGATGATCTTGCACCTCGAAAAACAGCTAGACACCC  
X 440 450 460 470 480 490 500  
ACAAAAACATATCAGGGGCAAAAGCATGTAATCTGATGATCTTGCACCTCGAAAAACAGCTAGACACCC  
ACAAAAACATATCAGGGGCAAAAGCATGTAATCTGATGATCTTGCACCTCGAAAAACAGCTAGACACCC  
ACAAAAACATATCAGGGGCAAAAGCATGTAATCTGATGATCTTGCACCTCGAAAAACAGCTAGACACCC  
X 510 520 530 540 550 560 570  
AACTGCTACCTATTTTCTGTCGCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGAGCTTATGAGTTAC  
AACTGCTACCTATTTTCTGTCGCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGAGCTTATGAGTTAC  
AACTGCTACCTATTTTCTGTCGCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGAGCTTATGAGTTAC  
X 510 520 530 540 550 560 570  
AACTGCTACCTATTTTCTGTCGCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGAGCTTATGAGTTAC  
AACTGCTACCTATTTTCTGTCGCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGAGCTTATGAGTTAC  
AACTGCTACCTATTTTCTGTCGCCAAGAGAGCCTGTCCATTGAAACCAAGAAAGAGCTTATGAGTTAC  
X 580 590 600 610 620 630 640  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGATTACCCAGAGAGTTCTTC  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGATTACCCAGAGAGTTCTTC  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGATTACCCAGAGAGTTCTTC  
X 580 590 600 610 620 630 640  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGATTACCCAGAGAGTTCTTC  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGATTACCCAGAGAGTTCTTC  
AGGATTAATTACAGATTTTCCATCTTTGACCAAGAAATTTGCCAAGCCAGAGATTACCCAGAGAGTTCTTC  
X 650 660 670 680 690 700 710 720  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
X 650 660 670 680 690 700 710 720  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
X 730 740 750 760 770 780 790  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
X 730 740 750 760 770 780 790  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT  
TTACATGCGCAATTTTCAACAAGCAGTCACTCCCTAGCCCATCATCAGACAGATTATTCAAGGCCACCGAT

```
ATCTCATGAGAGACACACTTTCTCAGAGTTTGGATCCTCAGATCACCTGGAGAACTATTTAAGTGGAT
|||||
ATCTCATGAGAGACACACTTTCTCAGAGTTTGGATCCTCAGATCACCTGGAGAACTATTTAAGTGGAT
730 740 750 760 770 780 790
800 810 820 830 840 850 860
GAAGCAAGTGGCCCAAGCTCCTTGCTTATAGAGAAAAAGGCCATTCTCAGAGTTCACAATTTCTCTGATCAA
|||||
GAAGCAAGTGGCCCAAGCTCCTTGCTTATAGAGAAAAAGGCCATTCTCAGAGTTCACAATTTCTCTGATCAA
800 810 820 830 840 850 860
870 880 890 900 910 920 930
GAAATAGCTCATCTGCTGCTGAAATGTAGTGCCTCCAGCTACGCTGCGAGTTGCTTCTCCACATACC
|||||
GAAATAGCTCATCTGCTGCTGAAATGTAGTGCCTCCAGCTACGCTGCGAGTTGCTTCTCCACATACC
870 880 890 900 910 920 930
940 950 960 970 980 990 1000
ACCTCGGCTACTCCAAAGCCCCGACCCCTTCTACCCCAATGCTTCAGTGACACACTTCTGGAGTTCCAG
|||||
ACCTCGGCTACTCCAAAGCCCCGACCCCTTCTACCCCAATGCTTCAGTGACACACTTCTGGAGTTCCAG
940 950 960 970 980 990 1000
1010 1020 1030 1040 1050 1060 1070 1080
CCACAGCTGGCCACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCTCCACGAGCCCTCATTTCTACA
|||||
CCACAGCTGGCCACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCTCCACGAGCCCTCATTTCTACA
1010 1020 1030 1040 1050 1060 1070 1080
1090 1100 1110 1120 1130 1140 1150
GTTTTCACGGGCTGCGGCTACACTCCAGCAATGGCTACAACAGCAGTTCTGACTACACCTTTGAGGCA
|||||
GTTTTCACGGGCTGCGGCTACACTCCAGCAATGGCTACAACAGCAGTTCTGACTACACCTTTGAGGCA
1090 1100 1110 1120 1130 1140 1150
1160 1170 1180 1190 1200 1210 1220
CCTACGGACTCGAAGGCGAGCTTAGAACCATTACCGTTTACAGAAATCTCCAATTAACTTTGAACACAGGG
|||||
CCTACGGACTCGAAGGCGAGCTTAGAACCATTACCGTTTACAGAAATCTCCAATTAACTTTGAACACAGGG
1160 1170 1180 1190 1200 1210 1220
1230 1240 1250 1260 1270 1280 1290
AATGTGTATTAACCTTACTGCACTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAACTGCTTCTGG
|||||
AATGTGTATTAACCTTACTGCACTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAACTGCTTCTGG
1230 1240 1250 1260 1270 1280 1290
1300 1310 1320 1330 1340 1350 1360
GAAGGTAGGGGCGCAGTCCAGGAGTTCCCTCCAGGGCAGTGTCCAGAAATCAGTAGCAGCCCTTCCATT
|||||
GAAGGTAGGGGCGCAGTCCAGGAGTTCCCTCCAGGGCAGTGTCCAGAAATCAGTAGCAGCCCTTCCATT
1300 1310 1320 1330 1340 1350 1360
1370 1380 1390 1400 1410 1420 1430 1440
GAAAAATGGCTTCTATCGGGTCCCTGCTTTGGTGTCTGTCCCTGCTGATAGGCCCTCGTCTCTCTGGGT
|||||
GAAAAATGGCTTCTATCGGGTCCCTGCTTTGGTGTCTGTCCCTGCTGATAGGCCCTCGTCTCTCTGGGT
1370 1380 1390 1400 1410 1420 1430 1440
1450 1460 1470 1480 1490 1500 1510
AGAATCCTTTGGGAATCACTCCGAGGAAAGCTTACTCAAGACTGGATTATTGGATCAATGGGATCTATGTG
|||||
AGAATCCTTTGGGAATCACTCCGAGGAAAGCTTACTCAAGACTGGATTATTGGATCAATGGGATCTATGTG
1450 1460 1470 1480 1490 1500 1510
1520 1530 1540 1550 1560 1570 1580
GACATCTTAAGATGGAATCGGTGCTCTTAATTCATTTAGTAACAGAGCCCAATGCAATGAGTTCTG
|||||
GACATCTTAAGATGGAATCGGTGCTCTTAATTCATTTAGTAACAGAGCCCAATGCAATGAGTTCTG
1520 1530 1540 1550 1560 1570 1580
1590 1600 1610 1620 1630 1640 1650
CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTGAAGACAGGAAATGCCCCCTTCTGCTTTT
```

```
|||||
CTGACTTGCTAGTCTTAGCAGAGGTTGTATTTGAAGACAGGAAATGCCCCCTTCTGCTTTT
1590 1600 1610 1620 1630 1640 1650
1660 1670 1680 1690 1700 1710 1720
TTTGGAGACAGAGTCTTGTCTGTGCTTCCAGGCTGAGTGCAGTACGATCTCGGCTCCACCGCAACC
|||||
TTTGGAGACAGAGTCTTGTCTGTGCTTCCAGGCTGAGTGCAGTACGATCTCGGCTCCACCGCAACC
1660 1670 1680 1690 1700 1710 1720
1730 1740 1750 1760 1770 1780 1790 1800
TCCGCTCCTGGGTTCAAGCGATTCTCTGCTCAGCCCTCCTAAGTATCTGGATTACAGGATGTCACC
|||||
TCCGCTCCTGGGTTCAAGCGATTCTCTGCTCAGCCCTCCTAAGTATCTGGATTACAGGATGTCACC
1730 1740 1750 1760 1770 1780 1790 1800
1810 1820 1830 1840 1850 1860 1870
ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACCATGTTGTCAGAGCTGTCTCAAACCTCC
|||||
ACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTCAACCATGTTGTCAGAGCTGTCTCAAACCTCC
1810 1820 1830 1840 1850 1860 1870
1880 1890 1900 1910 1920 1930 1940
TGACCTAGTGATCCACCCTCCTCGGCTCCCAAAGTGTGGGATTAACAGGATGAGCCACACAGCTGGCCC
|||||
TGACCTAGTGATCCACCCTCCTCGGCTCCCAAAGTGTGGGATTAACAGGATGAGCCACACAGCTGGCCC
1880 1890 1900 1910 1920 1930 1940
1950 1960 1970 1980 1990 2000 2010
CCTTCTGTTTATGTTTGGTTTGTAGAGAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT
|||||
CCTTCTGTTTATGTTTGGTTTGTAGAGAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT
1950 1960 1970 1980 1990 2000 2010
2020 2030 2040 2050 2060 2070 2080
CTCTAAATATTAGCTAAACCAAGCTCTATGTAAAGTAAATTAATTTGCCATATTAATTTCAAAAT
|||||
CTCTAAATATTAGCTAAACCAAGCTCTATGTAAAGTAAATTAATTTGCCATATTAATTTCAAAAT
2020 2030 2040 2050 2060 2070 2080
2090 2100 2110 2120 2130 2140 2150 2160
TCAACTGGCTTTATGCAAGAAACAGGTTAGACATCTAGGTTCCAATTCAATTCATTCATCTTGTTCCAGA
|||||
TCAACTGGCTTTATGCAAGAAACAGGTTAGACATCTAGGTTCCAATTCAATTCATTCATCTTGTTCCAGA
2090 2100 2110 2120 2130 2140 2150 2160
2170 2180 2190 2200 2210 2220 2230
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTATT
|||||
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTATT
2170 2180 2190 2200 2210 2220 2230
2240 2250 2260 2270 2280 X
CCAGATGAGTTCCTTCCAATTAATATTGAATAAATCTTTGTTACTCAA
|||||
CCAGATGAGTTCCTTCCAATTAATATTGAATAAATCTTTGTTACTCAA
2240 2250 2260 2270 2280 X
11. US-09-944-929-82 (1-2284)
AAC58593.SEQ Human PRO361 protein UNQ316 encoding cDNA SEQ ID N
TOIG of: aac58593 check: 6732 from: 1 to: 2418
ID AAC58593 standard; cDNA; 2418 BP.
XX
AC AAC58593;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human PRO361 protein UNQ316 encoding cDNA SEQ ID NO:71.
XX
KW Human; immune related disease; diagnosis; antiinflammatory; cardiant;
```

KW dermatological; antiarthritic; antirheumatic; immunosuppressive;  
KW haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;  
KW antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;  
KW antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis;  
KW osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;  
KW idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;  
KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;  
KW autoimmune thrombocytopaenia; immune-mediated renal disease;  
KW demyelinating disease; hepatobiliary disease; Whipple's disease;  
KW inflammatory bowel disease; gluten-sensitive enteropathy;  
KW autoimmune disease; immune-mediated skin disease; allergic disease;  
KW immunological disease; transplantation associated disease;  
KW graft rejection; graft-versus-host-disease; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200053758-A2.  
XX  
PD 14-SEP-2000.  
XX  
PF 02-MAR-2000; 2000WO-US005841.  
XX  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99US-0123618P.  
PR 12-MAR-1999; 99US-0123957P.  
PR 23-MAR-1999; 99US-0125775P.  
PR 12-APR-1999; 99US-0128849P.  
PR 20-APR-1999; 99WO-US008615.  
PR 28-APR-1999; 99US-0131445P.  
PR 04-MAY-1999; 99US-0132371P.  
PR 14-MAY-1999; 99US-0134287P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-OCT-1999; 99US-0162506P.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030999.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;  
PI Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;  
PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Yan M;  
XX  
DR MPI; 2000-572271/53.  
DR P-PSDB; AAB33428.  
XX  
PT Sixty four PRO polypeptides, useful in the diagnosis and treatment of  
PT immune related disorders, e.g. systemic lupus erythematosus, rheumatoid

PT arthritis, osteoarthritis, thyroiditis and diabetes mellitus.  
XX  
PS Claim 23; Fig 29; 309pp; English.  
XX  
CC The present invention describes sixty four human PRO proteins which can  
CC be used in the treatment of immune related diseases. The human PRO  
CC proteins, anti-PRO antibodies, agonists and antagonists are useful for  
CC treating and diagnosing immune related disorders. The disorders are  
CC selected from systemic lupus erythematosus, rheumatoid arthritis,  
CC osteoarthritis, juvenile chronic inflammatory myopathies, Sjogren's  
CC syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic  
CC anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,  
CC immune-mediated renal disease, demyelinating diseases of the central and  
CC peripheral nervous systems, hepatobiliary diseases, inflammatory bowel  
CC disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune  
CC or immune-mediated skin diseases, allergic diseases, immunological  
CC diseases of the lung, and transplantation associated diseases including  
CC graft rejection and graft-versus-host-disease. AAC58397 to AAC58578  
CC represent PCR primers and hybridisation probes used in the isolation of  
CC human PRO sequences. AAC58579 to AAC58642 and AAB33414 to AAB33477  
CC represent human PRO polynucleotide and protein sequences given in the  
CC exemplification of the present invention  
XX  
SQ Sequence 2418 BP; 657 A; 606 C; 481 G; 674 T; 0 U; 0 Other;  
AAC58593 Length: 2418 September 29, 2004 14:42 Type: N Check: 6732 ..  
Initial Score = 2284 Optimized Score = 2284 Significance = 0.55  
Residue Identity = 100% Matches = 2284 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0  
X 10 20 30 40 50 60 70  
GCGGAGCATCCGCTGCGGTCCTCGCCGAGACCCCGCGGATTGCGCGGTCTTCCGCGGCGCGCAGAGA  
GCGGATCCCGCTGCGGTCCTCGCCGAGACCCCGCGGATTGCGCGGTCTTCCGCGGCGCGCAGAGA  
X 10 20 30 40 50 60 70  
GCGGAGCATCCGCTGCGGTCCTCGCCGAGACCCCGCGGATTGCGCGGTCTTCCGCGGCGCGCAGAGA  
X 10 20 30 40 50 60 70  
GCTGTCTCGACCTGGATGGACGAGGGCGCGCGGTCTCTCGACGCCAGAGAAGAAATCTCATCATCTG  
GCTGTCTCGACCTGGATGGACGAGGGCGCGCGGTCTCTCGACGCCAGAGAAGAAATCTCATCATCTG  
80 90 100 110 120 130 140  
TGCAGCCTTCTTAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
TGCAGCCTTCTTAAGCAACTAAGACCCAGAGGAGGATTATCTTGACCTTTGAAGACCAAACTAACTG  
150 160 170 180 190 200 210  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTACACTTTGGTAATTAATTTGCTTCGACACTA  
AAATTTAAATGTTCTTCGGGGGAGAGGAGCTTGACTTACACTTTGGTAATTAATTTGCTTCGACACTA  
220 230 240 250 260 270 280  
AGGCTGTCTGCTAGTCAGAAATGCTCAAAAAGAGCTTAGAAGATGTTGCTTATGACATCCAGTCACTCTT  
AGGCTGTCTGCTAGTCAGAAATGCTCAAAAAGAGCTTAGAAGATGTTGCTTATGACATCCAGTCACTCTT  
290 300 310 320 330 340 350 360  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATTACTTCAACTCAAGAGACTGCATTAATTCTTGCTGTTC  
TCTAAGGGAATCAGAGGCAATGAGCCCGTATATTACTTCAACTCAAGAGACTGCATTAATTCTTGCTGTTC  
370 380 390 400 410 420 430  
ACAAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTAGCAACCC  
ACAAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTAGCAACCC  
440 450 460 470 480 490 500  
ACAAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGACACTCGAAAAACAGCTAGCAACCC  
440 450 460 470 480 490 500



```
510      520      530      540      550      560      570
AACTGCTACTATTTTTCTGTCCCAAGAGAACCTGTCCATTTGAACCAAGCAAAAGACTTTAGCTTAC
|||||
AACTGCTACTATTTTTCTGTCCCAAGAGAACCTGTCCATTTGAACCAAGCAAAAGACTTATGAGTTAC
510      520      530      540      550      560      570
AGGATATTACAGATTTTTCATCTTTGACCAAGAAATTTGCCAAGCCAAAGATTACCCAGAGACTTCTCTC
|||||
AGGATATTACAGATTTTTCATCTTTGACCAAGAAATTTGCCAAGCCAAAGATTACCCAGAGATTCTCTC
580      590      600      610      620      630      640
TTACATGGCCAAATTTTTCACAAGACGATCACTCCCTAGCCCATCATCACAGATTTATTCAAGCCCACCGAT
|||||
TTACATGGCCAAATTTTTCACAAGACGATCACTCCCTAGCCCATCATCACAGATTTATTCAAGCCCACCGAT
650      660      670      680      690      700      710      720
ATCTCATGAGAGACACACTTTCTCAGAGTTTGATCTCCAGATCACTGAGAGAACTATTTTAAGATGAT
|||||
ATCTCATGAGAGACACACTTTCTCAGAGTTTGATCTCCAGATCACTGAGAGAACTATTTTAAGATGAT
730      740      750      760      770      780      790
GAAGCAAGTCCCCAGCTCTGCTTATTAAGAAAAAGGCCATTTCTCAGAGTTCAACAATTTTCTCTGATCAA
|||||
GAAGCAAGTCCCCAGCTCTGCTTATTAAGAAAAAGGCCATTTCTCAGAGTTCAACAATTTTCTCTGATCAA
800      810      820      830      840      850      860
GAAATAGCTCATCTGCTGCTGAAATGAGTGCCTCCAGCTACGGTGGCAGTTGCTTCTTCACATACC
|||||
GAAATAGCTCATCTGCTGCTGAAATGAGTGCCTCCAGCTACGGTGGCAGTTGCTTCTTCACATACC
870      880      890      900      910      920      930
ACCTCGGCTACTCCAAAGCCCGCCACCTTTCTAACCACCAATGCTTCAAGTGACACACCTTCTGGACTTCCAG
|||||
ACCTCGGCTACTCCAAAGCCCGCCACCTTTCTAACCACCAATGCTTCAAGTGACACACCTTCTGGACTTCCAG
940      950      960      970      980      990      1000
CCACAGCTGGCCACCAACAGCTCCACCTGTAACCACTGTCACTTCTCAGCCTCCACAGACCTCAATTTCTACA
|||||
CCACAGCTGGCCACCAACAGCTCCACCTGTAACCACTGTCACTTCTCAGCCTCCACAGACCTCAATTTCTACA
1010      1020      1030      1040      1050      1060      1070      1080
GTTTTTACAGGGCTGCGGTACACTCACTCAAGCAATGCTTCAACAAGAGCTTGTACTACCACTTTCAGGCA
|||||
GTTTTTACAGGGCTGCGGTACACTCACTCAAGCAATGCTTCAACAAGAGCTTGTACTACCACTTTCAGGCA
1090      1100      1110      1120      1130      1140      1150
CCTACGGACTCGAAAGGCAAGCTTGAACAACCAATACCGTTTACAGAAATCTCCAACCTTAACCTTTGAACACAGGG
|||||
CCTACGGACTCGAAAGGCAAGCTTGAACAACCAATACCGTTTACAGAAATCTCCAACCTTAACCTTTGAACACAGGG
1160      1170      1180      1190      1200      1210      1220
AATGTGTATAACCTACTGCACTTCTATGTCAATGTGAGTCTTCCACTATGAATAAAACTGCTTCCCTGG
|||||
AATGTGTATAACCTACTGCACTTCTATGTCAATGTGAGTCTTCCACTATGAATAAAACTGCTTCCCTGG
1230      1240      1250      1260      1270      1280      1290
GAAGGTAGGAGGCGCAGTCCAGGCAAGTCTCCAGGCGAGTTCAGAAAAATCAGTACGGCTTCCATTT
|||||
GAAGGTAGGAGGCGCAGTCCAGGCAAGTCTCCAGGCGAGTTCAGAAAAATCAGTACGGCTTCCATTT
1300      1310      1320      1330      1340      1350      1360
```

```
1370      1380      1390      1400      1410      1420      1430      1440
GAAAAATGGCTTCTTATCGGGTCCCTGCTCTTTGGTGTCTCTGTTCTCTGTGATAGGCCCTGCTCTGGGT
|||||
GAAAAATGGCTTCTTATCGGGTCCCTGCTCTTTGGTGTCTCTGTTCTCTGTGATAGGCCCTGCTCTGGGT
1370      1380      1390      1400      1410      1420      1430      1440
AGAAATCCCTTCGGAATCACTCCCGAGAAACGTTACTCAAGACTGATATTATTTGATCAATGGAGTCTATGTG
|||||
AGAAATCCCTTCGGAATCACTCCCGAGAAACGTTACTCAAGACTGATATTATTTGATCAATGGAGTCTATGTG
1450      1460      1470      1480      1490      1500      1510
GACATCTAAGATGGAACCTCGGTGCTCTTAATTCATTAGTAACGAAAGCCCAATGCAATGAGTTCTG
|||||
GACATCTAAGATGGAACCTCGGTGCTCTTAATTCATTAGTAACGAAAGCCCAATGCAATGAGTTCTG
1520      1530      1540      1550      1560      1570      1580
CTGACTTGTAGTCTTTAGCAGAGAGTTGATTTTGAAGACAGAAATGCCCCCTTCTGCTTTCTTTT
|||||
CTGACTTGTAGTCTTTAGCAGAGAGTTGATTTTGAAGACAGAAATGCCCCCTTCTGCTTTCTTTT
1590      1600      1610      1620      1630      1640      1650
TTTGGAGACAGAGTCTGCTGCTGCTGCCAGGCTGAGTGACGACGATCTCGGCTCTCAACCGCAACC
|||||
TTTGGAGACAGAGTCTGCTGCTGCTGCCAGGCTGAGTGACGACGATCTCGGCTCTCAACCGCAACC
1660      1670      1680      1690      1700      1710      1720
TCCGCTCTCGGCTCAAGCGATCTCTGCTCAGCCCTCTAAGTATCTGGATTACAGGCAATGTCACCC
|||||
TCCGCTCTCGGCTCAAGCGATCTCTGCTCAGCCCTCTAAGTATCTGGATTACAGGCAATGTCACCC
1730      1740      1750      1760      1770      1780      1790      1800
ACACCTGGGTGATTTTGTATTTTGTAGTAGAGACGGGTTTCAACCATGTTGTCAGAGCTGTCTCAAACTCC
|||||
ACACCTGGGTGATTTTGTATTTTGTAGTAGAGACGGGTTTCAACCATGTTGTCAGAGCTGTCTCAAACTCC
1810      1820      1830      1840      1850      1860      1870
TGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGTGGATTACAGGATGAGCCACAGACTGGCCC
|||||
TGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGTGGATTACAGGATGAGCCACAGACTGGCCC
1880      1890      1900      1910      1920      1930      1940
CCTTCTGTTTATGTTTGGTTTGTGAGAAAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT
|||||
CCTTCTGTTTATGTTTGGTTTGTGAGAAAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGT
1950      1960      1970      1980      1990      2000      2010
CTCTAAATATTAGCTAAACCAAGCTCTATGTAAAGTAAATTAATTAATGTCATTAATTTCAAAAT
|||||
CTCTAAATATTAGCTAAACCAAGCTCTATGTAAAGTAAATTAATTAATGTCATTAATTTCAAAAT
2020      2030      2040      2050      2060      2070      2080
TCAACTGGCTTTTATGCAAGAAACAGGTTAGGACATCTAGGTTCCAAATTCATTACATTTCTGGTTCAGA
|||||
TCAACTGGCTTTTATGCAAGAAACAGGTTAGGACATCTAGGTTCCAAATTCATTACATTTCTGGTTCAGA
2090      2100      2110      2120      2130      2140      2150      2160
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTAT
|||||
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTAT
2170      2180      2190      2200      2210      2220      2230
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTAT
|||||
TAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATGATTCCTTTAAACTTAT
2240      2250      2260      2270      2280      X
```

```
CCAGATGTAGTTCCTTCCAATTAATTTGAATAAATCTTTGTTACTCAA
|||||
CCAGATGTAGTTCCTTCCAATTAATTTGAATAAATCTTTGTTACTCAAATTTCTGTGAAGAACCAA
2240      2250      2260      2270      2280      X      2290      2300
CTGATCTCCCCCACCCTTGATTAGAGTTTC
2310      2320      2330

12. US-09-944-929-82 (1-2284)
AAC59840.SEQ Human secreted protein encoding DNA clone vo27 1.

TOIG of: aac59840 check: 4624 from: 1 to: 2342

ID AAC59840 standard; DNA; 2342 BP.
XX
AC AAC59840;
XX
DT 26-JAN-2001 (first entry)
XX
DE Human secreted protein encoding DNA clone vo27 1.
XX
KW Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer;
KW systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke;
KW haematopoiesis regulation; tissue regrowth; wound healing; haemophilia;
KW Alzheimer's disease; Parkinson's disease; Shy-drager syndrome; cancer;
KW contraceptive; infection; growth inhibition; hyperproliferative disorder;
KW psoriasis; ds.
XX
XX Homo sapiens.
OS
XX WO200055375-A1.
PN
XX 21-SEP-2000.
PD
XX 17-MAR-2000; 2000WO-US007285.
PF
XX 17-MAR-1999; 99US-0124808P.
PR 17-MAR-1999; 99US-0124916P.
PR 17-AUG-1999; 99US-0149639P.
PR 01-OCT-1999; 99US-0157247P.
PR 29-NOV-1999; 99US-0167824P.
PR 15-FEB-2000; 2000US-0182711P.
XX
XX (ALPH-) ALPHAGENE INC.
PA
XX Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
PI
XX WPI; 2000-638211/61.
DR
DR P-PSDB; AAB34739.
XX
XX Novel proteins and polypeptides useful for the treatment of e.g multiple
PT sclerosis, systemic lupus erythematosus, rheumatoid arthritis, cancer,
PT Alzheimer's disease, Parkinson's disease, stroke, anemia and ulcers.
PT
XX
PS Claim 114; Page 453; 493pp; English.
XX
XX This invention relates to 59 human secreted proteins and the nucleotide
CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745
CC represent the proteins and their encoding nucleotide sequences, and
CC sequences AAB34746-B34771 represent fragments of the proteins. Probes for
CC the DNA sequences are represented by sequences AAC59847-C59596. The
CC proteins exhibit neuroprotective, dermatological, immunosuppressive,
CC antiinflammatory, antianaemic, nootropic, antiparkinsonian,
CC cerebroprotective, haemostatic, vulnerary, cytostatic, antipsoriatic,
CC antibacterial, virucide, and fungicide activity. The proteins and
CC nucleotide sequences are useful as nutritional sources or supplements and
CC in research. The proteins are useful for treating immune deficiency and
CC disorders, which may be genetic or resulting from infections, autoimmune
CC disorders such as multiple sclerosis, systemic lupus erythematosus,
CC rheumatoid arthritis, and for treating myeloid or lymphoid cell
CC deficiencies such as anaemias by regulating haematopoiesis. The proteins
CC are also useful in compositions for bone, cartilage, tendon, ligament
```

```
CC and/or nerve tissue growth or regeneration, for wound healing, tissue
CC repair and replacement and in the treatment of wounds, incisions and
CC ulcers. Other uses include in the treatment of central and peripheral
CC nervous system and neuropathies such as Alzheimer's and Parkinson's
CC diseases and Shy-Drager syndrome, and mechanical and traumatic disorders,
CC such as spinal cord disorders, head trauma and stroke. The proteins may
CC also be used as a contraceptive, and for treating coagulation disorders
CC such as haemophilias. The protein and nucleotide sequences with cadherin
CC activity are useful for treating cancer. Other uses for the protein
CC include for inhibiting the growth, infection or function of, or killing,
CC infectious agents such as bacteria, virus, fungi and other parasites, for
CC effecting bodily characteristics such as height, weight, hair colour,
CC effecting biorhythms or cardiac cycles or rhythms, effecting metabolism,
CC catabolism, anabolism, processing, utilization, storage or elimination of
CC dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors,
CC effecting behavioural characteristics, providing analgesic effects and
CC for treating hyperproliferative disorders such as psoriasis
XX
SQ Sequence 2342 BP; 644 A; 589 C; 475 G; 634 T; 0 U; 0 Other;
XX
AAC59840 Length: 2342 September 29, 2004 14:43 Type: N Check: 4624 ..

Initial Score = 1834 Optimized Score = 2282 Significance = -0.89
Residue Identity = 99% Matches = 2283 Mismatches = 1
Gaps = 1 Conservative Substitutions = 0

GAACACAAAACCCGCCAGCGCGGTGCGGAGCTGCGAGCATCCGTCGGTCTCGCGAGACCCCGCG
10 20 30 X 40 50 60
40 50 60 70 80 90 100 110
CGGATTGCCGGTCTCTCCCGCGGCGGAGAGCTGTCTCGACCTGGATGGCAGAGCGCGCGGG
CGGATTGCCGGTCTCTCCCGCGGCGGAGAGCTGTCTCGACCTGGATGGCAGAGCGCGCGGG
80 90 100 110 120 130 140
TCCTCTGCAGCGCCAGAGAAATCTCATCTGTGACGCCCTTCTTAAGCAAATAAGACCAGAGGAGA
120 130 140 150 160 170 180 190 200 210
TCCTCTGCAGCGCCAGAGAAATCTCATCTGTGACGCCCTTCTTAAGCAAATAAGACCAGAGGAGA
150 160 170 180 190 200 210
TTATCCTTGACCTTGAAGACCAAAACTGAATTTAAATGTTCTTCGGGGAGAGGAGCTTGAC
190 200 210 220 230 240 250
TTATCCTTGACCTTGAAGACCAAAACTGAATTTAAATGTTCTTCGGGGAGAGGAGCTTGAC
220 230 240 250 260 270 280
260 270 280 290 300 310 320
TTACACTTTGTAATTAATTTGCTTCTGACACTAAGGCTGTCTGTAGTCAGAAATGGCCTCAAAAAGACT
300 310 320 330 340 350 360
TTACACTTTGTAATTAATTTGCTTCTGACACTAAGGCTGTCTGTAGTCAGAAATGGCCTCAAAAAGACT
300 310 320 330 340 350 360
330 340 350 360 370 380 390
AGAAAGTGTGTCAATGACATCCAGTCACTCTTTCTTAAGGAATCAAGGCAATGAGCCCGTATATCTTC
400 410 420 430 440 450 460 470
AGAAAGTGTGTCAATGACATCCAGTCACTCTTTCTTAAGGAATCAAGGCAATGAGCCCGTATATCTTC
400 410 420 430 440 450 460 470
AACTCAAGAAAGACTGATTAATTTCTGTGTTCAAAAAACATATCAGGGGACAAAGCATGTATCTGAT
440 450 460 470 480 490 500
GATCTTCGACACTGAAAAACAGCTAGACAAACCACTGTACTATTTTCTGTCCCAAGAGAGAGCCTG
480 490 500 510 520 530 540
GATCTTCGACACTGAAAAACAGCTAGACAAACCACTGTACTATTTTCTGTCCCAAGAGAGAGCCTG
510 520 530 540 550 560 570
```

```
550 560 570 580 590 600 610
TCCATTGAAACCAAGAGCTTATGAGTTACAGGATATTTCCATCTTTGACCAAAATTT
|||||
TCCATTGAAACCAAGAGCTTATGAGTTACAGGATATTTCCATCTTTGACCAAAATTT
580 590 600 610 620 630 640
620 630 640 650 660 670 680
GCCAAGCCAGAGTTACCCAGGAGATTCTCTTACATGGCCCAATTTTCAAGCAGTCTCCCTAGC
|||||
GCCAAGCCAGAGTTACCCAGGAGATTCTCTTACATGGCCCAATTTTCAAGCAGTCTCCCTAGC
650 660 670 680 690 700 710 720
690 700 710 720 730 740 750
CCATCATCACAGATTATTCAAGCCCAAGATATCTCATGAGAGACACACTTTCTCAGAGTTGGATC
|||||
CCATCATCACAGATTATTCAAGCCCAAGATATCTCATGAGAGACACACTTTCTCAGAGTTGGATC
730 740 750 760 770 780 790
760 770 780 790 800 810 820 830
CTCAGATCACTGGAGAACTATTTAAGATGATGAGACAGAGTCCCACTCTTGTATTAAGGAAAAAG
|||||
CTCAGATCACTGGAGAACTATTTAAGATGATGAGACAGAGTCCCACTCTTGTATTAAGGAAAAAG
800 810 820 830 840 850 860
840 850 860 870 880 890 900
CCATTCTCAGAGTTCACAATTTTCTTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTAGTGCCT
|||||
CCATTCTCAGAGTTCACAATTTTCTTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTAGTGCCT
870 880 890 900 910 920 930
910 920 930 940 950 960 970
CCAGCTACGGTGGCAGTGTCTTCCACATACCACCTCGCTACTCCAAGCCCGCCACCTTACCCAC
|||||
CCAGCTACGGTGGCAGTGTCTTCCACATACCACCTCGCTACTCCAAGCCCGCCACCTTACCCAC
940 950 960 970 980 990 1000
980 990 1000 1010 1020 1030 1040
CAATGCTTCAGTGAACACCTTCTGGGACTTCCACAGCCACAGCTGGCCACCAAGCTCCACCTGTAACCACTGT
|||||
CAATGCTTCAGTGAACACCTTCTGGGACTTCCACAGCCACAGCTGGCCACCAAGCTCCACCTGTAACCACTGT
1010 1020 1030 1040 1050 1060 1070 1080
1050 1060 1070 1080 1090 1100 1110 1120
CACTTCTCAGCTCCACGACCTCATTTTCTACAGTTTTCACACGGGCTGCGCTACACTCCAAGCAATGGC
|||||
CACTTCTCAGCTCCACGACCTCATTTTCTACAGTTTTCACACGGGCTGCGCTACACTCCAAGCAATGGC
1090 1100 1110 1120 1130 1140 1150
1120 1130 1140 1150 1160 1170 1180 1190
TACAACAGCAGTTCTGACTACCACCTTCCAGCACCTAGCAGCTCGAAGGCAGCTTAGAAGCAATACCCTT
|||||
TACAACAGCAGTTCTGACTACCACCTTCCAGCACCTAGCAGCTCGAAGGCAGCTTAGAAGCAATACCCTT
1160 1170 1180 1190 1200 1210 1220
1200 1210 1220 1230 1240 1250 1260
TACAGAAATCTCCAATTAATTTGAACAGGGAATGTATTAACCTACTGCACTTCTATGTCAAAATGT
|||||
TACAGAAATCTCCAATTAATTTGAACAGGGAATGTATTAACCTACTGCACTTCTATGTCAAAATGT
1230 1240 1250 1260 1270 1280 1290
1270 1280 1290 1300 1310 1320 1330
GGAGTCTTCCACTATGATATAAACTGCTTCTGGAGAGTAGGAGGAGCCAGTCCAGCAGTCTCCCAAGG
|||||
GGAGTCTTCCACTATGATATAAACTGCTTCTGGAGAGTAGGAGGAGCCAGTCCAGCAGTCTCCCAAGG
1300 1310 1320 1330 1340 1350 1360
1340 1350 1360 1370 1380 1390 1400
CAGTGTTCAGAAATCAGTACGCGCTTCATTTGAAATGGCTTATCGGGTCCCTGCTTTGGTGT
|||||
CAGTGTTCAGAAATCAGTACGCGCTTCATTTGAAATGGCTTATCGGGTCCCTGCTTTGGTGT
1370 1380 1390 1400 1410 1420 1430 1440
```

```
1410 1420 1430 1440 1450 1460 1470
CCTGTTCCTGTGATAGGCTCTGCTCTCTGGGTAGAACTCTTCCGAATCACTCCGAGGAAACGTTACTC
|||||
CCTGTTCCTGTGATAGGCTCTGCTCTCTGGGTAGAACTCTTCCGAATCACTCCGAGGAAACGTTACTC
1450 1460 1470 1480 1490 1500 1510
1480 1490 1500 1510 1520 1530 1540 1550
AAGACTGGATTATTGATCAATGGGATCTATGTGACATCTTAAGATGAAGTCCGCTGCTCTTAATTCATT
|||||
AAGACTGGATTATTGATCAATGGGATCTATGTGACATCTTAAGATGAAGTCCGCTGCTCTTAATTCATT
1520 1530 1540 1550 1560 1570 1580
1560 1570 1580 1590 1600 1610 1620
TAGTAACCAAGAGCCCAATGCAATGAGTTTCTGCTGACTTGTCTTACAGAGAGTTGATTTGAAG
|||||
TAGTAACCAAGAGCCCAATGCAATGAGTTTCTGCTGACTTGTCTTACAGAGAGTTGATTTGAAG
1590 1600 1610 1620 1630 1640 1650
1630 1640 1650 1660 1670 1680 1690
ACAGGAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTGGAGACAGAGTCTTGTCTGTGCCAGGCTGG
|||||
ACAGGAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTGGAGACAGAGTCTTGTCTGTGCCAGGCTGG
1660 1670 1680 1690 1700 1710 1720
1700 1710 1720 1730 1740 1750 1760
AGTGCAGTAGCACGATCTCGGCTCTCACCCGCAACCTCCGCTCTGGTTCAAGCGATCTCCTGCCTCAGC
|||||
AGTGCAGTAGCACGATCTCGGCTCTCACCCGCAACCTCCGCTCTGGTTCAAGCGATCTCCTGCCTCAGC
1730 1740 1750 1760 1770 1780 1790 1800
1770 1780 1790 1800 1810 1820 1830
CTCCTAAGTATCTGGATTACAGGATGTGCCACACACCTGGGTGATTTTGTATTTTATAGAGACGGG
|||||
CTCCTAAGTATCTGGATTACAGGATGTGCCACACACCTGGGTGATTTTGTATTTTATAGAGACGGG
1810 1820 1830 1840 1850 1860 1870
1840 1850 1860 1870 1880 1890 1900
GTTTCAACATGTGTGTCAGGCTGTCTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTG
|||||
GTTTCAACATGTGTGTCAGGCTGTCTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTG
1880 1890 1900 1910 1920 1930 1940
1910 1920 1930 1940 1950 1960 1970 1980
CTGGGATTACAGGCATGAGCCACACAGCTGGCCCCCTCTGTTTATGTTTGGTTTTCAGAGAATGAA
|||||
CTGGGATTACAGGCATGAGCCACACAGCTGGCCCCCTCTGTTTATGTTTGGTTTTCAGAGAATGAA
1950 1960 1970 1980 1990 2000 2010
1990 2000 2010 2020 2030 2040 2050
GTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTCTTAATAATTAGCTAAACCAAGCTCTATGTAAA
|||||
GTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTCTTAATAATTAGCTAAACCAAGCTCTATGTAAA
2020 2030 2040 2050 2060 2070 2080
2060 2070 2080 2090 2100 2110 2120
GTAATTAAGTATAATTGCCATTAATAATTCAAAATTCAGCTGCTTTATGCAAAAGAACAGGTTAGACAT
|||||
GTAATTAAGTATAATTGCCATTAATAATTCAAAATTCAGCTGCTTTATGCAAAAGAACAGGTTAGACAT
2090 2100 2110 2120 2130 2140 2150 2160
2130 2140 2150 2160 2170 2180 2190
CTAGGTTCCAATTCATTCAATCTTGGTTCAGATTAATACTGTTTATATCAATTTCTAATGATTTG
|||||
CTAGGTTCCAATTCATTCAATCTTGGTTCAGATTAATACTGTTTATATCAATTTCTAATGATTTG
2170 2180 2190 2200 2210 2220 2230
2200 2210 2220 2230 2240 2250 2260
CTTTTCTTTTATATGATTCCTTTTAAACTTATTTCCAGATGATGTTCTTCCAAATTAATTTGAATAAA
|||||
CTTTTCTTTTATATGATTCCTTTTAAACTTATTTCCAGATGATGTTCTTCCAAATTAATTTGAATAAA
2240 2250 2260 2270 2280 2290 2300
2270 2280 X
```





760 770 780 790 800 810 820 830  
TCAGATCACCTGGAGAACTATTAAAGATGATGATGAAGCAAGTCCCAAGCTCCTTGTCTTATAAGAAAAAGCC  
TCAGATCACTTGGAGAACTATTAAAGATGATGATGAAGCAAGTCCCAAGCTCCTTGTCTTATAAGAAAAAGCC  
800 810 820 830 840 850 860  
CATTCTCAGAGTTCAACAATTTCTCTGATCAAGAAATAGCTCATCTGCTCCGTAAATGTGAGTGCCTC  
CATTCTCAGAGTTCAACAATTTCTCTGATCAAGAAATAGCTCATCTGCTCCGTAAATGTGAGTGCCTC  
870 880 890 900 910 920 930  
CCAGCTACGGTGGCAGTTGCTTCTCCACATACCACCCTCGGCTACTCCAAAGCCCGCCACCCTTCTAACCCACC  
CCAGCTACGGTGGCAGTTGCTTCTCCACATACCACCCTCGGCTACTCCAAAGCCCGCCACCCTTCTAACCCACC  
940 950 960 970 980 990 1000  
AATGCTTCAGTGACACCTTTGGGACTTCCAGCCACAGCTGGCCACACAGCTCCACCTGTAAACCACTGTCTC  
AATGCTTCAGTGACACCTTTGGGACTTCCAGCCACAGCTGGCCACACAGCTCCACCTGTAAACCACTGTCTC  
1010 1020 1030 1040 1050 1060 1070 1080  
ACTTCTCAGCCTCCCAAGCCTCTCATTTCTACAGTTTTTTACACGGGCTGCGGCTACACTCCAAAGCAATGGCT  
ACTTCTCAGCCTCCCAAGCCTCTCATTTCTACAGTTTTTTACACGGGCTGCGGCTACACTCCAAAGCAATGGCT  
1090 1100 1110 1120 1130 1140 1150  
ACAACAGCAGTTCTGACTACCACTTTTCAGGCACCTACGACTCGAAAGGACAGCTTAGAAACCATACCGTTT  
ACAACAGCAGTTCTGACTACCACTTTTCAGGCACCTACGACTCGAAAGGACAGCTTAGAAACCATACCGTTT  
1160 1170 1180 1190 1200 1210 1220  
ACAGAAATCTCCAATTAATTTGAACACAGGGAATGTGTATAACCTACTGCACCTTTCTATGTCAATGTG  
ACAGAAATCTCCAATTAATTTGAACACAGGGAATGTGTATAACCTACTGCACCTTTCTATGTCAATGTG  
1230 1240 1250 1260 1270 1280 1290  
GAGTCTTCCACTATGAATATAAAGTCTCTCTGGAGGTAGGAGGCGAGTCCAGGCAGTCTCTCCAGGGC  
GAGTCTTCCACTATGAATATAAAGTCTCTCTGGAGGTAGGAGGCGAGTCCAGGCAGTCTCTCCAGGGC  
1300 1310 1320 1330 1340 1350 1360  
AGTGTTCAGAAAATCAGTACGGCCTTCCATTGTGAAAAATGGCTTCTTATCGGGTCCCTGCTCTTTGTGTC  
AGTGTTCAGAAAATCAGTACGGCCTTCCATTGTGAAAAATGGCTTCTTATCGGGTCCCTGCTCTTTGTGTC  
1370 1380 1390 1400 1410 1420 1430 1440  
CTGTCTCTGGTATAGGCTGCTCTCTGGTATGAAATCCTCTGGAATCACTCCGACAGAAAGTTACTCA  
CTGTCTCTGGTATAGGCTGCTCTCTGGTATGAAATCCTCTGGAATCACTCCGACAGAAAGTTACTCA  
1450 1460 1470 1480 1490 1500 1510  
AGACTGGATTATTGATCAATGGATCTATGTGACATCTTAAGATGGAATCGGCTGCTCTTAATTCATTTT  
AGACTGGATTATTGATCAATGGATCTATGTGACATCTTAAGATGGAATCGGCTGCTCTTAATTCATTTT  
1520 1530 1540 1550 1560 1570 1580  
AGTAACCAAGAACCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGTATTTGAAGA  
AGTAACCAAGAACCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGTATTTGAAGA  
1590 1600 1610 1620 1630 1640 1650  
1630 1640 1650 1660 1670 1680 1690

CAGAAAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTGAGACAGAGTCTTGCTCTGTGCTGCCAGGCTGGA  
 |||||  
 CAGAAAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTGAGACAGAGTCTTGCTCTGTGCTGCCAGGCTGGA  
 1660 1670 1680 1690 1700 1710 1720  
 1700 1710 1720 1730 1740 1750 1760  
 GTGCAGTAGCACGATCTCGGCTCTCACCGCAACCTCCGTCCTGGGTTCAAGCGAATCTCCTGCTCAGCC  
 |||||  
 GTGCAGTAGCACGATCTCGGCTCTCACCGCAACCTCCGTCCTGGGTTCAAGCGAATCTCCTGCTCAGCC  
 1730 1740 1750 1760 1770 1780 1790 1800  
 1770 1780 1790 1800 1810 1820 1830  
 TCCTAAGTATCTGGAGTTACAGGCGATGCGCACACACCTGGGTGATTTTGTATTTTGTAGAGACGGGG  
 |||||  
 TCCTAAGTATCTGGAGTTACAGGCGATGCGCACACACCTGGGTGATTTTGTATTTTGTAGAGACGGGG  
 1810 1820 1830 1840 1850 1860 1870  
 1840 1850 1860 1870 1880 1890 1900 1910  
 TTTCACCATGTGGTGCAGGCTGGTCTCAAACCTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGC  
 |||||  
 TTTCACCATGTGGTGCAGGCTGGTCTCAAACCTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAGTGC  
 1880 1890 1900 1910 1920 1930 1940  
 1920 1930 1940 1950 1960 1970 1980  
 TGGGATTACAGGCGATGAGCCACACAGCTGGCCCCCTCTGTTTATGTTGTTTGAAGAAGATGAAG  
 |||||  
 TGGGATTACAGGCGATGAGCCACACAGCTGGCCCCCTCTGTTTATGTTGTTTGAAGAAGATGAAG  
 1950 1960 1970 1980 1990 2000 2010  
 1990 2000 2010 2020 2030 2040 2050  
 TGGGAACCAATTAAGTAATTTTGGGTATCTGTCTCTAAATATTAAGCTAAAAACAAGCTCTATGTAAG  
 |||||  
 TGGGAACCAATTAAGTAATTTTGGGTATCTGTCTCTAAATATTAAGCTAAAAACAAGCTCTATGTAAG  
 2020 2030 2040 2050 2060 2070 2080  
 2060 2070 2080 2090 2100 2110 2120  
 TAATAAGTATAATGCGCATATAAATTTCAAAATTCAACTGGCTTTTATGCAAGAAACAGGTTAGGACATC  
 |||||  
 TAATAAGTATAATGCGCATATAAATTTCAAAATTCAACTGGCTTTTATGCAAGAAACAGGTTAGGACATC  
 2100 2110 2120 2130 2140 2150 2160  
 2130 2140 2150 2160 2170 2180 2190  
 TAGGTTCCAATTCATTCACATTTCTGGTCCAGATAAATCAACTGTTATATCAATTTCTAATGATTTGC  
 |||||  
 TAGGTTCCAATTCATTCACATTTCTGGTCCAGATAAATCAACTGTTATATCAATTTCTAATGATTTGC  
 2170 2180 2190 2200 2210 2220 2230  
 2200 2210 2220 2230 2240 2250 2260 X 2270  
 TTTTCTTTTATATGATTCCTTTAAACCTTATTCAGATGATTCCTTCCAATTAATATTTGAATTAAT  
 |||||  
 TTTTCTTTTATATGATTCCTTTAAACCTTATTCAGATGATTCCTTCCAATTAATATTTG  
 2240 2250 2260 2270 2280 2290 X  
 2280  
 CTTTTGTACTCAA  
 14. US-09-944-929-82 (1-2284)  
 AAH13971.SEQ Human cDNA sequence SEQ ID NO:11027.  
 TOIG of: aah13971 check: 7816 from: 1 to: 2221  
 ID AAH13971 standard; cDNA; 2221 BP.  
 XX AC AAH13971;  
 XX DT 26-JUN-2001 (first entry)  
 DE Human cDNA sequence SEQ ID NO:11027.  
 XX  
 XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.  
 OS Homo sapiens.

```
XX EP1074617-A2.
XX
XX 07-FEB-2001.
XX
XX 28-JUL-2000; 2000EP-00116126.
XX
XX 29-JUL-1999; 99JP-00248036.
XX
XX 27-AUG-1999; 99JP-00300253.
XX
XX 11-JAN-2000; 2000JP-00118776.
XX
XX 02-MAY-2000; 2000JP-00183767.
XX
XX 09-JUN-2000; 2000JP-00241899.
XX
XX (HELI-) HELIX RES INST.
XX
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
XX Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
XX WPI; 2001-318749/34.
XX
XX
XX Primer sets for synthesizing polynucleotides, particularly the 5602 full-
XX length cDNAs defined in the specification, and for the detection and/or
XX diagnosis of the abnormality of the proteins encoded by the full-length
XX cDNAs.
XX
XX Claim 8; SEQ ID NO 11027; 2537bp + Sequence Listing; English.
XX
XX
XX The present invention describes primer sets for synthesizing 5602 full-
XX length cDNAs defined in the specification. Where a primer set comprises:
XX (a) an oligo-dt primer and an oligonucleotide complementary to the
XX complementary strand of a polynucleotide which comprises one of the 5602
XX nucleotide sequences defined in the specification, where the
XX oligonucleotide comprises at least 15 nucleotides; or (b) a combination
XX of an oligonucleotide comprising a sequence complementary to the
XX complementary strand of a polynucleotide which comprises a 5'-end
XX sequence and an oligonucleotide comprising a sequence complementary to a
XX polynucleotide which comprises a 3'-end sequence, where the
XX oligonucleotide comprises at least 15 nucleotides and the combination of
XX the 5'-end sequence/3'-end sequence is selected from those defined in the
XX specification. The primer sets can be used in antisense therapy and in
XX gene therapy. The primers are useful for synthesizing polynucleotides,
XX particularly full-length cDNAs. The primers are also useful for the
XX detection and/or diagnosis of the abnormality of the proteins encoded by
XX the full-length cDNAs. The primers allow obtaining of the full-length
XX cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
XX AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893
XX represent human amino acid sequences; and AAH13629 to AAH13632 represent
XX oligonucleotides, all of which are used in the exemplification of the
XX present invention
XX
XX
XX Sequence 2221 BP; 591 A; 573 C; 456 G; 601 T; 0 U; 0 Other;
XX
AAH13971 Length: 2221 September 29, 2004 14:43 Type: N Check: 7816 ..
Initial Score = 1467 Optimized Score = 2138 Significance = -2.06
Residue Identity = 95% Matches = 2173 Mismatches = 7
Gaps = 103 Conservative Substitutions = 0
GCTTGCTAACCAAAACCCGCGAGCGCGGTGCGGAGCTGCGGAGCATCCGCTGCGTCTCGCCGAGACC
10 20 30 40 50 60 70 80 90 100
110 120 130 140 150 160 170
CCGGGTCCTCTCGACGCGAGAGAAATCTCATCATCTGTGACGCTTCTTAAGCAAACTAAGACGAG
|||||
```

```
CCGGGTCCTCTCGACGCGCGAGAGAAATCTCATCTCCGTGACGCTTCTTAAGCAAACTAAGACGAG
150 160 170 180 190 200 210 220 230 240
GGAGATTATCTTGAACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGAGAGGAG
|||||
GGAGATTATCTTGAACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGAGAGGAG
220 230 240 250 260 270 280
CTTGACTTACACTTTGGTATAATATTGCTTCTGACACTAAGGCTGTCTGCTAGTCAGAATTGCTCAAAA
|||||
CTTGACTTACACTTT-----
290 300
GAGTCTAGAAGATGTTGTCATTGACATCCAGTCATCTTCTTAAGGAATCAGAGGCAATGAGCCGTATA
330 340 350 360 370 380 390
-----GGGAATCAGAGGCAATGAGCCGTATA
310 320 330
400 410 420 430 440 450 460
TACTTCAACTCAAGAGAAGCTGCATTAACTTCTGTTCAACAAAACATATCAGGGGACAAAGCATGTAA
|||||
TACTTCAACTCAAGAGAAGCTGCATTAACTTCTGTTCAACAAAACATATCAGGGGACAAAGCATGTAA
340 350 360 370 380 390 400
470 480 490 500 510 520 530
CTTGATGATCTTGCACACTCGAAAAACAGCTAGACAACCCAACTGCTACTATTTTCTGTCCCAAGAGA
|||||
CTTGATGATCTTGCACACTCGAAAAACAGCTAGACAACCCAACTGCTACTATTTTCTGTCCCAAGAGA
410 420 430 440 450 460 470
480 490 500 510 520 530 540
AGCCTGTCCATTGAAACCAAGAGAGCTTATGAGTTACAGGATTAATTAACAGATTTTCCATCTTGAACCA
AGCCTGTCCATTGAAACCAAGAGAGCTTATGAGTTACAGGATTAATTAACAGATTTTCCATCTTGAACCA
480 490 500 510 520 530 540
540 550 560 570 580 590 600
AGCCTGTCCATTGAAACCAAGAGAGCTTATGAGTTACAGGATTAATTAACAGATTTTCCATCTTGAACCA
AGCCTGTCCATTGAAACCAAGAGAGCTTATGAGTTACAGGATTAATTAACAGATTTTCCATCTTGAACCA
480 490 500 510 520 530 540
610 620 630 640 650 660 670 680
AAATTGGCCAAGCCAAGAGTTACCCCAAGAGATTCTCTTACATGCGCAATTTTCAACAGACGACTCC
|||||
AAATTGGCCAAGCCAAGAGTTACCCCAAGAGATTCTCTTACATGCGCAATTTTCAACAGACGACTCC
550 560 570 580 590 600 610
690 700 710 720 730 740 750
CCTAGCCCATCATCACAGATTATTCAAGGCCACCGATATCTCATGAGAGACACACTTCTCGAAGTT
|||||
CCTAGCCCATCATCACAGATTATTCAAGGCCACCGATATCTCATGAGAGACACACTTCTCGAAGTT
620 630 640 650 660 670 680 690
760 770 780 790 800 810 820
TGATTCCTCAGATCACCTGGAGAACTATTTAAGATGATGAGAGCAAGTGCCCAAGCTCTTGTATTAAGGA
|||||
TGATTCCTCAGATCACCTGGAGAACTATTTAAGATGATGAGAGCAAGTGCCCAAGCTCTTGTATTAAGGA
700 710 720 730 740 750 760
830 840 850 860 870 880 890
AAAAGGCATTTCTCAGAGTTCAACAATTTTCTGTATCAAGAAATAGCTCATCTGCTGAAATGTGAG
|||||
AAAAGGCATTTCTCAGAGTTCAACAATTTTCTGTATCAAGAAATAGCTCATCTGCTGAAATGTGAG
770 780 790 800 810 820 830
900 910 920 930 940 950 960
TGCGTCCAGCTACGGGTGGCAGTGTCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCCACTTCT
|||||
TGCGTCCAGCTACGGGTGGCAGTGTCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCCACTTCT
840 850 860 870 880 890 900
970 980 990 1000 1010 1020 1030 1040
ACCAACCAATGCTTCACTGACACACTTCTGGACTTCCAGCCACAGCTGGCCACACAGCTCCACTGTAA
|||||
ACCAACCAATGCTTCACTGACACACTTCTGGACTTCCAGCCACAGCTGGCCACACAGCTCCACTGTAA
```





PR 23-OCT-1998; 98US-0105368P.  
PR 08-JAN-1999; 99US-0115234P.  
PR 12-FEB-1999; 99US-0119931P.  
PR 18-FEB-1999; 99US-0120575P.  
PR 30-APR-1999; 99US-0132020P.  
PR 11-AUG-1999; 99US-0148424P.  
XX  
PA (GEMV ) GENETICS INST INC.  
XX  
PI Jacobs K, McCoy JM, Lavalie ER, Collins-Racie LA, Evans C;  
PI Merberg D, Treacy M, Agostino MJ, Steininger RJ, Spaulding V;  
PI Wong GG, Clark HF, Fechtel K;  
XX  
DR WPI; 2000-205979/18.  
DR P-PSDB; AAY94917.  
XX  
XX  
PT New polynucleotides encoding secreted proteins, which may have e.g.  
PT nutritional, chemokine, immune stimulating or suppressing, hematopoiesis  
PT regulating, tissue growth, activin/inhibin antiinflammatory or tumor  
PT inhibition activity.  
XX  
PS Claim 48; Page 506; 641pp; English.

CC AAA16618 to AAA16697 encode the human secreted proteins given in AAY94898  
CC to AAY94980, isolated from human adult brain, adult thyroid, adult  
CC retina, foetal carcinoma, adult blood, adult neural, foetal kidney, adult  
CC placenta, adult testis, whole embryo, adult cartilage, kidney, foetal  
CC brain, adult thymus, foetal placenta, adult uterus, adult tumour, and  
CC adult bladder, cDNA libraries. The polynucleotides and proteins are  
CC predicted to have biological activities which would make them suitable  
CC for treating, preventing or ameliorating medical conditions in humans and  
CC animals. The polynucleotides can be used as markers for tissues in which  
CC the protein is preferentially expressed, as molecular weight markers on  
CC Southern gels, and as chromosome markers or tags to identify chromosomes  
CC or to map gene positions. The proteins can be used in the treatment of  
CC immune deficiencies and disorders, such as severe combined  
CC immunodeficiency (SCID), as well as viral, bacterial, fungal and other  
CC infections. These infections include human immunodeficiency virus (HIV),  
CC hepatitis, herpesviruses, mycobacteria, Leishmania spp., malaria and  
CC candidiasis. The proteins can be used to treat autoimmune disorders such  
CC as connective tissue disease, multiple sclerosis, systemic lupus  
CC erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation,  
CC Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent  
CC diabetes mellitus, myasthenia gravis, graft-versus-host disease and  
CC autoimmune inflammatory eye disease. The proteins can also be used to  
CC treat allergic conditions, such as asthma. AAA16698 to AAA16774 represent  
CC probes for the human secreted proteins from the present invention  
XX  
XX Sequence 2015 BP; 562 A; 498 C; 388 G; 567 T; 0 U; 0 Other;

AAA16637 Length: 2015 September 29, 2004 14:43 Type: N Check: 8840 ..  
Initial Score = 1423 Optimized Score = 1983 Significance = -2.20  
Residue Identity = 99% Matches = 1987 Mismatches = 6  
Gaps = 4 Conservative Substitutions = 0

240 250 260 270 280 290 300 310  
GAGAAGGAGCTTGACTTACACTTGTGTAATATTGCTCTCTGACACTAAGGCTGTCTGTAAGCAATT  
GCCTCAAAAAGAGTCTAGAGATGTGTTCATTGACATCCAGTCATCTTTCTAAGGGAATCAGAGCAATG  
GCCTCAAAAAGAGTCTAGAGATGTGTTCATTGACATCCAGTCATCTTTCTAAGGGAATCAGAGCAATG  
30 40 50 60 70 80 90  
390 400 410 420 430 440 450  
AGCCGTATATCTTCAACTCAGAAGACTGCATTAATCTTGTCTGTTCACAAACAAACATATCAGGGGACA  
AGCCGTATATCTTCAACTCAGAAGACTGCATTAATCTTGTCTGTTCACAAACAAACATATCAGGGGACA  
100 110 120 130 140 150 160

460 470 480 490 500 510 520  
AAGCATGTAACCTTGATGATCTTTCGACACTCGAAAAACAGCTAGACAAACCAACTGCTACCTATTTTCTGTC  
AAGCATGTAACCTTGATGATCTTTCGACACTCGAAAAACAGCTAGACAAACCAACTGCTACCTATTTTCTGTC  
170 180 190 200 210 220 230  
530 540 550 560 570 580 590  
CCAACGAGGAGCCCTGCCATTTGAACACCAGCAAAAGACTTATGAGTTACAGATAATTACAGATTTTCCAT  
CCAACGAGGAGCCCTGCCATTTGAACACCAGCAAAAGACTTATGAGTTACAGATAATTACAGATTTTCCAT  
240 250 260 270 280 290 300 310  
600 610 620 630 640 650 660 670  
CTTTGACCAGAAATTTGCCCAAGCCCAAGAGTTACCCCGAAGAGATTCTTCTTACATGGCCAAATTTTCAAG  
CTTGACCAGAAATTTGCCCAAGCCCAAGAGTTACCCCGAAGAGATTCTTCTTACATGGCCAAATTTTCAAG  
320 330 340 350 360 370 380  
CAGTCACTCCCCCTTACCCATCATCACACAGATTATTCAAAAGCCCAAGGATATCTCATGAGAGACACACTTT  
CAGTCACTCCCCCTTACCCATCATCACACAGATTATTCAAAAGCCCAAGGATATCTCATGAGAGACACACTTT  
390 400 410 420 430 440 450  
750 760 770 780 790 800 810  
CTCAGAAGTTTGATTCCTCAGATCACCTGGAGAACTATTTAAGATGATGAAGCAAGTGCCAGCTCTTG  
CTCAGAAGTTTGATTCCTCAGATCACCTGGAGAACTATTTAAGATGATGAAGCAAGTGCCAGCTCTTG  
460 470 480 490 500 510 520  
820 830 840 850 860 870 880  
CTTATTAAGAAAAAGGCCATTTCTCAGAGTTTCAAAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTG  
CTTATTAAGAAAAAGGCCATTTCTCAGAGTTTCAAAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTG  
530 540 550 560 570 580 590  
890 900 910 920 930 940 950  
AAAATGTGAGTGGCTCCAGCTACGAGTGGAGTGTCTTCTCCACATACCACTGGCTACTCCAAAGCCCG  
AAAATGTGAGTGGCTCCAGCTACGAGTGGAGTGTCTTCTCCACATACCACTGGCTACTCCAAAGCCCG  
600 610 620 630 640 650 660 670  
960 970 980 990 1000 1010 1020 1030  
CCACCCTTCTACCCCAATGCTTCACTGAGCACTTCTGGAGTTCCTCCAGCAGCTGGCCACAGCTC  
CCACCCTTCTACCCCAATGCTTCACTGAGCACTTCTGGAGTTCCTCCAGCAGCTGGCCACAGCTC  
680 690 700 710 720 730 740  
1040 1050 1060 1070 1080 1090 1100  
CACTGTAAACCACTGCTCACTTCTCAGCCTCCCAAGACCTCATTTCTTACAGTTTTCACAGGGCTGGCCTA  
CACTGTAAACCACTGCTCACTTCTCAGCCTCCCAAGACCTCATTTCTTACAGTTTTCACAGGGCTGGCCTA  
750 760 770 780 790 800 810  
1110 1120 1130 1140 1150 1160 1170  
CACTCAAGCAATGGCTTACAACAGCAGTTCGACTACCACTTTTACGACCTACGAGCTCGAAAGCAGCT  
CACTCAAGCAATGGCTTACAACAGCAGTTCGACTACCACTTTTACGACCTACGAGCTCGAAAGCAGCT  
820 830 840 850 860 870 880  
1180 1190 1200 1210 1220 1230 1240  
TAGAAACCATACCGTTTACAGAATATCTCAACTTAACCTTGAACACAGGGAATGTATTAACCTTCTGAC  
TAGAAACCATACCGTTTACAGAATATCTCAACTTAACCTTGAACACAGGGAATGTATTAACCTTCTGAC  
890 900 910 920 930 940 950  
1250 1260 1270 1280 1290 1300 1310  
TTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAG  
TTTCTATGTCAAAATGTGAGTCTTCCACTATGAATAAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAG  
960 970 980 990 1000 1010 1020 1030

```
1320      1330      1340      1350      1360      1370      1380
GCAGTTCCT-CCGAGGGCAGGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTTATTCGGG
|||||
GCAGTTCCTCCCGCAGGGCAGGTGTCCAGAAATCAGTACGGCCTTCCATTGAAAAATGGCTTATTCGGG
1040      1050      1060      1070      1080      1090      1100
1390      1400      1410      1420      1430      1440      1450      1460
TCCCTGCTCTTTGGTGTCCTGTCTGTTGATGAGCCCTGCTCCTGCTGGAATCCTC
|||||
TCCCTGCTCTTTGGTGTCCTGTCTGTTGATGAGCCCTGCTCCTGCTGGAATCCTC
1110      1120      1130      1140      1150      1160      1170
1470      1480      1490      1500      1510      1520      1530
CGCAGGAAACGTTACTCAAGACTGATTTATGATCAATGGATCTATGTGACATCTAAGATGGAACCTCG
|||||
CGCAGGAAACGTTACTCAAGACTGATTTATGATCAATGGATCTATGTGACATCTAAGATGGAACCTCG
1180      1190      1200      1210      1220      1230      1240
1540      1550      1560      1570      1580      1590      1600
GTGCTCTTTAATTCATTTAGTAACCAAGACCAATGCAATGAGTTCTGCTGACTTGTAGTCTTACGAG
|||||
GTGCTCTTTAATTCATTTAGTAACCAAGACCAATGCAATGAGTTCTGCTGACTTGTAGTCTTACGAG
1250      1260      1270      1280      1290      1300      1310
1610      1620      1630      1640      1650      1660      1670
GAGTTGTATTTTGAAGACAGAGAAATGCCCCCTTCTGCTTCTTTTGGAGACAGAGCTTGTCT
|||||
GAGTTGTATTTTGAAGACAGAGAAATGCCCCCTTCTGCTTCTTTTGGAGACAGAGCTTGTCT
1320      1330      1340      1350      1360      1370      1380
1680      1690      1700      1710      1720      1730      1740
CTGTTGCCAGGCTGAGTGCAGTAGCAGATCTGGCTCTCACCGGAACCTCCGCTCTCGGTTCAAGCG
|||||
CTGTTGCCAGGCTGAGTGCAGTAGCAGATCTGGCTCTCACCGGAACCTCCGCTCTCGGTTCAAGCG
1390      1400      1410      1420      1430      1440      1450      1460
1750      1760      1770      1780      1790      1800      1810      1820
ATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTTACAGGCATGTGCCACCAACCTGGGATTTTGTAT
|||||
ATTCTCTGCTCAGCCTCCT-AGTATCTGGGATTTACAGGCATGTGCCACCAACCTGGGATTTTGTAT
1470      1480      1490      1500      1510      1520      1530
1830      1840      1850      1860      1870      1880      1890
TTTATGAGAGACGGGGTTTCAACCATGTTGGTCAGGCTGTCTCAAACTCCTGACCTAGTATCCACCTCC
|||||
TTTATGAGAGAC-GGGTTTCAACCATGTTGGTCAGGCTGTCTCAAACTCCTGACCTAGTATCCACCTCC
1540      1550      1560      1570      1580      1590      1600
1900      1910      1920      1930      1940      1950      1960
TCGGCCTCCCAAGTGTGGGATTTACAGGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTT
|||||
TCGGCCTCCCAAGTGTGGGATTTACAGGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTT
1610      1620      1630      1640      1650      1660      1670
1970      1980      1990      2000      2010      2020      2030
TTTGAGAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTTAAATATTTAGCTAAAAA
|||||
TTTGAGAGGAATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTTAAATATTTAGCTAAAAA
1680      1690      1700      1710      1720      1730      1740
2040      2050      2060      2070      2080      2090      2100
CAAAGCTCTATGTAAAGTAAATGAATATGATGATGATGATGATGATGATGATGATGATGATGATGATG
|||||
CAAAGCTCTATGTAAAGTAAATGAATATGATGATGATGATGATGATGATGATGATGATGATGATGATG
1750      1760      1770      1780      1790      1800      1810
2110      2120      2130      2140      2150      2160      2170      2180
AAACAGGTTAGACATCTAGGTTCCAATTCATTCACATTTCTGTTCCAGATAAATCAACTGTTTATATCA
|||||
AAACAGGTTAGACATCTAGGTTCCAATTCATTCACATTTCTGTTCCAGATAAATCAACTGTTTATATCA
1820      1830      1840      1850      1860      1870      1880      1890
2190      2200      2210      2220      2230      2240      2250
```

```
ATTCTAATGGAATTGCTTTCTTTTATATGGAATCCTTTAAACTTATTCAGATGATGCTTCCAT
|||||
ATTCTAATGGAATTGCTTTCTTTTATATGGAATCCTTTAAACTTATTCAGATGATGCTTCCAT
1900      1910      1920      1930      1940      1950      1960
2260      2270      2280      X
TAAATATTTGAATAAATCTTTGTTACTCAA
|||||
TAAATATTTGAATAAATCTTTGTTACTCAAAAAA
1970      1980      1990      X      2000      2010
```



if art w/utility  
give priority  
to parent

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 25, 2004, 05:27:34 ; Search time 8829 Seconds

(without alignments)  
11212.537 Million cell updates/sec

Title: US-09-944-929-82

Perfect score: 8284

Sequence: 1 gcggagcaccgcgtcggtc.....ataatcttctgtactca 2284

Scoring table: IDENTITY\_NUC

Searched: 3470272 seqs, 2167151695 residues

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1500 summaries

Database : GenEmbl:\*

1: gb\_ba:\*

2: gb\_htg:\*

3: gb\_in:\*

4: gb\_om:\*

5: gb\_ov:\*

6: gb\_pat:\*

7: gb\_ph:\*

8: gb\_pl:\*

9: gb\_pr:\*

10: gb\_ro:\*

11: gb\_sts:\*

12: gb\_sy:\*

13: gb\_un:\*

14: gb\_vi:\*

15: em\_ba:\*

16: em\_fun:\*

17: em\_hum:\*

18: em\_in:\*

19: em\_mu:\*

20: em\_om:\*

21: em\_or:\*

22: em\_ov:\*

23: em\_pat:\*

24: em\_ph:\*

25: em\_pl:\*

26: em\_ro:\*

27: em\_sts:\*

28: em\_un:\*

29: em\_vi:\*

30: em\_htg\_hum:\*

31: em\_htg\_inv:\*

32: em\_htg\_other:\*

33: em\_htg\_mus:\*

34: em\_htg\_pln:\*

35: em\_htg\_rtd:\*

36: em\_htg\_mam:\*

37: em\_htg\_vrt:\*

38: em\_sy:\*

39: em\_htgo\_hum:\*

40: em\_htgo\_mus:\*

41: em\_htgo\_other:\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2284	100.0	2284	6 AR252736	AR252736 Sequence
2	2284	100.0	2284	6 AR429104	AR429104 Sequence
3	2284	100.0	2284	6 AX403627	AX403627 Sequence
4	2284	100.0	2284	6 BD140585	BD140585 Polypepti
5	2284	100.0	2284	9 AY358563	AY358563 Homo sapi
6	2245.6	98.3	2297	6 AX883044	AX883044 Sequence
7	2245.6	98.3	2297	6 BD160088	BD160088 Primer fo
8	2245.6	98.3	2297	9 AK023622	AK023622 Homo sapi
9	2218.8	97.1	2233	9 BC032998	BC032998 Homo sapi
10	2045.8	89.6	2221	6 AX876122	AX876122 Sequence
11	2045.8	89.6	2221	6 BD155963	BD155963 Primer fo
12	2045.8	89.6	2221	9 AK001160	AK001160 Homo sapi
13	1939.4	84.9	2015	6 BD227259	BD227259 Secretd
14	1920.2	84.1	2345	9 AB060888	AB060888 Macaca fa
15	1687.2	73.9	188344	2 AC131617	AC131617 Homo sapi
16	1684	73.7	144000	9 AC007621	AC007621 Homo sapi
17	690.8	30.2	2288	10 BC039930	BC039930 Mus muscu
18	661.8	29.0	805	6 AX869834	AX869834 Sequence
19	661.8	29.0	805	6 BD149896	BD149896 Primer fo
20	583.6	25.6	855	6 AX867136	AX867136 Sequence
21	583.6	25.6	855	6 BD147198	BD147198 Primer fo
22	499.6	21.9	548	6 BD059530	BD059530 Secretd
23	470.2	20.6	522	6 AX874802	AX874802 Sequence
24	412.6	18.1	201474	2 AC126692	BD154864 Primer fo
25	412.6	18.1	236589	2 AC118035	AC126692 Mus muscu
26	395.8	17.3	250782	2 AC128093	AC118035 Mus muscu
27	391.8	17.2	224870	2 AC129657	AC128093 Rattus no
28	386.8	16.9	422	6 BD071236	AC129657 Rattus no
29	326.4	14.3	188344	2 AC131617	BD071236 Secretd
30	315.6	13.8	424	11 G27546	AC131617 Homo sapi
31	270.2	11.8	295	6 AX894034	G27546 human STS s
32	270.2	11.8	295	6 BD029567	AX894034 Sequence
33	262.2	11.5	1326	10 BC031372	BD029567 Sequence
34	245.2	10.7	7617	9 AL391693	BC031372 Mus muscu
35	245.2	10.7	178976	2 AL391095	AL391693 Human DNA
36	244.8	10.7	140974	2 AC068533	AL391095 Homo sapi
37	244.6	10.7	198838	2 AC093647	AC068533 Homo sapi
38	244.4	10.7	83528	9 AC073254	AC093647 Homo sapi
39	244.4	10.7	150942	9 AC017070	AC073254 Homo sapi
40	244.4	10.7	237931	9 AC022098	AC017070 Homo sapi
41	243.6	10.7	174559	9 AC015720	AC022098 Homo sapi
42	243.6	10.7	175033	9 AL445931	AC015720 Homo sapi
43	243.4	10.7	47036	9 AC002104	AL445931 Human DNA
44	243	10.6	150512	9 AC114324	AC002104 Genomic s
45					AC114324 Homo sapi

ALIGNMENTS

RESULT 1

AR252736

LOCUS AR252736 2284 bp DNA linear PAT 20-DEC-2002

DEFINITION Sequence 514 from patent US 6478825.

ACCESSION AR252736

VERSION AR252736.1 GI:27300644

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 2284)

AUTHORS Winterbottom,J.M., Shimp,L., Boyce,T.M. and Kaes,D.

TITLE Implant, method of making same and use of the implant for the treatment of bone defects

JOURNAL Patent: US 6478825-A 514 12-NOV-2002;

FEATURES		Location/Qualifiers	
source		1..2284	
		/organism="unknown"	
		/mol_type="genomic DNA"	
ORIGIN			
Query Match 100.0%; Score 2284; DB 6; Length 2284;			
Best Local Similarity 100.0%; Pred. No. 0;			
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTGCGCGTCTTCCGCG	60
Db	1	GCGGAGCATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTGCGCGTCTTCCGCG	60
QY	61	GGGCGGACAGAGCTGTCTCGCACTGTGATGGCAGAGGGCGCGGGTCTCTCGAC	120
Db	61	GGGCGGACAGAGCTGTCTCGCACTGTGATGGCAGAGGGCGCGGGTCTCTCGAC	120
QY	121	GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAGCAAACTAAGACGAGGGAG	180
Db	121	GCCAGAGAGAAATCTCATCTGTGACGCTTCTTAAGCAAACTAAGACGAGGGAG	180
QY	181	GATTATCCTTGACCTTTGAGAACCAAACTAACTGAATTTAAATGTTCTTGGGGGA	240
Db	181	GATTATCCTTGACCTTTGAGAACCAAACTAACTGAATTTAAATGTTCTTGGGGGA	240
QY	241	GAAAGGAGCTTGACTTACACTTTGGTAATATTGCTCTGACACTAAGGCTGTGCT	300
Db	241	GAAAGGAGCTTGACTTACACTTTGGTAATATTGCTCTGACACTAAGGCTGTGCT	300
QY	301	AGTCAGAAATGGCTCAAAAAGACTAGAAAGTGTGATGACATCCAGTCATCTCTT	360
Db	301	AGTCAGAAATGGCTCAAAAAGACTAGAAAGTGTGATGACATCCAGTCATCTCTT	360
QY	361	TCTAAGGGAATCAGAGGCAATGAGCCCGTATATACTTCACTCAAGAAGACTGATTAAT	420
Db	361	TCTAAGGGAATCAGAGGCAATGAGCCCGTATATACTTCACTCAAGAAGACTGATTAAT	420
QY	421	TCTTGCTGTTCAACAAAACATATCAGGGGACAAAGCATGTAACCTGATGATCTTCGAC	480
Db	421	TCTTGCTGTTCAACAAAACATATCAGGGGACAAAGCATGTAACCTGATGATCTTCGAC	480
QY	481	ACTCGAAAAACAGCTAGACAAACCAACTGCTACCTATTTTCTGTCCCAAGGAAAGCC	540
Db	481	ACTCGAAAAACAGCTAGACAAACCAACTGCTACCTATTTTCTGTCCCAAGGAAAGCC	540
QY	541	TGTCATTTGAAACCAAGCAAAAGACTTATGAGTTACAGATTAATTAAGATTTTCATCT	600
Db	541	TGTCATTTGAAACCAAGCAAAAGACTTATGAGTTACAGATTAATTAAGATTTTCATCT	600
QY	601	TTGACCAAGAAATTTGCCAAGCAAGTTACCCCAAGAGATTCTCTTACATGGCCAA	660
Db	601	TTGACCAAGAAATTTGCCAAGCAAGTTACCCCAAGAGATTCTCTTACATGGCCAA	660
QY	661	TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACAGATTAATCAAAAGCCACCGAT	720
Db	661	TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACAGATTAATCAAAAGCCACCGAT	720
QY	721	ATCTCATGAGAGACACACTTCTCAGAAGTTGGATCCTCAGATCACCTGGAGAAACTA	780
Db	721	ATCTCATGAGAGACACACTTCTCAGAAGTTGGATCCTCAGATCACCTGGAGAAACTA	780
QY	781	TTTAAGATGATGAAGCAAGTGCCCAAGCTCCTGCTTAAGGAAAAAGGCCATTTCTCAG	840
Db	781	TTTAAGATGATGAAGCAAGTGCCCAAGCTCCTGCTTAAGGAAAAAGGCCATTTCTCAG	840
QY	841	AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG	900
Db	841	AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG	900
QY	901	CTCCCAAGCTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCGC	960
Db	901	CTCCCAAGCTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCGC	960

QY	961	ACCTTCTACCCCAATGCTTCAGTGACACCTTCTGGACTTCCAGCCACAGCTGGCC	1020
Db	961	ACCTTCTACCCCAATGCTTCAGTGACACCTTCTGGACTTCCAGCCACAGCTGGCC	1020
QY	1021	ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACAGACCCTCAATTCTACA	1080
Db	1021	ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACAGACCCTCAATTCTACA	1080
QY	1081	GTTTTTACACGGGCTGGGCTACACTCCAAGCAATGGCTACACAGCAGATTCTGACTACC	1140
Db	1081	GTTTTTACACGGGCTGGGCTACACTCCAAGCAATGGCTACACAGCAGATTCTGACTACC	1140
QY	1141	ACCTTTCAGGCACTTACGGACTCGAAAAGCAGCTTAGAAAACCATACCCTTACAGAAATC	1200
Db	1141	ACCTTTCAGGCACTTACGGACTCGAAAAGCAGCTTAGAAAACCATACCCTTACAGAAATC	1200
QY	1201	TCCAATTAACCTTGAACACAGGGAATGTATTAACCTACTGCACTTTCTATGTCAAAAT	1260
Db	1201	TCCAATTAACCTTGAACACAGGGAATGTATTAACCTACTGCACTTTCTATGTCAAAAT	1260
QY	1261	GTGAGTCTTCCATATGAATAAATCTGCTGGAAGGTAGGAGGCGCATCCAGGC	1320
Db	1261	GTGAGTCTTCCATATGAATAAATCTGCTGGAAGGTAGGAGGCGCATCCAGGC	1320
QY	1321	AGTTCCTCCAGGCGAGTGTCCAGAAAATCACTACGCGCTTCCATTTGAAAATGGCTT	1380
Db	1321	AGTTCCTCCAGGCGAGTGTCCAGAAAATCACTACGCGCTTCCATTTGAAAATGGCTT	1380
QY	1381	CTTATCGGCTCCCTGCTTTTGGTGTCTCTGTTCTGTTGATAGGCTCGCTCCTGGGT	1440
Db	1381	CTTATCGGCTCCCTGCTTTTGGTGTCTCTGTTCTGTTGATAGGCTCGCTCCTGGGT	1440
QY	1441	AGAATCTTTGGAATCACTCCGAGGAAACGTTACTCAAGACTGATTAATTGATCAAT	1500
Db	1441	AGAATCTTTGGAATCACTCCGAGGAAACGTTACTCAAGACTGATTAATTGATCAAT	1500
QY	1501	GGGATCTATGTGACATCTAAGGATGGAACCTGCTCTCTTAATTCATTTAGTAACCAAG	1560
Db	1501	GGGATCTATGTGACATCTAAGGATGGAACCTGCTCTCTTAATTCATTTAGTAACCAAG	1560
QY	1561	AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGATTTTGA	1620
Db	1561	AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGATTTTGA	1620
QY	1621	AGACAGAAAAATGCCCCCTTCTGCTTCTCTTTTGGAGACAGAGCTTGTCTCTG	1680
Db	1621	AGACAGAAAAATGCCCCCTTCTGCTTCTCTTTTGGAGACAGAGCTTGTCTCTG	1680
QY	1681	TTGCCAAGGCTGAGTGCAGTAGACAGATCTCGGCTCTCACCGCAACCTCCCTCTCTG	1740
Db	1681	TTGCCAAGGCTGAGTGCAGTAGACAGATCTCGGCTCTCACCGCAACCTCCCTCTCTG	1740
QY	1741	GTTCAAGCGATTCTCTGCTCAGCCTCTTAAGTATCTGGATTACAGGCAATGTGCCACC	1800
Db	1741	GTTCAAGCGATTCTCTGCTCAGCCTCTTAAGTATCTGGATTACAGGCAATGTGCCACC	1800
QY	1801	ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTGGTCAAGGCTG	1860
Db	1801	ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTGGTCAAGGCTG	1860
QY	1861	GTCCTCAACTCTGACTAGTATCCACCTCTCGGCTCCCAAAGTGTGGGATTACA	1920
Db	1861	GTCCTCAACTCTGACTAGTATCCACCTCTCGGCTCCCAAAGTGTGGGATTACA	1920
QY	1921	GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTTGTGAGAGGAATGA	1980
Db	1921	GGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTTGTGAGAGGAATGA	1980
QY	1981	AGTGGGAACCAATTAAGTAATTTTGGGTAACTGTCTTAATAATTAAGCTAATAACAA	2040
Db	1981	AGTGGGAACCAATTAAGTAATTTTGGGTAACTGTCTTAATAATTAAGCTAATAACAA	2040



QY 2041 AGCTCTATGTAAAGTATATAAGTATATTGCCATATATAATTTCAAAATTCAACTGGCTTT 2100  
DB 2041 AGCTCTATGTAAAGTATATAAGTATATTGCCATATATAATTTCAAAATTCAACTGGCTTT 2100  
QY 2101 TATGCAAAAGAAACAGGTTAGACATCTAGGTTCCCAATTCATTCACATCTTGTTCAGA 2160  
DB 2101 TATGCAAAAGAAACAGGTTAGACATCTAGGTTCCCAATTCATTCACATCTTGTTCAGA 2160  
QY 2161 TAAATCAACTGTTTATATCAATTCTAATGATTGCTTTCTTTTATATGATTCTT 2220  
DB 2161 TAAATCAACTGTTTATATCAATTCTAATGATTGCTTTCTTTTATATGATTCTT 2220  
QY 2221 TTAATACTTATTCAGATGTAGTCTCTCCCAATTAATATTTGAATAATCTTTGTAC 2280  
DB 2221 TTAATACTTATTCAGATGTAGTCTCTCCCAATTAATATTTGAATAATCTTTGTAC 2280  
QY 2281 TCAA 2284  
DB 2281 TCAA 2284

RESULT 2  
AR429104 AR429104 2284 bp DNA linear PAT 18-DEC-2003  
LOCUS AR429104  
DEFINITION Sequence 82 from patent US 6642360.  
ACCESSION AR429104  
VERSION AR429104.1 GI:40189199  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 2284)  
AUTHORS Filvaroff,E., Goddard,A., Godowski,P.J., Grimaldi,J.C., Gurney,A.L.  
and Wood,W.I.  
TITLE Secreted polypeptides that stimulate release of proteoglycans from cartilage  
JOURNAL Patent: US 6642360-A 82 04-NOV-2003;  
FEATURES  
Source 1. 2284  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 100.0%; Score 2284; DB 6; Length 2284;  
Best Local Similarity 100.0%; Pred.No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGCATCCGCTGCGTCTCGCGGAGACCCCGCGCGGATTGCGCGTCTTCCGC 60  
DB 1 GCGGAGCATCCGCTGCGTCTCGCGGAGACCCCGCGCGGATTGCGCGTCTTCCGC 60  
QY 61 GGGCGGACAGAGCTGTCTCGCACTGGATGGCAGGCGCGCGGGTCTCTGCAC 120  
DB 61 GGGCGGACAGAGCTGTCTCGCACTGGATGGCAGGCGCGCGGGTCTCTGCAC 120  
QY 121 GCCAGAGAGAAATCTCATCATCTGTGCAGCCTTCTTAAAGCAAACTAAGACGAGGAG 180  
DB 121 GCCAGAGAGAAATCTCATCATCTGTGCAGCCTTCTTAAAGCAAACTAAGACGAGGAG 180  
QY 181 GATTATCTTGAACCTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA 240  
DB 181 GATTATCTTGAACCTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA 240  
QY 241 GAAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300  
DB 241 GAAGGAGCTTGACTTACACTTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300  
QY 301 AGTCGAATTGCTCAAAAAGAGTGAAGAATGTTGTCAATGACATCCAGTCATCTCT 360  
DB 301 AGTCGAATTGCTCAAAAAGAGTGAAGAATGTTGTCAATGACATCCAGTCATCTCT 360  
QY 361 TCTAAGGAATCAGAGCAATGAGCCGCTATATACCTTCAACTCAAGAAGACTGATTAAT 420  
DB 361 TCTAAGGAATCAGAGCAATGAGCCGCTATATACCTTCAACTCAAGAAGACTGATTAAT 420

DB 361 TCTAAGGAATCAGAGCAATGAGCCGCTATATACCTTCAACTCAAGAAGACTGATTAAT 420  
QY 421 TCTTGCTGTTCACAAAAAACATATCAGGGGACAAAGCATGTAACCTTGATGATCTTCGAC 480  
DB 421 TCTTGCTGTTCACAAAAAACATATCAGGGGACAAAGCATGTAACCTTGATGATCTTCGAC 480  
QY 481 ACTGAAAAACAGCTAGACAACTGCTACCTATTTTCTGTCTCCCAAGAGAGAGCC 540  
DB 481 ACTGAAAAACAGCTAGACAACTGCTACCTATTTTCTGTCTCCCAAGAGAGAGCC 540  
QY 541 TGTCCATTGAACACGCAAAAGACTTATAGTTACAGATAATTACAGATTTTCCATCT 600  
DB 541 TGTCCATTGAACACGCAAAAGACTTATAGTTACAGATAATTACAGATTTTCCATCT 600  
QY 601 TTGACCAAGAAATTTGCCAAGCCAAGATTACCCCAAGAGATTTCTCTTACATGGCCAA 660  
DB 601 TTGACCAAGAAATTTGCCAAGCCAAGATTACCCCAAGAGATTTCTCTTACATGGCCAA 660  
QY 661 TTTTCACAAGCAGTCACTCCCTTAGCCCATCATCACAGATTATTCAAAGCCACCGAT 720  
DB 661 TTTTCACAAGCAGTCACTCCCTTAGCCCATCATCACAGATTATTCAAAGCCACCGAT 720  
QY 721 ATCTCATGAGAGACACACTTCTCAGAAGTTTGATCTCAGATCACCTGAGAAACTA 780  
DB 721 ATCTCATGAGAGACACACTTCTCAGAAGTTTGATCTCAGATCACCTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTCCCACTCTGCTTTAAGAAAAAGCCATTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTCCCACTCTGCTTTAAGAAAAAGCCATTCTCAG 840  
QY 841 AGTTCACAATTTTCTCTGATTCAGAATAAGTCAATCTGCTGCTGAAATGTGATGCG 900  
DB 841 AGTTCACAATTTTCTCTGATTCAGAATAAGTCAATCTGCTGCTGAAATGTGATGCG 900  
QY 901 CTCCAGACTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
DB 901 CTCCAGACTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
QY 961 ACCCTTCTACCCCAACCAATGCTTCAAGTACACACTTCTGGGACTTCCCAAGCAGCTGGCC 1020  
DB 961 ACCCTTCTACCCCAACCAATGCTTCAAGTACACACTTCTGGGACTTCCCAAGCAGCTGGCC 1020  
QY 1021 ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCTCATTTCTACA 1080  
DB 1021 ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCTCATTTCTACA 1080  
QY 1081 GTTTTACACGGGCTGCGGCTACCTCCAAGCAATGGCTACAAAGAGATTCTGACTACC 1140  
DB 1081 GTTTTACACGGGCTGCGGCTACCTCCAAGCAATGGCTACAAAGAGATTCTGACTACC 1140  
QY 1141 ACCTTTCAGGACCTACCGACTCGAAAGGACGCTTAGAAACCATACCGTTACAGAAATC 1200  
DB 1141 ACCTTTCAGGACCTACCGACTCGAAAGGACGCTTAGAAACCATACCGTTACAGAAATC 1200  
QY 1201 TCCAACTTAACCTTGAACACAGGGAATGTGTATAACCTTACCTTCTATGTCAAT 1260  
DB 1201 TCCAACTTAACCTTGAACACAGGGAATGTGTATAACCTTACCTTCTATGTCAAT 1260  
QY 1261 GTGAGTCTTCCACTATGAATAAACTGCTTCTGGAAGGTAGGGAGGCCAGTCCAGGC 1320  
DB 1261 GTGAGTCTTCCACTATGAATAAACTGCTTCTGGAAGGTAGGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCCTCCAGGCGAGTGTCCAGAAAATCAGTACGGCTTCCATTGAAAAATGGCTT 1380  
DB 1321 AGTTCCTCCAGGCGAGTGTCCAGAAAATCAGTACGGCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTTATCGGGTCCCTGCTCTTGGTGTCTGTCTGTTGTAATAGCCCTGCTCTGGGT 1440  
DB 1381 CTTATCGGGTCCCTGCTCTTGGTGTCTGTCTGTTGTAATAGCCCTGCTCTGGGT 1440  
QY 1441 AGAATCTTTTGGGAATCACTCCGACGAGAAACGTTACTCAAGACTGATTATTGATCAAT 1500  
DB 1441 AGAATCTTTTGGGAATCACTCCGACGAGAAACGTTACTCAAGACTGATTATTGATCAAT 1500

QY 1501 GGGATCTATGTGACATCTAAGGATGGAACCTGGGTCTCTTAATTCATTTAGTAACCAAG 1560  
DB 1501 GGGATCTATGTGACATCTAAGGATGGAACCTGGGTCTCTTAATTCATTTAGTAACCAAG 1560  
QY 1561 AAGCCCAATGCAATGAGTTTCTGTGACTGTAGTCTTAGCAGAGGTTGTATTTGA 1620  
DB 1561 AAGCCCAATGCAATGAGTTTCTGTGACTGTAGTCTTAGCAGAGGTTGTATTTGA 1620  
QY 1621 AGACAGGAAATGCCCCCTTCTGCTTTCTTTTGGAGACAGAGTCTTGCTCTG 1680  
DB 1621 AGACAGGAAATGCCCCCTTCTGCTTTCTTTTGGAGACAGAGTCTTGCTCTG 1680  
QY 1681 TTGCCCAAGCTGAGTGCAGTGCAGATCTCGGCTCTCACCGCAACCTCCGCTCTG 1740  
DB 1681 TTGCCCAAGCTGAGTGCAGTGCAGATCTCGGCTCTCACCGCAACCTCCGCTCTG 1740  
QY 1741 GTTCAAGCATTTCTCTGCTCAGCTCTAAGTATCTGGGATTACAGGCATGTGCCACC 1800  
DB 1741 GTTCAAGCATTTCTCTGCTCAGCTCTAAGTATCTGGGATTACAGGCATGTGCCACC 1800  
QY 1801 ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTGTGTCAGGCTG 1860  
DB 1801 ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTGTGTCAGGCTG 1860  
QY 1861 GTCTCAAACTCCTGACCTAGTATCCACCTCTCGGCTCCCAAGTGTGGATTACA 1920  
DB 1861 GTCTCAAACTCCTGACCTAGTATCCACCTCTCGGCTCCCAAGTGTGGATTACA 1920  
QY 1921 GGCATGAGCACCACACAGCTGGCCCCCTCTGTTTATGTTGGTTTGAAGAAGATGA 1980  
DB 1921 GGCATGAGCACCACACAGCTGGCCCCCTCTGTTTATGTTGGTTTGAAGAAGATGA 1980  
QY 1981 AGTGGGAACCAATTAAGTATTTGGGTATCTGTCTTAAATATTAGCTAAACAA 2040  
DB 1981 AGTGGGAACCAATTAAGTATTTGGGTATCTGTCTTAAATATTAGCTAAACAA 2040  
QY 2041 AGCTCTATGTAAAGTAAATTAAGTATTAATGCGCATATAATTCAAAATTCAACTGGCTTT 2100  
DB 2041 AGCTCTATGTAAAGTAAATTAAGTATTAATGCGCATATAATTCAAAATTCAACTGGCTTT 2100  
QY 2101 TATGCAAAAGAACAGGTTAGGACATCTAGGTTCCAATTCAATTCACATCTTGTTCCAGA 2160  
DB 2101 TATGCAAAAGAACAGGTTAGGACATCTAGGTTCCAATTCAATTCACATCTTGTTCCAGA 2160  
QY 2161 TAAATCAACTGTTTATATCAATTTCTAAATGGAATTTGCTTTCTTTATATGATTCCT 2220  
DB 2161 TAAATCAACTGTTTATATCAATTTCTAAATGGAATTTGCTTTCTTTATATGATTCCT 2220  
QY 2221 TTAACACTATTCAGATGATGTTCTTCCAATTAATATTGAATAATCTTTGTAC 2280  
DB 2221 TTAACACTATTCAGATGATGTTCTTCCAATTAATATTGAATAATCTTTGTAC 2280  
QY 2281 TCMA 2284  
DB 2281 TCMA 2284

RESULT 3  
AX403627 2284 bp DNA linear PAT 14-JUN-2002  
LOCUS AX403627 Sequence 514 from Patent WO0073454.  
ACCESSION AX403627  
VERSION AX403627.1 GI:21437090  
KEYWORDS Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
REFERENCE 1 Ashkenazi, A.J., Baker, K.P., Botstein, D., Desnoyers, L., Eaton, D.,  
Ferrara, N., Gerber, H., Gertlisen, M., Goddard, A., Godowski, P.,  
Grimaldi, C.J., Gurney, A.L., Kijavlin, I., Napier, M.A., Pan, J.,

Paoni, N.F., Roy, M., Stewart, T.A., Tumas, D., Watanabe, C.K.,  
Williams, P., Wood, W.I. and Zhang, Z.  
Secreted and transmembrane polypeptides and nucleic acids encoding  
the same  
JOURNAL Patent: WO 0073454-A 514 07-DEC-2000;  
Genentech Inc. (US)  
FEATURES location/Qualifiers  
source 1..2284  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 100.0%; Score 2284; DB 6; Length 2284;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGGAGCATCCGCTGCGGTCTCTCGCGAGACCCCGCGGATTCGCCGCTTCCCGC 60  
DB 1 GCGGAGCATCCGCTGCGGTCTCTCGCGAGACCCCGCGGATTCGCCGCTTCCCGC 60  
QY 61 GGGCGGACAGAGCTGTCTCGCACTGATGGCAGCAGGGGCGCGGGTCTCTCGAC 120  
DB 61 GGGCGGACAGAGCTGTCTCGCACTGATGGCAGCAGGGGCGCGGGTCTCTCGAC 120  
QY 121 GCCAGAGAAATCTCATCTGTGACGCTTCTTAAAGCAACTAAGACAGAGGAG 180  
DB 121 GCCAGAGAAATCTCATCTGTGACGCTTCTTAAAGCAACTAAGACAGAGGAG 180  
QY 181 GATTATCTTGACCTTGAAGACCAAACTAACTGAATTTAAATGTTCTCGGGGA 240  
DB 181 GATTATCTTGACCTTGAAGACCAAACTAACTGAATTTAAATGTTCTCGGGGA 240  
QY 241 GAAGGAGCTTGACTTACACTTGGTAAATATTGCTTCTGACACTAAGGCTGTGCT 300  
DB 241 GAAGGAGCTTGACTTACACTTGGTAAATATTGCTTCTGACACTAAGGCTGTGCT 300  
QY 301 AGTCAGAAATTGCTCAAAAAGAGTCTAGAAAGTGTGTCAATGACATCCAGTCTCTT 360  
DB 301 AGTCAGAAATTGCTCAAAAAGAGTCTAGAAAGTGTGTCAATGACATCCAGTCTCTT 360  
QY 361 TCTAAGGAATCAGAGGCAATGAGCCGTATATACCTTCACTCAAGAAAGCTGATTAAT 420  
DB 361 TCTAAGGAATCAGAGGCAATGAGCCGTATATACCTTCACTCAAGAAAGCTGATTAAT 420  
QY 421 TCTTGTCTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATCTTCGAC 480  
DB 421 TCTTGTCTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATCTTCGAC 480  
QY 481 ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCCAAGAGAGGCC 540  
DB 481 ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCCAAGAGAGGCC 540  
QY 541 TGTCCATTGAAACCAAGAAAGACTTATGAGTTACAGGATTAATACAGATTTCCATCT 600  
DB 541 TGTCCATTGAAACCAAGAAAGACTTATGAGTTACAGGATTAATACAGATTTCCATCT 600  
QY 601 TTGACGAAATTTGCCAAGCCAGAGTTACCCCAAGAAATCTCTTACATGGCCAA 660  
DB 601 TTGACGAAATTTGCCAAGCCAGAGTTACCCCAAGAAATCTCTTACATGGCCAA 660  
QY 661 TTTTCAAGACGACTCCCTAGCCCATCATCACACAGATTATCAAAAGCCACCGAT 720  
DB 661 TTTTCAAGACGACTCCCTAGCCCATCATCACACAGATTATCAAAAGCCACCGAT 720  
QY 721 ATCTCATGAGAGACACACTTCTCAGAAGTTTGATCCTCAGATCACCTGAGAAACTA 780  
DB 721 ATCTCATGAGAGACACACTTCTCAGAAGTTTGATCCTCAGATCACCTGAGAAACTA 780  
QY 781 TTTAAGATGATGAAGCAAGTGGCCAGCTCTTGTCTTATAAGGAAAAAGCCATTCTCAG 840  
DB 781 TTTAAGATGATGAAGCAAGTGGCCAGCTCTTGTCTTATAAGGAAAAAGCCATTCTCAG 840

QY	841	AGTTCACAATTTTCTCTGTGATCAAGAAATAGCTCATCTGTGCTCCGTGAAAATGTGAGTGG	900
Db	841	AGTTCACAATTTTCTCTGTGATCAAGAAATAGCTCATCTGTGCTCCGTGAAAATGTGAGTGG	900
QY	901	CTCCAGCTACGGGTGGCAGTTGCTTCTCCACATACCACCTGGGCTACTCCAAAGCCGGC	960
Db	901	CTCCAGCTACGGGTGGCAGTTGCTTCTCCACATACCACCTGGGCTACTCCAAAGCCGGC	960
QY	961	ACGCTTCTACCCACCAATGCTTCAGTACACCTTCTGGGACTTCCAGCCACAGCTGGC	1020
Db	961	ACCTTCTACCCACCAATGCTTCAGTACACCTTCTGGGACTTCCAGCCACAGCTGGC	1020
QY	1021	ACCACAGCTCCACCTGTAAACACTGTCACTTCTCAGCCTCCACGACCCTCATTTCTACA	1080
Db	1021	ACCACAGCTCCACCTGTAAACACTGTCACTTCTCAGCCTCCACGACCCTCATTTCTACA	1080
QY	1081	GTTTTTACACGGGCTGGGCTACACTCCAAAGCAATGGCTTACAACAGCAGTTCTGACTACC	1140
Db	1081	GTTTTTACACGGGCTGGGCTACACTCCAAAGCAATGGCTTACAACAGCAGTTCTGACTACC	1140
QY	1141	ACCTTTCAGGCACCTTACGGACTCGAAAAGCAGCTTAGAAACCATACCCTTACAGAAATC	1200
Db	1141	ACCTTTCAGGCACCTTACGGACTCGAAAAGCAGCTTAGAAACCATACCCTTACAGAAATC	1200
QY	1201	TCCAACCTTAACCTTGAACAAGGAATGTATTAACCTTACCTGCACTTCTATGTCAAAT	1260
Db	1201	TCCAACCTTAACCTTGAACAAGGAATGTATTAACCTTACCTGCACTTCTATGTCAAAT	1260
QY	1261	GTGAGTCTTCCACTATGATTAACAAGTCTTCCCTGGGAAGTAGGAGGCCAGTCCAGGC	1320
Db	1261	GTGAGTCTTCCACTATGATTAACAAGTCTTCCCTGGGAAGTAGGAGGCCAGTCCAGGC	1320
QY	1321	AGTTCCTCCAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTTGAAAAATGGCTT	1380
Db	1321	AGTTCCTCCAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTTGAAAAATGGCTT	1380
QY	1381	CTTATCGGGTCCCTGCTCTTTGGTGTCTGTCTGTCTGTGTATGAGCCCTGCTCCTGGGT	1440
Db	1381	CTTATCGGGTCCCTGCTCTTTGGTGTCTGTCTGTGTGTATGAGCCCTGCTCCTGGGT	1440
QY	1441	AGAACTCTTTCGGAATCATCTCCGACAGAAACGTTACTCAAGCTGATTATTGATCAAT	1500
Db	1441	AGAACTCTTTCGGAATCATCTCCGACAGAAACGTTACTCAAGCTGATTATTGATCAAT	1500
QY	1501	GGGATCTATGTGACATCTAAGGATGGAACCTCGGTGCTCTTAATTCATTAGTAACAG	1560
Db	1501	GGGATCTATGTGACATCTAAGGATGGAACCTCGGTGCTCTTAATTCATTAGTAACAG	1560
QY	1561	AAGCCCAATGCAATGAGTTTCTGCTGACTTGTCTAGTCTTACAGAGGTTGTATTTGA	1620
Db	1561	AAGCCCAATGCAATGAGTTTCTGCTGACTTGTCTAGTCTTACAGAGGTTGTATTTGA	1620
QY	1621	AGACAGGAAAAATGCCCCCTTCTGCTTCTCTTTTTTTGGAGACAGAGTCTTGCTGTG	1680
Db	1621	AGACAGGAAAAATGCCCCCTTCTGCTTCTCTTTTTTTGGAGACAGAGTCTTGCTGTG	1680
QY	1681	TTGCCAGGCTGAGTGCAGTAGACAGATCTCGGCTCTCAACGCAACCTCCGCTCCTGG	1740
Db	1681	TTGCCAGGCTGAGTGCAGTAGACAGATCTCGGCTCTCAACGCAACCTCCGCTCCTGG	1740
QY	1741	GTTCAAGCGATTCTCCTGCTCAGCCTCCTAAGTATCTGGGATTAACAGGCATGTGCCAC	1800
Db	1741	GTTCAAGCGATTCTCCTGCTCAGCCTCCTAAGTATCTGGGATTAACAGGCATGTGCCAC	1800
QY	1801	ACACCTGGGTGATTTTGTATTTTATAGTAGAGACGGGGTTTCAACATGTTGTCAAGGCTG	1860
Db	1801	ACACCTGGGTGATTTTGTATTTTATAGTAGAGACGGGGTTTCAACATGTTGTCAAGGCTG	1860
QY	1861	GTCTCAAACCTCTGACCTTAGTATCCAACCTCCTCGGCTCTCCCAAAGTGTGGGATTACA	1920
Db	1861	GTCTCAAACCTCTGACCTTAGTATCCAACCTCCTCGGCTCTCCCAAAGTGTGGGATTACA	1920
QY	1921	GGCATGAGCCACCAAGCTGGCCCCCTTCTGTTTATGTGTGTTTTTGAAGAAATGA	1980

Db	1921	GGCATGAGCCACACAGCTGGCCCCCTCTGTTTATGTTTGGTTTGAAGAAGAAATGA	1980
QY	1981	AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCCTAAATATATAGCTAAAAACAA	2040
Db	1981	AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCCTAAATATATAGCTAAAAACAA	2040
QY	2041	AGCTCTATGTAAAGTAATAAAGTATATATGCCATATAAATTTCAAAATTCACCTGGCTTT	2100
Db	2041	AGCTCTATGTAAAGTAATAAAGTATATATGCCATATAAATTTCAAAATTCACCTGGCTTT	2100
QY	2101	TATGCAAGAAGAACAGGTTAGGACATCTAGGTTCCAATTCATTACATTCCTGGTTCAGA	2160
Db	2101	TATGCAAGAAGAACAGGTTAGGACATCTAGGTTCCAATTCATTACATTCCTGGTTCAGA	2160
QY	2161	TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTCTTTTAATGGAATTCCT	2220
Db	2161	TAAATCAACTGTTTATATCAATTTCTAATGGAATTTGCTTTCTTTTAATGGAATTCCT	2220
QY	2221	TTAAAACTTATTCAGATGTAGTTCCTTCCAATTAATATATTGAATAAATCTTTGTTCAC	2280
Db	2221	TTAAAACTTATTCAGATGTAGTTCCTTCCAATTAATATATTGAATAAATCTTTGTTCAC	2280
QY	2281	TCAA 2284	
Db	2281	TCAA 2284	

RESULT	4
LOCUS	BD140585
DEFINITION	BD140585
ACCESSION	Polypeptides and nucleic acids encoding the same.
VERSION	BD140585
KEYWORDS	GI:23235530
SOURCE	JF 2002505850-A/68.
ORGANISM	Homo sapiens (human)
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo. wood,W.I., Goddard,A., Gurney,A.L., Yuan,J., Baker,K.P. and Zheng,J. Poly peptides and nucletic acids encoding the same Patent: JP 2002505850-A 68 26-FEB-2002;
TITLE	POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
AUTHORS	GENENTECH INC
COMMENT	OS Homo sapiens (human) PN JP 2002505850-A/68 PD 26-FEB-2002 PF 01-DEC-1997 JP 2000523338 PR 03-DEC-1997 US 60/067411,11-DEC-1997 US 60/069334 PR 11-DEC-1997 US 60/069335,11-DEC-1997 US 60/069278 PR 12-DEC-1997 US 60/069425,16-DEC-1997 US 60/069696 PR 16-DEC-1997 US 60/069694,16-DEC-1997 US 60/069702 PR 17-DEC-1997 US 60/069870,17-DEC-1997 US 60/069873 PR 18-DEC-1997 US 60/068017,05-JAN-1998 US 60/070440 PR 09-FEB-1998 US 60/074086,09-FEB-1998 US 60/074092 PR 25-FEB-1998 US 60/075945
PI WILLIAM I WOOD,AUDREY GODDARD,AUSTIN L GURNEY,JEAN YUAN,KEVIN P BAKER,	
PI JIAN ZHENG	
PC C12N15/09,C07K14/47,C07K16/18,C12N1/19,C12N1/21,C12N5/10, PC	
C12P21/02,	
CC C12P21/08,C12Q1/68,C12N15/00,C12N5/00	
Key Poly peptides and nucletic acids encoding the same FH Key	
Location/Qualifiers	
FT source 1..2284	
location/Qualifiers	
organism='Homo sapiens (human)'	
. .	
source	
1..2284	
/organism="Homo sapiens"	
/mol_type="genomic DNA"	
/db_xref="taxon:9606"	



Query Match	100.0%	Score 2284;	DB 6;	Length 2284;
Best Local Similarity	100.0%	Pred. No. 0;		
Matches 2284; Conservative	0;	Mismatches	0;	Indels 0; Gaps 0;

QY	1	GGGGAGCATCCGCTGCGGTCTCTGCGCAGAACCCCGCGCGGATTGCGCGGTCTTCCCGC	60
Db	1	GGGAGCATCCGCTGCGGTCTCTGCGCAGAACCCCGCGCGGATTGCGCGGTCTTCCCGC	60
QY	61	GGGCGGCACAGAGCTGTCTCTGCACTTGATGGACAGGGGGCGCGGGGTCTCTGAC	120
Db	61	GGGCGGCACAGAGCTGTCTCTGCACTTGATGGACAGGGGGCGCGGGGTCTCTGAC	120
QY	121	GCCAGAGAAATCTCATCTGTGAGCCTTCTTAAAGCAAACTAAGACCAAGGAG	180
Db	121	GCCAGAGAAATCTCATCTGTGAGCCTTCTTAAAGCAAACTAAGACCAAGGAG	180
QY	181	GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA	240
Db	181	GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA	240
QY	241	GAAGGAGCTTGACTTACACTTTGGTAATTTGCTTCTGACACTAAGGCTGTGCT	300
Db	241	GAAGGAGCTTGACTTACACTTTGGTAATTTGCTTCTGACACTAAGGCTGTGCT	300
QY	301	AGTCAGATTGCTTCAAAAAGAGTCTGAAGATGTTGTCAATTGACATCCAGTCACTCTT	360
Db	301	AGTCAGATTGCTTCAAAAAGAGTCTGAAGATGTTGTCAATTGACATCCAGTCACTCTT	360
QY	361	TCTAAGGGAATCAGAGCAATGAGCCCGTATATATTCAACTCAAGAGACTGCTTAAT	420
Db	361	TCTAAGGGAATCAGAGCAATGAGCCCGTATATATTCAACTCAAGAGACTGCTTAAT	420
QY	421	TCTTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACCTTGATGATCTTGAC	480
Db	421	TCTTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACCTTGATGATCTTGAC	480
QY	481	ACTGAAAAACAGCTAGACAACCCTGCTACTAATTTTCTGTGCCCAAGGAAAGCC	540
Db	481	ACTGAAAAACAGCTAGACAACCCTGCTACTAATTTTCTGTGCCCAAGGAAAGCC	540
QY	541	TGTCATTGAAAACAGCAAAAGACTTATGAGTTACAGATAATTACAGATTTTCCATCT	600
Db	541	TGTCATTGAAAACAGCAAAAGACTTATGAGTTACAGATAATTACAGATTTTCCATCT	600
QY	601	TTGACCAAGAAATTTGCCAAGCCCAAGAGTTACCCCAGAGAGATTCTCTTACATGSCCA	660
Db	601	TTGACCAAGAAATTTGCCAAGCCCAAGAGTTACCCCAGAGAGATTCTCTTACATGSCCA	660
QY	661	TTTTACAAAGCAGTCACTCCCCCTAGCCCATCATCACACAGATTATTCAAAGCCCAACGAT	720
Db	661	TTTTACAAAGCAGTCACTCCCCCTAGCCCATCATCACACAGATTATTCAAAGCCCAACGAT	720
QY	721	ATCTCATGGAGAGACACTTCTCAGAAAGTTGGATTCCTCAGATCACCTGAGAACTA	780
Db	721	ATCTCATGGAGAGACACTTCTCAGAAAGTTGGATTCCTCAGATCACCTGAGAACTA	780
QY	781	TTTAAGATGATGAAGCAAGTGCACAGCTCCTTGCTTAATGAAGAAAAAGCCATTCTCAG	840
Db	781	TTTAAGATGATGAAGCAAGTGCACAGCTCCTTGCTTAATGAAGAAAAAGCCATTCTCAG	840
QY	841	AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG	900
Db	841	AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG	900
QY	901	CTCCAGCTACGCTGGCAGTTGCTTCTCCACATACACCTCGGCTACTCCAAAGCCGCG	960
Db	901	CTCCAGCTACGCTGGCAGTTGCTTCTCCACATACACCTCGGCTACTCCAAAGCCGCG	960
QY	961	ACCCTTCTACCAACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC	1020
Db	961	ACCCTTCTACCAACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC	1020

Qy	1021	ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGCAACCTCATTTCTACA	1080
Db	1021	ACCAAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGCAACCTCATTTCTACA	1080
Qy	1081	GTTTTTACACGGGGCTGCGGCTACACTCCAAAGCAATGGCTACAAACAGCAGTTCGACTACC	1140
Db	1081	GTTTTTACACGGGGCTGCGGCTACACTCCAAAGCAATGGCTACAAACAGCAGTTCGACTACC	1140
Qy	1141	ACCTTTACGGCACCTACGAGCTCGAAAAGGAGCTTAGAAAACCATACCGTTTACAGAAATC	1200
Db	1141	ACCTTTACGGCACCTACGAGCTCGAAAAGGAGCTTAGAAAACCATACCGTTTACAGAAATC	1200
Qy	1201	TCCAATTAACTTTGAACACAGGGAATGTGTAAACCTACTGCACTTTCTATGTCAAAAT	1260
Db	1201	TCCAATTAACTTTGAACACAGGGAATGTGTAAACCTACTGCACTTTCTATGTCAAAAT	1260
Qy	1261	GTGAGTCTTCCACTATGAAATAAAACCTGCTTCCTGGGAAGGTAGGAGGCCAGTCCAGGC	1320
Db	1261	GTGAGTCTTCCACTATGAAATAAAACCTGCTTCCTGGGAAGGTAGGAGGCCAGTCCAGGC	1320
Qy	1321	AGTTCCTCCCAAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTTGMAAAATGGCTT	1380
Db	1321	AGTTCCTCCCAAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTTGMAAAATGGCTT	1380
Qy	1381	CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTCTGGTGATAGGCCCTCGTCTCTGGGT	1440
Db	1381	CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTCTGGTGATAGGCCCTCGTCTCTGGGT	1440
Qy	1441	AGAATCCTTTCGGAATCACCTCCGACAGAAAACGTTACTCAAGACTGAGTTATTTGATCAAT	1500
Db	1441	AGAATCCTTTCGGAATCACCTCCGACAGAAAACGTTACTCAAGACTGAGTTATTTGATCAAT	1500
Qy	1501	GGGATCTATGTGACATCTAAGGATGGAATCGGCTCTTAAATTCAATTAGTAAACAG	1560
Db	1501	GGGATCTATGTGACATCTAAGGATGGAATCGGCTCTTAAATTCAATTAGTAAACAG	1560
Qy	1561	AAGCCCAATGCCAATGAGTTTCTGCTGACTTGCTAGTCTTACAGAGAGTTGTATTTTGA	1620
Db	1561	AAGCCCAATGCCAATGAGTTTCTGCTGACTTGCTAGTCTTACAGAGAGTTGTATTTTGA	1620
Qy	1621	AGACAGAAAAATGCCCCCTTCTGCTTTCCTTTTTTTGGAGACAGAGTCTTGCTCTG	1680
Db	1621	AGACAGAAAAATGCCCCCTTCTGCTTTCCTTTTTTTGGAGACAGAGTCTTGCTCTG	1680
Qy	1681	TTGCCAGGCTGAGTGACAGTACGATCTCGGCTCTACCGCAACCTCCGTCCTCTGG	1740
Db	1681	TTGCCAGGCTGAGTGACAGTACGATCTCGGCTCTACCGCAACCTCCGTCCTCTGG	1740
Qy	1741	GTTCAAGCGAATTCTCGCTGACCTCTCCTAAGTATCTGGATTACAGGCAATGTCCACC	1800
Db	1741	GTTCAAGCGAATTCTCGCTGACCTCTCCTAAGTATCTGGATTACAGGCAATGTCCACC	1800
Qy	1801	ACACCTGGGTATTTTGTATTTTATAGTAGAGCGGGTTTCACCATGTTGGTCAAGGCTG	1860
Db	1801	ACACCTGGGTATTTTGTATTTTATAGTAGAGCGGGTTTCACCATGTTGGTCAAGGCTG	1860
Qy	1861	GTTCAAACTCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTGTGGGATTACA	1920
Db	1861	GTTCAAACTCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTGTGGGATTACA	1920
Qy	1921	GGCATGAGCCACCAAGCTGGCCCCCTCTGTGTTTATGTTGGTTTGGTGGAGGAATGA	1980
Db	1921	GGCATGAGCCACCAAGCTGGCCCCCTCTGTGTTTATGTTGGTTTGGTGGAGGAATGA	1980
Qy	1981	AGTGGAAACCAATTAGTAAATTTGGGTAATCTGTCTCTAAAATATTAGCTAAAAACAA	2040
Db	1981	AGTGGAAACCAATTAGTAAATTTGGGTAATCTGTCTCTAAAATATTAGCTAAAAACAA	2040
Qy	2041	AGCTCTATGTAAAGTAAATAAGTAAATTTGCCATATAAATTTCAAAATTTCACTGGCTTT	2100
Db	2041	AGCTCTATGTAAAGTAAATAAGTAAATTTGCCATATAAATTTCAAAATTTCACTGGCTTT	2100
Qy	2101	TATGCAAGAAACAGGTTAGGACATCTAGGTTCCAAATTCAATTCACATTCCTTGSTTCCAGA	2160

|||||  
Db 2101 TATGCAAGAAACAGGTAGACATCTAGGTTCCAATTCATTCACATCTGTGTTCCAGA 2160  
Qy 2161 TAAATCAACTGTTATATCAATTTCTATGATTTGCTTTCTTTTATATGATTCCT 2220  
Db 2161 TAAATCAACTGTTATATCAATTTCTATGATTTGCTTTCTTTTATATGATTCCT 2220  
Qy 2221 TTAATACTTATTCAGATGTAGTTCCTTCCAATTAATATTTGAATTAATCTTTGTTAC 2280  
Db 2221 TTAATACTTATTCAGATGTAGTTCCTTCCAATTAATATTTGAATTAATCTTTGTTAC 2280  
Qy 2281 TCAA 2284  
Db 2281 TCAA 2284

RESULT 5  
AY358563  
LOCUS AY358563 2284 bp mRNA linear PRI 03-OCT-2003  
DEFINITION Homo sapiens clone DNA45410 FFGG316 (UNQ316) mRNA, complete cds.  
ACCESSION AY358563  
VERSION AY358563.1 GI:37182247  
KEYWORDS FLI CDNA.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 2284)  
AUTHORS Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,  
Chen,J., Chow,B., Chui,C., Crowell,B., Deuel,B.,  
Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,  
Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,  
Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C.,  
Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,  
Stinson,J., Vagts,A., Vandlen,R., Watanabe,C., Wieand,D., Woods,K.,  
Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,  
Goddard,A., Wood,W.I. and Godowski,P.  
The Secreted Protein Discovery Initiative (SPDI), a Large-Scale  
Effort to Identify Novel Human Secreted and Transmembrane Proteins:  
A Bioinformatics Assessment  
Genome Res. 13 (10), 2265-2270 (2003)  
PUBMED 12975309  
REFERENCE 2 (bases 1 to 2284)  
AUTHORS Clark,H.F.  
TITLE Direct Submission  
JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,  
Inc., 1 DNA Way, South San Francisco, CA 94080, USA

FEATURES  
Source  
1. 2284  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="DNA45410"  
1. 2284  
/locus\_tag="UNQ316"  
226. 1521  
/locus\_tag="UNQ316"  
/note="PRO361"  
/codon\_start=1  
/product="FFGG316"  
/protein\_id="AAQ86926.1"  
/db\_xref="GI:37182248"  
/translation="MFEGESLTYTLVIFCLTLRLSASQNLKSLSDVVIDIOSS  
LSKIRGNEPVYTSIOEDCINSCSTKNISGKACNLMIFDTRKTARQPNCYLFECPN  
EACPLKPAKGLMSYRITDFPSLTRNLPSQELPQEDSLHGQFSQAVTPLAHHTDY  
SKPTDISWRDTLSQKFSQHLLEKLPKDEASAOQLAYKXGHSQSOSQSDQETIAHL  
LPENVSALPATVAASPHTSATPKPATLLPTNASVPSGTSQOLATTAAPVTYVS  
QPTTLISTVTRAAATLQMAATTAVALTTTFOAPTDKSLSTETIPTETISNLTNTGN  
VYNPTALMSNVESSTMNKTASWEGREASPGSSQGSVPENQYGLPFKWLILGSLIF  
GVLFVLVIGLVLRILSESLRRKRYSLDYLINGIYDI"

ORIGIN  
Query Match 100.0%; Score 2284; DB 9; Length 2284;

Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 GCGGAGCATCCGTCGGTCCTCGCCGAGACCCCGCGGATTCGCGGTCCTCCGC 60  
Db 1 GCGGAGCATCCGTCGGTCCTCGCCGAGACCCCGCGGATTCGCGGTCCTCCGC 60  
Qy 61 GGGCGGACAGAGCTGTCTCGCACTGATGGCAGAGGGGGCGGGTCTCTGCAC 120  
Db 61 GGGCGGACAGAGCTGTCTCGCACTGATGGCAGAGGGGGCGGGTCTCTGCAC 120  
Qy 121 GCCAGAGAGAAATCTCATCTGTGTGACAGCCTTTAAAGCAAACTTAAGACCAGGGAG 180  
Db 121 GCCAGAGAGAAATCTCATCTGTGTGACAGCCTTTAAAGCAAACTTAAGACCAGGGAG 180  
Qy 181 GAATATCCTTGACCTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA 240  
Db 181 GAATATCCTTGACCTTGAAGACCAAACTAACTGAATTTAAATGTTCTTGGGGGA 240  
Qy 241 GAAGGAGCTTGACTTACCTTTGGTATATATTTGCTTCTGACACTAAGGCTGTGCT 300  
Db 241 GAAGGAGCTTGACTTACCTTTGGTATATATTTGCTTCTGACACTAAGGCTGTGCT 300  
Qy 301 AGTCAGAAATTCCTCAAAAAGAGCTAGAAAGATGTTCATTTGACATCCAGTCATCTT 360  
Db 301 AGTCAGAAATTCCTCAAAAAGAGCTAGAAAGATGTTCATTTGACATCCAGTCATCTT 360  
Qy 361 TCTAAGGGAATCAGAGGCAATGAGCCGTATATATCTCAACTCAAGAAAGCTGATTAAT 420  
Db 361 TCTAAGGGAATCAGAGGCAATGAGCCGTATATATCTCAACTCAAGAAAGCTGATTAAT 420  
Qy 421 TCTTCTGTTCACAAAAACATATCAGGGGCAAAAGATGTAATCTGATGATCTTGAC 480  
Db 421 TCTTCTGTTCACAAAAACATATCAGGGGCAAAAGATGTAATCTGATGATCTTGAC 480  
Qy 481 ACTCGAAAAACAGCTAGACAACTGCTACCTATTTTCTGTCCCAAGAGAAAGCC 540  
Db 481 ACTCGAAAAACAGCTAGACAACTGCTACCTATTTTCTGTCCCAAGAGAAAGCC 540  
Qy 541 TGTCATTTGAAACAGCAAAAGAGCTTATGAGTTACAGATTAATACAGATTTTCATCT 600  
Db 541 TGTCATTTGAAACAGCAAAAGAGCTTATGAGTTACAGATTAATACAGATTTTCATCT 600  
Qy 601 TTGACCAAGAAATTTGCCAAGCAAGATTACCCAGAGAAATTTCTCTTACATGGCCAA 660  
Db 601 TTGACCAAGAAATTTGCCAAGCAAGATTACCCAGAGAAATTTCTCTTACATGGCCAA 660  
Qy 661 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAGCCCAACCAT 720  
Db 661 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAGCCCAACCAT 720  
Qy 721 ATTCATGAGAGACACACTTCTCAGAAGTTGGATCTCAGATCCAGTGAAGAACTA 780  
Db 721 ATTCATGAGAGACACACTTCTCAGAAGTTGGATCTCAGATCCAGTGAAGAACTA 780  
Qy 781 TTTAAGATGATGAAGCAAGTCCCAAGCTCTTGCTTATTAAGAAAAAGGCCATTCTCAG 840  
Db 781 TTTAAGATGATGAAGCAAGTCCCAAGCTCTTGCTTATTAAGAAAAAGGCCATTCTCAG 840  
Qy 841 AGTTCACAAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAAATGTGAGTGC 900  
Db 841 AGTTCACAAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAAATGTGAGTGC 900  
Qy 901 CTCCAGCTACGGTGGCAGTGTCTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
Db 901 CTCCAGCTACGGTGGCAGTGTCTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
Qy 961 ACCCTTCAACCAACCAATGCTTCACTGACACCTTCTGGGACTTCCAGCCACAGCTG 960  
Db 961 ACCCTTCAACCAACCAATGCTTCACTGACACCTTCTGGGACTTCCAGCCACAGCTG 960  
Qy 1021 ACCAGAGCTCCACCTGTAAACAGCTGTCACTTCTAGCCTCCAGACCACTCATTT 1021  
Db 1021 ACCAGAGCTCCACCTGTAAACAGCTGTCACTTCTAGCCTCCAGACCACTCATTT 1021

Db 1021 ACCACAGCTCCACTGTATAACCACTGTACTTCTCAGCCTCCACGACGACCCCTCATTTCTACA 1080  
QY 1081 GTTTTACACGGGCTGCGGCTACACTCCAGCAATGGCTACACAGCAGTTCCTACTACC 1140  
Db 1081 GTTTTACACGGGCTGCGGCTACACTCCAGCAATGGCTACACAGCAGTTCCTACTACC 1140  
QY 1141 ACCTTTCAGGCACTACGGACTCGAAAGGCACTTAGAAACCATACCGTTTACAGAAATC 1200  
Db 1141 ACCTTTCAGGCACTACGGACTCGAAAGGCACTTAGAAACCATACCGTTTACAGAAATC 1200  
QY 1201 TCCAACTTAATTGAAACACAGGGAATGTATTAACCCCTACTGCACCTTCTATGTCAAT 1260  
Db 1201 TCCAACTTAATTGAAACACAGGGAATGTATTAACCCCTACTGCACCTTCTATGTCAAT 1260  
QY 1261 GTGAGTCTTCCACTATGATATAAACTGCTCTGGGAGGTAGGAGGCCAGTCCAGGC 1320  
Db 1261 GTGAGTCTTCCACTATGATATAAACTGCTCTGGGAGGTAGGAGGCCAGTCCAGGC 1320  
QY 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
Db 1321 AGTTCCTCCAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTGAAAAATGGCTT 1380  
QY 1381 CTTATCGGGTCTGCTCTTTGGTGTCTGTTCTGTTCTGTTAGGCTGCTCTGCTGCTG 1440  
Db 1381 CTTATCGGGTCTGCTCTTTGGTGTCTGTTCTGTTCTGTTAGGCTGCTCTGCTGCTG 1440  
QY 1441 AGAATCCTTCGGAATCACTCCGAGGAAACCTTACTCAAGACTGATTTATGATCAAT 1500  
Db 1441 AGAATCCTTCGGAATCACTCCGAGGAAACCTTACTCAAGACTGATTTATGATCAAT 1500  
QY 1501 GGGATCTATGTGACATCTAAGGATGAACTCGGTGTCTCTTAATTCATTAGTAACCA 1560  
Db 1501 GGGATCTATGTGACATCTAAGGATGAACTCGGTGTCTCTTAATTCATTAGTAACCA 1560  
QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGCTTAGCAGAGGTGATTTTGA 1620  
Db 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTGCTTAGCAGAGGTGATTTTGA 1620  
QY 1621 AGACAGGAAATGCCCCCTTCTGCTTTCTTTTGGAGACAGAGTCTGCTGTG 1680  
Db 1621 AGACAGGAAATGCCCCCTTCTGCTTTCTTTTGGAGACAGAGTCTGCTGTG 1680  
QY 1681 TTGCCAGGCTGAGTGCAGTAGCAGCAGATCTCGGCTCTCACCGCACTCCCTCTCTG 1740  
Db 1681 TTGCCAGGCTGAGTGCAGTAGCAGCAGATCTCGGCTCTCACCGCACTCCCTCTCTG 1740  
QY 1741 GTTCAAGCGATTCTCTGCTCAGCCTCTAAGTATCTGGGATTACAGGCATGTGCCACC 1800  
Db 1741 GTTCAAGCGATTCTCTGCTCAGCCTCTAAGTATCTGGGATTACAGGCATGTGCCACC 1800  
QY 1801 ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTTGTCAGGCTG 1860  
Db 1801 ACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTCAACCATGTTGTCAGGCTG 1860  
QY 1861 GTCTCAAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAAGTGTGGATTACA 1920  
Db 1861 GTCTCAAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAAGTGTGGATTACA 1920  
QY 1921 GGCAATGAGCCACCAAGCTGGCCCCCTTCTGTTTATGTTGGTTTGAAGGAATGA 1980  
Db 1921 GGCAATGAGCCACCAAGCTGGCCCCCTTCTGTTTATGTTGGTTTGAAGGAATGA 1980  
QY 1981 AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTAAATATATAGCTAAAAACAA 2040  
Db 1981 AGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTAAATATATAGCTAAAAACAA 2040  
QY 2041 AGCTCTATGTAAGTAATAAGTATATATGTCATATAATTTCAAAATCAACTGGCTTT 2100  
Db 2041 AGCTCTATGTAAGTAATAAGTATATATGTCATATAATTTCAAAATCAACTGGCTTT 2100  
QY 2101 TATGCAAGAAACAGGTTAGGACATCTAGTTCGAATTCATTCAATCTTGTGTTCCAGA 2160  
Db 2101 TATGCAAGAAACAGGTTAGGACATCTAGTTCGAATTCATTCAATCTTGTGTTCCAGA 2160

QY 2161 TAAATCACTGTTTATATCAATTTCTAATGATTTGCTT 1080  
Db 2161 TAAATCACTGTTTATATCAATTTCTAATGATTTGCTT 1080  
QY 2221 TTAACCTTATTCAGATGATGTTCTTCAATTAA 1020  
Db 2221 TTAACCTTATTCAGATGATGTTCTTCAATTAAATATTT 1020  
QY 2281 TCAA 2284 960  
Db 2281 TCAA 2284  
RESULT 6  
AX883044  
LOCUS AX883044 2297 bp DNA linear PAT 17-DEC-2003  
DEFINITION Sequence 17949 from Patent EP1074617.  
ACCESSION AX883044  
VERSION AX883044.1 GI:40037945  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
AUTHORS Ota, T., Isogai, T., Nishikawa, T., Hayashi, K., Saito, K., Yamamoto, J.,  
Ishii, S., Sugiyama, T., Wakematsu, A., Nagai, K., and Otsuki, T.  
TITLE Primers for synthesizing full-length cDNA and their use  
JOURNAL Patent: EP 1074617-A 17949 07-FEB-2001;  
Research Association for Biotechnology (JRP)  
FEATURES  
source location/Qualifiers  
1..2297  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
259..1554  
/note="unassigned protein product"  
/codon\_start=1  
/protein\_id="CAE91819.1"  
/db\_xref="GI:40037946"  
CDS  
1 GCGGAGCATCCGCTGCGGTCTCGCGGAGACCCCGCGGATTCGCGGCTTCCCGC 60  
Db 34 GCGGAGCATCCGCTGCGGTCTCGCGGAGACCCCGCGGATTCGCGGCTTCCCGC 93  
QY 61 GGGCGGACAGAGCTGTCTCGCACTGATGAGCAGAGGGCGCGGGTCTCTCGAC 120  
Db 94 GGGCGGACAGAGCTGTCTCGCACTGATGAGCAGAGGGCGCGGGTCTCTCGAC 153  
QY 121 GCCAGAGAAATCTCATCATCTGCGACGCTTCTTAAAGCAACTAAGACGAGAGGAG 180  
Db 154 GCCAGAGAAATCTCATCATCTGCGACGCTTCTTAAAGCAACTAAGACGAGAGGAG 213  
QY 181 GATTATCTTGAACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
Db 214 GATTATCTTGAACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 273  
QY 241 GAAGGAGCTTGACTTACACTTTGGTATTAATTTGCTTCTCGACACTAAGGCTGTCTGCT 300



Db 274 GAAGGAGCTTGACTTACACTTTGGTAATTAATTGGCTTCCGTGACACTAAGGCTGTCTGCT 333  
Qy 301 AGTCGAATTTGCCCTCAAAAAGAGTCTAGAAGATGTTGTTCATTGACATCCAGTCATCTCTT 360  
Db 334 AGTCGAATTTGCCCTCAAAAAGAGTCTAGAAGATGTTGTTCATTGACATCCAGTCATCTCTT 393  
Qy 361 TCTAAGGAATCAGAGGCAATGAGCCGTATATATTACTTCAACTCAAGAAAGACTGCATTAAT 420  
Db 394 TCTAAGGAATCAGAGGCAATGAGCCGTATATATTACTTCAACTCAAGAAAGACTGCATTAAT 453  
Qy 421 TCTTGTGTTCACAACAAAAACATATCAGGGGACAAGCATGTAACTTGATGATCTTGAC 480  
Db 454 TCTTGTGTTCACAACAAAAACATATCAGGGGACAAGCATGTAACTTGATGATCTTGAC 513  
Qy 481 ACTGAAAAACAGCTAGACACACCACTGCTACTATTTTCTGTCCCAAGAGAGCC 540  
Db 514 ACTGAAAAACAGCTAGACACCACTGCTACTATTTTCTGTCCCAAGAGAGCC 573  
Qy 541 TGTTCATTGAAAACAGCAAAAAGACTTATGAGTTACAGGATTAATTAAGATTTCCATCT 600  
Db 574 TGTTCATTGAAAACAGCAAAAAGACTTATGAGTTACAGGATTAATTAAGATTTCCATCT 633  
Qy 601 TTGACCAAAATTTGCCAAGCCAAAGTTACCCAGAAAGATTCTCTTACATGGCCAA 660  
Db 634 TTGACCAAAATTTGCCAAGCCAAAGTTACCCAGAAAGATTCTCTTACATGGCCAA 693  
Qy 661 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACAGATTAATCAAAAGCCACCGAT 720  
Db 694 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACAGATTAATCAAAAGCCACCGAT 753  
Qy 721 ATCTCATGAGAGACACACTTTCTCAGAAATTGGATCCTCAGATCACTGGAGAACTA 780  
Db 754 ATCTCATGAGAGACACACTTTCTCAGAAATTGGATCCTCAGATCACTGGAGAACTA 813  
Qy 781 TTTTAAGATGATGAAGCAAGTGCCCAAGTCTTGCTTATTAAGAAAAAGGCCATTCTCAG 840  
Db 814 TTTTAAGATGATGAAGCAAGTGCCCAAGTCTTGCTTATTAAGAAAAAGGCCATTCTCAG 873  
Qy 841 AGTTCACAATTTTCTCTGTATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG 900  
Db 874 AGTTCACAATTTTCTCTGTATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG 933  
Qy 901 CTCCCAAGTACGGTGGCAGTTGCTTCTCACAATACCACTCGGCTACTCCAAAGCCGCC 960  
Db 934 CTCCCAAGTACGGTGGCAGTTGCTTCTCACAATACCACTCGGCTACTCCAAAGCCGCC 993  
Qy 961 ACCCTTCAACCAACCAATGCTTCAGTGACACTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
Db 994 ACCCTTCAACCAACCAATGCTTCAGTGACACTTCTGGGACTTCCAGCCACAGCTGGCC 1053  
Qy 1021 ACCACAGTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCTCATTTCTACA 1080  
Db 1054 ACCACAGTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCTCATTTCTACA 1113  
Qy 1081 GTTTTACAGGGGCTGCGGCTACACTCCAAAGCAATGGCTACAACAGAGTCTGACTACC 1140  
Db 1114 GTTTTACAGGGGCTGCGGCTACACTCCAAAGCAATGGCTACAACAGAGTCTGACTACC 1173  
Qy 1141 ACCTTTCAGGCACTACGGACTCGAAAGGAGCTTAGAAACCATACGTTTACAGAAATC 1200  
Db 1174 ACCTTTCAGGCACTACGGACTCGAAAGGAGCTTAGAAACCATACGTTTACAGAAATC 1233  
Qy 1201 TCCAACTTAATTTGAACACAGGGAATGTATTAACCTACTGCACTTTCTATGTCAAT 1260  
Db 1234 TCCAACTTAATTTGAACACAGGGAATGTATTAACCTACTGCACTTTCTATGTCAAT 1293  
Qy 1261 GTGAGTCTTCCACTATGATATAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGC 1320  
Db 1294 GTGAGTCTTCCACTATGATATAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGC 1353  
Qy 1321 AGTTCTTCCAGGGCAGTGTTCAGAAATCAATAAGGCTTCCATTGAAAAATGGCTT 1380  
Db 1354 AGTTCTTCCAGGGCAGTGTTCAGAAATCAATAAGGCTTCCATTGAAAAATGGCTT 1413

Qy 1381 CTTATCGGGTCCCTGCTCTTGGTGTCTGTTCCCTGGTATAGGCTCGTCCCTGGGT 1440  
Db 1414 CTTATCGGGTCCCTGCTCTTGGTGTCTGTTCCCTGGTATAGGCTCGTCCCTGGGT 1473  
Qy 1441 AGAATCCTTTCGGATCCTCCGAGGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
Db 1474 AGAATCCTTTCGGATCCTCCGAGGAAACGTTACTCAAGACTGGATTATTGATCAAT 1533  
Qy 1501 GGGATCTATGTGACATCTAAGATGGAACCTGGTGTCTTAATTCATTAGTAACCAAG 1560  
Db 1534 GGGATCTATGTGACATCTAAGATGGAACCTGGTGTCTTAATTCATTAGTAACCAAG 1593  
Qy 1561 AAGCCAAATGCAATGAGTTTCTGCTGACTTGTAGTCTTACAGAGGTTGTATTGGA 1620  
Db 1594 AAGCCAAATGCAATGAGTTTCTGCTGACTTGTAGTCTTACAGAGGTTGTATTGGA 1653  
Qy 1621 AGACAGAAAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTTGGAGACAGAGTCTTGTCT 1679  
Db 1654 AGACAGAAAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTTGGAGACAGAGTCTTGTCT 1713  
Qy 1680 GTTGCCAGGCTGAGTGCATGACACGATCTCGGCTTCACCGCAACCTCCGTCTCTG 1739  
Db 1714 GTTGCCAGGCTGAGTGCATGACACGATCTCGGCTTCACCGCAACCTCCGTCTCTG 1773  
Qy 1740 GGTTCAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGCAATGTCCAC 1799  
Db 1774 GGTTCAGCGATTCTCTGCTCAGCCTCCTAAGTATCTGGGATTACAGGCAATGTCCAC 1833  
Qy 1800 CACACCTGGGTGATTTTGTATTTTATAGAGACAGGGGTTTCAACATGTTGTAGGCT 1859  
Db 1834 CACACCTGGGTGATTTTGTATTTTATAGAGACAGGGGTTTCAACATGTTGTAGGCT 1893  
Qy 1860 GGTTCAAAATCTCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTGTGGATTAC 1919  
Db 1894 GGTTCAAAATCTCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTGTGGATTAC 1953  
Qy 1920 AGGCATGAGCCACCAACAGCTGGCCCCCTTCTGTTTATGTTGGTTTTTGAGAAGGATG 1979  
Db 1954 AGGCATGAGCCACCAACAGCTGGCCCCCTTCTGTTTATGTTGGTTTTTGAGAAGGATG 2013  
Qy 1980 AAGTGGAAACCAATTAGGTAATTTGGGTAATCTGTCTTAATAATATTAGCTAAACA 2039  
Db 2014 AAGTGGAAACCAATTAGGTAATTTGGGTAATCTGTCTTAATAATATTAGCTAAACA 2073  
Qy 2040 AAGCTCTATGTAAAGTAATAAGTAATTTGCCATATAAATTTCAAAATTCAACTGGCTT 2099  
Db 2074 AAGCTCTATGTAAAGTAATAAGTAATTTGCCATATAAATTTCAAAATTCAACTGGCTT 2133  
Qy 2100 TTATGCAAGAAACAGGTTAGACATCTAGTTCCAATTCAATTCATCTGTGTCCAG 2159  
Db 2134 TTATGCAAGAAACAGGTTAGACATCTAGTTCCAATTCAATTCATCTGTGTCCAG 2193  
Qy 2160 ATAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATTC 2219  
Db 2194 ATAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATTC 2253  
Qy 2220 TTTAAACTTATTCCAGATGTAGTTCCTTCCAATTAAATATTG 2263  
Db 2254 TTTAAACTTATTCCAGATGTAGTTCCTTCCAATTAAATATTG 2297

RESULT 7  
BD160088 2297 bp DNA linear PAT 17-JAN-2003  
LOCUS BD160088  
DEFINITION Primer for synthesizing full-length cDNA and use thereof.  
ACCESSION BD160088  
VERSION BD160088.1 GI:27865846  
KEYWORDS JP 2002191363-A/14931.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 2297)  
AUTHORS Ota,T., Isegai,T., Nishikawa,T., Hayashi,K., Satto,K., Yamamoto,J.,  
Ishii,S., Sugiyama,T., Wakamatsu,A., Nagai,K. and Otsuki,T.  
TITLE Primer for synthesizing full-length cDNA and use thereof  
JOURNAL Patent: JP 2002191363-A 14931 09-JUL-2002;  
HELIX RESEARCH INSTITUTE  
COMMENT OS Homo sapiens (human)  
PN JP 2002191363-A/14931  
PD 09-JUL-2002  
PF 28-JUL-2000 JP 2000280990  
PI TOSHIO OTA,TAKAO ISOgai,TETSUO NISHIKAWA,KOJI HAYASHI,KAORU  
PI SAITO,  
PI JUNICHI YAMAMOTO,SHIZUKO ISHII,TOMOYASU SUGIYAMA,AI WAKAMATSU,  
PI KEIICHI NAGAI,TETSUJI OTSUKI  
PC C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC  
10', C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N5/00,C12N5/00 CC  
Primer for synthesizing full-length cDNA and use thereof FH Key  
FT CDS Location/Qualifiers  
source 1. 2297  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 98.3%; Score 2245.6; DB 6; Length 2297;  
Best Local Similarity 99.8%; Pred. No. 0;  
Matches 2259; Conservative 0; Mismatches 4; Indels 1; Gaps 1;  
QY 1 GCGGAGATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTCGCGGTCTTCCCGC 60  
Db 34 GCGGAGATCCGCTGCGGTCTCGCCGAGACCCCGCGGATTCGCGGTCTTCCCGC 93  
QY 61 GGGCGGACAGAGCTGTCTCGCACTTGATGGCAGCAGGGCGCGGGTCTCTCGAC 120  
Db 94 GGGCGGACAGAGCTGTCTCGCACTTGATGGCAGCAGGGCGCGGGTCTCTCGAC 153  
QY 121 GCCAGAGAGAAATCTCATCATCTGTGACGCTTTTAAAGCAACTAAGACAGAGGAG 180  
Db 154 GCCAGAGAGAAATCTCATCATCTGTGACGCTTTTAAAGCAACTAAGACAGAGGAG 213  
QY 181 GATTATCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTCGGGGA 240  
Db 214 GATTATCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTTCTCGGGGA 273  
QY 241 GAAGGAGCTGACTTACACTTTGTAATAATTGCTTCTGACACTAAGGCTGTGCT 300  
Db 274 GAAGGAGCTGACTTACACTTTGTAATAATTGCTTCTGACACTAAGGCTGTGCT 333  
QY 301 AGTCAGATTCCTCAAAAAGAGCTAGAGATGTTGTCAATGACATCAGTCATCTTT 360  
Db 334 AGTCAGATTCCTCAAAAAGAGCTAGAGATGTTGTCAATGACATCAGTCATCTTT 393  
QY 361 TCTAAGGGAATCAGAGGCAATGAGCCCGTATATACTTCAACTCAAGAGA CTGCATTAT 420  
Db 394 TCTAAGGGAATCAGAGGCAATGAGCCCGTATATACTTCAACTCAAGAGA CTGCATTAT 453  
QY 421 TCTTGCTGTTCAACAAAAACATATCAGGGGCAAAAGCATGTAAC TTGATGATCTTCGAC 480  
Db 454 TCTTGCTGTTCAACAAAAACATATCAGGGGCAAAAGCATGTAAC TTGATGATCTTCGAC 513  
QY 481 ACTGAAAAACAGCTAGACAACCCAACTGCTAATTTTCTGTC CCAAGAGAGCC 540  
Db 514 ACTGAAAAACAGCTAGACAACCCAACTGCTAATTTTCTGTC CCAAGAGAGCC 573  
QY 541 TGTCCATGTGAACAGCAAAAGGACTTATGAGTTACAGATAATTACAGATTTTCCATCT 600  
Db 574 TGTCCATGTGAACAGCAAAAGGACTTATGAGTTACAGATAATTACAGATTTTCCATCT 633  
QY 601 TTGACCAAGAAATTTGCCAAGCCAGAGATTACCCCAAGAGATTCTCTTACATGGCCAA 660

Db 634 TTGACCAAGAAATTTGCCAAGCCAGAGATTACCCCAAGAGATTCTCTTACATGGCCAA 693  
QY 661 TTTTCAGAGAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCCAAGCAT 720  
Db 694 TTTTCAGAGAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCCAAGCAT 753  
QY 721 ATCTCAGAGAGACACACTTTCTCAGAAAGTTTGATCTCAGATCACTGAGAAACTA 780  
Db 754 ATCTCAGAGAGACACACTTTCTCAGAAAGTTTGATCTCAGATCACTGAGAAACTA 813  
QY 781 TTTAAGATGATGAAGCAAGTCCCAAGCTCTGCTTATTAAGAAAGGCCATTCTCAG 840  
Db 814 TTTAAGATGATGAAGCAAGTCCCAAGCTCTGCTTATTAAGAAAGGCCATTCTCAG 873  
QY 841 AGTTCAGAAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG 900  
Db 874 AGTTCAGAAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGG 933  
QY 901 CTCCAGCTACGGGTGGAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
Db 934 CTCCAGCTACGGGTGGAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 993  
QY 961 ACCCTTCAACCAACCAATGCTTCAAGTACACCTTCTGGAGCTTCCAGCCACAGCTGGCC 1020  
Db 994 ACCCTTCAACCAACCAATGCTTCAAGTACACCTTCTGGAGCTTCCAGCCACAGCTGGCC 1053  
QY 1021 ACCAGCTCCACCTGTAAACCACTGTCACTTCTCAGCTCCCAAGCCCTCATTTCTACA 1080  
Db 1054 ACCAGCTCCACCTGTAAACCACTGTCACTTCTCAGCTCCCAAGCCCTCATTTCTACA 1113  
QY 1081 GTTTTACACGGGCTGCGGCTACCTCCAAGCAATGCTTCAACAGAGTTCTGACTACC 1140  
Db 1114 GTTTTACACGGGCTGCGGCTACCTCCAAGCAATGCTTCAACAGAGTTCTGACTACC 1173  
QY 1141 ACCTTTCAAGCACTTACGAGTCTGAAAGGCACTTGAAGCAATACCGTTTACAGAAATC 1200  
Db 1174 ACCTTTCAAGCACTTACGAGTCTGAAAGGCACTTGAAGCAATACCGTTTACAGAAATC 1233  
QY 1201 TCCAACCTTAACTTTGAACACAGGGAATGTGTATTAACCTTACCTGCACTTTCTATGTCAAAT 1260  
Db 1234 TCCAACCTTAACTTTGAACACAGGGAATGTGTATTAACCTTACCTGCACTTTCTATGTCAAAT 1293  
QY 1261 GTGAGCTTCCACTATGATTAATACTCTTCTGGGAAGTGGAGGCCAGTCCAGGC 1320  
Db 1294 GTGAGCTTCCACTATGATTAATACTCTTCTGGGAAGTGGAGGCCAGTCCAGGC 1353  
QY 1321 AGTTCCTCCAGGGCAGTGTTCAGAAATCAGTACGGCTTCCATTGAAAAATGCTT 1380  
Db 1354 AGTTCCTCCAGGGCAGTGTTCAGAAATCAGTACGGCTTCCATTGAAAAATGCTT 1413  
QY 1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTGCTGCTGATAGGCTCCTCCTGGGT 1440  
Db 1414 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTGCTGCTGATAGGCTCCTCCTGGGT 1473  
QY 1441 AGAATCTTTTGGGAATCACTCCGAGGAAACGTTACTCAAGACTGGAATTATTGATCAAT 1500  
Db 1474 AGAATCTTTTGGGAATCACTCCGAGGAAACGTTACTCAAGACTGGAATTATTGATCAAT 1533  
QY 1501 GGGATCTATGTGACATCTAAGATGAAACTCGGTGTCTCTTAATTCAATTAGTAACCAAG 1560  
Db 1534 GGGATCTATGTGACATCTAAGATGAAACTCGGTGTCTCTTAATTCAATTAGTAACCAAG 1593  
QY 1561 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAAGCAGAGGTTGATTTTGA 1620  
Db 1594 AAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAAGCAGAGGTTGATTTTGA 1653  
QY 1621 AGACAGAAATATGCCCCCTTCTGCTTCC-TTTT TTTTGGAGACAGAGTCTTGTCTCT 1679  
Db 1654 AGACAGAAATATGCCCCCTTCTGCTTCC-TTTT TTTTGGAGACAGAGTCTTGTCTCT 1713  
QY 1680 GTTGCCAGGCTGAGTGCAGTAGCAGATCTCGGCTTCTCAGCCGCACTCCGTTCTCTG 1739

Db	1714	GTTGCCCAAGGCTGGAGTGCAGTAGCAGATCTCGGCTCTCACCGCAACTCCGTCTCTG	1773
Qy	1740	GGTTCAAGCGATTTCTCCTGCTCAGCTCCTAAGTATCTGGGATTAACAGGCATGTGCCAC	1799
Db	1774	GGTTCAAGCGATTTCTCCTGCTCAGCTCCTAAGTATCTGGGATTAACAGGCATGTGCCAC	1833
Qy	1800	CACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTACCATGTTGGTCAGGCT	1859
Db	1834	CACACCTGGGTGATTTTGTATTTTGTAGAGACGGGGTTTACCATGTTGGTCAGGCT	1893
Qy	1860	GGTCTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTGTGGGATTAAC	1919
Db	1894	GGTCTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCCCAAAGTGTGGGATTAAC	1953
Qy	1920	AGGCATGAGCCACACACAGCTGGCCCTCTGTTTATGTTGGTTTTTGGAGAAGAATG	1979
Db	1954	AGGCATGAGCCACACACAGCTGGCCCTCTGTTTATGTTGGTTTTTGGAGAAGAATG	2013
Qy	1980	AAGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTCTAAATATTAGCTAAACA	2039
Db	2014	AAGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTCTAAATATTAGCTAAACA	2073
Qy	2040	AAGCTCTATGTAAAGTAATAAGTAATGTCATATAAATTCAAAATTCACCTGGCTT	2099
Db	2074	AAGCTCTATGTAAAGTAATAAGTAATGTCATATAAATTCAAAATTCACCTGGCTT	2133
Qy	2100	TTATGCAAAAGAAACAGGTAGACATCTAGTTCACATTCATTCATCTTGTTCAG	2159
Db	2134	TTATGCAAAAGAAACAGGTAGACATCTAGTTCACATTCATTCATCTTGTTCAG	2193
Qy	2160	ATAAATCAACTGTTATATCAATTTCTAATGATTTGCTTTCTTTATATGATTC	2219
Db	2194	ATAAATCAACTGTTATATCAATTTCTAATGATTTGCTTTCTTTATATGATTC	2253
Qy	2220	TTTAAAATTATTCAGATGTAGTTCCTTCCATTAATATTG	2263
Db	2254	TTTAAAATTATTCAGATGTAGTTCCTTCCATTAATATTG	2297

RESULT 8

AK023622 2297 bp mRNA linear PRI 01-AUG-2002  
LOCUS Homo sapiens cDNA FLJ13560 fis, clone PLACE1007877.  
DEFINITION AK023622  
ACCESSION AK023622  
VERSION AK023622.1 GI:10435603  
KEYWORDS oligo capping; fis (full insert sequence).  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE 1  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
Isogai,T., Ota,T., Hayashi,K., Sugiyama,T., Otsuki,T., Suzuki,Y.,  
Nishikawa,T., Nagai,K., Sugano,S., Shiratori,A., Sudo,H.,  
Wagatsuma,M., Hosoi,T., Kaku,Y., Kodaira,H., Kondo,H.,  
Sugawara,M., Takahashi,M., Chiba,Y., Ishida,S., Murakawa,K.,  
Ono,Y., Takiguchi,S., Watanabe,S., Kimura,K., Murakami,K.,  
Ishii,S., Kawai,Y., Saito,K., Yamamoto,J., Wakamatsu,A.,  
Nakamura,Y., Nagahari,K., Masuho,Y., Ninomiya,K. and Iwayanagi,T.  
NEDO human cDNA sequencing project

TITLE Unpublished  
JOURNAL 2 (bases 1 to 2297)  
REFERENCE 1  
AUTHORS Isogai,T. and Otsuki,T.  
TITLE Direct Submission  
JOURNAL Submitted (23-AUG-2000) Takao Isogai, Helix Research Institute,  
Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan  
(E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)  
NEDO human cDNA sequencing project supported by Ministry of  
International Trade and Industry of Japan; cDNA full insert  
sequencing: Research Association for Biotechnology; cDNA library  
construction, 5'- & 3'-end one pass sequencing and clone selection:  
Helix Research Institute (supported by Japan Key Technology Center  
etc.) and Department of Virology, Institute of Medical Science,  
University of Tokyo.

FEATURES		Location/Qualifiers
Source		1..2297
		/organism="Homo sapiens"
		/mol_type="mRNA"
		/db_xref="taxon:9606"
		/clone="PLACE1007877"
		/issue_type="placenta"
		/clone_lib="PLACE1"
		/note="cloning vector: pME18SFL3"
		259..1554
CDS		/note="unnamed protein product"
		/codon_start=1
		/protein_id="BAB14621.1"
		/db_xref="GI:10435604"
		/translation="MEFGEGSLTYTLVVICFLRLISASONCLKSLIEDVVDIOSS LSKGRNEPVYTSQEDICNSCSTKNI SGRACNLMI FDRKTARQPNCYLPCBN EACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHGQFSQAVTPLAHHTDY SKPTDISWRDLSQKFGSSDHLKLFKMDIASOQLAYKEKSHSQSSQFSSDQIAHL LPENVSALPATVAVASPHITTSATPKPATLPTNVA SVTPSGTSQPOLATTAPPTVTS QPPTLISVFTFRAATLQAMATTAVLTTFQAPPTDSKSLFTI PFTBISNLTINTGN VYNPTALSMNSVESSTMNKTASWEGREASPGSSQGSVPENQYGLPFEKMLIGSLIF GVLFVIGLVILGRILISESLRKRYSRLDYLINGIYVDI"

ORIGIN

Query Match 98.3%; Score 2245.6; DB 9; Length 2297;  
Best Local Similarity 99.8%; Pred. No. 0;  
Matches 2259; Conservative 0; Mismatches 4; Indels 1; Gaps 1;

Qy	1	GGGAGCATCCCGCTGCGGTCTCGCCGAGACCCCGCGCGGATTCGCGGCTTCCCGC	60
Db	34	GGGAGCATCCCGCTGCGGTCTCGCCGAGACCCCGCGCGGATTCGCGGCTTCCCGC	93
Qy	61	GGGCGGACAGAGCTGTCTCGACCTGGATGGCAGCAGGCGCGGGTCTCTCGAC	120
Db	94	GGGCGGACAGAGCTGTCTCGACCTGGATGGCAGCAGGCGCGGGTCTCTCGAC	153
Qy	121	GCCAGAGAAATCTCATCTGTGTGACAGCTTCTTAAAGAACTAAGACAGAGGAG	180
Db	154	GCCAGAGAAATCTCATCTGTGTGACAGCTTCTTAAAGAACTAAGACAGAGGAG	213
Qy	181	GATTATCTTGACCTTGAAGACCAAACTAAACTGAAATTTAAATGTTCTTGGGGG	240
Db	214	GATTATCTTGACCTTGAAGACCAAACTAAACTGAAATTTAAATGTTCTTGGGGG	273
Qy	241	GAGGAGCTTGACCTTACCTTTGTAATAATTGCTTCTGACACTAAGGCTGTGCT	300
Db	274	GAGGAGCTTGACCTTACCTTTGTAATAATTGCTTCTGACACTAAGGCTGTGCT	333
Qy	301	AGTCGAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCAATTGACATCCAGTCATCTT	360
Db	334	AGTCGAATTCCTCAAAAAGAGTCTAGAAGATGTTGTCAATTGACATCCAGTCATCTT	393
Qy	361	TCTAAGGAATCAGAGGCAATGAGCCCGTATATACCTTCACTCAAGAAGCTGCATTAAT	420
Db	394	TCTAAGGAATCAGAGGCAATGAGCCCGTATATACCTTCACTCAAGAAGCTGCATTAAT	453
Qy	421	TCTTGTCTGTCAACAAAAACATATCAGGGGACAAAGCAATGTAACCTTGATGATCTTCGAC	480
Db	454	TCTTGTCTGTCAACAAAAACATATCAGGGGACAAAGCAATGTAACCTTGATGATCTTCGAC	513
Qy	481	ACTCGAAAAACAGCTAGACACCAACTGCTACCTATTTTCTGTCCCAACGAGAAGCC	540
Db	514	ACTCGAAAAACAGCTAGACACCAACTGCTACCTATTTTCTGTCCCAACGAGAAGCC	573
Qy	541	TGTCATTTGAACCAAGCAAGCACTTATGAGTTACAGATTAATACAGATTTTCCATCT	600
Db	574	TGTCATTTGAACCAAGCAAGCACTTATGAGTTACAGATTAATTAAGATTTTCCATCT	633
Qy	601	TTGACCAGAATTTGGCAAGCAAGATTAACCCAGAGAAGTTCTCTTACATGGCCAA	660
Db	634	TTGACCAGAATTTGGCAAGCAAGATTAACCCAGAGAAGTTCTCTTACATGGCCAA	693
Qy	661	TTTTCACAAAGCAGTCACTCCCTAGCCCATCATCACAGATTATTCAAGCCACCGAT	720





TITLE Direct Submission  
JOURNAL Submitted (21-JUN-2002) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
On Aug 25, 2003 this sequence version replaced gi:21542502.  
Contact: MGC help desk  
Email: [cgabs-romail.nih.gov](mailto:cgabs-romail.nih.gov)  
Tissue Procurement: Miklos Palkovits, M.D., Ph.D.  
cDNA Library Preparation: Michael J. Brownstein (NHGRI) & Shiraki  
Toshiyuki and Piero Carninci (RIKEN)  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Institute for Systems Biology  
<http://www.systemsbio.org>  
contact: [amadan@systemsbiology.org](mailto:amadan@systemsbiology.org)  
Anup Madan, Jessica Fahey, Erin Helton, Mark Ketteman, Anuradha  
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Series: IRAK Plate: 33 Row: h Column: 14  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 8922334.  
location/Qualifiers

FEATURES  
source 1. .2333  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="MGC:26021 IMAGE:4824116"  
/tissue\_type="Testis"  
/clone\_lib="NIH MGC\_97"  
/lab\_host="DH10B"  
/note="Vector: pBluescript"

gene

1. .2333  
/gene="FLJ10298"  
/db\_xref="LocusID:54682"  
276. .1571  
/codon\_start=1  
/product="hypothetical protein FLJ10298"  
/protein\_id="AAH32998.1"  
/db\_xref="GI:21542503"  
/db\_xref="LocusID:54682"

CDS

/translation="MFGSGSLTYTLVILFLLRLSASONCLKSLSDVVIDIQSS  
LSKIRGNBPIYTSOEDCINSGDKACNLMIFDRKTAQPNVCYLPCBN  
EACPLKPAKGLMSYRITDFPSLTRNLPSOELPOEDSLHGQFSQAVTPLAHHTDY  
SKPTDISMRDLSQKFGSDHLEKLFKMDBASQQLAYKEKHSQSSQFSSDQETIHL  
LPEENTSLPATVAVASPHITSPKPAATLPTNASVTPGTSQPLATTAPPTVTS  
QPTTLISTVFTRAAATLQAMATAVLTTFQAPTDKSLLETIPTEISMLTANGN  
VNPPTALSMNSVESTWNTKTAWEAREASPGSSQGSVPENQYGLPFEKMLIGSLIF  
GVLFVLVIGLVLLGRILSESLRRKRYSLDYLINGIYDI"

ORIGIN

Query Match 97.1%; Score 2218.8; DB 9; Length 2333;  
Best Local Similarity 99.5%; Pred. No. 0;  
Matches 2258; Conservative 0; Mismatches 7; Indels 5; Gaps 3;

QY 1 GCGGAGCATCCGCTGCGGTCCTGCCGAGACCCCGCGGATTCGCGGTCCTCCCGC 60  
Db 51 GCGGAGCATCCGCTGCGGTCCTGCCGAGACCCCGCGGATTCGCGGTCCTCCCGC 110  
QY 61 GGGCGGACAGAGCTGTCTCGACCTGGATGGCAGCAGGGCGCGGGGTCCTCTGCAC 120  
Db 111 GGGCGGACAGAGCTGTCTCGACCTGGATGGCAGCAGGGCGCGGGGTCCTCTGCAC 170  
QY 121 GCCAGAGAAATCTCATCTGTGAGCCTTTAAAGCAAACTAAGACAGAGGAG 180  
Db 171 GCCAGAGAAATCTCATCTGTGAGCCTTTAAAGCAAACTAAGACAGAGGAG 230  
QY 181 GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTCTTCGGGGA 240  
Db 231 GATTATCCTTGACCTTTGAAGACCAAACTAACTGAATTTAAATGTCTTCGGGGA 290

QY 241 GAAGGAGCTTGACTTACACTTTGGTAATATTTGGCTTCCTGACACTAAGCTGTCTGCT 300  
Db 291 GAAGGAGCTTGACTTACACTTTGGTAATATTTGGCTTCCTGACACTAAGCTGTCTGCT 350  
QY 301 AGTCAGAAATGCTCTCAAAAAGAGCTAGAAAGATGTTGTCATGACATCCAGTCATCTCT 360  
Db 351 AGTCAGAAATGCTCTCAAAAAGAGCTAGAAAGATGTTGTCATGACATCCAGTCATCTCT 410  
QY 361 TCTAAGGGAATCAGAGCAATGAGCCGTATATCTTCAACTCAAGAAAGCTGCATTAA 420  
Db 411 TCTAAGGGAATCAGAGCAATGAGCCATATATATCTTCAACTCAAGAAAGCTGCATTAA 470  
QY 421 TCTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGAC 480  
Db 471 TCTGCTGTTCAACAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGAC 530  
QY 481 ACTGAAACACAGCTAGACACCCCACTGCTACTATTTTCTGTCCCAACGAGGAAGCC 540  
Db 531 ACTGAAACACAGCTAGACACCCCACTGCTACTATTTTCTGTCCCAACGAGGAAGCC 590  
QY 541 TGTCCATTGAAACAGCAAAAGACTTATGAGTTACAGGATTAATTAAGATTTCCATCT 600  
Db 591 TGTCCATTGAAACAGCAAAAGACTTATGAGTTACAGGATTAATTAAGATTTCCATCT 650  
QY 601 TTGACCAAAATTTGCCAAGCCAAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 660  
Db 651 TTGACCAAAATTTGCCAAGCCAAAGATTACCCAGGAAGATTCTCTTACATGGCCAA 710  
QY 661 TTTTCAACAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720  
Db 711 TTTTCAACAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 770  
QY 721 ATCTCATGAGAGACACACACTTTCTCAGAAAGTTTGATCTCTCAGATCACTCGAAGAACTA 780  
Db 771 ATCTCATGAGAGACACACACTTTCTCAGAAAGTTTGATCTCTCAGATCACTCGAAGAACTA 830  
QY 781 TTTAAGATGATGAAGCAAGTGCCAGCTCTGCTTATTAAGAAAAAGCCATTCTCAG 840  
Db 831 TTTAAGATGATGAAGCAAGTGCCAGCTCTGCTTATTAAGAAAAAGCCATTCTCAG 890  
QY 841 AGTTCAAAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGC 900  
Db 891 AGTTCAAAATTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGC 950  
QY 901 CTCCAGCTACGGTGCGAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 960  
Db 951 CTCCAGCTACGGTGCGAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCCGCC 1010  
QY 961 ACCCTTCAACCCCAATATGCTTCACTGACACACTTCTGGGACTTCCAGCCACAGCTGGCC 1020  
Db 1011 ACCCTTCAACCCCAATATGCTTCACTGACACACTTCTGGGACTTCCAGCCACAGCTGGCC 1070  
QY 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCAGACCCCTCATTTCTACA 1080  
Db 1071 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCAGACCCCTCATTTCTACA 1130  
QY 1081 GTTTTACACGGGCTGCGGCTACCTCAAGCAATGGCTACACAGCAGTTCTGACTACC 1140  
Db 1131 GTTTTACACGGGCTGCGGCTACCTCAAGCAATGGCTACACAGCAGTTCTGACTACC 1190  
QY 1141 ACCTTTCAAGGACCTACGAGCTCGAAAGCAGCTTAGAAACCAATACCGTTTACAGAAATC 1200  
Db 1191 ACCTTTCAAGGACCTACGAGCTCGAAAGCAGCTTAGAAACCAATACCGTTTACAGAAATC 1250  
QY 1201 TCCAACTTAATTGAAACACAGGAATGTGTATTAACCCCTACCTGCACTTCTATGTCAAT 1260  
Db 1251 TCCAACTTAATTGAAACACAGGAATGTGTATTAACCCCTACCTGCACTTCTATGTCAAT 1310  
QY 1261 GTGAGTCTTCCACTATGATTAATACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGC 1320  
Db 1311 GTGAGTCTTCCACTATGATTAATACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGC 1370  
QY 1321 AGTTCCTCCAGGCGAGTGTTCAGAAAAATCAGTACGGGCTTCCATTGAAAAATGGCTT 1380

Db	1371	AGTTCCTCCAGGGCAGTGTTCAGAAAATCAGTACGGCCTTCCATTGAAAAATGGCTT	1430
Qy	1381	CTTATCGGGTCCCTGCTCTTTGGTGTCTGTCTCTGTGATAGGCTCGTCTCTGGGT	1440
Db	1431	CTTATCGGGTCCCTGCTCTTTGGTGTCTGTCTCTGTGATAGGCTCGTCTCTGGGT	1490
Qy	1441	AGAATCCTTTCGGAATCCTCCGAGAAACGTTACTCAGACTGGATTATTGATCAAT	1500
Db	1491	AGAATCCTCTCGGAATCACTCCGAGAAACGTTACTCAGACTGGATTATTGATCAAT	1550
Qy	1501	GGGATCTATGTGACATCTAAGGATGGAATCGGTGTCTCTTAATTCATTAGTAACCA	1560
Db	1551	GGGATCTATGTGACATCT-AGGATGGAATCGGTGTCTCTTAATTCATTAGTAACCA	1609
Qy	1561	AAGCCCAATGCAATGAGTTTCTGCTGACTGTAGTCTTAGCAGAGGTTGATTTTGA	1620
Db	1610	AAGCCCAATGCAATGAGTTTCTGCTGACTGTAGTCT--AGGAGGTTGATTTTGA	1666
Qy	1621	AGACAGAAAATGCCCCCTTCTGCTTTC-TTTTTTTTTTGAGACAGAGTCTGCTCT	1679
Db	1667	AGACAGAAAATGCCCCCTTCTGCTTTCCTTTTTTTTTTTGAGACAGAGTCTGCTCT	1726
Qy	1680	GTTGCCAGCTGAGTGACAGTCTCGGCTCTCACCGCAACCTCCGCTCTCTG	1739
Db	1727	GTTGCCAGCTGAGTGACAGTCTCGGCTCTCACCGCAACCTCCGCTCTCTG	1786
Qy	1740	GTTCAAGCGATTCTCCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGTGCCAC	1799
Db	1787	GTTCAAGCGATTCTCCTGCTCAGCCTCCTAAGTATCTGGATTACAGGCATGTGCCAC	1846
Qy	1800	CACACCTGGGTGATTTTGTATTTTTATAGAGACGGGGTTTCAACCATGTGTCAGGCT	1859
Db	1847	CACACCTGGGTGATTTTGTATTTTTATAGAGACGGGGTTTCAACCATGTGTCAGGCT	1906
Qy	1860	GGTCTCAAACTCTGACCTAGTATCCACCTCTCGGCTCCCAAGTCTGGGATTAC	1919
Db	1907	GGTCTCAAACTCTGACCTAGTATCCACCTCTCGGCTCCCAAGTCTGGGATTAC	1966
Qy	1920	AGGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTTGTGTTGAGAAAGATG	1979
Db	1967	AGGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTTGTGTTGAGAAAGATG	2026
Qy	1980	AAGTGGAAACCAATTAGTAAATTTGGGTAATCTGTCTCTAAATATAGCTAAACA	2039
Db	2027	AAGTGGAAACCAATTAGTAAATTTGGGTAATCTGTCTCTAAATATAGCTAAACA	2086
Qy	2040	AAGCTCTATGTAAGTAAATTAAGTATTAATTCATATAAATTTCAAAATTCACCTGGCTT	2099
Db	2087	AAGCTCTATGTAAGTAAATTAAGTATTAATTCATATAAATTTCAAAATTCACCTGGCTT	2146
Qy	2100	TTATGCAAGAAACAGGTTAGACATCTAGGTTCCAAATTCATTCACATCTTGGTCCAG	2159
Db	2147	TTATGCAAGAAACAGGTTAGACATCTAGGTTCCAAATTCATTCACATCTTGGTCCAG	2206
Qy	2160	ATAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATTC	2219
Db	2207	ATAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTTATATGATTC	2266
Qy	2220	TTTAAACTTATTCAGATGAGTGTCTTCCAAATTAATATTGAATAA	2269
Db	2267	TTTAAACTTATTCAGATGAGTGTCTTCCAAATTAATATTGAATAA	2316

RESULT 10  
AX876122 2221 bp DNA linear PAT 17-DEC-2003  
LOCUS AX876122  
DEFINITION Sequence 11027 from Patent EP1074617.  
ACCESSION AX876122  
VERSION AX876122.1 GI:40030858  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE  
1 Ota,T., Isogai,T., Nishikawa,T., Hayashi,K., Saito,K., Yamamoto,J.,  
Ishii,S., Sugiyama,T., Wakamatsu,A., Nagai,K. and Otsuki,T.  
TITLE  
JOURNAL  
Patent: EP 1074617-A 11027 07-FEB-2001;  
Research Association for Biotechnology (JP)  
FEATURES  
source  
1..2221  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
266..1459  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAE89131.1"  
/db\_xref="GI:40030859"  
/translation="MFEFGEGSLTYTLGIRGNEPVYTSQEDCINSCSTKNISGDKA  
CNIMIFDTRKTRQPNLYLFFCPNEBACPLKPAKILMSYRIITDPSLTRNLPSEL  
QEDSLHGFSQAVTPPLAHHTDYSKPTDISWROTSQKESDHLKLFKMDASAQ  
LNAVKEGHSQSQFSDOEIALHPENVSALPATVAVSPHTSATPKPATLPTNA  
SVTPSGTSQPQLATAPPTVTVTSQPTTLISTVFTHAATLQAMATVAVLTTFQAP  
TDSKSLETIPFTEISLNTLTGNVNPALSMNSVSSMTNKTASWEGREASPGSS  
QGSVPENQYGLPFEKWLIGSLFLGVLPVIGLVLAGRILSESLRKRYSRLDYLING  
IYVDI"

ORIGIN

Query Match 89.6%; Score 2045.8; DB 6; Length 2221;  
Best Local Similarity 95.2%; Pred. No. 0;  
Matches 2173; Conservative 0; Mismatches 7; Indels 103; Gaps 2;

Qy	1	GCGGAGCATCCGCTGCGGTCTCGCGAGACCCCGCGGATTGCGCGTCCCGC	60
Db	41	GCGGAGCATCCGCTGCGGTCTCGCGAGACCCCGCGGATTGCGCGTCCCGC	100
Qy	61	GGGCGGACAGAGCTGTCTCGACCTGATGGACAGGGGCGCGGCTCTCTCGAC	120
Db	101	GGGCGGACAGAGCTGTCTCGACCTGATGGACAGGGGCGCGGCTCTCTCGAC	160
Qy	121	GCCAGAGAAATCTCATCTGTGTGACGCTTCTTAAGCAAACTAAGACAGAGGAG	180
Db	161	GCCAGAGAAATCTCATCTGTGTGACGCTTCTTAAGCAAACTAAGACAGAGGAG	220
Qy	181	GATTATCTTGACCTTTGAAGACCAAACTAACTGAAATTTAAATGTTCTTGGGGGA	240
Db	221	GATTATCTTGACCTTTGAAGACCAAACTAACTGAAATTTAAATGTTCTTGGGGGA	280
Qy	241	GAAGGAGCTTGACTTACCTTTGGTAATTAATTGCTTCTGACATAAGGCTGTGCT	300
Db	281	GAAGGAGCTTGACTTACCTTTGGTAATTAATTGCTTCTGACATAAGGCTGTGCT	303
Qy	301	AGTCAGAAATGCTCAAAAAGAGTGAAGATGTTGTCATGACATCCAGTCATCTT	360
Db	304	-----	303
Qy	361	TCTAAGGATCAGAGCAATGAGCCGTATATACTTCAACTCAAGAACTGCATTAAT	420
Db	304	-----GGGATCAGAGCAATGAGCCGTATATACTTCAACTCAAGAACTGCATTAAT	358
Qy	421	TCTTGTGTTCACAAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGAC	480
Db	359	TCTTGTGTTCACAAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTGAC	418
Qy	481	ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCAAAGAGAAAGCC	540
Db	419	ACTGAAAAACAGCTAGACAAACCACTGCTACTATTTTCTGTCCAAAGAGAAAGCC	478
Qy	541	TGTCATTGAAACAGCAAAAGACTTATGAGTTACAGAGTAATTAAGATTTTCCATCT	600
Db	479	TGTCATTGAAACAGCAAAAGACTTATGAGTTACAGAGTAATTAAGATTTTCCATCT	538
Qy	601	TTGACCAAAATTTGCCAAGCAAGAGTTAACCCAGGAAGATTTCTCTTACATGGCCAA	660



Db 539 TTGACCAAGAAATTTGCCAAGCCAGAGTTACCCAGGAAGATCTCTTACATGGCCAA 598  
QY 661 TTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTTCAAAGCCACCGAT 720  
Db 599 TTTTCAACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTTCAAAGCCACCGAT 658  
QY 721 ATCTCATGGAAGACACACTTTCTCAGAAAGTTGGATCCCTCAGATCACCTGGAGAACTA 780  
Db 659 ATCTCATGGAAGACACACTTTCTCAGAAAGTTGGATCCCTCAGATCACCTGGAGAACTA 718  
QY 781 TTTAAGATGATGAAGCAAGTCCAGCTCCTTGCTTATAGGAAAAAGGCCATTCTCAG 840  
Db 719 TTTAAGATGATGAAGCAAGTCCAGCTCCTTGCTTATAGGAAAAAGGCCATTCTCAG 778  
QY 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGC 900  
Db 779 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAATGTGAGTGC 838  
QY 901 CTCACGCTACGGGTGAGTGTCTCTCCACATACCACTGGCTACTCCAAAGCCCGCC 960  
Db 839 CTCACGCTACGGGTGAGTGTCTCTCCACATACCACTGGCTACTCCAAAGCCCGCC 898  
QY 961 ACCCTTCTACCCCAATGCTTCACTGACACACCTTCTGGGACTTCCACGCCACAGCTGCC 1020  
Db 899 ACCCTTCTACCCCAATGCTTCACTGACACACCTTCTGGGACTTCCACGCCACAGCTGCC 958  
QY 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCCTCATTTCTACA 1080  
Db 959 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCACGACCCTCATTTCTACA 1018  
QY 1081 GTTTTTCACGCGGTGCGGCTACCTCCAAGCAATGGCTACAACAGAGTTCTGACTACC 1140  
Db 1019 GTTTTTCACGCGGTGCGGCTACCTCCAAGCAATGGCTACAACAGAGTTCTGACTACC 1078  
QY 1141 ACCTTTCAGGCACCTACGAGCTCGAAAGGAGCTTAGAACCATAACCGTTTACAGAAATC 1200  
Db 1079 ACCTTTCAGGCACCTACGAGCTCGAAAGGAGCTTAGAACCATAACCGTTTACAGAAATC 1138  
QY 1201 TCCAACTTAACCTTTGAACACAGGAATGTGTATAACCCCTACTGCACTTTCTATGTCAAT 1260  
Db 1139 TCCAACTTAACCTTTGAACACAGGAATGTGTATAACCCCTACTGCACTTTCTATGTCAAT 1198  
QY 1261 GTGAGTCTTCCACTATGATATAAACTGCTTCTGGAAGGTAGGGAGGCCAGTCCAGGC 1320  
Db 1199 GTGAGTCTTCCACTATGATATAAACTGCTTCTGGAAGGTAGGGAGGCCAGTCCAGGC 1258  
QY 1321 AGTTCTTCCAGGGCAGTGTTCAGAAATCAGTACGCGCTTCCATTGTAATAATGGCTT 1380  
Db 1259 AGTTCTTCCAGGGCAGTGTTCAGAAATCAGTACGCGCTTCCATTGTAATAATGGCTT 1318  
QY 1381 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTGCTGATAGGCTCGTCTCCTGGGT 1440  
Db 1319 CTTATCGGGTCCCTGCTCTTTGGTGTCTGTTCTGCTGATAGGCTCGTCTCCTGGGT 1378  
QY 1441 AGAATCTTTTCCGAATCACTCCGACGAAACGTTACTCAAGACTGGATTATTGATCAAT 1500  
Db 1379 AGAATCTTTTCCGAATCACTCCGACGAAACGTTACTCAAGACTGGATTATTGATCAAT 1438  
QY 1501 GGGATCTATGTGACATCTAAGATGGAACCTCGGTGTCTTTAATTCAATTAGTAACCA 1560  
Db 1439 GGGATCTATGTGACATCTAAGATGGAACCTCGGTGTCTTTAATTCAATTAGTAACCA 1498  
QY 1561 AAGCCCAATGCAATGAGTTTCTGTGACTTGTAGTCTTAGAGAGAGGTGTATTGTA 1620  
Db 1499 AAGCCCAATGCAATGAGTTTCTGTGACTTGTAGTCTTAGAGAGAGGTGTATTGTA 1558  
QY 1621 AGACAGAAATGCCCCCTTCTGCTTCC-TTTTCTTTTGGAGACAGAGTCTTGTCT 1679  
Db 1559 AGACAGAAATGCCCCCTTCTGCTTCTTTTCTTTTGGAGACAGAGTCTTGTCTCT 1618  
QY 1680 GTTGCCCAAGGCTGAGTGAAGACGATCTCGCTCTCACGCCAACCTCGTCTCTG 1739

Db 1619 GTTGCCCAAGGCTGAGTGCAGTAGCACGATCTCGGCTCTCACCCGAACCTCCGCTCTCTG 1678  
QY 1740 GGTTCAAGCGATTCTCTGCTCTCAGCCTCTAAGTATCTGGGATTACAGGCATGTGCCAC 1799  
Db 1679 GGTTCAAGCGATTCTCTGCTCTCAGCCTCTAAGTATCTGGGATTACAGGCATGTGCCAC 1738  
QY 1800 CACACCTGGGTGATTTTGTATTTTTAGTAGAGACGGGTTTCAACCATGTGTGTCAGGCT 1859  
Db 1739 CACACCTGGGTGATTTTGTATTTTTAGTAGAGACGGGTTTCAACCATGTGTGTCAGGCT 1798  
QY 1860 GGTTCAAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAAGTGTGGGATTAC 1919  
Db 1799 GGTTCAAACTCTGACCTAGTATCCACCCTCTCGGCTCCCAAAGTGTGGGATTAC 1858  
QY 1920 AGGCATGAGCCACCAAGTGGCCCCCTCTGTTTATGTTTGGTTTGGAGAAGGAATG 1979  
Db 1859 AGGCATGAGCCACCAAGTGGCCCCCTCTGTTTATGTTTGGTTTGGAGAAGGAATG 1918  
QY 1980 AAGTGGGAACCAATTAGTAATTTGGGTAATCTGTCTTAATAATTAGCTAAACAA 2039  
Db 1919 AAGTGGGAACCAATTAGTAATTTGGGTAATCTGTCTTAATAATTAGCTAAACAA 1978  
QY 2040 AAGCTCTATGTAAAGTAATAAGTATTAATTGCCATATAAATTCAAATTCACCTGGCTT 2099  
Db 1979 AAGCTCTATGTAAAGTAATAAGTATTAATTGCCATATAAATTCAAATTCACCTGGCTT 2038  
QY 2100 TTAATGCAAGAAGACAGGTAGACATCTAGTTCCAATTCAATTCATTCATCTGTTCCAG 2159  
Db 2039 TTAATGCAAGAAGACAGGTAGACATCTAGTTCCAATTCAATTCATTCATCTGTTCCAG 2098  
QY 2160 ATAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTATATGATTTCC 2219  
Db 2099 ATAAATCAACTGTTTATATCAATTTCTAATGATTTGCTTTCTTTATATGATTTCC 2158  
QY 2220 TTTAAACTTATTCCAGATGATGTTCTTCCAAATTAATAATTGAATAAATCTTTGTGA 2279  
Db 2159 TTTAAACTTATTCCAGATGATGTTCTTCCAAATTAATAATTGAATAAATCTTTGTGA 2218  
QY 2280 CTC 2282  
Db 2219 CTC 2221

RESULT 11  
BD155963  
LOCUS 2221 bp DNA linear PAT 17-JAN-2003  
DEFINITION Primer for synthesizing full-length cDNA and use thereof.  
ACCESSION BD155963  
VERSION BD155963.1 GI:27861721  
KEYWORDS JP 2002191363-A/10806.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 2221)  
AUTHORS Oda,T., Isogai,T., Nishikawa,T., Hayashi,K., Saito,K., Yamamoto,J.,  
Ishii,S., Sugiyama,T., Wakamatsu,A., Nagai,K. and Otsuki,T.  
TITLE Primer for synthesizing full-length cDNA and use thereof  
JOURNAL Patent: JP 2002191363-A 10806 09-JUL-2002;  
HELIX RESEARCH INSTITUTE  
OS Homo sapiens (human)  
PN JP 2002191363-A/10806  
PD 09-JUL-2002  
PF 28-JUL-2000 JP 2000280990  
PI TOSHIO ODA, TAKAO ISOGAI, TETSUO NISHIKAWA, KOJI HAYASHI, KAORU  
PI SAITO,  
PI JUNICHI YAMAMOTO, SHIZUKO ISHII, TOMOYASU SUGIYAMA, AI WAKAMATSU,  
PI KEIICHI NAGAI, TETSUJI OTSUKI  
PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/PC  
10, C12P21/02, C12Q1/68//C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC  
Primer for synthesizing full-length cDNA and use thereof FH Key

Location/Qualifiers  
(266) . . (1456) .  
Location/Qualifiers  
1. .2221  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

ORIGIN

Query Match 89.6%; Score 2045.8; DB 6; Length 2221;  
Best Local Similarity 95.2%; Pred. No. 0;  
Matches 2173; Conservative 0; Mismatches 7; Indels 103; Gaps 2;

QY 1 GCGGAGCATCCGCTGCGGTCTCGCGAGAGACCCCGCGGATTCGCCGCTTCCCGC 60  
Db 41 GCGGAGCATCCGCTGCGGTCTCGCGAGAGACCCCGCGGATTCGCCGCTTCCCGC 100  
QY 61 GGGCGGACAGAGCTGTCTCGCACTGGAATGGCAGAGGGCGCGGGTCTCTCGAC 120  
Db 101 GGGCGGACAGAGCTGTCTCGCACTGGAATGGCAGAGGGCGCGGGTCTCTCGAC 160  
QY 121 GCCAGAGAAATCTCATCTGTGAGCCTTCTTAAGCAAACTAAGACGAGGGAG 180  
Db 161 GCCAGAGAAATCTCATCTGTGAGCCTTCTTAAGCAAACTAAGACGAGGGAG 220  
QY 181 GATTATCTTGAACCTTGAAGACCAAACTAACTGAATTTAAATGTCTTCGGGGA 240  
Db 221 GATTATCTTGAACCTTGAAGACCAAACTAACTGAATTTAAATGTCTTCGGGGA 280  
QY 241 GAAGGAGCTTGACTTACCTTGGTAATATTGCTTCTGACACTAAGGCTGTGCT 300  
Db 281 GAAGGAGCTTGACTTACCTT----- 303  
QY 301 AGTCAGAAATGCTCAAAAAGAGTCTAAGAGATGTGTCAATGACATCCAGTCATCTT 360  
Db 304 ----- 303  
QY 361 TCTAAGGAATCAGAGCAATGAGCCCGTATATACTTCAACTCAAGAGACTGCATTAAT 420  
Db 304 -----GGGAATCAGAGCAATGAGCCCGTATATACTTCAACTCAAGAGACTGCATTAAT 358  
QY 421 TCTTGCTGTTCACAAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 480  
Db 359 TCTTGCTGTTCACAAAAAACATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC 418  
QY 481 ACTCGAAAAACAGCTAGACAAACCACTGCTAATTTTCTGTGCCAAGAGAGCC 540  
Db 419 ACTCGAAAAACAGCTAGACAAACCACTGCTAATTTTCTGTGCCAAGAGAGCC 478  
QY 541 TGTCCATGAAACAGCAAAAAGACTTATGAGTTACAGGATAATTACAGATTTCCATCT 600  
Db 479 TGTCCATGAAACAGCAAAAAGACTTATGAGTTACAGGATAATTACAGATTTCCATCT 538  
QY 601 TTGACCAGAAATTTGCCAAGCCAAAGATTACCCCAAGAGATTCTCTTACATGGCCAA 660  
Db 539 TTGACCAGAAATTTGCCAAGCCAAAGATTACCCCAAGAGATTCTCTTACATGGCCAA 598  
QY 661 TTTTCAAGAGCATCTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 720  
Db 599 TTTTCAAGAGCATCTCCCTAGCCCATCATCACACAGATTATTCAAAGCCACCGAT 658  
QY 721 ATCTCATGAGAGACACACTTTCTCAGAAGTTGGATCCTCAGATCACCCTGAGAAACTA 780  
Db 659 ATCTCATGAGAGACACACTTTCTCAGAAGTTGGATCCTCAGATCACCCTGAGAAACTA 718  
QY 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATAAGAAAAAGGCCATTCTCAG 840  
Db 719 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGCTTATAAGAAAAAGGCCATTCTCAG 778  
QY 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCCCTGAAAAATGTAGTGG 900  
Db 779 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCCCTGAAAAATGTAGTGG 838

QY 901 CTCACAGCTACGGTGGAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCC 960  
Db 839 CTCACAGCTACGGTGGAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCC 898  
QY 961 ACCCTTCAACCAACCAATGCTTCAGTGACACACTTCTGGGACTTCCCAAGCCACAGCTGGCC 1020  
Db 899 ACCCTTCAACCAACCAATGCTTCAGTGACACACTTCTGGGACTTCCCAAGCCACAGCTGGCC 958  
QY 1021 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCCTCATTTCTACA 1080  
Db 959 ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCCTCATTTCTACA 1018  
QY 1081 GTTTTACACGGGCTGCGGCTACACTCCAAAGCAATGGCTACACACAGAGTTCTGACTACC 1140  
Db 1019 GTTTTACACGGGCTGCGGCTACACTCCAAAGCAATGGCTACACACAGAGTTCTGACTACC 1078  
QY 1141 ACCTTCAAGCACCTACGAGCTCGAAAGCAGCTTAAGAAACCATACCGTTTACAGAAATC 1200  
Db 1079 ACCTTCAAGCACCTACGAGCTCGAAAGCAGCTTAAGAAACCATACCGTTTACAGAAATC 1138  
QY 1201 TCCAATTAATTTGAACACAGGGAATGTATAAACCTACTGCACTTCTATGTCAAAAT 1260  
Db 1139 TCCAATTAATTTGAACACAGGGAATGTATAAACCTACTGCACTTCTATGTCAAAAT 1198  
QY 1261 GTGAGTCTTCCACTATGAATAAACTGCTTCTGGAAGGTAGGAGGCCAGTCCAGGC 1320  
Db 1199 GTGAGTCTTCCACTATGAATAAACTGCTTCTGGAAGGTAGGAGGCCAGTCCAGGC 1258  
QY 1321 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGGGCTTCCATTGAAAAATGGCTT 1380  
Db 1259 AGTTCCTCCAGGGCAGTGTCCAGAAATCAGTACGGGCTTCCATTGAAAAATGGCTT 1318  
QY 1381 CTTATCGGGTCCCTGCTCTTGGGTCTCTGTTCTGTTAGGCTCGTCTCTGGGT 1440  
Db 1319 CTTATCGGGTCCCTGCTCTTGGGTCTCTGTTCTGTTAGGCTCGTCTCTGGGT 1378  
QY 1441 AGAATCCTTTCGGAATCACTCCGCAAGAAAGTTACTCAAGACTGGAATTTTGATCAAT 1500  
Db 1379 AGAATCCTTTCGGAATCACTCCGCAAGAAAGTTACTCAAGACTGGAATTTTGATCAAT 1438  
QY 1501 GGGATCTATGTGACATCTAAGATGGAATCCTGGTGTCTCTTAATTCAATTAGTAACCAAG 1560  
Db 1439 GGGATCTATGTGACATCTAAGATGGAATCCTGGTGTCTCTTAATTCAATTAGTAACCAAG 1498  
QY 1561 AAGCCAAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGTATTTGA 1620  
Db 1499 AAGCCAAATGCAATGAGTTTCTGCTGACTTGTAGTCTTAGCAGAGGTTGTATTTGA 1558  
QY 1621 AGACAGAAAAATGCCCTTCTGCTTCC-TTTTTTTTTTGGAGACAGAGTCTGTCT 1679  
Db 1559 AGACAGAAAAATGCCCTTCTGCTTCC-TTTTTTTTTTGGAGACAGAGTCTGTCT 1618  
QY 1680 GTTGCCAGGCTGAGTGCATGACAGATCTCGGCTCACCAGCACTCCGCTCTCTG 1739  
Db 1619 GTTGCCAGGCTGAGTGCATGACAGATCTCGGCTCACCAGCACTCCGCTCTCTG 1678  
QY 1740 GGTTCAGGCAATTCTCTGCTCAGCCTCCTAAGTATCTGGATTAAGGATGTGCCAC 1799  
Db 1679 GGTTCAGGCAATTCTCTGCTCAGCCTCCTAAGTATCTGGATTAAGGATGTGCCAC 1738  
QY 1800 CACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTACCATGTGTGTCAGGCT 1859  
Db 1739 CACACCTGGGTGATTTTGTATTTTATAGAGACGGGGTTTACCATGTGTGTCAGGCT 1798  
QY 1860 GGTCCTAAACTCTGACCTAGTATCAACCTCTCGGCTCCCAAAGTGCTGGATTAC 1919  
Db 1799 GGTCCTAAACTCTGACCTAGTATCAACCTCTCGGCTCCCAAAGTGCTGGATTAC 1858  
QY 1920 AGCATGAGCCACACAGCTGAGCCCTTCTGTTTATGTTTGTGTTTGAAGAAGATG 1979  
Db 1859 AGCATGAGCCACACAGCTGAGCCCTTCTGTTTATGTTTGTGTTTGAAGAAGATG 1918  
QY 1980 AAGTGGAACCAATTAAGTATTTTGGGTAACTGTCTCTAAATATTAAGCTAAAAACA 2039

Db 1919 AAGTGGGAACCAATTAGTAATTTGGGTAATCTGCTCTAAATAATAGCTAAAAACA 1978  
Qy 2040 AAGCTCTATGTAAGTAATAAGTAATTCGCCATATAAATTCGAAATTCACACTGGCTT 2099  
Db 1979 AAGCTCTATGTAAGTAATAAGTAATTCGCCATATAAATTCGAAATTCACACTGGCTT 2038  
Qy 2100 TTATGCAAGAAACAGGTAGGACATCTAGGTTCCCAATTCATTCACATCTTGGTCCAG 2159  
Db 2039 TTATGCAAGAAACAGGTAGGACACTAGGTTCCCAATTCATTCACATCTTGGTCCAG 2098  
Qy 2160 ATAAATCAACTGTTATATCAATTCTAATGGAATTGCTTTCTTTTATATGGAATCC 2219  
Db 2099 ATAAATCAACTGTTATATCAATTCTAATGGAATTGCTTTCTTTTATATGGAATCC 2158  
Qy 2220 TTTAAACTTATTCAGATGATGTTCTTCCAATTAATATTTGAATAAATCTTTGTGA 2279  
Db 2159 TTTAAACTTATTCAGATGATGTTCTTCCAATTAATATTTGAATAAATCTTTGTGA 2218  
Qy 2280 CTC 2282  
Db 2219 CTC 2221

RESULT 12  
AK001160 2221 bp mRNA linear PRI 01-AUG-2002  
LOCUS Homo sapiens cDNA FLJ10298 fis, clone NT2RM100115, weakly similar  
DEFINITION to ENDOCHITINASE 2 PRECURSOR (EC 3.2.1.14).

ACCESSION AK001160.1 GI:7022238  
VERSION oligo capping; fis (full insert sequence).  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens

REFERENCE 1  
AUTHORS Isogai,T., Ota,T., Hayashi,K., Sugiyama,T., Otsuki,T., Suzuki,Y.,  
Nishikawa,T., Nagai,K., Sugano,S., Shiratori,A., Sudo,H.,  
Wagatsuma,M., Hosoi,T., Kaku,Y., Kodaira,H., Kondo,H.,  
Sugawara,M., Takahashi,M., Chiba,Y., Ishida,S., Murakawa,K.,  
Ono,Y., Takiguchi,S., Watanabe,S., Kimura,K., Murakami,K.,  
Ishii,S., Kawai,Y., Saito,K., Yamamoto,J., Wakamatsu,A.,  
Nakamura,Y., Nagahari,K., Masuho,Y., Ninomiya,K. and Iwayanagi,T.  
NEDO human cDNA sequencing project

TITLE Unpublished  
JOURNAL 2 (bases 1 to 2221)  
REFERENCE Isogai,T. and Otsuki,T.  
AUTHORS Direct Submission  
JOURNAL Submitted (16-FEB-2000) Takao Isogai, Helix Research Institute,  
Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan  
(E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)  
COMMENT NEDO human cDNA sequencing project supported by Ministry of  
International Trade and Industry of Japan; cDNA full insert  
sequencing: Research Association for Biotechnology; cDNA library  
construction, 5'- & 3'-end one pass sequencing and clone selection:  
Helix Research Institute (supported by Japan Key Technology Center  
etc.) and Department of Virology, Institute of Medical Science,  
University of Tokyo.

FEATURES  
source 1. 2221  
location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="NT2RM1001115"  
/cell\_line="NT2"  
/cell\_type="teratocarcinoma"  
/clone\_lib="NT2RM1"  
/note="cloning vector: pUC19FL3-mRNA from uninduced NT2  
neuronal precursor cells."  
266. 1459  
/note="unnamed protein product"  
/codon\_start=1

/protein\_id="BAA91526.1"  
/db\_xref="GI:7022239"  
translation="MFRGEGSLTYTLGIRNEPVYTSQEDCINSCSTKNISGDKA  
CNLMIFDRTKARQPNVCYLFECPNEACPLKPAKGLMSYRIITDFSLTRNPSQELP  
QEDSLHGQFSQAVTPLAHHTDYSKPTDISWEDTLQKPGSSDHLKLFKMEASAO  
LLAYKEKHSQSQSSDQELIAHLLENVSALPATAVASPHTSATPKPATLPTNA  
SVTPSGTSQPOLATPAPVTVTSQPTTLISVTFVTRAAATLQAMATTAVALTTTQAP  
TDSKSLFTIPFTEISNLTNTGNVNPPTALSMNVESSTMNKRASMEGREASPGSS  
QGSVPENOYGLPFEXKLLIGSLFLGVLFVLIGVLLRILSESLRKRYSRLDYLLNG  
IYVDI"

ORIGIN

Query Match 89.6%; Score 2045.8; DB 9; Length 2221;  
Best Local Similarity 95.2%; Pred. No. 0;  
Matches 2173; Conservative 0; Mismatches 7; Indels 103; Gaps 2;

Qy 1 GCGGAGCATCCGCTCGGCTCTCGCCGAGACCCCGCGGATTCGCGGCTCCCGC 60  
Db 41 GCGGAGCATCCGCTCGGCTCTCGCCGAGACCCCGCGGATTCGCGGCTCCCGC 100  
Qy 61 GGGCGGACAGAGCTGTCTCGCAGCTGGATGGCAGAGGGCGCGGCTCTCGAC 120  
Db 101 GGGCGGACAGAGCTGTCTCGCAGCTGGATGGCAGAGGGCGCGGCTCTCGAC 160  
Qy 121 GCCAGAGAAATCTCATCATCTGTGCAAGCCTTCTTAAAGCAAACTAAGACGAGGAG 180  
Db 161 GCCAGAGAAATCTCATCATCTGTGCAAGCCTTCTTAAAGCAAACTAAGACGAGGAG 220  
Qy 181 GATTATCCTTGACCTTGAAGCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 240  
Db 221 GATTATCCTTGACCTTGAAGCAAACTAACTGAATTTAAATGTTCTTCGGGGGA 280  
Qy 241 GAAGGAGCTTGACTTACACTTTCGTAATTAATTGCTTCTCGACACTAAGGCTGTGCT 300  
Db 281 GAAGGAGCTTGACTTACACTTTCGTAATTAATTGCTTCTCGACACTAAGGCTGTGCT 303  
Qy 301 AGTCAGAAATTCCTCAAAAAGAGTCTAGAAAGATGTTGTCATTGACATCCAGTCATCTT 360  
Db 304 ----- 303  
Qy 361 TCTAAGGAATCAGAGCAATGAGCCGTATATATCTTCAACTCAAGAAGACTGCATTAAT 420  
Db 304 -----GGAATCAGAGCAATGAGCCGTATATATCTTCAACTCAAGAAGACTGCATTAAT 358  
Qy 421 TCTTGTCTTCAACAAAAAATATCAGGGGACAAAGCATGTAACCTTGATGATCTTCGAC 480  
Db 359 TCTTGTCTTCAACAAAAAATATCAGGGGACAAAGCATGTAACCTTGATGATCTTCGAC 418  
Qy 481 ACTCGAAAAACAGCTAGACCAACCACTGCTACTATTTTCTGCCAACGAGAGGCC 540  
Db 419 ACTCGAAAAACAGCTAGACCAACCACTGCTACTATTTTCTGCCAACGAGAGGCC 478  
Qy 541 TGTCCATTGAAACCAAGCAAAAGACTTATGAGTTACAGAGTAATTAACAGATTTCATCT 600  
Db 479 TGTCCATTGAAACCAAGCAAAAGACTTATGAGTTACAGAGTAATTAACAGATTTCATCT 538  
Qy 601 TTGACCAGAAATTTGCCAAGCCAGAGTTACCCCAAGAGATTCTCTTACATGGCCAA 660  
Db 539 TTGACCAGAAATTTGCCAAGCCAGAGTTACCCCAAGAGATTCTCTTACATGGCCAA 598  
Qy 661 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATCAAAAGCCACCGAT 720  
Db 599 TTTTCAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATCAAAAGCCACCGAT 658  
Qy 721 ATCTCATGAGAGACACACTTCTCAGAAGTTGGATTCCTCAGATCACTTGAGAAACTA 780  
Db 659 ATCTCATGAGAGACACACTTCTCAGAAGTTGGATTCCTCAGATCACTTGAGAAACTA 718  
Qy 781 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGTCTTATTAAGAAAAAGCCATTCTCAG 840  
Db 719 TTTAAGATGATGAAGCAAGTGCCCAAGCTCTTGTCTTATTAAGAAAAAGCCATTCTCAG 778  
Qy 841 AGTTCACAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCTGAAAATGTGAGTGGC 900



D	b	779	AGTTCACAATTTCTCTGATCAAGAAATAGCTCATCTGCTCTGAAATGTGAGTGG	838
Q	y	901	CTCCAGCTACGGTGGCAGTGTCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCC	960
D	b	839	CTCCAGCTACGGTGGCAGTGTCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCC	898
Q	y	961	ACCTTCTACCCACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC	1020
D	b	899	ACCTTCTACCCACCAATGCTTCAGTGACACCTTCTGGGACTTCCAGCCACAGCTGGCC	958
Q	y	1021	ACCACAGCTCCACCTGTAAACACTGTCACTTCTCAGCCTTCCACGACCCTCATTTCTACA	1080
D	b	959	ACCACAGCTCCACCTGTAAACACTGTCACTTCTCAGCCTTCCACGACCCTCATTTCTACA	1018
Q	y	1081	GTTTTTACACGGGCTGCGGCTACACTCCAAGCAATGGCTTCAACAGCAGTTCGTACACC	1140
D	b	1019	GTTTTTACACGGGCTGCGGCTACACTCCAAGCAATGGCTTCAACAGCAGTTCGTACACC	1078
Q	y	1141	ACCTTTCAGGCACCTACGGACTCGAAAGCAGCTTAGAAACATACCGTTTACAGAAATC	1200
D	b	1079	ACCTTTCAGGCACCTACGGACTCGAAAGCAGCTTAGAAACATACCGTTTACAGAAATC	1138
Q	y	1201	TCCAACCTTAACCTTGAACACAGGGAATGTGTATAACCCCTACTGCACCTTCTATGTCAAAT	1260
D	b	1139	TCCAACCTTAACCTTGAACACAGGGAATGTGTATAACCCCTACTGCACCTTCTATGTCAAAT	1198
Q	y	1261	GTGGAGTCTTCCACTATGATATAAACTGCTTCTCGGGAAGGTAGGGAGCCAGTCCAGCC	1320
D	b	1199	GTGGAGTCTTCCACTATGATATAAACTGCTTCTCGGGAAGGTAGGGAGCCAGTCCAGCC	1258
Q	y	1321	AGTTCCTCCCAGGGCAGTGTTCAGAAATCAGTACGGCCTTCCATTTGAAAAATGGCTT	1380
D	b	1259	AGTTCCTCCCAGGGCAGTGTTCAGAAATCAGTACGGCCTTCCATTTGAAAAATGGCTT	1318
Q	y	1381	CTTATCGGGTCCCCTGCTCTTGTGTCTCTGTTCCTGTGTATAGGCCCTCGTCCCTCGGT	1440
D	b	1319	CTTATCGGGTCCCCTGCTCTTGTGTCTCTGTTCCTGTGTATAGGCCCTCGTCCCTCGGT	1378
Q	y	1441	AGAATCCTTTCGGAATCACTCCGACAGAAACGTTACTCAAGACTGATTATTGTATCAAT	1500
D	b	1379	AGAATCCTTTCGGAATCACTCCGACAGAAACGTTACTCAAGACTGATTATTGTATCAAT	1438
Q	y	1501	GGGATCTATGTGACATCTAAGATGGAACCTCGGTGTCTTAAATTCATTTAGTAACAG	1560
D	b	1439	GGGATCTATGTGACATCTAAGATGGAACCTCGGTGTCTTAAATTCATTTAGTAACAG	1498
Q	y	1561	AAGCCCAATGCAATGAGTTCTGTCTGACTTGCTAGTCTTATAGCAGGAGGTGTATTTGA	1620
D	b	1499	AAGCCCAATGCAATGAGTTCTGTCTGACTTGCTAGTCTTATAGCAGGAGGTGTATTTGA	1558
Q	y	1621	AGACAGGAAAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTGGAGACAGAGTCTTGCTCT	1679
D	b	1559	AGACAGGAAAAATGCCCCCTTCTGCTTCC-TTTTTTTTTTGGAGACAGAGTCTTGCTCT	1618
Q	y	1680	GTTGCCCAAGCTGAGTGCATGACAGATCTCGGCTCTCAACGCAACCTCCGCTCTCTG	1739
D	b	1619	GTTGCCCAAGCTGAGTGCATGACAGATCTCGGCTCTCAACGCAACCTCCGCTCTCTG	1678
Q	y	1740	GGTTCAGCGCATTTCTCTGCTCAGCCTCCTAAGTATCTGGGATTCACAGCATGTGCCAC	1799
D	b	1679	GGTTCAGCGCATTTCTCTGCTCAGCCTCCTAAGTATCTGGGATTCACAGCATGTGCCAC	1738
Q	y	1800	CACACCTGGGTGATTTTGTATTTTATAGTAGACGGGGTTTCAACATGTTGTCAGGCT	1859
D	b	1739	CACACCTGGGTGATTTTGTATTTTATAGTAGACGGGGTTTCAACATGTTGTCAGGCT	1798
Q	y	1860	GGTTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCTCCAAAGTCTGGGATTAC	1919
D	b	1799	GGTTCAAACTCCTGACCTAGTATCCACCCTCCTCGGCTCTCCAAAGTCTGGGATTAC	1858
Q	y	1920	AGGCATGAGCCACACAGCTGGCCCCCTTCTGTTTATGTTGGTTTGTGAGAGGAATG	1979

Db	1855	AGGCATGAGCCACCACAGCTGGCCCCCTCTGTTTATGTTTGGTGTTTTGAGAGAAGATG	1918
QY	1980	AAGTGGGAACCAATTAAGTAATTTTGGGTAATCTGCTCTAAATATTAGCTAAAAACA	2039
Db	1919	AAGTGGGAACCAATTAAGTAATTTTGGGTAATCTGCTCTAAATATTAGCTAAAAACA	1978
QY	2040	AAGCTCTATGTAAAGTAATAAAGTATATTGCCATATAAATTTCAAATTCAACTGGCTT	2099
Db	1979	AAGCTCTATGTAAAGTAATAAAGTATATTGCCATATAAATTTCAAATTCAACTGGCTT	2038
QY	2100	TTATGCAAGAACAACAGSTTAGGACATCTAGGTTCCAATTCATTACATTTCTTGGTTCCAG	2159
Db	2039	TTATGCAAGAACAACAGSTTAGGACACCTAGGTTCCAATTCATTACATTTCTTGGTTCCAG	2098
QY	2160	ATAAATCAACTGTGTTATATCAATTTCTTAATGGAATTTGCTTTCTTTTATATGGAATTCC	2219
Db	2099	ATAAATCAACTGTGTTATATCAATTTCTTAATGGAATTTGCTTTCTTTTATATGGAATTCC	2158
QY	2220	TTTAAACTTATTCGAGTGTAGTTCCTTCCAATTAAATATTGAATAAAATCTTTTGTTA	2279
Db	2159	TTTAAACTTATTCGAGTGTAGTTCCTTCCAATTAAATATTGAATAAAATCTTTTGTTA	2218
QY	2280	CTC 2282	
Db	2219	CTC 2221	

RESULT	13
LOCUS	BD227259
DEFINITION	BD227259 2015 bp DNA linear PAT 17-JUL-2003
ACCESSION	Secreted proteins and polynucleotides encoding them.
VERSION	BD227259
KEYWORDS	BD227259.1 GI:33037029
SOURCE	JP 2002522062-A/20.
ORGANISM	Homo sapiens (human)
REFERENCE	Homo sapiens
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE	1 (bases 1 to 2015)
JOURNAL	Jacobs, K., McCoy, J.M., Lavallie, E.R., Racie, L.A.C., Evans, C., Werberg, D., Treacy, M., Agostino, M.J., Il, R.J.S., Spaulding, V., Wong, G.G., Clark, H.F. and Fechtel, K.
COMMENT	Secreted proteins and polynucleotides encoding them
	Patent: JP 2002522062-A 20 23-JUL-2002;
	GENETICS INSTITUTE INC
	OS Homo sapiens (human)
	PN JP 2002522062-A/20
	PD 23-JUL-2002
	PF 13-AUG-1999 JP 2000565001
	PR 14-AUG-1998 US 60/096622,17-AUG-1998 US 60/096815 PR
	04-SEP-1998 US 60/099229,23-OCT-1998 US 60/105368 PR
	08-JAN-1999 US 60/115234,12-FEB-1999 US 60/119931 PR
	18-FEB-1999 US 60/120575,30-APR-1999 US 60/132020 PR
	11-AUG-1999 US 60/148424
	PI KENNETH JACOBS,JOHN M MCCOY,EDWARD R LAVALLIE,LISA A COLLINS
	PI RACIE,
	PI CHERYL EVANS,DAVID MERBERG,MAURICE TREACY,MICHAEL J AGOSTINO,
	PI ROBERT J STEININGER II,VIKKI SPAULDING,GORDON G WONG,HILARY F
	PI CLARK,
	PI KIM FECHTEL
	PC C12N15/09,A61K38/00,A61K39/395,A61K39/395,A61K45/00,A61K48/00,
	PC A61P7/00,
	PC A61P7/02,A61P7/04,A61P7/06,A61P13/00,A61P29/00,A61P35/00, PC
	A61P37/02,
	PC A61P43/00,A61P43/00,C07K14/47,C12N5/10,C12P21/02,G01N33/15, PC
	G01N33/50,
	PC C12N15/00,C12N5/00,A61K37/02
	CC Secreted proteins and polynucleotides encoding them FH Key
	Location/Qualifiers
FT	1..2015
FT	source
FEATURES	Location/Qualifiers
source	1..2015
	location/Qualifiers
	1..2015
	organism='Homo sapiens (human)'
	1..2015

/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

ORIGIN

```
Query Match      84.9%; Score 1939.4; DB 6; length 2015;  
Best Local Similarity 99.5%; Pred. No. 0;  
Matches 1987; Conservative 0; Mismatches 6; Indels 4; Gaps 4;  
  
QY      289 AGGCTGCTCTAGTCAAGATTGCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATC 348  
Db      1  AGGCTGTCTAGTCAAGATTGCTCAAAAAGAGTCTAGAAGATGTTGTCATTGACATC 60  
  
QY      349 CAGTCATCTCTTCTAAGGGAATCAGAGCAATGAGCCCGTATATATCTTCAACTCAAGAA 408  
Db      61  CAGTCATCTCTTCTAAGGGAATCAGAGCAATGAGCCCGTATATATCTTCAACTCAAGAA 120  
  
QY      409 GACTGCATTAATTCTGTGCTGTTCAAAAAACATATCAGGGGCAAAAGCATGTAATCTG 468  
Db      121 GACTGCATTAATTCTGTGCTGTTCAAAAAACATATCAGGGGCAAAAGCATGTAATCTG 180  
  
QY      469 ATGATCTTCGACACTCGAAAAACAGCTAGACAACCCAACTGCTACTATTTTCTGTCCC 528  
Db      181 ATGATCTTCGACACTCGAAAAACAGCTAGACAACCCAACTGCTACTATTTTCTGTCCC 240  
  
QY      529 AACGAGGAAGCCTGTCCATTGAAACAGCAAAAGGACTTATGAGTTACAGGATTAATACA 588  
Db      241 AACGAGGAAGCCTGTCCATTGAAACAGCAAAAGGACTTATGAGTTACAGGATTAATACA 300  
  
QY      589 GATTTTCCATCTTTGACAGAAATTTGCCAAGCCAAGAGTTAACCCAGGAAGTTCTCTC 648  
Db      301 GATTTTCCATCTTTGACAGAAATTTGCCAAGCCAAGAGTTAACCCAGGAAGTTCTCTC 360  
  
QY      649 TTACATGGCCAAATTTTCAACAAGCACTCCTCCCTAGCCCATCATCACACAGATTATCA 708  
Db      361 TTACATGGCCAAATTTTCAACAAGCACTCCTCCCTAGCCCATCATCACACAGATTATCA 420  
  
QY      709 AAGCCACCGATATCTCATGAGAGACACACTTCTCAGAAAGTTTGGATCTCAGATCAC 768  
Db      421 AAGCCACCGATATCTCATGAGAGACACACTTCTCAGAAAGTTTGGATCTCAGATCAC 480  
  
QY      769 CTGAGAAACTATTTAAGATGATGAAGCAAGTGCCTGCTGCTTATAAGGAAAA 828  
Db      481 CTGAGAAACTATTTAAGATGATGAAGCAAGTGCCTGCTGCTTATAAGGAAAA 540  
  
QY      829 GGCATTTCTAGAGTTCACAATTTTCTCTGATCAAGAAATAGCTATCTGCTGCTGAA 888  
Db      541 GGCATTTCTAGAGTTCACAATTTTCTCTGATCAAGAAATAGCTATCTGCTGCTGAA 600  
  
QY      889 AATGTAGTGCCTCCAGCTACGCTGAGGAGTGTCTCTCCACATACCACTCGGCTACT 948  
Db      601 AATGTAGTGCCTCCAGCTACGCTGAGGAGTGTCTCTCCACATACCACTCGGCTACT 660  
  
QY      949 CCAAGCCCGCCACCTTCTACCAACCAATGCTTCACTGACACCTTCTGGGACTTCCAG 1008  
Db      661 CCAAGCCCGCCACCTTCTACCAACCAATGCTTCACTGACACCTTCTGGGACTTCCAG 720  
  
QY      1009 CCAAGCTGGCCACCAAGCTCCACTGTAAACCACTGTCACTTCTCAGCCTCCACGACC 1068  
Db      721 CCAAGCTGGCCACCAAGCTCCACTGTAAACCACTGTCACTTCTCAGCCTCCACGACC 780  
  
QY      1069 CTCAATTTCTACAGTTTCTACACGGGCTGCGGCTACACTCCAAAGCAATGGCTACAACAGCA 1128  
Db      781 CTCAATTTCTACAGTTTCTACACGGGCTGCGGCTACACTCCAAAGCAATGGCTACAACAGCA 840  
  
QY      1129 GTTCTGACTACCACTTTCAAGCACTACGAGCTCGAAAGGCACTTAGAAACCATACCG 1188  
Db      841 GTTCTGACTACCACTTTCAAGCACTACGAGCTCGAAAGGCACTTAGAAACCATACCG 900  
  
QY      1189 TTTCAGAAATCTCCAACCTTAACCTTGAACAAGGAATGTATTAACCTACTGCACTT 1248  
Db      901 TTTCAGAAATCTCCAACCTTAACCTTGAACAAGGAATGTATTAACCTACTGCACTT 960
```

```
QY      1249 TCTATGTCAATGTGAGTCTTCCACTATGATATAAACTGCTTCTCTGGAGGTAGGAG 1308  
Db      961 TCTATGTCAATGTGAGTCTTCCACTATGATATAAACTGCTTCTCTGGAGGTAGGAG 1020  
  
QY      1309 GCCAGTCCAGGCAATTCTT-CCAGGGCAGTGTCCAGAAAATCAGTACGGCCTTCATT 1367  
Db      1021 GCCAGTCCAGGCAATTCTTCCAGGGCAGTGTCCAGAAAATCAGTACGGCCTTCATT 1080  
  
QY      1368 TGAATAATGCTTCTTATCGGGTCCCTGCTCTTTGGTCTCTGTCTCTGTATAGGCT 1427  
Db      1081 TGAATAATGCTTCTTATCGGGTCCCTGCTCTTTGGTCTCTGTCTCTGTATAGGCT 1140  
  
QY      1428 CGTCTCTGGGTAGAAATCTTTCGGAATCACTCCGAGGAAACGTTACTCAAGACTGGA 1487  
Db      1141 CGTCTCTGGGTAG-ATCTCTCGGAATCACTCCGAGGAAACGTTACTCAAGACTGGA 1199  
  
QY      1488 TTATTTGATCAATGGGATCTATGTGACATCTAAGATGGAACCTGGTGTCTTAATTC 1547  
Db      1200 TTATTTGATCAATGGGATCTATGTGACATCTAAGATGGAACCTGGTGTCTTAATTC 1259  
  
QY      1548 ATTTAGTAACAGAAAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGCTTAGCAGA 1607  
Db      1260 ATTTAGTAACAGAAAGCCCAATGCAATGAGTTTCTGCTGACTTGTAGCTTAGCAGA 1319  
  
QY      1608 GGTGTATTTTGAAGACAGAAATGCCCTTCTGCTTCTTTTCTTTTGGAGACA 1667  
Db      1320 GGTGTATTTTGAAGACAGAAATGCCCTTCTGCTTCTTTTCTTTTGGAGACA 1379  
  
QY      1668 GAGCTTGCTCTGTTGCCAGGCTGAGTGCAGTAGACAGATCTCGGCTCTCACCGCAAC 1727  
Db      1380 GAGCTTGCTCTGTTGCCAGGCTGAGTGCAGTAGACAGATCTCGGCTCTCACCGCAAC 1439  
  
QY      1728 CTCCTCTCTCTGGGTTCAAGCGATTCTCTGCTCAAGCTCTTAAGTATCTGGGATTACA 1787  
Db      1440 CTCCTCTCTCTGGGTTCAAGCGATTCTCTGCTCAAGCTCTTAAGTATCTGGGATTACA 1498  
  
QY      1788 GGCATGTGCCACCAACACCTGGGTGATTTTGTATTTTATAGACAGGGGTTTACCAAT 1847  
Db      1499 GGCATGTGCCACCAACACCTGGGTGATTTTGTATTTTATAGACAGGGGTTTACCAAT 1557  
  
QY      1848 GTTGTCAAGGCTGTCTCAAATCTCTGACCTAGTATCAACCTCTCGGCTCCCAAAG 1907  
Db      1558 GTTGTCAAGGCTGTCTCAAATCTCTGACCTAGTATCAACCTCTCGGCTCCCAAAG 1617  
  
QY      1908 TGTGGGATTTACAGGATAGGCCAACACAGCTGGCCCTTCTGTTTATGTTGGTTT 1967  
Db      1618 TGTGGGATTTACAGGATAGGCCAACACAGCTGGCCCTTCTGTTTATGTTGGTTT 1677  
  
QY      1968 TGAAGAAGATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTAAATAT 2027  
Db      1678 TGAAGAAGATGAAGTGGGAACCAATTAGGTAATTTGGGTAATCTGTCTAAATAT 1737  
  
QY      2028 TAGCTAAAAACAAAGCTCTATGTAAAGTAATAAGTATATGCCATATAAATTTCAAAA 2087  
Db      1738 TAGCTAAAAACAAAGCTCTATGTAAAGTAATAAGTATATGCCATATAAATTTCAAAA 1797  
  
QY      2088 TTCAACTGGCTTTTATGCAAGAAACAGGTTAGACATCTAGGTTCCAATTCATTCAAT 2147  
Db      1798 TTCAACTGGCTTTTATGCAAGAAACAGGTTAGACATCTAGGTTCCAATTCATTCAAT 1857  
  
QY      2148 TCTTGGTTCCAGATAAAATCAACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTT 2207  
Db      1858 TCTTGGTTCCAGATAAAATCAACTGTTTATATCAATTTCTAATGAGATTGCTTTCTTTT 1917  
  
QY      2208 TATATGATTCCTTTAAACTTATTTCCAGATGATGTTCTTCCAATTAATATTTGAATA 2267  
Db      1918 TATATGATTCCTTTAAACTTATTTCCAGATGATGTTCTTCCAATTAATATTTGAATA 1977  
  
QY      2268 AATCTTTTGTACTCAA 2284  
Db      1978 AATCTTTTGTACTCAA 1994
```

RESULT	14
LOCUS	AB060888
DEFINITION	AB060888 2345 bp mRNA linear PRI 13-JUN-2001 Macaca fascicularis brain cDNA clone:Qtra-13483, full insert sequence.
ACCESSION	AB060888
VERSION	AB060888.1 GI:13874554
KEYWORDS	oligo capping; fig (full insert sequence).
SOURCE	Macaca fascicularis (craab-eating macaque)
ORGANISM	Macaca fascicularis Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Cercopitheciinae; Macaca.
REFERENCE	1 (sites) Osada,N., Hida,M., Kusunda,J., Tanuma,R., Iseki,K., Hirai,M., Terao,K., Suzuki,Y., Sugano,S. and Hashimoto,K. Isolation of full-length cDNA clones from macaque brain cDNA libraries
JOURNAL	Unpublished
REFERENCE	2 (bases 1 to 2345) Hashimoto,K., Osada,N., Hida,M., Kusunda,J. and Sugano,S. Direct Submission
AUTHORS	Submitted (27-APR-2001) Katsuyuki Hashimoto, National Institute of Infectious Diseases, Division of Genetic Resources; 23-1, Toyama 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan (E-mail:khashi@nih.go.jp, URL:http://www.nih.go.jp/yoken/genebank/, Tel:81-3-5285-1111(ex.2120), Fax:81-3-5285-1181)
JOURNAL	Lab host: TOP10 Vector: PME18S-FL3 (Acc.No. AB009864) R. Site1: DraIII (CACTGTGTCG) R. Site2: DraIII (CACCATGTG)
COMMENT	Description: 1st strand cDNA was primed with an oligo(dt) primer [ATGTGGCCCTTTTCTTTTCTTTT]; double-stranded cDNA was synthesized using specific 5' and 3' primers and amplified by PCR. The PCR product was digested with SfiI and size selection was performed to exclude fragments <1.5kb.The SfiI-digested PCR product was cloned into distinct DraIII sites of pME18S-FL3. XhoI sites just outside the DraIII sites can be used to isolate the cDNA insert. Libraries were constructed by oligo-capping method (Sugano et al., , Institute of Medical Science, University of Tokyo). Custom primer used for sequencing ( 5' end primer [CTTCTGCTCTAAAGCTGCG] ; 3' end primer [CGACCTGCAGCTCGACGACA] ).
FEATURES	location/Qualifiers 1..2345 /organism="Macaca fascicularis" /mol_type="mRNA" /db_xref="taxon:9541" /clone="Qtra-13483" /sex="male" /tissue_type="temporal lobe right" /clone_lib="macaque brain cDNA library Qtra" /dev_stage="adult" 255..1550 /codon_start=1 /product="hypothetical protein" /protein_id="BAB46892.1" /db_xref="GI:13874555" /translation="MEFGKGSLTYTLVVICFLRLRLAASQNCLNKLSEVDVIDIOSSLSKIGIRNEPIYTSOEDCINSCTKIISGDACNFMIPTRKIARPNCYLFCFENBEACPLPKAKGLRSYRIIRDPSLTRNLPSQELPQEDSLLPGFQSQAVTPLARHHIVYSKPTDISWRETLPOKFGSSDHLLEKLFNMDKASADLVYKEKGSQSQSISSQDEIAHLLPENVSVPATVAVASPHITSATPKPAIRLPYNASVTSPGTSQPOLATSPPVTVTSOPPTLIISTGFTRAVATLQAMATTAVLTTFQAPFDLKSGLETIPTETISNTLNTGNVVNPALSMNSNVKSATNKKTASWEGRASPGRSSQGNVPENOYGLPFKKMLIGSLLEGVLFVLVIGLVLLGRILISESLRKRYSRLDYLINGIYVDI"
CDS	
ORIGIN	

QY	1	GGGGAGCATCCGGCTGCGGGTCCCTCGCCGAGACCCCCCGCGGGATTGCGCCGGTCTTCCCGC	60
Db	30	GGGAGCATCCCCCTGCGGTCTCGCCGAGACCCCCCGCGGGATTGCGCCGGTCTTCCCGC	89
QY	61	GGGGCGGACAGAGCTGTCTCGCACCTGGATGGACAGGGGGCGCGGGGTCTCTCGAC	120
Db	90	GAGCGGACAGAGCTGTCTCGCACCCGGAGGGGACAGGGGGCCCCGGGGCCCTCTCGCC	149
QY	121	GCCAGAGAGAAATCATCATCTGTGAGCCCTTTAAAGCAAACTAAGACCAAGAGGAG	180
Db	150	TCCAGAGAGAAATTCGTCTGTGCAACTTTCTTAAAGCAAACTAAGACCAAGAGGAG	209
QY	181	GATTATCCTTGACCTTGAAGACCAAACTAACTGAATTTAAATGTCTTCGGGGGA	240
Db	210	AATTATCCTTGACCTTGAAGACCAAACTAACTGAATTTAAATGTCTTCGGGGGA	269
QY	241	GAAAGGAGCTTGACTTACACTTTGGTATATTTGCTTCTGACACTAAGGCTGTGCT	300
Db	270	AAAAGGAGCTTGACTTACACTTTGGTATATTTGCTTCTGACACTAAGGCTGTGCT	329
QY	301	AGTCAGAAATGCTCAAAAAGAGCTTAGAAGATGTGTCAATTGACATCCAGTCACTCTT	360
Db	330	AGTCAGAAATGCTCAAAAAGAGCTTAGAAGATGTGTCAATTGACATCCAGTCACTCTT	389
QY	361	TCTAAGGGAATCAGAGCAATGAGCCCGTATATCTTCAACTCAAGAGAGCTGCAATTAAT	420
Db	390	TCTAAGGGAATCAGAGCAATGAGCCCGTATATCTTCAACTCAAGAGAGCTGCAATTAAT	449
QY	421	TCTTGCTGTTCAACAAAAAATATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC	480
Db	450	TCTTGCTGTTCAACAAAAAATATATCAGGGGACAAAGCATGTAACTTGATGATCTTCGAC	509
QY	481	ACTCGAAAAACAGCTAGACAACCCCACTGCTACTATTTTCTGTCCCAAGAGAGACC	540
Db	510	ACTCGAAAAATAGCCAGACGACCCCACTGCTACTATTTTCTGTCCCAATGAGAGAGCC	569
QY	541	TGTCCATTGAAACCAGCAAAAGGACTTATGAGTTACAGATAATTACAGATTTTCCATCT	600
Db	570	TGTCCACTGAAACCAGCAAAAGGACTTATGAGATAATTACAGATAATTTCATCT	629
QY	601	TTGACCCAGAAATTTGCCAAGCCCAAGAGTTACCCCGAGAGAGATTCTCTTACATGSCCA	660
Db	630	TTGACCCAGAAATTTGCCAAGCCCAAGAGTTACCCCGAGAGAGATTCTCTTACATGSCCA	689
QY	661	TTTTCACAAGCAGTCACTCCCTAGCCCATCATCACACAGATTATTCAAGGCCCAACGAT	720
Db	690	TTTTCACAAGCAGTCACTCCCTAGCCCATCATCATAGTTATTCAAGGCCCAACGAT	749
QY	721	ATCTCATGAGAGACACTTCTCAGAAATTGGATCCTCAGATCACCTGGAGAACTA	780
Db	750	ATCTCATGAGAGACACTTCTCAGAAATTGGATCCTCAGATCACCTGGAGAACTA	809
QY	781	TTTAAGATGGATGAGCAAGTGCCCAAGCTCCTTGCTTAATAAGAAAAAGGCCATTCTCAG	840
Db	810	TTTAATATGACAAAGCAAGTGCCCAAGCTCCTTGCTTAATAAGAAAAAGGCCATTCTCAG	869
QY	841	AGTTCACAAATTTTCTCTGATCAAGAAATAGCTCATCTGCTGCCCTGAAAAATGTGAGTGCG	900
Db	870	AGTTCACAGATTTCTCTGATCAAGAAATAGCTCATCTGCTGCCCTGAAAAATGTGAGTGCG	929
QY	901	CTCCAGCTACGGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCGC	960
Db	930	TTCCAGCTACAGTGGCAGTTGCTTCTCCACATACCACTCGGCTACTCCAAAGCCGCGC	989
QY	961	ACCCTTCTACCCACCAATGCTTCAAGTACACCTTCTGGGACTTCCAGCCACAGCTGGCC	1020
Db	990	ATCCGTCTACCCACCAATGCTTCAAGTACACCTTCTGGGACTTCCAGCCACAGCTGGCC	1049
QY	1021	ACCACAGCTCCACCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCCTCATTTCTACA	1080
Db	1050	ACCACATCTCCGCTGTAAACCACTGTCACTTCTCAGCCTCCCAAGACCCTCATTTCTACA	1109
QY	1081	GTTTTTACACGGGCTGCGGCTACACTCCAAAGCAATGCTTCAACAACAGCATTTCTGACTACC	1140



```

Db      1110 GGTTTTACAGGGGCTGTGGCTACACTCCAGCAATGGCTACACAGCAGTTCGACTACC 1169
Qy      1141 ACCTTCAGGCACCTACGAGCTCGAAGGCACTTAGAACCACCTTTCAGAAATC 1200
Db      1170 ACCTTCAGGCACCTACGAGCTCGAAGGCACTTAGAACCACCTTTCAGAAATC 1229
Qy      1201 TCCTAATTAACTTTGAAACACAGGGAATGTGTATAACCCCTACTGCACTTCTATGTCAAT 1260
Db      1230 TCCTAATTAACTTTGAAACACAGGGAATGTGTATAACCCCTACTGCACTTCTATGTCAAT 1289
Qy      1261 GTGAGTCTTCCACTATGATATAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGC 1320
Db      1290 GTGAAGTCTTCCGCTACGAAATAAACTGCTTCTGGGAAGGTAGGAGGCCAGTCCAGGT 1349
Qy      1321 AGTTCCTCCAGGGCAGTGTTCAGAAATCAGTACGGCCCTTCCATTGAAAAATGGCTT 1380
Db      1350 CGTTCCTCCAGGGCAGTGTTCAGAAATCAGTATGCCCTTCCATTGAAAAATGGCTT 1409
Qy      1381 CTATCGGGTCCCTGCTCTTGTGTCTGTCTCTGTGTATAGGCTCGTCCCTGGGT 1440
Db      1410 CTATCGGATCCCTGCTCTTGTGTCTGTCTGTGTATAGGCTCGTCCCTGGGC 1469
Qy      1441 AGAATCCTTCGGAATCACTCCGAGAAACGTTACTCAAGACTGATATTGATCAAT 1500
Db      1470 AGAATCCTTCGGAATCACTCCGAGAAACGTTACTCAAGACTGATATTGATCAAT 1529
Qy      1501 GGGATCTATGTGACATCTAAGAGTGAATCTGGGTCTCTTAATTCATTAGTAACCAAG 1560
Db      1530 GGGATCTATGTGACATCTAAGAGTGAATCTGAGTCTCTTCAATTAGTAACCAAG 1589
Qy      1561 AAGCCAAATGCAATGAGTTCTGTGACTGTAGTCTTAGCAGAGGTGTATTGTA 1620
Db      1590 AAGCCAAATGCAATGAGTTCTGTGACTGTAGTCTTAGCAGAGGTGTACTTTGA 1649
Qy      1621 AGACAGAAAAATGCCCCCTTCTGCTTCC-----TTTT 1653
Db      1650 AGACAGAAAAATGCCCCCATCTGCTTCTTTTTCATTTTGTGTTTGTGTTT 1709
Qy      1654 TTTTGTGAGACAGAGTCTGTCTGTGCCCCAGGCTGAGTGCAGTACAGCATCTCG 1713
Db      1710 TTTTGTGAGATAGAGTCTGTCTGTGCCCCAGGCTGAGTGCAGTACAGCATCTCG 1769
Qy      1714 GCTCTCACCGCAACCTCCGTCTCTGGGTTCAGCGATTTCTCTGCTCAGCCTCTAAG 1773
Db      1770 G--CTCAGTCAACCTCCATCTCTGGGTTCAGCGATTTCTCTGCTCAGCCTCTAAG 1827
Qy      1774 TATCTGGGATTCACAGGCAATGTGCCACACACCTGGGTGATTTTGTATTGTAAGAGA 1833
Db      1828 TAGCTGAGATTCACAGGCAATGTGCCACACACCTGGGTGATTTTGTATTGTAAGAGA 1887
Qy      1834 CGGGTTTCAACCATGTGTGTCAGGCTGTCTCAAACTCTGACCTAGTATCCACCCCTCC 1893
Db      1888 TGGGTTTCAACCATGTGTGTCAGGCTGTCTCAAACTCTGACCTAGTATCCGCCCACG 1947
Qy      1894 TCGGCTCCCAAGTGTGGATTCACAGGCAATGAGCCACCAACAGTGGCCCCCTTCTGT 1953
Db      1948 TTGGCTCCCAAGTGTGGATTCACAGGCAATGAGTACCAACCAACAGTGGCCCCCTTCTGT 2007
Qy      1954 TTATGTTGTTTTTGGAGAGGAATGAAGTGGGAACCAATTAAGTAATTT-TGGGTAAAT 2012
Db      2008 TTATGTTGTTTTTGGAGAGGAATGAAGTGGGAACCAATTAAGTAATTTGGGGGTAAAT 2067
Qy      2013 CTGTCTCTAAATATTAGCTAAACCAAGCTCTATGTAAAGTAATTAAGTATAATTGCC 2072
Db      2068 CTGTCTCTAAATATTAGCTAAACCAAGCTCTATCTA----- 2106
Qy      2073 ATATAAATTCAAAATTCAACTGGCTTTATGCAAGAAACAGTTAGGACATCTAGGTT 2132
Db      2107 -----AAAATTTGATTGGCTTTATGCAAGAAACAGTTAGGACATCTAGGTT 2155
Qy      2133 CCAATTCATTCACATCTCTGTTCAGATAAAATCAACTGTTTATCAATTTCTAATGG 2192

```

```

Db      2156 CCAATTAATTCACATCTCTGGTCCAGATAAAATCAACTGTTTATATCAATTTCTAATGC 2215
Qy      2193 ATTGCTTTTCTTTTATATGATTCCTTTAAACTTATTCAGATGATGTTCTTCCA 2252
Db      2216 ATTGCTTTTCTTTTATATGATTCCTTTAAACTTATTCAGATGATGTTCTTCCA 2275
Qy      2253 TTAATATTGATAATA 2269
Db      2276 TTAATATTGAAAAAA 2292

RESULT 15
AC131617/c
LOCUS
DEFINITION
Homo sapiens clone Rpl1-613M22, *** SEQUENCING IN PROGRESS ***
AC131617
AC131617.3 GI:22953886
KEYWORDS
HTG; HTGS_PHASE1; HTGS_ACTIVEFIN.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
REFERENCE
AUTHORS
Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C.,
Albrooks,S.L., Amaralunge,H.C., Are,J.R., Ayele,M., Banks,T.,
Barbata,J., Benton,J., Bimage,K., Blankenburg,K., Bonnin,D.,
Bouck,J., Bowie,S., Brieva,M., Brown,E., Brown,M., Bryant,N.P.,
Buhay,C., Burch,P., Burkett,C., Burrell,K.L., Byrd,N.C.,
Carroll,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D.,
Chen,G., Chen,R., Chen,Z., Chowdhry,I., Christopoulos,C.,
Cleveland,C.D., Cox,C., Coyle,M.D., Dathorne,S.R., David,R.,
Davila,M.L., Davis,C., Davy-Carroll,L., Dederich,D.A.,
Delaney,K.R., Delgado,O., Denn,A.L., Ding,Y., Dinh,H.H.,
Douthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J.,
Earnhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Escotto,M.,
Falls,T., Ferraguto,D., Flagg,N., Ford,J., Foster,P., Frantz,P.,
Gabriel,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R.,
Gorell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K.,
Harris,C., Harris,K., Hart,M., Havlak,P., Hawes,A., Hernandez,J.,
Hernandez,O., Hodgson,A., Hognes,M., Holloway,C., Hollins,B.,
Homsf,F., Howard,S., Huber,J., Hulyk,S., Hume,J., Jackson,L.B.,
Jacobson,B., Jia,Y., Johnson,R., Jolivet,S., Joudah,S.,
Karlsbom,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C.,
Kratovic,J., Kureshi,A., Landry,N., Leal,B., Lewis,L.C., Lewis,L.,
Li,J., Li,Z., Lichtarge,O., Lieu,C., Liu,J., Liu,W., Louisedge,H.,
Lozano,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J.,
Maheshwari,M., Mapua,P., Martin,R., Martindale,A., Martinez,E.,
Massey,E., Mawhiney,E., Mcleod,M.P., Meador,M., Mei,G., Metzker,M.,
Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Morgan,M., Morris,S.,
Moser,M., Neal,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N.,
Nguyen,N., Nickerson,E., Nwokenkwo,S., Ogih,M., Okuwon,G.,
Oragunye,N., Oviedo,R., Pace,A., Payton,B., Peery,J., Perez,L.,
Peterson,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Ren,Y.,
Rivers,M., Rojas,A., Rojubenkan,I., Rolfe,M., Ruiz,S., Savary,G.,
Scherer,S., Scott,G., Shen,H., Shooshitari,N., Sisson,I.,
Sodergren,E., Sonalke,T., Sparks,A., Stanley,H., Stone,H.,
Sutton,A., Svatek,A., Tabor,P., Tamerisa,A., Tamerisa,K., Tang,H.,
Tansley,J., Taylor,C., Taylor,T., Telford,B., Thomas,N., Thomas,S.,
Umanan,K., Vasquez,L., Vera,V., Villalon,D., Vinson,R., Wang,Q.,
Wang,S., Ward-Moore,S., Warren,R., Washington,C., Watlington,S.,
Williams,G., Williamson,A., Wleczyk,R., Wooden,S., Worley,K.,
Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Nelson,D.,
Weinstock,G., and Gibbs,R.
TITLE
Direct Submission
JOURNAL
Unpublished
AUTHORS
Worley,K.C.
REFERENCE
2 (bases 1 to 188344)
Direct Submission
Submitted (25-AUG-2002) Human Genome Sequencing Center, Department
of Molecular and Human Genetics, Baylor College of Medicine, One
Baylor Plaza, Houston, TX 77030, USA
3 (bases 1 to 188344)
REFERENCE

```



QY 1884 TCCACCTCTCGGCTCCCAAAGTCTGGGATTACAGGCATGAGCCACACAGCTGGCC 1943  
|||  
Db 7429 TCCACCTCTCGGCTCCCAAAGTCTGGGATTACAGGCATGAGCCACACAGCTGGCC 7370  
QY 1944 CCCTTCTGTTTATGTTGGTTTGAAGAAGATGAAGTGGGAACCAATTAGTAAAT 2003  
|||  
Db 7369 CCCTTCTGTTTATGTTGGTTTGAAGAAGATGAAGTGGGAACCAATTAGTAAAT 7310  
QY 2004 TTGGGTAATCTGTCTTAAATATAGCTAAAAACAAGCTCTATGTAAAGTAAATAAGT 2063  
|||  
Db 7309 TTGGGTAATCTGTCTTAAATATAGCTAAAAACAAGCTCTATGTAAAGTAAATAAGT 7250  
QY 2064 ATAAATGCCATATAAATTTCAAAATCAACTGGCTTTTATGCAAGAACAAGTTAGGAC 2123  
|||  
Db 7249 ATAAATGCCATATAAATTTCAAAATCAACTGGCTTTTATGCAAGAACAAGTTAGGAC 7190  
QY 2124 ATCTAGGTTCCAATTTCATTCACATCTTGGTTCCAGATAAAATCAACTGTTATATCAAT 2183  
|||  
Db 7189 ATCTAGGTTCCAATTTCATTCACATCTTGGTTCCAGATAAAATCAACTGTTATATCAAT 7130  
QY 2184 TTCTAATGGATTGCTTTCTTTTATATGAGATTCCCTTAAAACTTATTCAGATGTAGT 2243  
|||  
Db 7129 TTCTAATGGATTGCTTTCTTTTATATGAGATTCCCTTAAAACTTATTCAGATGTAGT 7070  
QY 2244 TCCTTCCAATTAAATATTTGAATAAATCTTTGTACTCA 2283  
|||  
Db 7069 TCCTTCCAATTAAATATTTGAATAAATCTTTGTACTCA 7030

Search completed: September 25, 2004, 12:45:11  
Job time : 9027 secs



**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2004, 14:10:53 / Search time 52 Seconds  
(without alignments)  
2615.160 Million cell updates/sec

Title: US-09-944-929-83

Perfect score: 2211

Sequence: 1 MFEGEGSLTYTLVICFLT.....LRRKRYSLDYLINGIYVDI 431

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 1500 summaries

Database :

- 1: sp\_archaea:\*
- 2: sp\_bacteria:\*
- 3: sp\_fungi:\*
- 4: sp\_human:\*
- 5: sp\_invertebrate:\*
- 6: sp\_mammal:\*
- 7: sp\_mhc:\*
- 8: sp\_organelle:\*
- 9: sp\_phage:\*
- 10: sp\_plant:\*
- 11: sp\_rodent:\*
- 12: sp\_virus:\*
- 13: sp\_vertebrate:\*
- 14: sp\_unclassified:\*
- 15: sp\_rvirus:\*
- 16: sp\_bacteriap:\*
- 17: sp\_archaeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	2211	100.0	431	4	Q9H8J5	Q9h8j5 homo sapien
2	2210	100.0	431	4	Q8NEC1	Q8nec1 homo sapien
3	2039	92.2	431	6	Q95KG7	Q95kg7 macaca fasc
4	2022	91.5	397	4	Q9NM60	Q9nm60 homo sapien
5	1179.5	53.3	414	11	Q80V71	Q80v71 mus musculu
6	1164.5	52.7	414	11	Q9CR33	Q9cr33 mus musculu
7	503	22.7	194	11	Q8K0I0	Q8k0i0 mus musculu
8	197.5	8.9	392	11	Q8VCP2	Q8vcp2 mus musculu
9	197	8.9	449	4	Q9H2K4	Q9h2k4 homo sapien
10	196.5	8.9	392	11	Q9D8N1	Q9d8n1 mus musculu
11	188	8.5	449	4	Q96F05	Q96f05 homo sapien
12	180.5	8.2	1349	4	Q8WWQ4	Q8wwq4 homo sapien
13	168	7.6	519	5	Q7YTR7	Q7ytr7 caenorhabdi
14	160.5	7.3	477	4	Q14887	Q14887 homo sapien
15	157.5	7.1	2448	4	Q8WWQ5	Q8wwq5 homo sapien
16	156.5	7.1	328	4	O00446	O00446 homo sapien

17	155.5	7.0	769	5	Q17921	Q17921 caenorhabdi
18	155.5	7.0	770	5	Q20908	Q20908 caenorhabdi
19	154	7.0	534	3	O94317	O94317 schizosacch
20	152	6.9	744	3	Q8TFG9	Q8tf99 schizosacch
21	150.5	6.8	382	5	Q9XZ28	Q9xz28 litomosoid
22	147.5	6.7	790	5	Q20599	Q20599 caenorhabdi
23	147.5	6.7	842	5	Q95QF5	Q95qf5 caenorhabdi
24	146	6.6	316	12	Q8V0M4	Q8v0m4 equine herp
25	146	6.6	457	5	Q86AK1	Q86ak1 dictyosteli
26	145.5	6.6	629	5	Q24017	Q24017 drosophila
27	145.5	6.6	716	4	Q9NYE4	Q9nye4 homo sapien
28	145	6.6	1079	5	Q9N4S7	Q9n4s7 caenorhabdi
29	144.5	6.5	377	4	Q8TAX7	Q8tax7 homo sapien
30	144.5	6.5	505	4	Q14395	Q14395 homo sapien
31	144.5	6.5	683	5	Q8MRH5	Q8mrh5 drosophila
32	144.5	6.5	787	5	Q9VEY6	Q9vey6 drosophila
33	144	6.5	22152	4	Q8WX17	Q8wx17 homo sapien
34	143.5	6.5	1414	11	Q80Z22	Q80z22 mus musculu
35	143.5	6.5	2850	11	Q80T03	Q80t03 mus musculu
36	142.5	6.4	826	12	Q8V0L5	Q8v0l5 equine herp
37	142.5	6.4	866	12	Q39781	Q39781 equine herp
38	142.5	6.4	867	12	Q39782	Q39782 equine herp
39	142.5	6.4	1444	5	Q9VTN2	Q9vtn2 drosophila
40	142.5	6.4	1514	5	Q8SY55	Q8sy55 drosophila
41	142	6.4	483	5	Q9W4M2	Q9w4m2 drosophila
42	142	6.4	873	5	Q9W468	Q9w468 drosophila
43	141.5	6.4	1391	13	Q7ZW07	Q7zw07 brachydanio
44	141	6.4	374	12	Q8V0L6	Q8v0l6 equine herp
45	141	6.4	626	11	Q9CZB2	Q9czb2 mus musculu

ALIGNMENTS

RESULT 1

ID	Q9H8J5	PRELIMINARY;	PRT;	431 AA.
AC	Q9H8J5;			
DT	01-MAR-2001 (Tremblrel. 16, Created)			
DT	01-MAR-2001 (Tremblrel. 16, Last sequence update)			
DT	01-OCT-2002 (Tremblrel. 22, Last annotation update)			
DE	Hypothetical protein FLJ13560.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Placenta;			
RA	Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,			
RA	Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,			
RA	Wagatsuma M., Hosoi T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,			
RA	Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,			
RA	Watanabe S., Kimura K., Murakami K., Ishi S., Kawai Y., Saito K.,			
RA	Yamamoto J., Wakamatsu A., Nakamura Y., Nagahari K., Masuo Y.,			
RA	Ninomiya K., Iwayanagi T.;			
RT	"NEDO human cDNA sequencing project."			
RL	Submitted (AUG-2000) to the EMBL/Genbank/DBJ databases.			
DR	EMBL; AK023622; BAB14621.1; ..			
KW	Hypothetical protein.			
SQ	SEQUENCE 431 AA; 46810 MW; 189136416F0F89AE CRC64;			

Query Match 100.0%; Score 2211; DB 4; Length 431;  
Best Local Similarity 100.0%; Pred. No. 8.2e-159;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MFEGEGSLTYTLVICFLTRLASQNCIKSLSDVDVIDIQSSISKIRGNEPVYTSTQ	60
DB	1	MFEGEGSLTYTLVICFLTRLASQNCIKSLSDVDVIDIQSSISKIRGNEPVYTSTQ	60
QY	61	EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEBACPLKPAKGLMSYRII	120
DB	61	EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEBACPLKPAKGLMSYRII	120

[illegible]

RESULT 2	
ID Q8NEC1	PRELIMINARY; PRT; 431 AA.
AC Q8NEC1;	
DT 01-OCT-2002 (TREMBlrel. 22, Created)	
DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)	
DT 01-MAR-2003 (TREMBlrel. 23, Last annotation update)	
DE Hypothetical protein FLJ10298.	
OS Homo sapiens (Human).	
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
OX NCBI_TaxID=9606;	
RN [1]	
RP SEQUENCE FROM N.A.	
RC TISSUE=Testis;	
RA Strausberg R.;	
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.	
DR EMBL; BC032998; AAH32998.1; -.	
KW Hypothetical protein.	
SQ SEQUENCE 431 AA; 46824 MW; 1BCEBBD168AC839D CRC64;	
Query Match	100.0%; Score 2210; DB 4; Length 431;
Best Local Similarity	99.8%; Pred. No. 9.7e-159;
Matches 430; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY 1 MFFGEGSLTYTLVVICFLTLRLSASQNCCLKSLEDVIDIQSSLSKIRGNPEVYSTQ 60	
DB 1 MFFGEGSLTYTLVVICFLTLRLSASQNCCLKSLEDVIDIQSSLSKIRGNPEVYSTQ 60	
QY 61 EDCINSCSTKNISGDKACNLMIFPTRKTARQPNCYLFFCPNEEACPLKPAKGLMSYRII 120	
DB 61 EDCINSCSTKNISGDKACNLMIFPTRKTARQPNCYLFFCPNEEACPLKPAKGLMSYRII 120	
QY 121 TDFPSLTRNLPSQELPQEDSLHGQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180	
DB 121 TDFPSLTRNLPSQELPQEDSLHGQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180	
QY 181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240	
DB 181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240	
QY 241 TPKPATLLPTNASVTPSGTSQPQLATTAPVTTVTTSQPTTLISIVFTRAATLQAMATT 300	
DB 241 TPKPATLLPTNASVTPSGTSQPQLATTAPVTTVTTSQPTTLISIVFTRAATLQAMATT 300	
QY 301 AVLTTFQAPTDKSGSLETFPTEISNLTNTGNVYNPTALSMNSVSSSTMNKTASWEGR 360	

Db	301	AVLTFTTQAPTDSSKGSLETIPFTEISNLTNTGNVYNPTALSMSNVESSTIMNKKTASWEGR	360
QY	361	EASPGSSSQGSPENQYGLPFEKWLIGSLLFGVLFLVIGLVLLGRILSESLRRKRYSRL	420
Db	361	EASPGSSSQGSPENQYGLPFEKWLIGSLLFGVLFLVIGLVLLGRILSESLRRKRYSRL	420
QY	421	DYLINGIYVDI	431
Db	421	DYLINGIYVDI	431

### RESULT 3

ID	Q95KG7	PRELIMINARY;	PRT;	431 AA.
AC	Q95KG7;			
DT	01-DEC-2001	(TREMBLrel. 19, Created)		
DT	01-DEC-2001	(TREMBLrel. 19, Last sequence update)		
DT	01-OCT-2003	(TREMBLrel. 25, Last annotation update)		
DE	Hypothetical protein.			
OS	Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;			
OC	Cercopithecinae; Macaca.			
OX	NCBI_TaxID=9541;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Temporal cortex;			
RA	Osada N., Hida M., Kusunida J., Tanuma R., Iseki K., Hirai M., Terao K.,			
RA	Suzuki Y., Sugano S., Hashimoto K.;			
RT	"Isolation of full-length cDNA clones from macaque brain cDNA			
RT	libraries ";			
RL	Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.			
DR	EMBL; AB060888; BAB46892.1; -.			
KW	Hypothetical protein.			
SQ	SEQUENCE 431 AA; 47104 MW; BF10996E87F76C69 CRC64;			

Query Match	92.2%;	Score 2039;	DB 6;	Length 431;
Best Local Similarity	92.3%;	Pred. No. 8.1e-146;		
Matches 398;	Conservative	9;	Mismatches 24;	Indels 0;
				Gaps 0;

QY	1	MEFGEGSLTYTLVVICFLTRLSASONCLKKSLEDVIDIOSSLKGIKRGNEPYTSTQ	60
Db	1	MEFGGKSLTYTLVVICFLTRLASONCLNKSLLEDVIDIOSSLKGIKRGNEPYTSTQ	60
QY	61	EDCINSCCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEEACPLKPAKGLMSYRII	120
Db	61	EDCINSCCSTKIIISGDKACNFMIFDTRKIARRPNCYLFFCPNEEACPLKPAKGLRSYRII	120
QY	121	TDFPSLTRNLPSOELPOEDSLHGQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD	180
Db	121	RDFPSLTRNLPSOELPQEDSLPGQFSQAVTPLARHHIVYSKPTDISWRETLPOKFGSSD	180
QY	181	HLEKLFKMEDEASAOQLAYKEKGHSOSSQSSDQEI AHL PENVSALPATVAVASPHTTSA	240
Db	181	HLEKLFNMDKASAOQLVYKEKGHSOSSQISSDQEI AHL PENVS VF PATVAVASPHTTSA	240
QY	241	TPKPATLLPTNASVTPSGTSQPOLATTA BPVTTVTSQ PPTLLISTVFTRAATLOAMATT	300
Db	241	TPKPAIRLPTNASVTPSGTSQPOLATTSBPVTTVTSQ PPTLLISTGFTRAATLOAMATT	300
QY	301	AVLTTTFOAPTD SKSLETIPFTEISNULTNTGNVYNPTALSMSNVESSTMNKTA SWEGR	360
Db	301	AVLTTTFOAPTD LKGSLETIPFTEISNULTNTGNVYNPTALSMSNVKSSATNKTA SWEGR	360
QY	361	EASPGSSSQGSVPENQYGLPFEKMLLIGSLLFGVLFVLVIGVLLGRILSESLRRKRSRL	420
Db	361	EASPGRSSQGNVPENQYGLPFEKMLLIGSLLFGVLFVLVIGVLLGRILSESLRRKRSRL	420
QY	421	DYLINGIYVDI 431	
Db	421	DYLINGIYVDI 431	



RESULT 4  
Q9NW60 PRELIMINARY; PRT; 397 AA.  
AC Q9NW60;  
DT 01-OCT-2000 (TREMBlrel. 15, Created)  
DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)  
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
DE Hypothetical protein FLJ10298.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxId=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,  
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,  
RA Wagatsuma M., Hosoi T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,  
RA Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,  
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,  
RA Yamamoto J., Wakamatsu A., Nakamura Y., Nagahari K., Masuho Y.,  
RA Ninomiya K., Iwayanagi T.,  
RT "NEDO human cDNA sequencing project."  
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AK001160; BAA91526.1; -.  
KW Hypothetical protein.  
SQ SEQUENCE 397 AA; 43062 MW; E2FEFF2E61122C62 CRC64;

Query Match 91.5%; Score 2022; DB 4; Length 397;  
Best Local Similarity 92.1%; Pred. No. 1.4e-14;  
Matches 397; Conservative 0; Mismatches 0; Indels 34; Gaps 1;

QY 1 MFFGEGSLTYTVIIICFLTLRLSASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
DB 1 MFFGEGSLTYTVI-----GIRGNEPVYTSTQ 26  
QY 61 EDCINSCCSTKNISGDKACNLMIFDTRKTARQPCYLFPCPNEACPLKPAKGLMSYRII 120  
DB 27 EDCINSCCSTKNISGDKACNLMIFDTRKTARQPCYLFPCPNEACPLKPAKGLMSYRII 86  
QY 121 TDFPSLTRNLPSQELPQEDSLHGOFSQAVTPLAHHTDYSKPTDISWRDLSQKFGSSD 180  
DB 87 TDFPSLTRNLPSQELPQEDSLHGOFSQAVTPLAHHTDYSKPTDISWRDLSQKFGSSD 146  
QY 181 HLEKLFKMDASAOQLAYKEKGHSQSSQFSSDOEIAHLLENVSALPATVAVASPHTTSA 240  
DB 147 HLEKLFKMDASAOQLAYKEKGHSQSSQFSSDOEIAHLLENVSALPATVAVASPHTTSA 206  
QY 241 TPKPATLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLISTVFTRAATLQAMATT 300  
DB 207 TPKPATLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLISTVFTRAATLQAMATT 266  
QY 301 AVLTTTFOAPTDKGSLETIPTEISNLTNTGNVYNPTALSMNSVSSSTMNKTASWEGR 360  
DB 267 AVLTTTFOAPTDKGSLETIPTEISNLTNTGNVYNPTALSMNSVSSSTMNKTASWEGR 326  
QY 361 EASPGSSSGSVPENQYGLPFEKMLLIGSLFGVLFLVIGLVLLGRILSESLRKRYSRL 420  
DB 327 EASPGSSSGSVPENQYGLPFEKMLLIGSLFGVLFLVIGLVLLGRILSESLRKRYSRL 386  
QY 421 DYLINGIYVDI 431  
DB 387 DYLINGIYVDI 397

RESULT 5  
Q8OV71 PRELIMINARY; PRT; 414 AA.  
AC Q8OV71;  
DT 01-JUN-2003 (TREMBlrel. 24, Created)  
DT 01-JUN-2003 (TREMBlrel. 24, Last sequence update)  
DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)  
DE 9130403P13Rik protein.  
OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxId=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=FVB/N; TISSUE=Breast tumor;  
RX MEDLINE=22388257; PubMed=12477932;  
RA Strausberg R.L., Feingold E.A., Grouse J.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
RA Krzywinski M.I., Skalska U., Smalins D.E., Schnerch A., Schein J.E.,  
RA Jones S.J., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences."  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=FVB/N; TISSUE=Breast tumor;  
RA Strausberg R.;  
RL Submitted (NOV-2002) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC039930; AAH39930.1; -.  
SQ SEQUENCE 414 AA; 44531 MW; 84AFB759D1B22755 CRC64;

Query Match 53.3%; Score 1179.5; DB 11; Length 414;  
Best Local Similarity 60.3%; Pred. No. 6.5e-81;  
Matches 260; Conservative 36; Mismatches 118; Indels 17; Gaps 6;

QY 1 MFFGEGSLTYTVIIICFLTLRLSASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
DB 1 MLFRGT-SLAYALVISFLTPRSSAGQNCCLKSLEDVIDIQSSLSKGRGNEPIHVAQ 59  
QY 61 EDCINSCCSTKNISGDKACNLMIFDTRKTARQPCYLFPCPNEACPLKPAKGLMSYRII 120  
DB 60 EDCVGAACCTKDIAGDKACNLMIFDTRKTDRQPCYLFPCPSEDACPLKPAKGLVTRYLI 119  
QY 121 TDFPSLTRNLPSQELPQEDSLHGOFSQAVTPLAHHTDYSKPTDISWRDLSQKFGSSD 180  
DB 120 RDPFLTSANSSLQQLTQGESLLDHSSPGATPGRTPAGYPRKPGISWSDGSSLSKSTAPL 179  
QY 181 HLEKLFKMDASAOQLAYKEKGHSQSSQFSSDOEIAHLLENVSALPATVAVASPHTTSA 240  
DB 180 HLRKHIADETSQTL--PEEKSHSQSLQLPSCLKMAHLPKVTPPTVAVAPLRNVSA 237  
QY 241 TPKPATLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLISTVFTRAATLQAMATT 300  
DB 238 TLKPAALL-TSISVTAKTLKQKE-ATTASPVTTVTSKLPAPVSGTSFT-----PVTHTQ 289  
QY 301 AVLTTTFOAPTDKGSLETIPTEISNLTNTGNVYNPTALSMNSVSSSTMNKTASWEGR 360  
DB 290 AALTNTFOAHTDSKGILETMPFGGSGTLT-----SDPRHGKSSSTSSSITNKTASWEDR 343  
QY 361 EASPGSSSGSVPENQYGLPFEKMLLIGSLFGVLFLVIGLVLLGRILSESLRKRYSRL 420  
DB 344 RVSVGASLNGPKPSQHGSLFEKMLLIGTLGCVLFLVIGLVLLGRMLVEALRKRYSRL 403  
QY 421 DYLINGIYVDI 431  
DB 404 DYLINGIYVDI 414

RESULT 6

Q9CR33 ID Q9CR33 PRELIMINARY; PRT; 414 AA.  
AC Q9CR33;  
DT 01-JUN-2001 (TReMBLrel. 17, Created)  
DT 01-JUN-2001 (TReMBLrel. 17, last sequence update)  
DT 01-MAR-2003 (TReMBLrel. 23, last annotation update)  
DE 9130403P13RIK protein (weakly similar to NT2RM1001115 protein).  
GN 9130403P13RIK.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6J; TISSUE=Cecum;  
RX MEDLINE=21085660; PubMed=11217851;  
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaoka I.,  
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
RA Schriml L.M., Staudli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,  
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
RA Gustingich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,  
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Wittaker C., Wilming L.,  
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohsaki S.,  
RA Hayashizaki Y.;  
RT "Functional annotation of a full-length mouse cDNA collection";  
RL Nature 409:685-690(2001).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6J; TISSUE=Colon, and Medulla oblongata;  
RX MEDLINE=22354683; PubMed=12466851;  
RA The FANTOM Consortium,  
RA the RIKEN Genome Exploration Research Group Phase I & II Team;  
RT "Analysis of the mouse transcriptome based on functional annotation of  
RT 60,770 full-length cDNAs";  
RL Nature 420:563-573(2002).  
RL EMBL; AK018660; BAB31329.1; -.  
DR EMBL; AK018635; BAB31319.1; -.  
DR EMBL; AK033526; BAC28341.1; -.  
DR EMBL; AK033557; BAC28357.1; -.  
DR EMBL; AK046837; BAC32892.1; -.  
DR MGD; MGI:1914979; 9130403P13RIK.  
SQ SEQUENCE 414 AA; 44822 MW; 29BB9197C916BA8E CRC64;  
Query Match 52.7%; Score 1164.5; DB 11; Length 414;  
Best Local Similarity 59.9%; Pred. No. 8.9e-80;  
Matches 258; Conservative 37; Mismatches 119; Indels 17; Gaps 6;  
QY 1 MFFGEGSLTYTLVVICFLTRLASQNLKKSLEDVIDIOSSLSKIRGNEPVYTSQ 60  
DB 1 MLFRGT-SLAYSLLVISFLTPRSSAGQNCITKSLEDVIDIQSSLSKIRGNEPIHLATQ 59  
QY 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
DB 60 EDCIGACSTKDIAGDKACNLMIFDTRKTRQPNCYLFFCPSEDA CPLKPAKGLVYRLI 119  
QY 121 TDFPSLTRNLPSQELPQEDSLHGFQAVTPPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
DB 120 RDFPLTSANSSILQLTQGEFLLDHSSPGATPGFRTPA GYPKPTGWSWSDRSSLKSTAPL 179  
QY 181 HLEKLFKMDASAQLLAYKKEGHSQSSSDQEI AHLLENVSALPATVAVASPHTTSA 240  
DB 180 HLRKHIAKADERTSMQL--PEEKSHSQSLQLPSELKMAHL LPKTVPTPTTVAVAPLRNVA 237

QY 241 TPKPATLLPTNASVTPSGTSQPOLATTA PVTVTTSQPPPTLLISTVETRAAATLQAMATT 300  
DB 238 TLKPELLL-TSISVTAKTLKQKE-ATTAS PVTVTTSKLPVGSGTSFT-----PVVTHQ 289  
QY 301 AVLTTTFOAPTDSKGSLETIPFTEISNLT LNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
DB 290 AALTPTFOAHTDSKGILETMPFGGSTLT- ----SDPRHGKSTSESSITNKTASWEDR 343  
QY 361 EASPGSSSQGSVPENQYGLPFEEKWLLIGS LLFGVLFLVIGLVLLGRILSESLRRKRY SRL 420  
DB 344 RVSVGASLNLKGPKSQHGSLFEKWL IIGTLGCVLFLVIGLVLLGRMLVEALRRKRY SRL 403  
QY 421 DYLINGIYVDI 431  
DB 404 DYLINGIYVDI 414  
RESULT 7  
Q8K010 ID Q8K010 PRELIMINARY; PRT; 194 AA.  
AC Q8K010;  
DT 01-OCT-2002 (TReMBLrel. 22, Created)  
DT 01-OCT-2002 (TReMBLrel. 22, last sequence update)  
DT 01-OCT-2002 (TReMBLrel. 22, last annotation update)  
DE Similar to hypothetical protein FLJ10298 (Fragment).  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Liver;  
RA Strausberg R.;  
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC031372; AAH31372.1; -.  
KW Hypothetical protein.  
FT NON TER 1  
SQ SEQUENCE 194 AA; 20701 MW; 11C1F299E1FB3C44 CRC64;  
Query Match 22.7%; Score 503; DB 11; Length 194;  
Best Local Similarity 59.5%; Pred. No. 3.1e-30;  
Matches 122; Conservative 13; Mismatches 56; Indels 14; Gaps 4;  
QY 227 PATVAVASPHHTSATPKPATLLPTNASVTPSGTSQPOLATTA PVTVTTSQPPPTLLISTV 286  
DB 4 PTVAVAPLRNVSATLKPALLL-TSISVTAKTLKQKE-ATTAS PVTVTTSKLPVAVGSGTS 61  
QY 287 FTTRAAATLQAMATTAVLTTPFOAPTDSKGSLETIPFTEISNLT LNTGNVYNPTALSMNSV 346  
DB 62 FT-----PVVTHQAALTNTFOAHTDSKGILETMPFGGSTLT-----SDPRHGKSGTS 109  
QY 347 ESSTMNKTASWEGREASPGSSSQGSVPENQYGLPFEEKWLLIGS LLFGVLFLVIGLVLLGR 406  
DB 110 ESSITNKTASWEDRVS VSGSASLNKGPKSQHGSLFEKWL IIGTLGCVLFLVIGLVLLGR 169  
QY 407 ILSESLRRKRYRLDYLINGIYVDI 431  
DB 170 MLVEALRRKRYRLDYLINGIYVDI 194  
RESULT 8  
Q8VCP2 ID Q8VCP2 PRELIMINARY; PRT; 392 AA.  
AC Q8VCP2;  
DT 01-MAR-2002 (TReMBLrel. 20, Created)  
DT 01-MAR-2002 (TReMBLrel. 20, last sequence update)  
DT 01-OCT-2002 (TReMBLrel. 22, last annotation update)  
DE RIKEN cDNA 1810055G02 gene.  
GN 1810055G02RIK.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;





	Query Match	8.9%;	Score 196.5;	DB 11;	Length 392;
	Best Local Similarity	26.1%;	Pred. No. 1.1e-06;		
	Matches	88;	Conservative 42;	Mismatches 110;	Indels 97; Gaps 15,
QY	156 HHTDYSKPTDISWRDTLSQKFGSSDHLEKLFKMDEASAOALLAYKEKHQSQSSQFSSDOEI	215			
	:     :	:	:     :	:	:
Db	88 HGNTNSTPT-----TREGTTDRV-----TSRTLAVPTSSGPPSAEQTRPTTI	129			
QY	216 AHL-----LPE-NVSALPAT--VAVASPHTT-----SATPKPATLLPT	250			
	:     :	:	:     :	:	:
Db	130 AGLPSLSTPHAEVPRTNASVSFRMAATAVAPHTATLAAGTVNTSDPHRTPTSPAKSTPT	189			
QY	251 N-ASVTPSGTSQPQLATTAPVVT-----VTSQRPPTLLISTVFTRAA	292			
	:   :         :	:	:         :	:	:
Db	190 DTSSKNPIPTSGAQIQGTIVQLTTDQPVHSTAGRALSPSNATLEPTTQVOYTK-EPSAS	248			
QY	293 TLQAMATTAVLTTFQAPFTDSKGSLETIIPTEISNLTLNTGNVNYETALISMNSVESSTM	352			
	:     :	:	:     :	:	:
Db	249 TVPARATSLSPDVDVISPTTPQS--PTLP-----TGCTGG--PGTLLTTQEVGTKTTS	297			
QY	353 KTASWEGREASPSSSQGSV-----PENQYGLPFE-----KWLLIGSLLF	393			
	:	:	:           :	:	:
Db	298 GTAS-----AGPTRSRSSGDIKVPITTDSCQPOSTQGQYLVTIDALTSLVNKMILLVLVG	352			
QY	394 VLFVLIGLVLLGRILSESLRRKRYSRLDYLINGIYVD	430			
	:				
Db	353 VTLEFAVLVMFALQAYESYKKKDYTQVDYLLINGMYAD	389			

RESULT 11			
Q96F05	ID	Q96F05	PRELIMINARY; PRT; 449 AA.
AC	Q96F05;		
DT	01-DEC-2001 (TREMBLrel. 19, Created)		
DT	01-DEC-2001 (TREMBLrel. 19, Last sequence update)		
DT	01-OCT-2003 (TREMBLrel. 25, Last annotation update)		
DE	Chromosome 11 open reading frame 24.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
OX	NCBI_TaxID=9606;		
RN	(1)		
RP	SEQUENCE FROM N.A.		
RC	TISSUE=Skin;		
RA	Strausberg R.;		
RL	Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.		
DR	EMBL; BC011765; AAH11765.1; -.		
DR	Genew; HGNC:1174; C11orf24.		
DR	InterPro; IPR001395; Aldo/ket red.		
DR	PROSITE; PS00063; ALDOKETO REDUCTASE 3; 1.		
SQ	SEQUENCE 449 AA; 46142 MW; BF984AA360F6C415 CRC64;		
Query Match 8.5%; Score 188; DB 4; Length 449;			
Best Local Similarity 22.0%; Pred. No. 5.8e-06;			
Matches 116; Conservative 49; Mismatches 167; Indels 196; Gaps 18			
QY	13 LVIIICFLRLSASQNCCLKSLSDVVIDIQSSLSKGRGNEPVYTSQEDCINSCSTKN	72	
Db	5 LVLIWIFSLSLSESHAASNDPRNFPENKMKWGLVKRNASVETVDNKTSEDVTMAAAS---	61	
QY	73 ISGDKACNLMIFDTRKTARQPNICYLFCFPNEACPLKPAKGLMSYRIITDPSLTRNLPS	132	
Db	62 -----PVTLTG-----TSAHLNS	76	
QY	133 QELPQEDSLHGFSSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMEAS	192	
Db	77 MEVTTEDT-----SRDVSER-----ATSGVADGVTSIAPTAVAS	112	
QY	193 AQLLAYKEKGHSQSSQFSSDQEIALLPENVSALPATVAVASPHT-----TSATPKPATL	247	
Db	113 STTAA-----SITTAASSMTVAASSAP-TTAAASSTVASIAPTAAASSMTTAAASSTPMTL	164	
QY	248 ---LPTNASV--TPS--GTSQDQLATTAPVTTVTSQPTTLISIVFTRAAATLQAMATT	300	

Dd	165	ALPAPTSTSTGRTPSTATTACHPSLSTALAQVPKSSALPRATLATLATRA-----QTVAIT	220
Qy	301	A-----VLTTFQAPTDSKG	315
Dd	221	ANTSSPMSTRPPSPSKHMPSDTAAFPVPMRPOAQGPISQVSVDQPVVNTTNKSTPMPSNT	280
Qy	316	SLETIPFTEISNLTNLNGVNYPAL-----SMS-NVESSTNKKTASWEG-	359
Dd	281	TPEAPFTPV--VTTKAQAAREPTASPVPVPHTSPIPEMEAMSPPTQPSMPTYTORAACP	338
Qy	360	-----REASPGSSSGSVENQYG-LP-----FE	382
Dd	339	GTSQAPEQOVETEATPGTDISTGTPRSSGGTKMAPATDSCQPSIQGYMVVTTPEBLTQAVD	398
Qy	383	KMLIGSLLFGLFLVLIGLVLLGRILSESLRRKRYSRLDYLLINGIYVD	430
Dd	399	KTLLLVLLLGVTLEFIVLVLPALQAYESYKKDKYTQVDYLINGMYAD	446

RESULT 12		
Q8BWMQ4		
ID	Q8BWMQ4	PRELIMINARY; PRT; 1349 AA.
AC	Q8BWMQ4;	
DT	01-MAR-2002 (TREMBLrel. 20, Created)	
DT	01-MAR-2002 (TREMBLrel. 20, Last sequence update)	
DT	01-OCT-2003 (TREMBLrel. 25, Last annotation update)	
DE	Mucin 5 (Fragment).	
GN	MUC5AC.	
OS	Homo sapiens (Human).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Primates; Catarrhini; Homiinae; Homo.	
OX	NCBI_TaxID=9606;	
RN	[1]	
RP	SEQUENCE FROM N.A.	
RX	MEDLINE=21426417; PubMed=11535137;	
RA	Escande F., Aubert J.P., Porchet N., Buisine M.P.;	
RT	"Human mucin gene MUC5AC: organization of its 5'-region and central	
RT	repetitive region.";	
RL	Biochem. J. 358:763-772(2001).	
DR	EMBL; AJ298318; CAC83675.1; -.	
FT	NON_TER	1
FT	NON_TER	1349 1349
SO	SEQUENCE	1349 AA; 135600 MW; 4DC3C1544F1E5EBA CRC64;

Query Match	8.2%;	Score 180.5;	DB 4;	Length 1349;
Best Local Similarity	21.6%;	Pred. No. 9.2e-05;		
Matches	88;	Conservative 62;	Mismatches 174;	Indels 83;
				Gaps 14
QY	4	GGEGLTYTLVI-----ICFLTRLISASQNC LKKSLEDVID-----IOSLSKGRGNE	53	
DB	517	GGDKE-TYNNIIRSGEKICRPQETRLQ-CRAKSHPEVSIENLGQVQCSREGL----	570	
QY	54	PVYTSTQEDCINSCCSTKNISGD-KACNLMIFDTRKTARQPNCYLFCPNEACPLKPAK	112	
DB	571	-----VCRNQDQGGPFKMC-LNYEVR-----VLCCEPDKCPVTSTS	606	
QY	113	GLMSYRIITDFSLTRNLPSQELPQEDSLHGQFSQ-----AVTPLAHHTDY	160	
DB	607	VTAESPVLGEPRAQTOSTSSWQKSRHTLLVTSSITSTQTSTTSAPTSTFPASIPSTS	666	
QY	161	SKPTDISWRDTLSQKFGSSDHLEKLFKMDASAQLLAYKEKGHSQSSQFSDDQEI AHL P	220	
DB	667	APTSTTSAPTTs-----TTSAPTSTSTPQTSTTSAPTSTTSAPT	710	
QY	221	ENVSALPATVAVASP-HTTSATPKPATLLPTNASVTP-----SGTSQPOLATTA	268	
DB	711	STISA-PTSTISAPTTSTTSAPLASTTSAPTSTSSAPTNTTTSAPTSTTSAPITSTIS	769	
QY	269	PPVTVTQSOPPTTLISTVFTRAAATLQAMATTAVLTTFQAPFTDSKGSLETIPTFEISNL	328	
DB	770	APTSTSTSTPQSTSISSPTSTSTTPQOSTSTSSPTSTTSAPTSTTSAPTSTSTSTPQT	829	

OY 329 TLNTGNVNYPT-ALSMNVESSTMNKTASWEGREASPGSSQGSVPE 374  
Db 830 SSSAPTSSSTSAPTASTSAPTSTSTSFHTTSTSPPTSSTSTPQ 876

RESULT 13

O7YTR7 PRELIMINARY; PRT; 519 AA.  
AC Q7YTR7;  
DT 01-OCT-2003 (TReMBLrel. 25, Created)  
DT 01-OCT-2003 (TReMBLrel. 25, last sequence update)  
DT 01-OCT-2003 (TReMBLrel. 25, last annotation update)  
DE Hypothetical protein C30H6.11.  
GN C30H6.11.  
OS Caenorhabditis elegans.  
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
OC Rhabditidae; Peloderinae; Caenorhabditis.  
OX NCBI\_TaxID=6239;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RX MEDLINE=99069613; PubMed=9851916;  
RA none;  
RT "Genome sequence of the nematode C.elegans: A platform for  
RT investigating biology."  
RL Science 282:2012-2018(1998).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RA Mortimore B.J.;  
RL Submitted (OCT-1996) to the EMBL/GenBank/DBJ databases.  
DR EMBL; 281044; CAE17706.1; -.  
KW Hypothetical protein.  
SQ SEQUENCE 519 AA; 56012 MW; 93C2CF9EC339D1A CRC64;

Query Match 7.6%; Score 168; DB 5; Length 519;  
Best Local Similarity 27.1%; Pred. No. 0.00023;  
Matches 58; Conservative 22; Mismatches 96; Indels 38; Gaps 7;

OY 229 TVAVASPHTSATPKPATILPTNASVTPSGTSQPOLATAPVTTVTSQPPTLISVFT 288  
Db 155 TTTTTPPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTT 214  
OY 289 RAAATLQAMATTAVLTTFEQAPTDSKSLPTIPTEISNLTLNTGNVYNPTALSMNVES 348  
Db 215 TVPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTTPTTTT 269  
OY 349 -----STMNKTASWEGREASPGSSQGSVPE-----QYGLPFE---KWLIGSL----- 390  
Db 270 AYNVYNTNDNAHYD-----NNSNNHNYSENFMRLMLPIAFSINFTLNLSTYLOHMK 323  
OY 391 --LFGVLFLVIGLVLGRIISESLRRKRYSLDY 422  
Db 324 YDLTSLFNALGTVTL-----LMRKIFCNIQY 350

RESULT 14

O14887 PRELIMINARY; PRT; 477 AA.  
AC Q14887;  
DT 01-NOV-1996 (TReMBLrel. 01, Created)  
DT 01-NOV-1996 (TReMBLrel. 01, last sequence update)  
DT 01-JUN-2003 (TReMBLrel. 24, last annotation update)  
DE Mucin (Fragment).  
GN MUC5AC.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Tracheobronchial mucosa;  
RA Guyonnet-Duperrat V., Audie J., Debailleul V., Laine A., Buisine M.,

RA Zoutina-Galiegue S., Pigny P., Aubert J., Porchet N.;  
RT "Characterization of the human mucin gene MUC5AC: a consensus  
RT cysteine-rich domain for 11p15 mucin genes."  
RL Biochem. J. 0:0-0(1994).  
DR EMBL; 234277; CAA84031.1; -.  
DR PIR; S53362; S53362.  
FT NON\_TER 1 1  
FT NON\_TER 477 477  
SQ SEQUENCE 477 AA; 50666 MW; E7360031BA451311 CRC64;

Query Match 7.3%; Score 160.5; DB 4; Length 477;  
Best Local Similarity 24.4%; Pred. No. 0.00075;  
Matches 66; Conservative 42; Mismatches 114; Indels 49; Gaps 9;

OY 147 SQAVTPLAHHTDYSKPTDISW-----RDTLSQKFGSSDHL----EKLFKMD---- 189  
Db 15 SQPVRDCHLRCTWTWKFDVDFPSPGPHGDKETVNNIRSGEKICRBPBEITRLQCRAE 74  
OY 190 ---EASAQLLAY-----KEKG-----HSQSSQFSS--DQEIAPHLPENVSALPATVAVAS 234  
Db 75 SHPEVSIHGLGVQCSREBGLVCRNODQOGPFKMCINYEVRVLCCEPDKCPVT---ST 131  
OY 235 PHTSATPKPATILPTNAS-----VTPSGTSQPOLATAPVTTVTSQPPTLI 283  
Db 132 PVTAPSTPSGRATSPQTSTSSWQKSRTTLVTTSTSTPQTSTTSAPTSTTSAPTSTT 191  
OY 284 STVFTRAATLQAMATTAVLTTFEQAPTDSKSLPT--IPTEISNLTLNTGNVYNPTA 340  
Db 192 SAPTSTSTPQSTSSAPTSSSTSAPTSTTSAPTSTTSAPTSTTSAPTSTTSAPTSTT 251  
OY 341 LSMNVESSTMNKTASWEGREASPGSSQGS 371  
Db 252 TSTTSAPTSSSTSPTQTSKTSAAATSTTSGS 282

RESULT 15

O8WMQ5 PRELIMINARY; PRT; 2448 AA.  
AC Q8WMQ5;  
DT 01-MAR-2002 (TReMBLrel. 20, Created)  
DT 01-MAR-2002 (TReMBLrel. 20, last sequence update)  
DT 01-OCT-2003 (TReMBLrel. 25, last annotation update)  
DE Mucin 5 (Fragment).  
GN MUC5AC.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Trachea;  
RX MEDLINE=21426417; PubMed=11535137;  
RA Escande F., Aubert J.P., Porchet N., Buisine M.P.;  
RT "Human mucin gene MUC5AC: organization of its 5'-region and central  
RT repetitive region."  
RL Biochem. J. 358:763-772(2001).  
DR EMBL; AJ298317; CAC83674.1; -.  
DR Genew; HGNC:7515; MUC5AC.  
DR GO; GO:0005622; C:intracellular; IEA.  
DR GO; GO:0005840; C:ribosome; IEA.  
DR GO; GO:0003735; F:structural constituent of ribosome; IEA.  
DR GO; GO:0006412; P:protein biosynthesis; IEA.  
DR InterPro; IPR001209; Ribosomal\_S14.  
DR InterPro; IPR002919; TIL\_Cysrich.  
DR InterPro; IPR001007; VWF\_C.  
DR InterPro; IPR001846; VWF\_D.  
DR Pfam; PF01826; TIL; 2.  
DR Pfam; PF00094; vwd; 3.  
DR SMART; SM00214; VWC; 3.  
DR SMART; SM00216; VWD; 3.  
DR PROSITE; PS00527; RIBOSOMAL\_S14; 2.  
FT NON\_TER 2448 2448  
SQ SEQUENCE 2448 AA; 260970 MW; A5C1BD6278444D952 CRC64;

Query Match	7.1%;	Score 157.5;	DB 4;	Length 2448;
Best Local Similarity	23.1%;	Pred. No. 0.011;		
Matches	87;	Conservative	38;	Mismatches 142;
				Indels 109;
				Gaps 16;

QY	63	CIN----	SCCSTKNISGDKACNLMIFDTRKTAROPNCYLFFCPNEACPLKPAKGLMSY	117
Db	2034	CYNYEIRIQCCETVNV-----	CRDITRPPKTVATRPPTH-----	PTGAQTQT 2076
QY	118	RIITDFPSLTRNLP--	SOELPQEDSLHGFQSAVTPLAHHTDYSKPTDISW-----	168
Db	2077	TFTTHMPASTEQTATSRGPTATSVTQGTHTTPTRNCHPRCTWTWTFDVPSPGPH		2136
QY	169	---RDTLSQKFGSSDHLKFLKMWDEASAOQLLAYKEKHSQS-----	QFSGQ----	213
		: :	: :	
Db	2137	GDKETYNNNIRSG--	EKICRPEEITRLQC-RAKSHPEVSIHLGQVWQCSNREGLVC	2192
QY	214	-----EIAHLBENVSAALPATVAVASPHHTSATPKPATLLPTNAS-----		253
			: :	
Db	2193	RNODQOGPFKMCMLNIEVRVLCCECTPKGCPVT--	STPVTA PSTPSGRAISPTQSISSWQK	2249
QY	254	-----VTPSGTSQPOLAT-----	AP-----	PVTVTISQPTTLISIVFTRAA 291
Db	2250	SRITTLVTTSTSTPQTSITTYAHTTSTTSAPARTATSAPTSTSVPTSTISGPKTTPS		2309
QY	292	ATLOAMATTAVLTTTFQAPRDSKGSLETIPFTEISNLTLNTGNVNPITALSMSNVESSTM		351
			: :	
Db	2310	PVPPTSTTSATSTISAPTSTTS--	VPGTTPSPV-LTTSTTSAPT-----	TR 2355
QY	352	NKTASWEGREASPGSS		367
		:	:	
Db	2356	TTSASPA GTTSGPGNT		2371

Search completed: September 24, 2004, 14:16:34  
Job time : 128 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2004, 14:09:17 ; Search time 59 Seconds  
(without alignments)  
2064.033 Million cell updates/sec

Title: US-09-944-929-83  
Perfect score: 2211  
Sequence: 1 MFFGGEGSLTYTLVVICFLT.....LRRKRYSLDYLINGIYVDI 431

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 1500 summaries

Database : A\_Geneseq\_29Jan04:\*  
1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. NO. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2211	100.0	431	2 AAY17834	Aay17834 Human PRO
2	2211	100.0	431	3 AAB33428	Aab33428 Human PRO
3	2211	100.0	431	3 AAB01325	Aab01325 Human PRO
4	2211	100.0	431	3 AAB34739	Aab34739 Human sec
5	2211	100.0	431	4 AAB95464	Aab95464 Human PRO
6	2211	100.0	431	4 AAB65299	Aab65299 Human PRO
7	2211	100.0	431	6 ABUS5934	Abu55934 Human sec
8	2211	100.0	431	6 ABUS8114	Abu58114 Human PRO
9	2211	100.0	431	6 ABUS9192	Abu59192 Novel hum
10	2211	100.0	431	6 ABUS2704	Abu82704 Human sec
11	2211	100.0	431	6 ABUS60623	Abu60623 Human sec
12	2211	100.0	431	6 ABUS14005	Abu14005 Human PRO
13	2211	100.0	431	6 ABUS60244	Abu60244 Human PRO
14	2211	100.0	431	6 ABUS72590	Abu72590 Novel hum
15	2211	100.0	431	6 ABUS64930	Abu64930 Human sec
16	2211	100.0	431	6 ABUS8364	Abu58364 Novel hum
17	2211	100.0	431	6 ABUS7250	Abu57250 Human PRO
18	2211	100.0	431	6 ABUS9339	Abu59339 Human sec
19	2211	100.0	431	6 ABUS26036	Abu26036 Human PRO
20	2211	100.0	431	6 ABUS6315	Abu56315 Human sec
21	2211	100.0	431	6 ABUS60355	Abu60355 Novel hum
22	2211	100.0	431	6 ABUS9045	Abu59045 Human sec
23	2211	100.0	431	6 ABUS92423	Abu92423 Novel hum
24	2211	100.0	431	6 ABUS9488	Abu9488 Novel hum
25	2211	100.0	431	6 ABUS92254	Abu92254 Novel hum

26	2211	100.0	431	6 ABU10960	Abu10960 Human PRO
27	2211	100.0	431	6 ABU11316	Abu11316 Human PRO
28	2211	100.0	431	6 ABU67135	Abu67135 Human PRO
29	2211	100.0	431	6 ABU81712	Abu81712 Novel hum
30	2211	100.0	431	6 ABU88651	Abu88651 Human sec
31	2211	100.0	431	6 ABO34165	Abu34165 Human PRO
32	2211	100.0	431	6 ADA38026	Ada38026 Human sec
33	2211	100.0	431	6 ADA21712	Ada21712 Human sec
34	2211	100.0	431	6 ADA10499	Ada10499 Human sec
35	2211	100.0	431	6 ADA18043	Ada18043 Human PRO
36	2211	100.0	431	6 ADA28151	Ada28151 Human sec
37	2211	100.0	431	6 ADA94731	Ada94731 Human sec
38	2211	100.0	431	6 ADA38956	Ada38956 Human sec
39	2211	100.0	431	6 ADA93077	Ada93077 Human sec
40	2211	100.0	431	7 ABO53251	Abu53251 Human sec
41	2211	100.0	431	7 ADA22638	Ada22638 Human sec
42	2211	100.0	431	7 ABO22621	Abu22621 Human sec
43	2211	100.0	431	7 ADA06804	Ada06804 Human sec
44	2211	100.0	431	7 ADA39497	Ada39497 Human sec
45	2211	100.0	431	7 ADB96523	Adb96523 Human PRO
46	2211	100.0	431	7 ADC57995	Adc57995 Human PRO
47	2211	100.0	431	7 ADC25839	Adc25839 Human PRO
48	2211	100.0	431	7 ADC25597	Adc25597 Human sec
49	2211	100.0	431	7 ADC55359	Adc55359 Human PRO
50	2211	100.0	431	7 ADC12226	Adc12226 Human sec
51	2211	100.0	431	7 ADC56648	Adc56648 Human PRO
52	2211	100.0	431	7 ADC11693	Adc11693 Human sec
53	2211	100.0	431	7 ADC25718	Adc25718 Human sec
54	2211	100.0	431	7 ADC14815	Adc14815 Novel hum
55	2211	100.0	431	7 ADD08347	Add08347 Novel hum
56	2211	100.0	431	7 ADC82172	Adc82172 Human PRO
57	2211	100.0	431	7 ADD07814	Add07814 Novel hum
58	2211	100.0	431	7 ADC82705	Adc82705 Human PRO
59	2211	100.0	431	7 ADD08885	Add08885 Novel hum
60	2211	100.0	431	7 ADD07134	Add07134 Novel hum
61	2211	100.0	431	7 ADC83381	Adc83381 Human PRO
62	2211	100.0	431	7 ADD55488	Add55488 Human PRO
63	2211	100.0	431	7 ADD56446	Add56446 Human PRO
64	2211	100.0	431	7 ADD54884	Add54884 Human PRO
65	2211	100.0	431	7 ADE31903	Adc31903 Human sec
66	2211	100.0	431	7 ADE27038	Adc27038 Novel hum
67	2211	100.0	431	7 ADE26505	Adc26505 Novel hum
68	2211	100.0	431	8 ADE71552	Adc71552 Human sec
69	2022	91.5	397	4 AAB92667	Aab92667 Human pro
70	1877	84.9	365	4 AAM25899	Aam25899 Human pro

ALIGNMENTS

RESULT 1  
AAY17834  
ID AAY17834 standard; protein; 431 AA.  
XX  
AC AAY17834;  
XX  
DT 12-AUG-1999 (first entry)  
XX  
DE Human PRO361 protein sequence.  
XX  
KW Human; PRO protein; tumour necrosis factor family; TNF; cytokine;  
secreted protein; transmembrane protein; inflammation disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO9928462-A2.  
XX  
PD 10-JUN-1999.  
XX  
PF 01-DEC-1998; 98WO-US025108.  
XX  
PR 03-DEC-1997; 97US-0067411P.

PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.

XX (GETH ) GENENTECH INC.

XX  
PI Wood WI, Goddard A, Gurney AL, Yuan J, Baker KP, Chen J;  
XX WPI; 1999-371118/31.  
DR N-PSDB; AAX80059.

XX  
PT Nucleic acids encoding PRO secreted and transmembrane proteins.

XX  
PS Claim 12; Fig 37; 123pp; English.

XX  
CC The present invention describes nucleic acids encoding PRO secreted and  
CC transmembrane proteins used therapeutically. The PRO proteins have  
CC cytosstatic, anti-inflammatory, anti-proliferative and immunosuppressive  
CC activity. The proteins and polynucleotides can be used in therapy,  
CC identification of homologues, raising antibodies and design of probes and  
CC primers. They can be used in a range of diseases related to proteins that  
CC they have homology with, e.g. a PRO protein having homology to complement  
CC proteins may be used in inflammatory responses

XX  
SQ Sequence 431 AA;

Query Match 100.0%; Score 2211; DB 2; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFFGGEGSLTYTLVVICFLTLRLSASQNCLEKSLSDVIDIQSSLKGRGNEPVYTSTQ 60  
Db 1 MFFGGEGSLTYTLVVICFLTLRLSASQNCLEKSLSDVIDIQSSLKGRGNEPVYTSTQ 60  
QY 61 EDCINSCSTKNIISGDKACNLMIFDTRKTAQPNCYLFFCPNEBACPLKPAKGLMSYRII 120  
Db 61 EDCINSCSTKNIISGDKACNLMIFDTRKTAQPNCYLFFCPNEBACPLKPAKGLMSYRII 120  
QY 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPFLAHHHTDYSKPTDISMRDTLSQKFGSSD 180  
Db 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPFLAHHHTDYSKPTDISMRDTLSQKFGSSD 180  
QY 181 HLEKLFKMEASAOQLLAYKEKGHSQSSQSSDOEIAHLLENVSALPATVAVASPHTTSA 240  
Db 181 HLEKLFKMEASAOQLLAYKEKGHSQSSQSSDOEIAHLLENVSALPATVAVASPHTTSA 240  
QY 241 TPKPATLLPTNASVTPSGTSQPOLATTAPVTVTSQPTLLISTVFTRAAATLQAMATT 300  
Db 241 TPKPATLLPTNASVTPSGTSQPOLATTAPVTVTSQPTLLISTVFTRAAATLQAMATT 300  
QY 301 AVLTTTFOAPTDSKGSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMNKTASMEGR 360  
Db 301 AVLTTTFOAPTDSKGSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMNKTASMEGR 360  
QY 361 EASPGSSSGSVPENQYGLPFEKWLIGSLFGVLFLVIGVLGRIISESLRKRY SRL 420  
Db 361 EASPGSSSGSVPENQYGLPFEKWLIGSLFGVLFLVIGVLGRIISESLRKRY SRL 420  
QY 421 DYLINGIYVDI 431  
Db 421 DYLINGIYVDI 431

RESULT 2  
AAB33428  
ID AAB33428 standard; protein; 431 AA.  
XX  
AC AAB33428;  
XX  
DT 29-JAN-2001 (first entry)  
XX  
DE Human PRO361 protein UNQ316 SEQ ID NO:72.  
XX  
KW Human; immune related disease; diagnosis; antiinflammatory; cardiant;  
KW dermatological; antiarthritic; antirheumatic; immunosuppressive;  
KW haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;  
KW antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;  
KW antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis;  
KW osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;  
KW idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;  
KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;  
KW autoimmune thrombocytopenia; immune-mediated renal disease;  
KW demyelinating disease; hepatobiliary disease; Whipple's disease;  
KW inflammatory bowel disease; gluten-sensitive enteropathy;  
KW autoimmune disease; immune-mediated skin disease; allergic disease;  
KW immunological disease; transplantation associated disease;  
KW graft rejection; graft-versus-host-disease.

OS Homo sapiens.  
XX  
PN WO200053758-A2.

XX  
PD 14-SEP-2000.

XX  
PF 02-MAR-2000; 2000WO-US005841.

XX  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99US-0123618P.  
PR 12-MAR-1999; 99US-0123957P.  
PR 23-MAR-1999; 99US-0125775P.  
PR 12-APR-1999; 99US-0128849P.  
PR 20-APR-1999; 99WO-US008615.  
PR 28-APR-1999; 99US-0131445P.  
PR 04-MAY-1999; 99US-0132371P.  
PR 14-MAY-1999; 99US-0134287P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-OCT-1999; 99US-0162506P.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030999.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.





CC proteins have various industrial applications, including as  
CC pharmaceutical and diagnostic agents. The membrane-bound proteins can  
CC also be employed for screening of potential peptide or small molecule  
CC inhibitors of the relevant receptor/ligand interaction. Anti-PRO  
CC antibodies are useful for the affinity purification of PRO from  
CC recombinant cell culture or natural sources

XX Sequence 431 AA;

Query Match 100.0%; Score 2211; DB 3; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MFFGEGSLTYLVIIICFLTRLASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
1 MFFGEGSLTYLVIIICFLTRLASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
DB 1 MFFGEGSLTYLVIIICFLTRLASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
OY 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
DB 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
OY 121 TDFPSLTRNLPSQELPQEDSLHGFSAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
121 TDFPSLTRNLPSQELPQEDSLHGFSAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
DB 121 TDFPSLTRNLPSQELPQEDSLHGFSAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
OY 181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240  
181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240  
DB 181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240  
OY 241 TPKPATLPTNASVTPSGTSQPOLATTAPVTVTSQPTTLISTVFTRAAATLQAMATT 300  
241 TPKPATLPTNASVTPSGTSQPOLATTAPVTVTSQPTTLISTVFTRAAATLQAMATT 300  
DB 241 TPKPATLPTNASVTPSGTSQPOLATTAPVTVTSQPTTLISTVFTRAAATLQAMATT 300  
OY 301 AVLTTFOAPTDSKGSLETIPTEISNLTNTGVNYPNTALSMNSNVESSTMNKTASWEGR 360  
301 AVLTTFOAPTDSKGSLETIPTEISNLTNTGVNYPNTALSMNSNVESSTMNKTASWEGR 360  
DB 301 AVLTTFOAPTDSKGSLETIPTEISNLTNTGVNYPNTALSMNSNVESSTMNKTASWEGR 360  
OY 361 EASPGSSSGSVPENQYGLPFEKWLIGSLFGVLFLVIGLVLGRISBSLRKRYSRL 420  
361 EASPGSSSGSVPENQYGLPFEKWLIGSLFGVLFLVIGLVLGRISBSLRKRYSRL 420  
DB 361 EASPGSSSGSVPENQYGLPFEKWLIGSLFGVLFLVIGLVLGRISBSLRKRYSRL 420  
OY 421 DYLINGIYVDI 431  
421 DYLINGIYVDI 431  
DB 421 DYLINGIYVDI 431

RESULT 4  
AAB34739  
ID AAB34739 standard; protein; 431 AA.

XX AC AAB34739;

XX DT 26-JAN-2001 (first entry)

DE Human secreted protein encoded by DNA clone vo27 1.

KW Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer;  
KW systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke;  
KW haematopoiesis regulation; tissue regrowth; wound healing; haemophilia;  
KW Alzheimer's disease; Parkinson's disease; Shy-drager syndrome; cancer;  
KW contraceptive; infection; growth inhibition; hyperproliferative disorder;  
KW psoriasis.

OS Homo sapiens.

PN WO200055375-A1.

PD 21-SEP-2000.

PF 17-MAR-2000; 2000WO-US007285.

PR 17-MAR-1999; 99US-0124808P.

PR 17-MAR-1999; 99US-0124916P.

PR 17-AUG-1999; 99US-0149639P.  
PR 01-OCT-1999; 99US-0157247P.  
PR 29-NOV-1999; 99US-0167824P.  
PR 15-FEB-2000; 2000US-0182711P.

XX (ALPH-) ALPHAGENE INC.

PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;

DR WPI; 2000-638211/61.

XX N-PSDB; AAC59840.

PT Novel proteins and polypeptides useful for the treatment of e.g multiple  
PT sclerosis, systemic lupus erythematosus, rheumatoid arthritis, cancer,  
PT Alzheimer's disease, Parkinson's disease, stroke, anemia and ulcers.

PS Claim 114; Page 453-455; 493pp; English.

XX This invention relates to 59 human secreted proteins and the nucleotide  
CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745  
CC represent the proteins and their encoding nucleotide sequences, and  
CC sequences AAB34746-B34771 represent fragments of the proteins. Probes for  
CC the DNA sequences are represented by sequences AAC59847-C59596. The  
CC proteins exhibit neuroprotective, dermatological, immunosuppressive,  
CC antiinflammatory, antianaemic, nootropic, antiparkinsonian,  
CC cerebroprotective, haemostatic, vulnerrary, cyostatic, antipsoriatic,  
CC antibacterial, virucide, and fungicide activity. The proteins and  
CC nucleotide sequences are useful as nutritional sources or supplements and  
CC in research. The proteins are useful for treating immune deficiency and  
CC disorders, which may be genetic or resulting from infections, autoimmune  
CC disorders such as multiple sclerosis, systemic lupus erythematosus,  
CC rheumatoid arthritis, and for treating myeloid or lymphoid cell  
CC deficiencies such as anaemias by regulating haematopoiesis. The proteins  
CC are also useful in compositions for bone, cartilage, tendon, ligament  
CC and/or nerve tissue growth or regeneration, for wound healing, tissue  
CC repair and replacement and in the treatment of wounds, incisions and  
CC ulcers. Other uses include in the treatment of central and peripheral  
CC nervous system and neuropathies such as Alzheimer's and Parkinson's  
CC diseases and Shy-Drager syndrome, and mechanical and traumatic disorders,  
CC such as spinal cord disorders, head trauma and stroke. The proteins may  
CC also be used as a contraceptive, and for treating coagulation disorders  
CC such as haemophilias. The protein and nucleotide sequences with cadherin  
CC activity are useful for treating cancer. Other uses for the protein  
CC include for inhibiting the growth, infection or function of, or killing,  
CC infectious agents such as bacteria, virus, fungi and other parasites, for  
CC effecting bodily characteristics such as height, weight, hair colour,  
CC catabolism, anabolism, processing, utilization, storage or elimination of  
CC dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors,  
CC effecting behavioural characteristics, providing analgesic effects and  
CC for treating hyperproliferative disorders such as psoriasis

XX Sequence 431 AA;

Query Match 100.0%; Score 2211; DB 3; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MFFGEGSLTYLVIIICFLTRLASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
1 MFFGEGSLTYLVIIICFLTRLASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
DB 1 MFFGEGSLTYLVIIICFLTRLASQNCCLKSLEDVIDIQSSLSKGRGNEPVYTSTQ 60  
OY 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
DB 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
OY 121 TDFPSLTRNLPSQELPQEDSLHGFSAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
121 TDFPSLTRNLPSQELPQEDSLHGFSAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
DB 121 TDFPSLTRNLPSQELPQEDSLHGFSAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
OY 181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240  
181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240  
DB 181 HLEKLFKMDASAOQLLAYKEKGHSQSSQFSSDQEIHAHLLPENVSALPATVAVASPHTTSA 240

[illegible]

RESULT 5  
 AAB95464  
 ID AAB95464 standard; protein; 431 AA.  
 XX  
 AC AAB95464;  
 XX  
 DT 26-JUN-2001 (first entry)  
 XX  
 DE Human protein sequence SEQ ID NO:17950.  
 XX  
 KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EPI074617-A2.  
 XX  
 PD 07-FEB-2001.  
 XX  
 PF 28-JUL-2000; 2000EP-00116126.  
 XX  
 PR 29-JUL-1999; 99JP-00248036.  
 PR 27-AUG-1999; 99JP-00300253.  
 PR 11-JAN-2000; 2000JP-00118776.  
 PR 02-MAY-2000; 2000JP-00183767.  
 PR 09-JUN-2000; 2000JP-00241899.  
 XX  
 PA (HELI-) HELIX RES INST.  
 XX  
 PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;  
 PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;  
 XX  
 DR WPI; 2001-318749/34.  
 XX  
 PT Primer sets for synthesizing polynucleotides, particularly the 5602 full-  
 PT length cDNAs defined in the specification, and for the detection and/or  
 PT diagnosis of the abnormality of the proteins encoded by the full-length  
 PT cDNAs.  
 XX  
 PS Claim 8; SEQ ID NO 17950; 2537pp + Sequence Listing; English.  
 XX  
 CC The present invention describes primer sets for synthesising 5602 full-  
 CC length cDNAs defined in the specification. Where a primer set comprises:  
 CC (a) an oligo-dT primer and an oligonucleotide complementary to the  
 CC complementary strand of a polynucleotide which comprises one of the 5602  
 CC nucleotide sequences defined in the specification, where the  
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination  
 CC of an oligonucleotide comprising a sequence complementary to the  
 CC complementary strand of a polynucleotide which comprises a 5'-end  
 CC sequence and an oligonucleotide comprising a sequence complementary to a  
 CC polynucleotide which comprises a 3'-end sequence, where the  
 CC oligonucleotide comprises at least 15 nucleotides and the combination of  
 CC the 5'-end sequence/3'-end sequence is selected from those defined in the  
 CC specification. The primer sets can be used in antisense therapy and in  
 CC gene therapy. The primers are useful for synthesising polynucleotides,  
 CC particularly full-length cDNAs. The primers are also useful for the

```

CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893
CC represent human amino acid sequences; and AAH13629 to AAH13632 represent
CC oligonucleotides, all of which are used in the exemplification of the
CC present invention
XX
XX
SQ Sequence 431 AA;
Query Match 100.0%; Score 2211; DB 4; Length 431;
Best Local Similarity 100.0%; Pred. No. 3.6e-173;
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

RESULT 6	
ID AAB652299	
AC AAB652299;	AAB652299 standard; protein; 431 AA.
DT 02-APR-2001	(first entry)
DE Human PRO361	protein sequence SEQ ID NO:515.
KW Human; secreted and transmembrane protein; PRO; cytostatic; cell death;	
KW cancer; chromosomal mapping; gene mapping; tissue typing;	
KW diagnostic assay.	
OS Homo sapiens.	
PN WO200073454-A1.	
PD 07-DEC-2000.	
PF 30-MAR-2000;	2000WO-US008439.
PR 02-JUN-1999;	99WO-US012252.
PR 23-JUN-1999;	99US-0141037P.
PR 07-JUL-1999;	99US-0143048P.
PR 20-JUL-1999;	99US-0144758P.

PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
XX  
XX  
PA (GETH ) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Griltsen ME, Goddard A, Godowski PJ;  
PI Grimaldi CJ, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;

DR WPI; 2001-032160/04.  
DR N-PSDB; AAF44268.

PT PRO polynucleotides used to produce polypeptides used to target bioactive  
PT molecules such as toxins, radiolabels or antibodies, to specific cells,  
PT to cause targeted cell death.

PS Claim 12; Fig 328; 935pp; English.

XX The present invention describes human secreted and transmembrane PRO  
CC proteins. The PRO proteins have cytostatic activity. The PRO proteins can  
CC be used for targeted delivery of bioactive molecules, such as toxins,  
CC radiolabels or antibodies, that cause cell death. PRO nucleotide  
CC sequences, and their fragments, can be used as hybridisation probes, in  
CC chromosomal and gene mapping, and in the generation of anti-sense RNA and  
CC DNA. They may also be used to produce transgenic animals which are used  
CC to develop and screen therapeutically useful reagents. The PRO nucleotide  
CC and protein sequence can be used for tissue typing and in treating  
CC cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to  
CC AAF44470 represent PCR primers and hybridisation probes used in the  
CC isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to  
CC AAB65300 represent human PRO polynucleotide and protein sequences given  
CC in the exemplification of the present invention

XX Sequence 431 AA;

Query Match 100.0%; Score 2211; DB 4; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFFGGEGSLTYTLVVICFLTLRLSASQNCCLKSLEDVIDIQSSLKGRGNEPVYTSTQ 60  
DB 1 MFFGGEGSLTYTLVVICFLTLRLSASQNCCLKSLEDVIDIQSSLKGRGNEPVYTSTQ 60  
QY 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPCYLFECPNBEACPLKPAKGLMSYRII 120  
DB 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPCYLFECPNBEACPLKPAKGLMSYRII 120  
QY 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPLAHHHTDYSKPTDISWRDTLSQKFGSSD 180  
DB 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPLAHHHTDYSKPTDISWRDTLSQKFGSSD 180  
QY 181 HLEKLFKMDASAGQLLAYKEKGHSQSSQFSSDQEIHAHLLENVSALPATVAVASPHTTSA 240  
PT ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

DB 181 HLEKLFKMDASAGQLLAYKEKGHSQSSQFSSDQEIHAHLLENVSALPATVAVASPHTTSA 240  
QY 241 TPKPATLLPTNASVTPSGTSQPOLATTAPEVTTVTSQPTTLISTVFTRAATLQAMATT 300  
DB 241 TPKPATLLPTNASVTPSGTSQPOLATTAPEVTTVTSQPTTLISTVFTRAATLQAMATT 300  
QY 301 AVLTTFQAPTDKSGSLETIPFTETISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
DB 301 AVLTTFQAPTDKSGSLETIPFTETISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
QY 361 EASPGSSQGSVPENQYGLPFEKWLIGSLFGVLFLVIGLVIGRILSESLRRKYSRL 420  
DB 361 EASPGSSQGSVPENQYGLPFEKWLIGSLFGVLFLVIGLVIGRILSESLRRKYSRL 420  
QY 421 DYLLNGIYVDI 431  
DB 421 DYLLNGIYVDI 431

RESULT 7

ABUS5934  
ID ABUS5934 standard; protein; 431 AA.

XX AC ABUS5934;  
XX DT 26-MAR-2003 (first entry)  
XX DE Human secreted/transmembrane protein PRO361.

KW Human; PRO; secreted protein; transmembrane protein; anti-HIV;  
KW cytostatic; antiarteriosclerotic; antiinflammatory; antidiabetic;  
KW cardiant; AIDS; acquired immunodeficiency syndrome; cancer;  
KW atherosclerosis; inflammatory disease; diabetic complication;  
KW cardiac injury; organ failure.

OS Homo sapiens.

XX US2002142959-A1.

XX 03-OCT-2002.

XX 31-AUG-2001; 2001US-00944654.

XX 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.

XX (GETH ) GENENTECH INC.

PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Griltsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX WPI; 2003-174141/17.  
DR N-PSDB; ABX75504.

PT New isolated PRO polypeptide and encoding nucleic acid, useful for the  
PT diagnosis and treatment of disorders associated with the PRO polypeptide,  
PT such as AIDS, cancer, atherosclerosis, inflammatory disease and diabetes.



XX Claim 12; Fig 32; 178bp; English.  
PS  
XX The invention relates to an isolated PRO polypeptide (a secreted or  
CC transmembrane protein) comprising: (a) at least 80% sequence identity or  
CC positives when compared to any of 15 sequences, fully defined in the  
CC specification, lacking or with its associated signal peptide; or (b) at  
CC least 80% sequence identity to a sequence encoded by the full-length  
CC coding sequence of a DNA deposited in the American Type Culture  
CC Collection (ATCC). Also included are: (1) an isolated nucleic acid  
CC comprising: (a) at least 80% sequence identity to a nucleotide sequence  
CC that encodes a PRO protein; (b) at least 80% sequence identity to a  
CC nucleotide sequence or full-length coding sequence with any of 15 fully  
CC defined sequences of 957-3441 base pairs, given in the specification; or  
CC (c) at least 80% sequence identity to a full-length coding sequence of a  
CC DNA deposited under ATCC Accession No. 209526, 209508, 209524, 209528,  
CC 209530, 209523, 209492, 209532, 209531, 209529, 209527, 209570, 209618,  
CC 209621 or 209619; (2) a vector comprising the nucleic acid; (3) a host  
CC cell comprising the vector which, when cultured under conditions suitable  
CC for expression of the PRO polypeptide, produces the PRO protein; (4) a  
CC chimeric molecule comprising PRO fused to a heterologous amino acid  
CC sequence; and (5) an anti-PRO antibody. The methods and compositions of  
CC the present invention are useful for the diagnosis and treatment of  
CC disorders associated with the PRO polypeptide, such as AIDS (acquired  
CC immunodeficiency syndrome), cancer, atherosclerosis, inflammatory  
CC disease, diabetic complications, cardiac injury and organ failure. The  
CC antibodies can also be used in the different screening, therapeutic and  
CC biological assays. The present sequence represents a PRO protein  
XX  
SQ Sequence 431 AA;

Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFEFGESLTYTLVVICFLTLRLASQNCCLKSLSDVVIDIQSSLSKIRGNEPVYTSQ 60  
Db 1 MFEFGESLTYTLVVICFLTLRLASQNCCLKSLSDVVIDIQSSLSKIRGNEPVYTSQ 60  
QY 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRI 120  
Db 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRI 120  
QY 121 TDFPSLTRNLPSQELPQEDSLHGFQFSAVTPLAHHHTDYSKPTDISWRDLSQKFGSSD 180  
Db 121 TDFPSLTRNLPSQELPQEDSLHGFQFSAVTPLAHHHTDYSKPTDISWRDLSQKFGSSD 180  
QY 181 HLEKLFKMDASAOQLAYKEKHSQSSQFSSDQEI AHLLENVSALPATVAVASPHTTSA 240  
Db 181 HLEKLFKMDASAOQLAYKEKHSQSSQFSSDQEI AHLLENVSALPATVAVASPHTTSA 240  
QY 241 TPKPATLLPTNASVTPSGTSQPOLATTA PVTVTTSQPTTLISTVETRAATLQAMATT 300  
Db 241 TPKPATLLPTNASVTPSGTSQPOLATTA PVTVTTSQPTTLISTVETRAATLQAMATT 300  
QY 301 AVLTTFOAPTDSKGLSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMKTASNEGR 360  
Db 301 AVLTTFOAPTDSKGLSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMKTASNEGR 360  
QY 361 EASPGSSSQSVPENQYGLPFKMWLLIGSLFVGLFVLIGVLGRILSESLRRKRYSL 420  
Db 361 EASPGSSSQSVPENQYGLPFKMWLLIGSLFVGLFVLIGVLGRILSESLRRKRYSL 420  
QY 421 DYLINGIYVDI 431  
Db 421 DYLINGIYVDI 431

RESULT 8  
ABUS8114  
ID ABUS8114 standard; protein; 431 AA.  
XX  
AC ABUS8114;

XX 14-APR-2003 (first entry)  
DT  
XX Human PRO polypeptide #146.  
DE  
XX Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;  
KW horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;  
KW antibody-dependent enzyme mediated prodrug therapy.  
XX  
OS Homo sapiens.  
XX  
PN US2003027163-A1.  
XX  
PD 06-FEB-2003.  
XX  
PF 15-NOV-2001; 2001US-00997666.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.

PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.

PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 07-SEP-2000; 2000US-0230978P.

Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFFGEGSLTYTLVVICFLTLRLSASQNCLKSLLEDVVIDIQSLSGIRGNEPVYTSTQ 60  
|||||  
DB 1 MFFGEGSLTYTLVVICFLTLRLSASQNCLKSLLEDVVIDIQSLSGIRGNEPVYTSTQ 60  
61 EDCINSCCSTKNISGDKACNLMFPDTRKTARQPNCYLFFCPNEEACPLKPAKGLMSYRII 120  
|||||  
DB 61 EDCINSCCSTKNISGDKACNLMFPDTRKTARQPNCYLFFCPNEEACPLKPAKGLMSYRII 120  
121 TDFPSLTRNLPSQELPOEDSLHGFQSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
|||||  
DB 121 TDFPSLTRNLPSQELPOEDSLHGFQSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
QY 181 HLEKLFKXDEASAQLLAYKEKGHSQSSQFSSDQEI AHLPLENVSALPATVAVASPHTTSA 240  
|||||  
DB 181 HLEKLFKXDEASAQLLAYKEKGHSQSSQFSSDQEI AHLPLENVSALPATVAVASPHTTSA 240  
QY 241 TPKPATLPLPTNASVTPSPSGTSQPQLATTA PVTVTTSQPPTTLISTVFTRAAATLQAMATT 300

Db 241 TPKPATLLPTNASVTPSGTSQPQLAITAPVTTVTISQPTTLISTVFTRAAATLQAMATT 300  
QY 301 AVLTTTFOAPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
Db 301 AVLTTTFOAPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
QY 361 EASPGSSSQGSVPENQYGLPFEXKMLLIGSLFGVLFLVIGLVLLGRILSESLRKRYSRL 420  
Db 361 EASPGSSSQGSVPENQYGLPFEXKMLLIGSLFGVLFLVIGLVLLGRILSESLRKRYSRL 420  
QY 421 DYLINGIYVDI 431  
Db 421 DYLINGIYVDI 431  
RESULT 9  
ABU59192  
ID ABU59192 standard; protein; 431 AA.  
XX  
AC ABU59192;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Novel human secreted or transmembrane protein PRO361.  
XX  
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
KW cardiac insufficiency disorder; cancer; tumour; immune response;  
KW adrenal cortical capillary endothelial growth; c-fos induction;  
KW vascular endothelial growth factor inhibitor; VEGF inhibition;  
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;  
KW retinal neurons cell survival; rod photoreceptor cell survival;  
KW retinal disorder; retinitis pigmentosum; kidney disorder;  
KW mammalian kidney mesangial cell proliferation; Berger disease;  
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;  
KW chondrocyte redifferentiation; sports injury; arthritis.  
XX  
OS Homo sapiens.  
XX  
PN US2002132252-A1.  
XX  
PD 19-SEP-2002.  
XX  
PF 14-NOV-2001; 2001US-00990442.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
(GETH ) GENENTECH INC.  
PA  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,  
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ,  
PI Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF,  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,  
PI Zhang Z;



XX WPI; 2003-247083/24.  
DR N-PSDB; ABX80473.  
XX  
PT Novel isolated PRO polypeptides e.g.. PRO826, PRO1068, PRO1184, PRO1346  
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
PT are therapeutically useful for enhancing immune response and in cancer  
PT treatments.

XX  
PS Claim 12; Fig 328; 648bp; English.

XX  
CC The invention describes an isolated human PRO polypeptide. The PRO  
CC polypeptides are useful in detecting PRO polypeptides in a sample, in  
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
CC in modulating at least one biological activity of a cell expressing a PRO  
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186  
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,  
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,  
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus  
CC useful for treating conditions or disorders where angiogenesis would be  
CC beneficial, e.g. wound healing and antagonist of this polypeptide are  
CC useful for treating cancerous tumours. PRO812 inhibits vascular  
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial  
CC cells and is thus useful for inhibiting endothelial cell growth in  
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,  
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of  
CC stimulated T-lymphocytes and are therapeutically useful for enhancing  
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of  
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of  
CC rod photoreceptor cells) and therefore are useful for treating retinal  
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813  
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,  
CC and therefore are useful for treating kidney disorders associated with  
CC decreased mesangial cell function such as Berger disease or other  
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's  
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the  
CC proliferation and/or redifferentiation of chondrocytes in culture and are  
CC thus useful for treating sports injuries, and arthritis. This is the  
CC amino acid sequence of a novel human PRO protein  
XX  
SQ Sequence 431 AA;

Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MFPGEGSLTYLVIIICFLTRLSASQNCLESDVIDIQSSLSKGRNEPVYTSTQ 60  
|||  
Db 1 MFPGEGSLTYLVIIICFLTRLSASQNCLESDVIDIQSSLSKGRNEPVYTSTQ 60  
OY 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFPCPNEBACPAPAKGLMSYRII 120  
|||  
Db 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFPCPNEBACPAPAKGLMSYRII 120  
OY 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPLAHHHTDYSKPTDISMRDTLSQKFGSSD 180  
|||  
Db 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPLAHHHTDYSKPTDISMRDTLSQKFGSSD 180  
OY 181 HLEKLFKMEASQAQLLAYKEKHSQSSQSFSSDQEIHAHLLENVSALPATVAVASPHTTSA 240  
|||  
Db 181 HLEKLFKMEASQAQLLAYKEKHSQSSQSFSSDQEIHAHLLENVSALPATVAVASPHTTSA 240  
OY 241 TPKPATLPTNASVTPSGTSQPQLATTAPVTVTSQPTTLISTVFTRAAATLQAMATT 300  
|||  
Db 241 TPKPATLPTNASVTPSGTSQPQLATTAPVTVTSQPTTLISTVFTRAAATLQAMATT 300  
OY 301 AVLTTTFOAPTDSKGSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
|||  
Db 301 AVLTTTFOAPTDSKGSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
OY 361 EASPGSSSQGSVPENQYGLPFKMWLLIGSLFGLVFLVIGLVLLGRILSESLRRKYSRL 420  
|||

Db 361 EASPGSSSQGSVPENQYGLPFKMWLLIGSLFGLVFLVIGLVLLGRILSESLRRKYSRL 420  
OY 421 DYLINGIYVDI 431  
|||  
Db 421 DYLINGIYVDI 431  
RESULT 10  
ABU82704  
ID ABU82704 standard; protein; 431 AA.  
XX  
AC ABU82704;  
XX  
DT 26-JUN-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein PRO361.  
XX  
KW Human; PRO; secreted protein; transmembrane protein; healing;  
KW cardiac insufficiency disorders; angiogenesis; wound healing;  
KW cancerous tumour; immune response; retinal disorder; sight loss;  
KW retinitis pigmentosum; age-related macular degeneration; AMD;  
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpeticiformis;  
KW Crohn's disease; sports injury; arthritis.  
XX  
OS Homo sapiens.  
XX  
PN US2003032023-A1.  
XX  
PD 13-FEB-2003.  
XX  
PF 14-NOV-2001; 2001US-00990711.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.

PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 31-AUG-1998; 98US-0098525P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MFFGGESLTYTVIICFLTRLSASONCLKSLEDVVIDIOSLSKGRNEPVTSTQ 60  
Db 1 MFFGGESLTYTVIICFLTRLSASONCLKSLEDVVIDIOSLSKGRNEPVTSTQ 60  
Qy 61 EDCINSCSTKNISGDKACNLMITDTRKTARQPNCYLFECPEBEACPLKPAKGLMSYRII 120

Db 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFPCPNEACPLKPAKGLMSYRII 120  
Qy 121 TDFPSLTRNLPSQELPOEDSLHGQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
Db 121 TDFPSLTRNLPSQELPOEDSLHGQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
Qy 181 HLEKLFKMDASAQLLAYKEKHSQSSQSSDQEI AHL PENVSALPATVAVASPHTTSA 240  
Db 181 HLEKLFKMDASAQLLAYKEKHSQSSQSSDQEI AHL PENVSALPATVAVASPHTTSA 240  
Qy 241 TPKPATLLEPTNASVTPSGTSQPLATPAPVTTVTSQPTTLISTVETRAAATLQAMATT 300  
Db 241 TPKPATLLEPTNASVTPSGTSQPLATPAPVTTVTSQPTTLISTVETRAAATLQAMATT 300  
Qy 301 AVLTTFQAPTDKSGSLETIPFTEISNLTNTGNVYNPTALSMNSVSSTMNKTASWEGR 360  
Db 301 AVLTTFQAPTDKSGSLETIPFTEISNLTNTGNVYNPTALSMNSVSSTMNKTASWEGR 360  
Qy 361 EASPGSSSQGSVPENQYGLPFEKWLIGSLLFGVLPLVIGLVLLGRILSESLRRKRY SRL 420  
Db 361 EASPGSSSQGSVPENQYGLPFEKWLIGSLLFGVLPLVIGLVLLGRILSESLRRKRY SRL 420  
Qy 421 DYLINGIYVDI 431  
Db 421 DYLINGIYVDI 431

RESULT 11  
ABU60623  
ID ABU60623 standard; protein; 431 AA.  
XX AC ABU60623;  
XX DT 01-MAY-2003 (first entry)  
XX DE Human secreted/transmembrane protein, #182.  
KW Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;  
KW diagnostic; therapeutic; gene therapy.  
XX OS Homo sapiens.  
XX PN US2002160384-A1.  
XX PD 31-OCT-2002.  
XX PF 14-NOV-2001; 2001US-00992598.  
XX PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US02006P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-008876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023352.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-009941992.  
PA (GETH ) GENENTECH INC.  
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;



PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Guirney AL, Kljavin IU, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Matanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
DR WPI; 2003-288106/28.  
DR N-PSDB; ABX90451.  
XX  
PT New transmembrane polypeptides and nucleic acids encoding the  
PT polypeptides, useful in gene therapy, in chromosome identification, as  
PT chromosome markers, or in generating probes.  
XX  
PS Claim 12; Fig 328; 650pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC comprising a sequence without signal peptide and the nucleic acid  
CC encoding them. The polypeptides can be used to raise antibodies that  
CC specifically bind to the PRO polypeptide, for linking a bioactive  
CC molecule to a cell expressing a PRO protein and for modulating at least  
CC one biological activity of a cell. The PRO polypeptides or  
CC polynucleotides are also useful in gene therapy, in chromosome  
CC identification, as chromosome markers, or in generating probes. The PRO  
CC polypeptides are useful as molecular markers for protein electrophoresis,  
CC and the isolated nucleic acids may be used for recombinantly expressing  
CC those markers. The PRO polypeptides and nucleic acids may also be used in  
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for  
CC PRO, and in affinity purification of PRO from recombinant cell culture or  
CC natural sources. The sequences presented in ABU60478-ABU60624 are the PRO  
CC polynucleotides of the invention. Note: The sequence data for this patent  
CC is also available in electronic format from USPTO at  
CC seqdata.uspto.gov/sequence.html  
XX  
SQ Sequence 431 AA;

Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFPGEGSLTYTLVIICFLTLRLSASQNLKSLSDVVIDIQSSLKSGIRGNEPVYTSIQ 60  
Db 1 MFPGEGSLTYTLVIICFLTLRLSASQNLKSLSDVVIDIQSSLKSGIRGNEPVYTSIQ 60  
QY 61 EDCINSCCSTKNISGDKACNLMFDTRKTARQPNCYLFCPNEEACPLKPAKGLMSYRII 120  
Db 61 EDCINSCCSTKNISGDKACNLMFDTRKTARQPNCYLFCPNEEACPLKPAKGLMSYRII 120  
QY 121 TDFPSLTRNLPSQELPOEDSLHGFQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
Db 121 TDFPSLTRNLPSQELPOEDSLHGFQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
QY 181 HLEKLFKMDEASAOQLLAYKEKHSOSSQFSSDOEIAHLLENVSALPATVAVASPHTTSA 240  
Db 181 HLEKLFKMDEASAOQLLAYKEKHSOSSQFSSDOEIAHLLENVSALPATVAVASPHTTSA 240  
QY 241 TPKPATLLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLISTVFTRAAATLQAMATT 300  
Db 241 TPKPATLLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLISTVFTRAAATLQAMATT 300  
QY 301 AVLTTFQAPTDKSGLETIPTEISNLTINTGNVYNPTALSMNSVESSTMNKTASWGR 360  
Db 301 AVLTTFQAPTDKSGLETIPTEISNLTINTGNVYNPTALSMNSVESSTMNKTASWGR 360  
QY 361 BASPGSSSQSVPENQYGLPFEXKULLIGSLFGVLFLVIGLVLLGRILSESLRRKRYRL 420  
Db 361 BASPGSSSQSVPENQYGLPFEXKULLIGSLFGVLFLVIGLVLLGRILSESLRRKRYRL 420  
QY 421 DYLINGIYVDI 431  
Db 421 DYLINGIYVDI 431

RESULT 12  
ABU14005

ID ABU14005 standard; protein; 431 AA.  
XX  
AC ABU14005;  
XX  
DT 26-FEB-2003 (first entry)  
XX  
DE Human PRO361 polypeptide.  
XX  
KW Human; PRO polypeptide; secreted protein; transmembrane protein;  
KW genetic disorder; antibacterial; immunosuppressive.  
XX  
OS Homo sapiens.  
XX  
PN US2002103125-A1.  
XX  
PD 01-AUG-2002.  
XX  
PF 20-NOV-2001; 2001US-00989731.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH LTD.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gertlisen MB, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gunney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
XX WPI; 2003-102117/09.  
DR N-PSDB; ABX64297.  
XX  
PT Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, identifying agonists or  
PT antagonists of polypeptide, and as molecular weight markers.  
XX  
XX  
PS Claim 12; Fig 328; 649pp; English.  
XX  
CC The present invention relates to the isolation of novel human PRO  
CC polypeptides, and the polynucleotide sequences encoding them. The PRO  
CC polypeptides are secreted and transmembrane proteins. The PRO  
CC polypeptides are useful for detecting other PRO polypeptides, for linking  
CC bioactive molecules to cells expressing PRO polypeptides, for modulating  
CC biological activities of cells expressing PRO polypeptides, and for for  
CC identifying agonists or antagonists. The polynucleotide sequences  
CC encoding PRO polypeptides are useful as hybridisation probes, in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC in the preparation of PRO polypeptides, for generating transgenic animals  
CC or knockout animals, to construct hybridisation probes for mapping the  
CC gene which encodes the PRO polypeptide, and for the genetic analysis of  
CC individuals with genetic disorders, in gene therapy, for chromosome  
CC identification, as chromosome markers, and for generating probes for PCR,  
CC Northern analysis, Southern analysis and Western analysis. ABU13860-  
CC ABU14006 represent the human PRO polypeptides of the invention. Note: The

CC sequence data for this patent was obtained in electronic format directly  
CC from the USPTO web site at [seqdata.uspto.gov/patids/IDentry.html](http://seqdata.uspto.gov/patids/IDentry.html)  
XX  
SQ Sequence 431 AA;  
Query Match 100.0%; Score 221; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MPFGEGSLTYTLVVICFLTRLSASQNLKKSLEDVVIDIQSSLSKGRGNEPVYTSTQ 60  
DB 1 MPFGEGSLTYTLVVICFLTRLSASQNLKKSLEDVVIDIQSSLSKGRGNEPVYTSTQ 60  
QY 61 EDCINSCSTKNISGDKACNLMFDTRKTARQPNCYLFFCENEAACPLKPAKGLMSYRII 120  
DB 61 EDCINSCSTKNISGDKACNLMFDTRKTARQPNCYLFFCENEAACPLKPAKGLMSYRII 120  
QY 121 TDFPSLTRNLPSEQELPQEDSLHGFSAQVTPLAHHHTDYSKPTDISWRDTLSQKFGSSD 180  
DB 121 TDFPSLTRNLPSEQELPQEDSLHGFSAQVTPLAHHHTDYSKPTDISWRDTLSQKFGSSD 180  
QY 181 HLEKLFKMDASAQLLAYKEKGHSQSSQFSSDOEIAHLBPENVSALEPATVAVASPHTTSA 240  
DB 181 HLEKLFKMDASAQLLAYKEKGHSQSSQFSSDOEIAHLBPENVSALEPATVAVASPHTTSA 240  
QY 241 TPKPATLLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLISTVETRAAATLQAMATT 300  
DB 241 TPKPATLLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLISTVETRAAATLQAMATT 300  
QY 301 AVLTTTFOAPTDSKGSLETIPTEISNLTNTGNVNPFTALSMNSVESSTMNKTASWEGR 360  
DB 301 AVLTTTFOAPTDSKGSLETIPTEISNLTNTGNVNPFTALSMNSVESSTMNKTASWEGR 360  
QY 361 EASPGSSSQGSVPENQYGLPFEXKLLIGSLLFVGLFLVIGLVLLGRILSESLRKRYRSL 420  
DB 361 EASPGSSSQGSVPENQYGLPFEXKLLIGSLLFVGLFLVIGLVLLGRILSESLRKRYRSL 420  
QY 421 DYLINGIYVDI 431  
DB 421 DYLINGIYVDI 431  
RESULT 13  
ABU60244  
ID ABU60244 standard; protein; 431 AA.  
XX  
XX AC ABU60244;  
XX  
XX DT 24-APR-2003 (first entry)  
XX  
XX DE Human PRO polypeptide #15.  
XX  
KW Human; PRO; secreted polypeptide; transmembrane polypeptide; cancer;  
KW inflammatory disease; atherosclerosis; cardiac injury; AIDS; infertility;  
KW birth defect; premature aging; diabetes; dog; cat; horse;  
KW acquired immunodeficiency syndrome; cow; sheep; pig; goat; rabbit;  
KW industry; cytostatic; antiinflammatory; cardiant; antiinfertility;  
KW anti-HIV; antiarteriosclerotic; antidiabetic.  
XX  
OS Homo sapiens.  
XX  
XX PN US2002132768-A1.  
XX  
XX PD 19-SEP-2002.  
XX  
XX PF 31-AUG-2001; 2001US-00945015.  
XX  
XX PR 03-DEC-1997; 97US-0067411P.  
XX PR 11-DEC-1997; 97US-0069278P.  
XX PR 11-DEC-1997; 97US-0069334P.  
XX PR 11-DEC-1997; 97US-0069335P.  
XX PR 12-DEC-1997; 97US-0069425P.  
XX PR 16-DEC-1997; 97US-0069694P.

PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 16-DEC-1998; 98US-00216021.  
PR 16-DEC-1998; 98US-0112850P.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 03-MAR-1999; 99US-00254311.  
PR 22-JUN-1999; 99WO-US012252.  
PR 28-JUL-1999; 99US-0146222P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Gerritsen MB, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX  
DR WPI; 2003-174088/17.  
DR N-PSDB; ABX89495.  
XX  
PT New secreted and transmembrane polypeptides (e.g. PRO241, for use in  
PT pharmaceuticals, diagnostics or bioreactors, particularly for detecting  
PT or treating e.g. cancers, infertility or acquired immunodeficiency  
PT syndrome in mammals.  
XX  
PS Claim 1; Fig 32; 173pp; English.  
XX  
XX The invention relates to a human secreted and transmembrane polypeptide  
CC (PRO) and the polynucleotide encoding it. The PRO polypeptide or  
CC polynucleotide is useful in pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are particularly useful for detecting or treating  
CC cancers, inflammatory diseases, atherosclerosis, cardiac injury,  
CC infertility, birth defects, premature aging, acquired immunodeficiency  
CC syndrome (AIDS) and diabetic complications in mammals, e.g. humans, dogs,  
CC cats, cattle, horses, sheep, pigs, goats or rabbits. The sequences are  
CC also useful in biotechnological and medical research and in various  
CC industrial applications. Sequences ABU60230-ABU60245 represent human PRO  
CC polypeptides of the invention  
XX  
SQ Sequence 431 AA;  
  
Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPNCYLFFCPNEEACPLKPAKGLMSYRI 120  
QY 121 TDFPSLTRNLPSQELPQEDSLHGQFSQAVTPLAHHTDYSKPTDISWRDLSQKFGSSD 180  
DB 121 TDFPSLTRNLPSQELPQEDSLHGQFSQAVTPLAHHTDYSKPTDISWRDLSQKFGSSD 180  
QY 181 HLEKLFKMEDEASAQLLAYKKEKHSQSSQFSSDQEI AHLBPENVSALPATVAVASPHITSA 240  
DB 181 HLEKLFKMEDEASAQLLAYKKEKHSQSSQFSSDQEI AHLBPENVSALPATVAVASPHITSA 240  
QY 241 TPKPATLLPTNASVTPSGTSQPOLATTA PVTVTVSQPTLLISTVFTRAATLQAMATT 300  
DB 241 TPKPATLLPTNASVTPSGTSQPOLATTA PVTVTVSQPTLLISTVFTRAATLQAMATT 300  
QY 301 AVLTTTFOAPTDSKGSLETTPTTEISNLT LNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
DB 301 AVLTTTFOAPTDSKGSLETTPTTEISNLT LNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
QY 361 EASPGSSSQGSVPENQYGLPFEKWLIGSLFGVLFVIGVLGRI LSESLRRKYSRL 420  
DB 361 EASPGSSSQGSVPENQYGLPFEKWLIGSLFGVLFVIGVLGRI LSESLRRKYSRL 420  
QY 421 DYLINGIYVDI 431  
DB 421 DYLINGIYVDI 431  
  
RESULT 14  
ABU72590  
ID ABU72590 standard; protein; 431 AA.  
XX AC ABU72590;  
XX DT 17-JUN-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO361.  
XX KW Human; secreted and transmembrane protein; cyostatic; anti-HIV;  
KW virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;  
KW PRO; pharmaceutical; diagnostic; biosensor; bioreactor; malignancy;  
KW cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;  
KW lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;  
XX KW drug screening.  
XX OS Homo sapiens.  
XX PN US2003003531-A1.  
XX PD 02-JAN-2003.  
XX PF 19-NOV-2001; 2001US-00989734.  
XX PR 16-JUN-1997; 97US-0049787P.  
XX PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.



PA 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX

PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kijaviri IU, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams FM, Wood WI;  
PI Zhang Z;  
XX  
DR WPI; 2003-352829/33.  
DR N-PSDB; ACA64519.  
XX  
PT New genes and secreted and transmembrane polypeptides (e.g. PRO183 or  
PT PRO184), useful for treating or diagnosing e.g. ovarian cancer, Kaposi's  
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's  
PT disease.  
XX  
PS Claim 12; Fig 328; 663pp; English.  
XX  
CC The invention describes a new isolated nucleic acid molecule comprising  
CC the full length coding sequence of the DNA deposited with the American  
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,  
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DNA  
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are  
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These  
CC are particularly useful for detecting or treating e.g. malignancies or  
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,  
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's  
CC disease in mammals. The PRO polypeptides are useful in drug screening,  
CC and in the diagnostic determination of the presence of these diseases.  
CC The PRO polypeptides are also useful as molecular weight markers, or for  
CC chromosome identification. The PRO genes are useful as hybridisation  
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.  
CC The PRO genes may also be used in gene therapy, particularly for  
CC replacing a defective gene. This is the amino acid sequence of a novel  
CC human secreted and transmembrane PRO polypeptide  
XX  
SQ Sequence 431 AA;  
  
Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 MFFGEGSLTYTLVIICFLTLRLSASQNLKKSLEDDVIDIQSSLSKIGRNEPVYTSTQ 60  
DB 1 MFFGEGSLTYTLVIICFLTLRLSASQNLKKSLEDDVIDIQSSLSKIGRNEPVYTSTQ 60  
  
QY 61 EDCINSCCSTKNISGDKACNLMTDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
DB 61 EDCINSCCSTKNISGDKACNLMTDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRII 120  
  
QY 121 TDFPSLTRNLPSQELPQEDSLHGFQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
DB 121 TDFPSLTRNLPSQELPQEDSLHGFQFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSD 180  
  
QY 181 HLEKLFKNDDEASAQLLAYKKEKGHSQSSQFSSDQIEAHLPENVSALPATVAVASPHITSA 240  
DB 181 HLEKLFKNDDEASAQLLAYKKEKGHSQSSQFSSDQIEAHLPENVSALPATVAVASPHITSA 240  
  
QY 241 TPKPATLLPTNASVTPSGTSQPOLATTAAPVTTVTSQPTTLISTVFTRAATLQAMATT 300  
DB 241 TPKPATLLPTNASVTPSGTSQPOLATTAAPVTTVTSQPTTLISTVFTRAATLQAMATT 300  
  
QY 301 AVLTTTQAPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
DB 301 AVLTTTQAPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR 360  
  
QY 361 EASPGSSSQGSVPENQYGLPFPEKMLIGSLLFGLVFLVIGVLGRILSESLRKRYSRL 420  
DB 361 EASPGSSSQGSVPENQYGLPFPEKMLIGSLLFGLVFLVIGVLGRILSESLRKRYSRL 420  
  
QY 421 DYLINGIYVDI 431  
DB 421 DYLINGIYVDI 431

Db 421 DYLINGIYVDI 431

RESULT 15  
ABU64930  
ID ABU64930 standard; protein; 431 AA.  
XX ABU64930;  
XX 15-MAY-2003 (first entry)  
DT  
XX Human secreted/transmembrane protein PRO361.  
DE  
XX Human; PRO; secreted protein; transmembrane protein;  
KW Cornelia de Lange syndrome; gene therapy; immune disorder;  
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;  
KW infertility; birth defect; premature aging; cardiac injury; AIDS; cancer;  
KW diabetic complication.  
XX Homo sapiens.  
OS  
XX US2002173463-A1.  
PN  
XX 21-NOV-2002.  
PD  
XX 31-AUG-2001; 2001US-00944944.  
PF  
XX 03-DEC-1997; 97US-0067411P.  
XX 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 16-DEC-1998; 98US-0112850P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 28-JUL-1999; 99US-0146222P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX WPI; 2003-311003/30.  
DR N-PSDB; ABX96832.  
XX  
PT New transmembrane polypeptides and polynucleotides useful for chromosome

PT identification, tissue typing, gene therapy, in chromosome and gene  
PT mapping, or as molecular weight markers.  
XX  
XX Claim 12; Fig 32; 172pb; English.  
PS  
CC The invention relates to an isolated nucleic acid encoding a secreted/  
CC transmembrane polypeptide (designated as PRO proteins). 15 PRO  
CC polypeptides and their encoding polynucleotides are disclosed. Also  
CC included are a vector comprising the PRO nucleic acid, a host cell  
CC comprising the vector, a process for producing a PRO polypeptide (by  
CC culturing the host cell under conditions for the expression of the PRO  
CC polypeptide, and recovering the PRO polypeptide from the cell culture, an  
CC isolated polypeptide having at least 80% amino acid sequence identity to  
CC the PRO polypeptides, a chimeric molecule comprising PRO fused to a  
CC heterologous amino acid sequence and an antibody which specifically binds  
CC to PRO. The PRO nucleotide sequences are useful as hybridisation probes,  
CC in chromosome and gene mapping, in generating sense and antisense RNA or  
CC DNA, in generating transgenic or knock-out animals which can be used in  
CC the development and screening of therapeutically useful reagents, and in  
CC gene therapy. The polypeptides may be used as molecular weight markers  
CC for protein electrophoresis purposes. The PRO polypeptides and nucleic  
CC acids may also be used for chromosome identification, and tissue typing.  
CC PRO241 (identified as Chordin) is a candidate gene for Cornelia de Lange  
CC syndrome. Other PRO proteins are variously implicated in immune  
CC disorders, inflammatory disease, organ failure, atherosclerosis, cardiac  
CC injury, infertility, birth defects, premature aging, cardiac injury,  
CC AIDS, cancer and diabetic complications. The present sequence represents  
CC a PRO protein  
XX  
XX Sequence 431 AA;  
SQ

Query Match 100.0%; Score 2211; DB 6; Length 431;  
Best Local Similarity 100.0%; Pred. No. 3.6e-173;  
Matches 431; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFFGEGSLTYTVITICFLTLRLSASQNCLESDVIDIQSSLKGRGNEPYTSTQ 60  
Db 1 MFFGEGSLTYTVITICFLTLRLSASQNCLESDVIDIQSSLKGRGNEPYTSTQ 60

QY 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPCNYLFCPNEBACPLKPAKGLMSYRII 120  
Db 61 EDCINSCSTKNISGDKACNLMIFDTRKTARQPCNYLFCPNEBACPLKPAKGLMSYRII 120

QY 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPPLAHHHTDYSKPTDISWRDTLSQKFGSSD 180  
Db 121 TDFPSLTRNLPSQELPQEDSLHGFQSAVTPPLAHHHTDYSKPTDISWRDTLSQKFGSSD 180

QY 181 HLEKLFKXMDASAOQLAYKEKGHSQSSQFSSDOEIAHLLENVSALPATVAVAPHTTSA 240  
Db 181 HLEKLFKXMDASAOQLAYKEKGHSQSSQFSSDOEIAHLLENVSALPATVAVAPHTTSA 240

QY 241 TPKPATLLPTNASVTPSGTSQPQLATTAPPVTVTSQPPTLLISTVFTRAATLQAMATT 300  
Db 241 TPKPATLLPTNASVTPSGTSQPQLATTAPPVTVTSQPPTLLISTVFTRAATLQAMATT 300

QY 301 AVLTTFOAPTDSKGSLETIPTEISNLTANTGVNYPNTALSMNSVSSITWNTASWEGR 360  
Db 301 AVLTTFOAPTDSKGSLETIPTEISNLTANTGVNYPNTALSMNSVSSITWNTASWEGR 360

QY 361 EASPGSSSQGSVPENQGLPFEKMLLIGSLFGVLVIGLVLLGRILSESLRRKYSRL 420  
Db 361 EASPGSSSQGSVPENQGLPFEKMLLIGSLFGVLVIGLVLLGRILSESLRRKYSRL 420

QY 421 DYLINGIYVDI 431  
Db 421 DYLINGIYVDI 431

**THIS PAGE BLANK (USPTO)**




> O < IntelliGenetics  
> O <  
FastDB - Fast Pairwise Comparison of Sequences  
Release 5.4

Results file 944929\_83\_x\_ageneSelect.res made by spaula on Thu 30 Sep 104 8:26:57-PST.

Query sequence being compared:US-09-944-929-83 (1-431)  
Number of sequences searched: 11  
Number of scores above cutoff: 11

Results of the initial comparison of US-09-944-929-83 (1-431) with:  
File : vogel-agene.pep



PARAMETERS

Similarity matrix Unitary K-tuple  
Mismatch penalty 1 Joining penalty 2  
Gap penalty 1.00 Window size 20  
Gap size penalty 0.05  
Cutoff score 0  
Randomization group 0

SEARCH STATISTICS

Scores: Mean 353 Median 432 Standard Deviation 172.12  
Times: CPU 00:00:00.00 Total Elapsed 00:00:01.00

Number of residues: 4930  
Number of sequences searched: 11  
Number of scores above cutoff: 11

The scores below are sorted by initial score.  
Significance is calculated based on initial score.

9 100% identical sequences to the query sequence were found:

Sequence Name	Description	Init. Score	Opt. Score	Sig. Frame
-----	-----	-----	-----	-----

The list of other best scores is:

Sequence Name	Description	Length	Score	Init. Opt.	Sig. Frame
1. ADE71552.PEP	Human secreted/transmembrane	431	431	431	0.45 0
2. ABU82704.PEP	Human secreted/transmembrane	431	431	431	0.45 0
3. ABU72590.PEP	Novel human secreted and tran	431	431	431	0.45 0
4. ABU64930.PEP	Human secreted/transmembrane	431	431	431	0.45 0
5. ABU60623.PEP	Human secreted/transmembrane	431	431	431	0.45 0
6. ABU59192.PEP	Novel human secreted or trans	431	431	431	0.45 0
7. ABU58364.PEP	Novel human secreted protein	431	431	431	0.45 0
8. ABU55934.PEP	Human secreted/transmembrane	431	431	431	0.45 0
9. AAB34739.PEP	Human secreted protein encode	431	431	431	0.45 0

Sequence Name	Description	Length	Score	Init. Opt.	Sig. Frame
10. AAM25899.PEP	TOIG of: aam25899 check: 599	633	6	66	-2.02 0
11. AAB92667.PEP	TOIG of: aab92667 check: 542	418	5	67	-2.02 0

1. US-09-944-929-83 (1-431)  
ADE71552.PEP Human secreted/transmembrane PRO polypeptide #15.  
TOIG of: ade71552 check: 2687 from: 1 to: 431

ID ADE71552 standard; protein; 431 AA.

AC ADE71552;

DT 29-JAN-2004 (first entry)

DE Human secreted/transmembrane PRO polypeptide #15.

KW human; sports-related joint problem; articular cartilage defect;

KW osteoarthritis; rheumatoid arthritis; cancer; PRO; secreted protein;

OS Homo sapiens.

PN US2003096742-A1.

PD 22-MAY-2003.

PF 30-AUG-2001; 2001US-00943780.

XX	03-DEC-1997;	97US-0067411P.
PR	11-DEC-1997;	97US-0069278P.
PR	11-DEC-1997;	97US-0069334P.
PR	11-DEC-1997;	97US-0069335P.
PR	12-DEC-1997;	97US-0069425P.
PR	16-DEC-1997;	97US-0069694P.
PR	16-DEC-1997;	97US-0069696P.
PR	16-DEC-1997;	97US-0069702P.
PR	17-DEC-1997;	97US-0069870P.
PR	18-DEC-1997;	97US-0069873P.
PR	05-JAN-1998;	98US-0070440P.
PR	09-FEB-1998;	98US-0074086P.
PR	09-FEB-1998;	98US-0074092P.
PR	25-FEB-1998;	98US-0075945P.
PR	16-SEP-1998;	98WO-US019330.
PR	01-DEC-1998;	98WO-US025108.
PR	16-DEC-1998;	98US-0112850P.
PR	22-DEC-1998;	98US-0113296P.
PR	02-JUN-1999;	99WO-US012252.
PR	28-JUL-1999;	99US-0146222P.
PR	15-SEP-1999;	99WO-US021090.
PR	30-NOV-1999;	99WO-US028313.
PR	30-NOV-1999;	99WO-US028409.
PR	01-DEC-1999;	99WO-US028301.
PR	16-DEC-1999;	99WO-US030095.
PR	11-FEB-2000;	2000WO-US003565.
PR	22-FEB-2000;	2000WO-US004414.

PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.

XX  
PA (GETH ) GENENTECH INC.

PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kijavir IJ, Napier MA, Roy MA, Tumas D, Wood WI;

XX  
DR WPI; 2004-008951/01.  
DR N-PSDB; ADE71551.

XX  
PT New PRO polypeptide for diagnosing or treating inflammatory diseases,  
PT organ failure, atherosclerosis, cardiac injury, infertility, cancer,  
PT acquired immunodeficiency disease, Alzheimer's disease or Parkinson's  
PT disease.

XX  
PS Claim 12; SEQ ID NO 83; 172pp; English.

XX  
CC The invention relates to isolated nucleic acids and their encoded PRO  
CC proteins. The PRO polypeptides are useful in diagnosing and treating a  
CC condition that is responsive to the PRO polypeptide, e.g., in the  
CC treatment of sports-related joint problems, articular cartilage defects,  
CC osteoarthritis, rheumatoid arthritis and cancer. The PRO polypeptides are  
CC also useful in identifying agonists/antagonists of the PRO polypeptide.  
CC The nucleic acid is useful as hybridisation probe, in chromosome and gene  
CC mapping, and in the generation of anti-sense RNA and DNA. The present  
CC sequence represent the amino acid sequence of a human  
CC secreted/transmembrane PRO polypeptide.

XX  
SQ Sequence 431 AA;

ADE71552 Length: 431 September 30, 2004 08:13 Type: P Check: 2687 ..

Initial Score = 431 Optimized Score = 431 Significance = 0.45  
Residue Identity = 100% Matches = 431 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
MEFGEGSLTYTLVLCFLTLRLSASQNCIKKSLIEDVVIDIQSSLKIGRGNPEPVYTSQEDCINSCCSTKN  
|||||  
MEFGEGSLTYTLVLCFLTLRLSASQNCIKKSLIEDVVIDIQSSLKIGRGNPEPVYTSQEDCINSCCSTKN  
X 10 20 30 40 50 60 70

ISGDKACNLMIFDTRKTARQPCNYLFCFPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHG  
|||||  
ISGDKACNLMIFDTRKTARQPCNYLFCFPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHG  
ISGDKACNLMIFDTRKTARQPCNYLFCFPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHG  
80 90 100 110 120 130 140

QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASQAQLLAYKKEKHSQSSQFSSDQEIA  
|||||  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASQAQLLAYKKEKHSQSSQFSSDQEIA  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASQAQLLAYKKEKHSQSSQFSSDQEIA  
150 160 170 180 190 200 210

HLLPENVSALPATVAVASPHHTSSTPKPATLLPTNASVTPSGTSQPOLATTAPPVTVTSQPPPTLLISTVFT  
|||||  
HLLPENVSALPATVAVASPHHTSSTPKPATLLPTNASVTPSGTSQPOLATTAPPVTVTSQPPPTLLISTVFT  
HLLPENVSALPATVAVASPHHTSSTPKPATLLPTNASVTPSGTSQPOLATTAPPVTVTSQPPPTLLISTVFT  
220 230 240 250 260 270 280

RAAATLQAMATTAVLTTFQAPPTDSKGSLETIPFTEISNLTNTGNVNYPTALSMNSVSSSTMNKTASWEGR  
|||||  
RAAATLQAMATTAVLTTFQAPPTDSKGSLETIPFTEISNLTNTGNVNYPTALSMNSVSSSTMNKTASWEGR  
RAAATLQAMATTAVLTTFQAPPTDSKGSLETIPFTEISNLTNTGNVNYPTALSMNSVSSSTMNKTASWEGR  
290 300 310 320 330 340 350 360

EASPGSSSQGSVPENQYGLPFKEKMLLIGSLFGVLFLVIGVLVLLGRIKRLRRKRYSLDYLLINGIYVDI  
|||||  
EASPGSSSQGSVPENQYGLPFKEKMLLIGSLFGVLFLVIGVLVLLGRIKRLRRKRYSLDYLLINGIYVDI  
370 380 390 400 410 420 430

2. US-09-944-929-83 (1-431)  
ABU82704.PEP Human secreted/transmembrane protein PRO361.

TOIG of: abu82704 check: 2687 from: 1 to: 431

ID ABU82704 standard; protein; 431 AA.

XX  
AC ABU82704;

XX  
DT 26-JUN-2003 (first entry)

XX  
DE Human secreted/transmembrane protein PRO361.

XX  
KW Human; PRO; secreted protein; transmembrane protein;  
KW cardiac insufficiency disorders; angiogenesis; wound healing;  
KW cancerous tumour; immune response; retinal disorder; sight loss;  
KW retinitis pigmentosum; age-related macular degeneration; AMD;  
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpeticiformis;  
KW Crohn's disease; sports injury; arthritis.

XX  
OS Homo sapiens.

XX  
PN US2003032023-A1.

XX  
PD 13-FEB-2003.

XX  
PF 14-NOV-2001; 2001US-00990711.

XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.

PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 19-JUN-1998; 98US-0089948P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 23-JUN-1998; 98US-0090355P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090431P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090472P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090542P.  
PR 24-JUN-1998; 98US-0090557P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091360P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091633P.  
PR 02-JUL-1998; 98US-0091646P.  
PR 02-JUL-1998; 98US-0091673P.  
PR 07-JUL-1998; 98US-0091978P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 09-JUL-1998; 98US-0092182P.  
PR 10-JUL-1998; 98US-0092472P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095301P.  
PR 04-AUG-1998; 98US-0095302P.  
PR 04-AUG-1998; 98US-0095318P.  
PR 04-AUG-1998; 98US-0095321P.  
PR 04-AUG-1998; 98US-0095325P.  
PR 10-AUG-1998; 98US-0095916P.  
PR 10-AUG-1998; 98US-0095929P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096894P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096950P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 24-AUG-1998; 98US-0097661P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0097978P.  
PR 26-AUG-1998; 98US-0097979P.  
PR 26-AUG-1998; 98US-0097986P.  
PR 31-AUG-1998; 98US-0098014P.  
PR 16-SEP-1998; 98US-0100634P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 12-MAR-1999; 99US-0123957P.  
PR 02-JUN-1999; 99WO-US012252.  
PR 23-JUN-1999; 99US-0141037P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 17-AUG-1999; 99US-0149396P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99US-0158663P.  
PR 08-OCT-1999; 99US-0158663P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-JUN-2000; 2000US-0213637P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 07-SEP-2000; 2000US-0230978P.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.



PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrera N, Fong S, Gerber H, Gertlesen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
XX WPI; 2003-331911/31.  
DR N-PSDB; ACA69380.  
XX  
PT New isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and  
PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and  
PT are therapeutically useful for enhancing an immune response.  
XX  
XX Claim 12; Fig 328; 653pp; English.  
XX  
CC The invention relates to an isolated PRO polypeptide having 80 % sequence  
CC identity to: (i) one of 147 polypeptide sequences, given in the  
CC specification; or (ii) The polypeptide lacking its associated signal  
CC peptide or an isolated extracellular domain of PRO polypeptide with or  
CC without its associated signal peptide. Also included are an isolated  
CC nucleic acid having 80 % identity to a nucleotide sequence encoding PRO,  
CC an isolated nucleic acid comprising a full-length coding sequence of one  
CC of 141 DNA sequences deposited under an American Type Culture Collection  
CC (ATCC) Accession No. given in the specification, a PRO vector, a host  
CC cell comprising the PRO vector, a chimeric molecule comprising PRO fused  
CC to a heterologous amino acid sequence and an anti-PRO antibody. PRO  
CC proteins are used to detect PRO polypeptides in a sample, the sample  
CC comprises cells suspected of expressing the PRO polypeptide. PRO  
CC polypeptides which are contacted with the sample are labeled with a  
CC detectable label or a solid support. The PRO polypeptides are also used  
CC to link a bioactive molecule to a cell expressing a PRO polypeptide where  
CC the bioactive molecule is a toxin, radiolabel or antibody, which causes  
CC the death of the cell. The PRO polypeptides are used to modulate a  
CC biological activity of a cell expressing the PRO polypeptides. The PRO  
CC polypeptides are used as therapeutic agents for diseases associated with  
CC each PRO protein e.g. PRO1312 (cardiac insufficiency disorders),  
CC PRO1154/PRO1186 (disorders where angiogenesis would be beneficial, e.g.,  
CC wound healing and cancerous tumours), PRO812 (vascular endothelial growth  
CC factor (VEGF) inhibitor used to inhibit tumour growth),  
CC PRO826/PRO1068/PRO1184/PRO1346/PRO1375 (stimulate proliferation of  
CC stimulated T-lymphocytes and are used to enhancing immune response),  
CC PRO828/PRO826/PRO1068/PRO1132 (retinal disorders e.g. sight loss in  
CC mammals due to retinitis pigmentosum and age-related macular degeneration  
CC (AMD)), PRO536/PRO943/PRO828/PRO826/PRO1068/PRO1132 (retinitis  
CC pigmentosum, and AMD), PRO535/PRO826/PRO819/PRO1126/PRO1360/ PRO1387  
CC (angiogenesis e.g. wound healing and cancerous tumours),  
CC PRO819/PRO813/PRO11066 (kidney disorders e.g. Berger disease or other  
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's  
CC disease) and PRO1310/PRO844/PRO1312/PRO1192/PRO1387 (sports injuries and  
CC arthritis). The present sequence represents a PRO protein  
XX  
SQ Sequence 431 AA;

ABU82704 Length: 431 September 30, 2004 08:12 Type: P Check: 2687 ..

Initial Score = 431 Optimized Score = 431 Significance = 0.45  
Residue Identity = 100% Matches = 431 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
MFGEGSLTYTLVILCFLLRLASQNCLEKSLSDVVIDIQSSLSKIRGNPEVYTSQEDCINSCSTKN  
MFGEGSLTYTLVILCFLLRLASQNCLEKSLSDVVIDIQSSLSKIRGNPEVYTSQEDCINSCSTKN  
X 10 20 30 40 50 60 70  
80 90 100 110 120 130 140

ISGDACNLMIEDTRKTARQPNCYLFFCPNBEACPLKPAKGLMSYRIITDFPSLTRNLPSELPQEDSLIHG  
QFSQAVTPLAHHTDYSKPTDISWRDLSQKFGSSDHLLEKLFKMDEASAGLLAYKEKGHSOSSQFSSDOEIA  
QFSQAVTPLAHHTDYSKPTDISWRDLSQKFGSSDHLLEKLFKMDEASAGLLAYKEKGHSOSSQFSSDOEIA  
HLLPENVSALPATVAVASPHHTSATPKPATLLPTNASVTPSGTSQPOLATTAPEVTTVTSQPTTLISTVFT  
HLLPENVSALPATVAVASPHHTSATPKPATLLPTNASVTPSGTSQPOLATTAPEVTTVTSQPTTLISTVFT  
RAAATLQAMATTAVLTTFQAPTDKSGLETIPFTBISNLTNTGNVYNPTALSMSNVESTMNKTASWEGR  
RAAATLQAMATTAVLTTFQAPTDKSGLETIPFTBISNLTNTGNVYNPTALSMSNVESTMNKTASWEGR  
EASPGSSSQGSVPENQGLPFEKMLLIGSLFGLVLTGLVLLGRILSGLRRKRSRLDYLINGIYVDI  
EASPGSSSQGSVPENQGLPFEKMLLIGSLFGLVLTGLVLLGRILSGLRRKRSRLDYLINGIYVDI  
X 370 380 390 400 410 420 430

3. US-09-944-929-83 (1-431)  
ABU72590.PEP Novel human secreted and transmembrane protein PRO  
TOIG of: abu72590 check: 2687 from: 1 to: 431

ID ABU72590 standard; protein; 431 AA.  
AC ABU72590;  
XX  
DT 17-JUN-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO361.  
XX  
KW Human; secreted and transmembrane protein; cytosol; anti-HIV;  
KW virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;  
KW PRO; pharmaceutical; diagnostic; biosensor; bioreactor; malignancy;  
KW cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;  
KW lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;  
KW drug screening.  
XX  
OS Homo sapiens.  
XX  
XX US2003003531-A1.  
PN  
XX  
PD 02-JAN-2003.  
XX  
XX  
PF 19-NOV-2001; 2001US-00989734.  
XX  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US020069.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.

PR	04-JUN-1998;	98US-0088021P.
PR	04-JUN-1998;	98US-0088025P.
PR	04-JUN-1998;	98US-0088026P.
PR	04-JUN-1998;	98US-0088028P.
PR	04-JUN-1998;	98US-0088029P.
PR	04-JUN-1998;	98US-0088030P.
PR	04-JUN-1998;	98US-0088033P.
PR	04-JUN-1998;	98US-0088326P.
PR	05-JUN-1998;	98US-0088167P.
PR	05-JUN-1998;	98US-0088202P.
PR	05-JUN-1998;	98US-0088212P.
PR	05-JUN-1998;	98US-0088217P.
PR	09-JUN-1998;	98US-0088655P.
PR	10-JUN-1998;	98US-0088734P.
PR	10-JUN-1998;	98US-0088738P.
PR	10-JUN-1998;	98US-0088742P.
PR	10-JUN-1998;	98US-0088810P.
PR	10-JUN-1998;	98US-0088824P.
PR	10-JUN-1998;	98US-0088826P.
PR	11-JUN-1998;	98US-0088858P.
PR	11-JUN-1998;	98US-0088861P.
PR	11-JUN-1998;	98US-0088876P.
PR	12-JUN-1998;	98US-0089105P.
PR	16-JUN-1998;	98US-0089440P.
PR	16-JUN-1998;	98US-0089512P.
PR	16-JUN-1998;	98US-0089514P.
PR	16-JUN-1998;	98US-0089532P.
PR	17-JUN-1998;	98US-0089538P.
PR	17-JUN-1998;	98US-0089598P.
PR	17-JUN-1998;	98US-0089599P.
PR	17-JUN-1998;	98US-0089600P.
PR	17-JUN-1998;	98US-0089653P.
PR	18-JUN-1998;	98US-0089801P.
PR	18-JUN-1998;	98US-0089907P.
PR	18-JUN-1998;	98US-0089908P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98WO-US019437.
PR	07-OCT-1998;	98WO-US021141.
PR	01-DEC-1998;	98WO-US025106.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	02-JUN-1999;	99WO-US012252.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	30-NOV-1999;	99WO-US028313.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006834.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-2000;	2000WO-US013358.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.

```

PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GERTH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-352829/33.
DR N-PSDB; ACA64519.
XX
PT New genes and secreted and transmembrane polypeptides (e.g. PRO183 or
PT PRO184), useful for treating or diagnosing e.g. ovarian cancer, Kaposi
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn'
PT disease.
XX
PS Claim 12; Fig 328; 663pp; English.
XX
CC The invention describes a new isolated nucleic acid molecule comprising
CC the full length coding sequence of the DNA deposited with the American
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DN
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides ar
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. The
CC are particularly useful for detecting or treating e.g. malignancies or
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's
CC disease in mammals. The PRO polypeptides are useful in drug screening,
CC particularly as targets for therapeutic intervention in these diseases.
CC and in the diagnostic determination of the presence of these diseases.
CC The PRO polypeptides are also useful as molecular weight markers, or f
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO polypeptide
XX
SQ Sequence 431 AA;
ABU72590 Length: 431 September 30, 2004 08:12 Type: P Check: 2687 ..
Initial Score = 431 Optimized Score = 431 Significance = 0.45
Residue Identity = 100% Matches = 431 Mismatches = 0
Gaps = 0 Conservative Substitutions = 0
X 10 20 30 40 50 60 70
MFFGGSGSLVTLVIICFLTRLRLSASQNCUKKSLEDVVIDIQSSLSKGIRGNPEPYTSTQEDCINSCCSTKN
MFFGGESLVTTLVICFLTRLRLSASQNCUKKSLEDVVIDIQSSLSKGIRGNPEPYTSTQEDCINSCCSTKN
MFFGGESLVTTLVICFLTRLRLSASQNCUKKSLEDVVIDIQSSLSKGIRGNPEPYTSTQEDCINSCCSTKN
X 10 20 30 40 50 60 70
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
X 80 90 100 110 120 130 140
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
X 80 90 100 110 120 130 140
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
ISGDKACNLMIEDTRKTARQPNCYLFPCNEEACPLPKAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHLHG
X 150 160 170 180 190 200 210
QFSQAATPLAAHTTDYSKPTDISWRDITLSOKFGSSDHLEKLFKMDASAQLLAYKEKGHSOSSQSOFSSDOEIA
QFSQAATPLAAHTTDYSKPTDISWRDITLSOKFGSSDHLEKLFKMDASAQLLAYKEKGHSOSSQSOFSSDOEIA
QFSQAATPLAAHTTDYSKPTDISWRDITLSOKFGSSDHLEKLFKMDASAQLLAYKEKGHSOSSQSOFSSDOEIA
X 150 160 170 180 190 200 210
QFSQAATPLAAHTTDYSKPTDISWRDITLSOKFGSSDHLEKLFKMDASAQLLAYKEKGHSOSSQSOFSSDOEIA
QFSQAATPLAAHTTDYSKPTDISWRDITLSOKFGSSDHLEKLFKMDASAQLLAYKEKGHSOSSQSOFSSDOEIA
QFSQAATPLAAHTTDYSKPTDISWRDITLSOKFGSSDHLEKLFKMDASAQLLAYKEKGHSOSSQSOFSSDOEIA
X 220 230 240 250 260 270 280
HLLPENVSALPATVAVASPHTTSATPKCATLLFTNASVTPSGTSQPOLATTAPAVTTVTTSQPPTTLISTVFT
HLLPENVSALPATVAVASPHTTSATPKCATLLFTNASVTPSGTSQPOLATTAPAVTTVTTSQPPTTLISTVFT
HLLPENVSALPATVAVASPHTTSATPKCATLLFTNASVTPSGTSQPOLATTAPAVTTVTTSQPPTTLISTVFT

```

```

220      230      240      250      260      270      280
290      300      310      320      330      340      350      360
RAAATLQAMATTAVLTTFQAPFDSKSLFTIPFTEISNLTLTNGVNPPTALSMNSVSSSTMNKTASWEGR
|||||
RAAATLQAMATTAVLTTFQAPFDSKSLFTIPFTEISNLTLTNGVNPPTALSMNSVSSSTMNKTASWEGR
290      300      310      320      330      340      350      360
370      380      390      400      410      420      430
EASFGSSSGSVPENQYGLPFKEKWLIGSLFGLVFLVIGLVIGRILSESLRKRKYSRLDYLINGIYVDI
|||||
EASFGSSSGSVPENQYGLPFKEKWLIGSLFGLVFLVIGLVIGRILSESLRKRKYSRLDYLINGIYVDI
EASFGSSSGSVPENQYGLPFKEKWLIGSLFGLVFLVIGLVIGRILSESLRKRKYSRLDYLINGIYVDI
370      380      390      400      410      420      430
```

4. US-09-944-929-83 (1-431)  
ABU64930.PEP Human secreted/transmembrane protein PRO361.

TOIG of: abu64930 check: 2687 from: 1 to: 431

```

ID  ABU64930 standard; protein; 431 AA.
XX
AC  ABU64930;
XX
DT  15-MAY-2003 (first entry)
XX
DE  Human secreted/transmembrane protein PRO361.
XX
KW  Human; PRO; secreted protein; transmembrane protein;
KW  Cornelia de Lange syndrome; gene therapy; immune disorder;
KW  inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW  infertility; birth defect; premature aging; cardiac injury; AIDS; cancer;
KW  diabetic complication.
XX
OS  Homo sapiens.
XX
PN  US2002173463-A1.
XX
PD  21-NOV-2002.
XX
PF  31-AUG-2001; 2001US-00944944.
XX
PR  03-DEC-1997; 97US-0067411P.
PR  11-DEC-1997; 97US-0069278P.
PR  11-DEC-1997; 97US-0069334P.
PR  11-DEC-1997; 97US-0069335P.
PR  12-DEC-1997; 97US-0069425P.
PR  16-DEC-1997; 97US-0069694P.
PR  16-DEC-1997; 97US-0069696P.
PR  16-DEC-1997; 97US-0069702P.
PR  17-DEC-1997; 97US-0069870P.
PR  17-DEC-1997; 97US-0069873P.
PR  18-DEC-1997; 97US-0068017P.
PR  05-JAN-1998; 98US-0070440P.
PR  09-FEB-1998; 98US-0074086P.
PR  09-FEB-1998; 98US-0074092P.
PR  25-FEB-1998; 98US-0075945P.
PR  16-SEP-1998; 98WO-US019330.
PR  01-DEC-1998; 98WO-US025108.
PR  16-DEC-1998; 98US-0112850P.
PR  22-DEC-1998; 98US-0113296P.
PR  02-JUN-1999; 99WO-US012252.
PR  28-JUL-1999; 99US-0146222P.
PR  15-SEP-1999; 99WO-US021090.
PR  30-NOV-1999; 99WO-US028313.
PR  30-NOV-1999; 99WO-US028409.
PR  01-DEC-1999; 99WO-US028301.
PR  16-DEC-1999; 99WO-US030095.
PR  11-FEB-2000; 2000WO-US003565.
PR  22-FEB-2000; 2000WO-US004414.
PR  02-MAR-2000; 2000WO-US005841.
PR  30-MAR-2000; 2000WO-US008439.
PR  22-MAY-2000; 2000WO-US014042.
```

```

PR  28-JUL-2000; 2000WO-US020710.
PR  01-DEC-2000; 2000WO-US032678.
PR  28-FEB-2001; 2001WO-US006520.
PR  25-MAY-2001; 2001US-00866028.
XX
PA  (GETH ) GENENTECH INC.
XX
PI  Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;
PI  Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;
PI  Hillan KJ, Kijavlin IJ, Napier MA, Roy MA, Tumas D, Wood WI;
XX
DR  WPI; 2003-311003/30.
DR  N-PSDB; ABX96832.
XX
PT  New transmembrane polypeptides and polynucleotides useful for chromosome
PT  identification, tissue typing, gene therapy, in chromosome and gene
PT  mapping, or as molecular weight markers.
XX
PS  Claim 12; Fig 32; 172pp; English.
XX
CC  The invention relates to an isolated nucleic acid encoding a secreted/
CC  transmembrane polypeptide (designated as PRO proteins). 15 PRO
CC  polypeptides and their encoding polynucleotides are disclosed. Also
CC  included are a vector comprising the PRO nucleic acid, a host cell
CC  comprising the vector, a process for producing a PRO polypeptide (by
CC  culturing the host cell under conditions for the expression of the PRO
CC  polypeptide, and recovering the PRO polypeptide from the cell culture, an
CC  isolated polypeptide having at least 80% amino acid sequence identity to
CC  the PRO polypeptides, a chimaeric molecule comprising PRO fused to a
CC  heterologous amino acid sequence and an antibody which specifically binds
CC  to PRO. The PRO nucleotide sequences are useful as hybridisation probes,
CC  in chromosome and gene mapping, in generating sense and antisense RNA or
CC  DNA, in generating transgenic or knock-out animals which can be used in
CC  the development and screening of therapeutically useful reagents, and in
CC  gene therapy. The polypeptides may be used as molecular weight markers
CC  for protein electrophoresis purposes. The PRO polypeptides and nucleic
CC  acids may also be used for chromosome identification, and tissue typing.
CC  PRO241 (identified as Chordin) is a candidate gene for Cornelia de Lange
CC  syndrome. Other PRO proteins are variously implicated in immune
CC  disorders, inflammatory disease, organ failure, atherosclerosis, cardiac
CC  injury, infertility, birth defects, premature aging, cardiac injury,
CC  AIDS, cancer and diabetic complications. The present sequence represents
CC  a PRO protein
XX
SQ  Sequence 431 AA;
ABU64930 Length: 431 September 30, 2004 08:12 Type: P Check: 2687 ..
Initial Score = 431 Optimized Score = 431 Significance = 0.45
Residue Identity = 100% Matches = 431 Mismatches = 0
Gaps = 0 Conservative Substitutions = 0
X 10 20 30 40 50 60 70
MFFGEGSLTYTLVILICFLTLRLSASQNCLEKSLSDVVIDIQSSLKSGIRGNEPVYTSTQEDCINSCCTKN
|||||
MFFGEGSLTYTLVILICFLTLRLSASQNCLEKSLSDVVIDIQSSLKSGIRGNEPVYTSTQEDCINSCCTKN
X 10 20 30 40 50 60 70
ISGDKACNLMIFDRKTAQPNCYLFFCPNEACPLKPAKGLMSYRITDPPSLTRNLPSEQLPQEDSLHG
|||||
ISGDKACNLMIFDRKTAQPNCYLFFCPNEACPLKPAKGLMSYRITDPPSLTRNLPSEQLPQEDSLHG
ISGDKACNLMIFDRKTAQPNCYLFFCPNEACPLKPAKGLMSYRITDPPSLTRNLPSEQLPQEDSLHG
80 90 100 110 120 130 140
QFSQAVTPLAHHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASAQLLAYKEKGHSQSSQFSSDOEIA
|||||
QFSQAVTPLAHHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASAQLLAYKEKGHSQSSQFSSDOEIA
QFSQAVTPLAHHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASAQLLAYKEKGHSQSSQFSSDOEIA
150 160 170 180 190 200 210
HLLPENVSALPATVAVASPHTTATPKPATLLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLSTVFT
|||||
HLLPENVSALPATVAVASPHTTATPKPATLLPTNASVTPSGTSQPOLATTAPVTTVTSQPTTLSTVFT
|||||
```





PT polypeptides, useful in gene therapy, in chromosome identification, as  
PT chromosome markers, or in generating probes.  
XX  
PS Claim 12; Fig 328; 650pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC comprising a sequence without signal peptide and the nucleic acid  
CC encoding them. The polypeptides can be used to raise antibodies that  
CC specifically bind to the PRO polypeptide, for linking a bioactive  
CC molecule to a cell expressing a PRO protein and for modulating at least  
CC one biological activity of a cell. The PRO polypeptides or  
CC polynucleotides are also useful in gene therapy, in chromosome  
CC identification, as chromosome markers, or in generating probes. The PRO  
CC polypeptides are useful as molecular markers for protein electrophoresis,  
CC and the isolated nucleic acids may be used for recombinantly expressing  
CC those markers. The PRO polypeptides and nucleic acids may also be used in  
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for  
CC PRO, and in affinity purification of PRO from recombinant cell culture or  
CC natural sources. The sequences presented in ABU60478-ABU60624 are the PRO  
CC polynucleotides of the invention. Note: The sequence data for this patent  
CC is also available in electronic format from USPTO at  
CC seqdata.uspto.gov/sequence.html  
XX  
XX  
SQ Sequence 431 AA;

ABU60623 Length: 431 September 30, 2004 08:12 Type: P Check: 2687 ..

Initial Score = 431 Optimized Score = 431 Significance = 0.45  
Residue Identity = 100% Matches = 431 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
MFFGEGSLTYTLVVICFLTLRLASQNCCLKSLLEDVVIDIOSSLKSGIRGNEPVYTSQEDCINSCCSTKN  
MFFGEGSLTYTLVVICFLTLRLASQNCCLKSLLEDVVIDIOSSLKSGIRGNEPVYTSQEDCINSCCSTKN  
X 10 20 30 40 50 60 70  
ISGDKACNLMIFDTRKTARQPNCYLFCPNEACPLKPAKGLMSYRIITDPPSLTRNLPQEDSLHLG  
ISGDKACNLMIFDTRKTARQPNCYLFCPNEACPLKPAKGLMSYRIITDPPSLTRNLPQEDSLHLG  
ISGDKACNLMIFDTRKTARQPNCYLFCPNEACPLKPAKGLMSYRIITDPPSLTRNLPQEDSLHLG  
X 80 90 100 110 120 130 140  
QFSQAVTPLAAHHTDYSKPTDISMRDLSQKFGSSDHLKLFKMDASAOQLLAYKKEKHSQSSQFSSDQEIA  
QFSQAVTPLAAHHTDYSKPTDISMRDLSQKFGSSDHLKLFKMDASAOQLLAYKKEKHSQSSQFSSDQEIA  
QFSQAVTPLAAHHTDYSKPTDISMRDLSQKFGSSDHLKLFKMDASAOQLLAYKKEKHSQSSQFSSDQEIA  
X 150 160 170 180 190 200 210  
HLLPENVSALPATVAVASPHHTSATPKPATLLPTNASVTPSGTSOPOLATTAPPVTVTSQPPPTLLISTVFT  
HLLPENVSALPATVAVASPHHTSATPKPATLLPTNASVTPSGTSOPOLATTAPPVTVTSQPPPTLLISTVFT  
HLLPENVSALPATVAVASPHHTSATPKPATLLPTNASVTPSGTSOPOLATTAPPVTVTSQPPPTLLISTVFT  
X 220 230 240 250 260 270 280  
RAAATIQAMATTAVLTTFQAPTDKSGLETIPFTEISNLTTLNTGNVYNPTALSMNSNVESSTNKKTASWEGR  
RAAATIQAMATTAVLTTFQAPTDKSGLETIPFTEISNLTTLNTGNVYNPTALSMNSNVESSTNKKTASWEGR  
RAAATIQAMATTAVLTTFQAPTDKSGLETIPFTEISNLTTLNTGNVYNPTALSMNSNVESSTNKKTASWEGR  
X 290 300 310 320 330 340 350 360  
EASPGSSSGSVPENQYGLPFKEKWLIGLFLVIGLVILGRILSESLRKRYSRDLVILNGIYVDI  
EASPGSSSGSVPENQYGLPFKEKWLIGLFLVIGLVILGRILSESLRKRYSRDLVILNGIYVDI  
EASPGSSSGSVPENQYGLPFKEKWLIGLFLVIGLVILGRILSESLRKRYSRDLVILNGIYVDI  
X 370 380 390 400 410 420 430  
EASPGSSSGSVPENQYGLPFKEKWLIGLFLVIGLVILGRILSESLRKRYSRDLVILNGIYVDI  
EASPGSSSGSVPENQYGLPFKEKWLIGLFLVIGLVILGRILSESLRKRYSRDLVILNGIYVDI  
EASPGSSSGSVPENQYGLPFKEKWLIGLFLVIGLVILGRILSESLRKRYSRDLVILNGIYVDI

6. US-09-944-929-83 (1-431)  
ABU59192.PEP Novel human secreted or transmembrane protein PRO3  
TOIG of: abu59192 check: 2687 from: 1 to: 431

ID ABU59192 standard; protein; 431 AA.  
XX  
AC ABU59192;  
XX  
DT 28-APR-2003 (first entry)  
XX  
DE Novel human secreted or transmembrane protein PRO361.  
XX  
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
KW cardiac insufficiency disorder; cancer; tumour; immune response;  
KW adrenal cortical capillary endothelial growth; c-fos induction;  
KW vascular endothelial growth factor inhibition; VEGF inhibition;  
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;  
KW retinal neurons cell survival; rod photoreceptor cell survival;  
KW retinal disorder; retinitis pigmentosa; kidney disorder;  
KW mammalian kidney mesangial cell proliferation; Berger disease;  
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;  
KW chondrocyte redifferentiation; sports injury; arthritis.  
XX  
OS Homo sapiens.  
XX  
PN US2002132252-A1.  
XX  
PD 19-SEP-2002.  
XX  
PF 14-NOV-2001; 2001US-00990442.  
XX  
PR 16-JUN-1997; 97US-0049787P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 05-NOV-1997; 97WO-US02006P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 28-APR-1998; 98US-0083322P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 02-JUN-1998; 98US-0087607P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088021P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088734P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088742P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089440P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089532P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089801P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 02-JUN-1999; 99WO-US012252.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 06-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 15-MAY-2000; 2000WO-US013358.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUN-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 28-AUG-2001; 2001US-00941992.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;  
PI Ferrara N, Fong S, Geiber H, Gerritsen ME, Goddard A, Godowski PJ;  
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;  
PI Zhang Z;  
XX  
DR WPI; 2003-247083/24.  
DR N-PSDB; ABX80473.  
XX  
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346  
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
PT are therapeutically useful for enhancing immune response and in cancer  
PT treatments.  
XX  
PS Claim 12; Fig 328; 648bp; English.  
XX  
CC The invention describes an isolated human PRO polypeptide. The PRO  
CC polypeptides are useful in detecting PRO polypeptides in a sample, in  
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
CC in modulating at least one biological activity of a cell expressing a PRO  
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186  
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,

CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,  
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus  
CC useful for treating conditions or disorders where angiogenesis would be  
CC beneficial, e.g. wound healing and antagonist of this polypeptide are  
CC useful for treating cancerous tumours. PRO812 inhibits vascular  
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial  
CC cells and is thus useful for inhibiting endothelial cell growth in  
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,  
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of  
CC stimulated T-lymphocytes and are therapeutically useful for enhancing  
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of  
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of  
CC rod photoreceptor cells) and therefore are useful for treating retinal  
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813  
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,  
CC and therefore are useful for treating kidney disorders associated with  
CC decreased mesangial cell function such as Berger disease or other  
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's  
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the  
CC proliferation and/or redifferentiation of chondrocytes in culture and are  
CC thus useful for treating sports injuries, and arthritis. This is the  
CC amino acid sequence of a novel human PRO protein  
XX  
SQ Sequence 431 AA;  
ABU59192 Length: 431 September 30, 2004 08:11 Type: P Check: 2687 ..  
Initial Score = 431 Optimized Score = 431 Significance = 0.45  
Residue Identity = 100% Matches = 431 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0  
X 10 20 30 40 50 60 70  
MFFGEGSLTYTLVVICFLTRLISASQNCLEKSLSDVVIDIQSSLKGRGNEPVYTSQEDCINSCCSTKN  
|||||  
MFFGEGSLTYTLVVICFLTRLISASQNCLEKSLSDVVIDIQSSLKGRGNEPVYTSQEDCINSCCSTKN  
X 10 20 30 40 50 60 70  
ISGDKACNLMIFDTRKTKARQNCYLFFCPNEACPLKPAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHG  
|||||  
ISGDKACNLMIFDTRKTKARQNCYLFFCPNEACPLKPAKGLMSYRIITDPFSLTRNLPSQELPQEDSLHG  
X 80 90 100 110 120 130 140  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLKELFKMDEASAQLLAYKEKGHSQSSQFSSDQEIA  
|||||  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLKELFKMDEASAQLLAYKEKGHSQSSQFSSDQEIA  
X 150 160 170 180 190 200 210  
HILPENVSALPATVAVASPHRTSATPKPATLLPTNASVTPSGTSQPOLATTAPVTVTSQPTTLISTVFT  
|||||  
HILPENVSALPATVAVASPHRTSATPKPATLLPTNASVTPSGTSQPOLATTAPVTVTSQPTTLISTVFT  
X 220 230 240 250 260 270 280  
RAAATLQAMATTAVLTTRQAPPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMNSVSSSTMKTASWEGR  
|||||  
RAAATLQAMATTAVLTTRQAPPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMNSVSSSTMKTASWEGR  
X 290 300 310 320 330 340 350 360  
EASPGSSSQGSVPENQYGLPFEKWLIGSLFGVLFVLVIGLVLGRILSLSLRKRYSRDLYLINGIYVDI  
|||||  
EASPGSSSQGSVPENQYGLPFEKWLIGSLFGVLFVLVIGLVLGRILSLSLRKRYSRDLYLINGIYVDI  
X 370 380 390 400 410 420 430  
EASPGSSSQGSVPENQYGLPFEKWLIGSLFGVLFVLVIGLVLGRILSLSLRKRYSRDLYLINGIYVDI  
|||||  
EASPGSSSQGSVPENQYGLPFEKWLIGSLFGVLFVLVIGLVLGRILSLSLRKRYSRDLYLINGIYVDI  
X 370 380 390 400 410 420 430  
7. US-09-944-929-83 (1-431)  
ABU58364.PEP Novel human secreted protein PRO361.  
TOIG of: abu58364 check: 2687 from: 1 to: 431



ID ABU58364 standard; protein; 431 AA.  
XX  
AC ABU58364;  
XX  
DT 14-APR-2003 (first entry)  
XX  
DE Novel human secreted protein PRO361.  
XX  
KW Human; antiinflammatory; antiarteriosclerotic; cardiant; gynecological;  
KW anti-HIV; cytostatic; antidiabetic; BMP-agonist; BMP-Antagonist;  
KW cytokine-agonist; cytokine-antagonist; gene-Therapy;  
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;  
KW infertility; birch defect; premature aging; AIDS; cancer;  
KW diabetic complication.  
XX  
OS Homo sapiens.  
XX  
PN US2002150976-A1.  
XX  
PD 17-OCT-2002.  
XX  
PF 30-AUG-2001; 2001US-00943851.  
XX  
PR 03-DEC-1997; 97US-0067411P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 16-DEC-1997; 97US-0069696P.  
PR 16-DEC-1997; 97US-0069702P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 17-DEC-1997; 97US-0069873P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 05-JAN-1998; 98US-0070440P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 25-FEB-1998; 98US-0075945P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 01-DEC-1998; 98WO-US025108.  
PR 16-DEC-1998; 98US-00216021.  
PR 16-DEC-1998; 98US-0112850P.  
PR 22-DEC-1998; 98US-00218517.  
PR 22-DEC-1998; 98US-0113296P.  
PR 03-MAR-1999; 99US-00254311.  
PR 02-JUN-1999; 99WO-US012252.  
PR 28-JUL-1999; 99US-0146222P.  
PR 15-SEP-1999; 99WO-US021090.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 16-DEC-1999; 99WO-US030095.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 25-MAY-2001; 2001US-00866028.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;  
PI Geritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;  
PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;  
XX  
DR WPI; 2003-198285/19.  
DR N-PSDB; ABX78486.  
XX  
PT New isolated PRO polypeptide and encoding nucleic acids, useful for the  
PT diagnosis and treatment of disorders such as inflammatory disease,

PT atherosclerosis, cardiac injury, infertility, AIDS, cancer and diabetic  
PT complications.  
XX  
PS Claim 12; Fig 32; 171pp; English.  
XX  
CC The invention describes a novel isolated PRO polypeptide. The methods and  
CC compositions of the present invention are useful for the diagnosis and  
CC treatment of disorders such as inflammatory disease, organ failure,  
CC atherosclerosis, cardiac injury, infertility, birth defects, premature  
CC aging, AIDS, cancer, diabetic complications and mutations in general.  
CC This is the amino acid sequence of a novel human secreted PRO protein  
XX  
SQ Sequence 431 AA;  
ABU58364 Length: 431 September 30, 2004 08:12 Type: P Check: 2687 ..  
Initial Score = 431 Optimized Score = 431 Significance = 0.45  
Residue Identity = 100% Matches = 431 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0  
X 10 20 30 40 50 60 70  
MFFGEGSLTYTVVICFLTLRLSASQNCLEKSLIEDVIDIQSSLKGRGNEPVYTSTQEDCINSCSTKN  
|||||  
MFFGEGSLTYTVVICFLTLRLSASQNCLEKSLIEDVIDIQSSLKGRGNEPVYTSTQEDCINSCSTKN  
X 10 20 30 40 50 60 70  
ISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHG  
|||||  
ISGDKACNLMIFDTRKTARQPNCYLFFCPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHG  
80 90 100 110 120 130 140  
QFSQAVTPLAAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMDASAOQLLAYKEKHSQSSQFSSDOEIA  
|||||  
QFSQAVTPLAAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMDASAOQLLAYKEKHSQSSQFSSDOEIA  
150 160 170 180 190 200 210  
HLLPENVSALPATVAVASPHTTSATPKPATLLPTNASVTPSGTSQPOLATTAAPVTTVTSQPTTLISTVFT  
|||||  
HLLPENVSALPATVAVASPHTTSATPKPATLLPTNASVTPSGTSQPOLATTAAPVTTVTSQPTTLISTVFT  
220 230 240 250 260 270 280  
RAAATLQAMATTAVLTTFQAPTDSKGSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR  
|||||  
RAAATLQAMATTAVLTTFQAPTDSKGSLETIPTEISNLTNTGNVYNPTALSMNSVESSTMNKTASWEGR  
290 300 310 320 330 340 350 360  
EASPGSSSQGSVPENQYGLPFEKWLIGSLFGLVFLVIGLVLLGRILISESLRRKYSRLDYLLINGIYVDI  
|||||  
EASPGSSSQGSVPENQYGLPFEKWLIGSLFGLVFLVIGLVLLGRILISESLRRKYSRLDYLLINGIYVDI  
370 380 390 400 410 420 430  
8. US-09-944-929-83 (1-431)  
ABU55934.PEP Human secreted/transmembrane protein PRO361.  
TOIG of: abu55934 check: 2687 from: 1 to: 431  
ID ABU55934 standard; protein; 431 AA.  
XX  
AC ABU55934;  
XX  
DT 26-MAR-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein PRO361.  
XX  
KW Human; PRO; secreted protein; transmembrane protein; anti-HIV;  
KW cytostatic; antiarteriosclerotic; antiinflammatory; antidiabetic;  
KW cardiant; AIDS; acquired immunodeficiency syndrome; cancer;

KW atherosclerosis; inflammatory disease; diabetic complication;  
cardiac injury; organ failure.

OS Homo sapiens.

PN US2002142959-A1.

PD 03-OCT-2002.

PF 31-AUG-2001; 2001US-00944654.

PR 16-SEP-1998; 98WO-US019330.

PR 01-DEC-1998; 98WO-US025108.

PR 22-JUN-1999; 99WO-US012352.

PR 15-SEP-1999; 99WO-US021090.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 16-DEC-1999; 99WO-US030095.

PR 11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.

PR 02-MAR-2000; 2000WO-US005841.

PR 30-MAR-2000; 2000WO-US008439.

PR 22-MAY-2000; 2000WO-US014042.

PR 28-JUL-2000; 2000WO-US020710.

PR 01-DEC-2000; 2000WO-US032678.

PR 28-FEB-2001; 2001WO-US006520.

PR 25-MAY-2001; 2001US-00866028.

PA (GETH ) GENENTECH INC.

PI Baker KP, Botstein D, Eaton DL, Ferrara N, Filvaroff E;

PI Gerltsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL;

PI Hillan KJ, Kljavin IJ, Napier MA, Roy MA, Tumas D, Wood WI;

DR WPI; 2003-174141/17.

DR N-PSDB; ABX75504.

PT New isolated PRO polypeptide and encoding nucleic acid, useful for the

PT diagnosis and treatment of disorders associated with the PRO polypeptide,

PT such as AIDS, cancer, atherosclerosis, inflammatory disease and diabetes.

PS Claim 12; Fig 32; 178pp; English.

XX The invention relates to an isolated PRO polypeptide (a secreted or

XX transmembrane protein) comprising: (a) at least 80% sequence identity or

XX positives when compared to any of 15 sequences, fully defined in the

XX specification, lacking or with its associated signal peptide; or (b) at

XX least 80% sequence identity to a sequence encoded by the full-length

XX coding sequence of a DNA deposited in the American Type Culture

XX Collection (ATCC). Also included are: (1) an isolated nucleic acid

XX comprising: (a) at least 80% sequence identity to a nucleotide sequence

XX that encodes a PRO protein; (b) at least 80% sequence identity to a

XX nucleotide sequence or full-length coding sequence with any of 15 fully

XX defined sequences of 957-3441 base pairs, given in the specification; or

XX (c) at least 80% sequence identity to a full-length coding sequence of a

XX DNA deposited under ATCC Accession No. 209526, 209508, 209524, 209528,

XX 209530, 209523, 209492, 209532, 209531, 209529, 209527, 209570, 209618,

XX 209621 or 209619; (2) a vector comprising the nucleic acid; (3) a host

XX cell comprising the vector which, when cultured under conditions suitable

XX for expression of the PRO polypeptide, produces the PRO protein; (4) a

XX chimeric molecule comprising PRO fused to a heterologous amino acid

XX sequence; and (5) an anti-PRO antibody. The methods and compositions of

XX the present invention are useful for the diagnosis and treatment of

XX disorders associated with the PRO polypeptide, such as AIDS (acquired

XX immunodeficiency syndrome), cancer, atherosclerosis, inflammatory

XX disease, diabetic complications, cardiac injury and organ failure. The

XX antibodies can also be used in the different screening, therapeutic and

XX biological assays. The present sequence represents a PRO protein

XX Sequence 431 AA;

ABU55934 Length: 431 September 30, 2004 08:11 Type: P Check: 2687 ..

Initial Score = 431 Optimized Score = 431 Significance = 0.45  
Residue Identity = 100% Matches = 431 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
MFEFGESLTYTLVITCFILRLSASQNCCLKSLLEDVVIDIQSSLSKGRGNEPVYTSTQEDCINSCCSTKN  
MFEFGESLTYTLVITCFILRLSASQNCCLKSLLEDVVIDIQSSLSKGRGNEPVYTSTQEDCINSCCSTKN  
X 10 20 30 40 50 60 70

ISGDACNLMI FDRKTRARQPCYLFECPEEACPLKPAKGLMSYRIITDFPSLITNLPSCQLPOEDSLHG  
ISGDACNLMI FDRKTRARQPCYLFECPEEACPLKPAKGLMSYRIITDFPSLITNLPSCQLPOEDSLHG  
X 80 90 100 110 120 130 140

QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASAQLLAYKEKGHSQSSQFSSDOEIA  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLKLFKMDASAQLLAYKEKGHSQSSQFSSDOEIA  
X 150 160 170 180 190 200 210

HLLENVSALPATVAVASPHTSATPKPATLLPTNASVTPSGTSQPOLATTAPPTVTSQPPTLISTVFT  
HLLENVSALPATVAVASPHTSATPKPATLLPTNASVTPSGTSQPOLATTAPPTVTSQPPTLISTVFT  
X 220 230 240 250 260 270 280

RAAATLQAMATTAVLTTFPOAPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMGNEVSTMNKTASWEGR  
RAAATLQAMATTAVLTTFPOAPTDSKGSLETIPFTEISNLTNTGNVYNPTALSMGNEVSTMNKTASWEGR  
X 290 300 310 320 330 340 350 360

EASPGSSSQGSVPENQYGLPEKXLLIGSLFGVLFLVIGLVLLGRILSESLRRKRYSRDLYLINGIYVDI  
EASPGSSSQGSVPENQYGLPEKXLLIGSLFGVLFLVIGLVLLGRILSESLRRKRYSRDLYLINGIYVDI  
X 370 380 390 400 410 420 430

9. US-09-944-929-83 (1-431)  
AAB34739.PEP Human secreted protein encoded by DNA clone vo27 1

TOIG of: aab34739 check: 2687 from: 1 to: 431

ID AAB34739 standard; protein; 431 AA.

AC AAB34739;

DT 26-JAN-2001 (first entry)

XX Human secreted protein encoded by DNA clone vo27 1.

XX Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer;

XX systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke;

XX haematopoiesis regulation; tissue regrowth; wound healing; haemophilia;

XX Alzheimer's disease; Parkinson's disease; Shy-drager syndrome; cancer;

XX contraceptive; infection; growth inhibition; hyperproliferative disorder;

XX psoriasis.

XX Homo sapiens.

XX WO200055375-A1.

XX 21-SEP-2000.

XX 17-MAR-2000; 2000WO-US007285.

XX 17-MAR-1999; 99US-0124808P.

XX 17-MAR-1999; 99US-0124916P.

XX 17-AUG-1999; 99US-0149639P.

PR 01-OCT-1999; 99US-0157247P.  
PR 29-NOV-1999; 99US-0167824P.  
PR 15-FEB-2000; 2000US-0182711P.  
XX  
PA (ALPH-) ALPHAGENE INC.  
XX  
PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;  
XX  
DR WPI: 2000-638211/61.  
DR N-PSDB; AAC59840.  
XX

PT Novel proteins and polypeptides useful for the treatment of e.g multiple  
PT sclerosis, systemic lupus erythmatosus, rheumatoid arthritis, cancer,  
PT Alzheimer's disease, Parkinson's disease, stroke, anemia and ulcers.  
XX  
PS Claim 114; Page 453-455; 493pp; English.

XX  
CC This invention relates to 59 human secreted proteins and the nucleotide  
CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745  
CC represent the proteins and their encoding nucleotide sequences, and  
CC sequences AAB34746-B34771 represent fragments of the proteins. Probes for  
CC the DNA sequences are represented by sequences AAC59847-C59596. The  
CC proteins exhibit neuroprotective, dermatological, immunosuppressive,  
CC antiinflammatory, antianaemic, nootropic, antiparkinsonian,  
CC cerebroprotective, haemostatic, vulnery, cyostatic, antipsoriatic,  
CC antibacterial, virucide, and fungicide activity. The proteins and  
CC nucleotide sequences are useful as nutritional sources or supplements and  
CC in research. The proteins are useful for treating immune deficiency and  
CC disorders, which may be genetic or resulting from infections, autoimmune  
CC disorders such as multiple sclerosis, systemic lupus erythmatosus,  
CC rheumatoid arthritis, and for treating myeloid or lymphoid cell  
CC deficiencies such as anaemias by regulating haematopoiesis. The proteins  
CC are also useful in compositions for bone, cartilage, tendon, ligament  
CC and/or nerve tissue growth or regeneration, for wound healing, tissue  
CC repair and replacement and in the treatment of wounds, incisions and  
CC ulcers. Other uses include in the treatment of central and peripheral  
CC nervous system and neuropathies such as Alzheimer's and Parkinson's  
CC diseases and Shy-Drager syndrome, and mechanical and traumatic disorders,  
CC such as spinal cord disorders, head trauma and stroke. The proteins may  
CC also be used as a contraceptive, and for treating coagulation disorders  
CC such as haemophilias. The protein and nucleotide sequences with cadherin  
CC activity are useful for treating cancer. Other uses for the protein  
CC include for inhibiting the growth, infection or function of, or killing,  
CC infectious agents such as bacteria, virus, fungi and other parasites, for  
CC effecting bodily characteristics such as height, weight, hair colour,  
CC effecting biorhythms or cardiac cycles or rhythms, effecting metabolism,  
CC catabolism, anabolism, processing, utilization, storage or elimination of  
CC dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors,  
CC effecting behavioural characteristics, providing analgesic effects and  
CC for treating hyperproliferative disorders such as psoriasis

XX  
SQ Sequence 431 AA;

AAB34739 Length: 431 September 30, 2004 08:09 Type: P Check: 2687 ..

Initial Score = 431 Optimized Score = 431 Significance = 0.45  
Residue Identity = 100% Matches = 431 Mismatches = 0  
Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70  
MFFGEGSLTYTLVLCFLTLRLSASQNCCLKSLEDVVIDIQSSLKSGIRGNPEPVYTSQEDCINSCCSTKN  
MFFGEGSLTYTLVLCFLTLRLSASQNCCLKSLEDVVIDIQSSLKSGIRGNPEPVYTSQEDCINSCCSTKN  
X 10 20 30 40 50 60 70  
ISGDKACNLMIFDTRKTARQPCNYLFCFPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHGG  
ISGDKACNLMIFDTRKTARQPCNYLFCFPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHGG  
X 80 90 100 110 120 130 140  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMDASAOQLLAYKKGHSQSSQFSSDQEIA  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMDASAOQLLAYKKGHSQSSQFSSDQEIA

|||||  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMDASAOQLLAYKKGHSQSSQFSSDQEIA  
150 160 170 180 190 200 210

220 230 240 250 260 270 280  
HLLPENVSALPATVAVASPHHTSATPKPATLLPTNASVTPSGTSQPOLATTAPEVTVTSQPPTLSTVFT  
HLLPENVSALPATVAVASPHHTSATPKPATLLPTNASVTPSGTSQPOLATTAPEVTVTSQPPTLSTVFT  
220 230 240 250 260 270 280

290 300 310 320 330 340 350 360  
RAAATLQAMATTAVLTTFQAPTDSKGSLETIPFTEISNLTNTGNVNPALSMNSVESSTMNKTASWEGR  
RAAATLQAMATTAVLTTFQAPTDSKGSLETIPFTEISNLTNTGNVNPALSMNSVESSTMNKTASWEGR  
290 300 310 320 330 340 350 360

370 380 390 400 410 420  
EASPGSSSQSVPENQYGLPFEKMLLIGSLRGVLFVLVIGLVLLGRILSESLRKRYSRLDYLLINGIYVDI  
EASPGSSSQSVPENQYGLPFEKMLLIGSLRGVLFVLVIGLVLLGRILSESLRKRYSRLDYLLINGIYVDI  
370 380 390 400 410 420 430

10. US-09-944-929-83 (1-431)  
AAM25899.PEP TOIG of: aam25899 check: 5992 from: 1 to: 633

TOIG of: aam25899 check: 5992 from: 1 to: 633

AAM25899 GB:AE013217 NAD/FAD-utilizing enzyme apparently involved in cell  
division [Thermoanaerobacter tengcongensis] (ver 1)

AAM25899 Length: 633 September 30, 2004 08:13 Type: P Check: 5992 ..

Initial Score = 6 Optimized Score = 66 Significance = -2.02  
Residue Identity = 20% Matches = 99 Mismatches = 218  
Gaps = 166 Conservative Substitutions = 0

10 20 30 40 50 60 70  
MFFGEGSLTYTLVLCFLTLRLSASQNCCLKSLEDVVIDIQSSLKSGIRGNPEPVYTSQEDCINSCCSTKN  
MFFGEGSLTYTLVLCFLTLRLSASQNCCLKSLEDVVIDIQSSLKSGIRGNPEPVYTSQEDCINSCCSTKN  
X 80 90 100 110 120 130 140  
ISGDKACNLMIFDTRKTARQPCNYLFCFPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHGG  
ISGDKACNLMIFDTRKTARQPCNYLFCFPNEACPLKPAKGLMSYRIITDFPSLTRNLPSQELPQEDSLHGG  
X 20 30 40 50 60  
HAGSEA-----ALASARLGLATVGFATNLDAL-----MACNPSIGGPAKAQ-LVREIDALGG

150 160 170 180 190 200  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMDASAOQLLAYKKGHSQSSQF  
QFSQAVTPLAHHTDYSKPTDISWRDTLSQKFGSSDHLLEKLFKMDASAOQLLAYKKGHSQSSQF  
--EMAV-----NTDKS---LQMRRLNTSKG-----PAVRSIRAQVDKLLYQANMKHTLEROK  
70 80 90 100 110

210 220 230 240 250  
SSD---QEIHLHPEN-----VSALPA-TVAVASPHHTSATPKPATL-----PTNASVTPSG-----  
SSD---QEIHLHPEN-----VSALPA-TVAVASPHHTSATPKPATL-----PTNASVTPSG-----  
NLDIKQAEIVDILVENNKVGVVTKLGAIVKCAIITTT-----GTFLRGRVIGEVGFESGSPGLPPAKE  
NLDIKQAEIVDILVENNKVGVVTKLGAIVKCAIITTT-----GTFLRGRVIGEVGFESGSPGLPPAKE  
260 270 280 290 300 310 320  
TSQPOLATTAPPVTVTSQPTTLISTVFTRAAATLQAMATTAVLTTFQAPTDSKGSLETIP--FTEISNL  
TSQPOLATTAPPVTVTSQPTTLISTVFTRAAATLQAMATTAVLTTFQAPTDSKGSLETIP--FTEISNL  
LSEAIKRLGFKMMRFNTSTPPRVDKRTV-----DFSKMIMQPGDEVITPFSFMHD-KIEIEQIPCWLTYYTNEK  
LSEAIKRLGFKMMRFNTSTPPRVDKRTV-----DFSKMIMQPGDEVITPFSFMHD-KIEIEQIPCWLTYYTNEK  
190 200 210 220 230 240 250

330 340 350 360 370  
T-----LNTGNV-----YNP--TALSMNSVESSTMNKTASWEGREASPGSSSQG---SVPENQY  
T-----LNTGNV-----YNP--TALSMNSVESSTMNKTASWEGREASPGSSSQG---SVPENQY  
THKIIRDNIHRAPLYTGEVEGVGVRYCPSIEDKVMKFPHRDRHQIFVEDEGR-DTYEMYIQGLFSSFPB---  
THKIIRDNIHRAPLYTGEVEGVGVRYCPSIEDKVMKFPHRDRHQIFVEDEGR-DTYEMYIQGLFSSFPB---





**THIS PAGE BLANK (USPTO)**